0000049071-24-000055.txt : 20241030 0000049071-24-000055.hdr.sgml : 20241030 20241030141734 ACCESSION NUMBER: 0000049071-24-000055 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANA INC CENTRAL INDEX KEY: 0000049071 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 610647538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-05975 FILM NUMBER: 241409312 BUSINESS ADDRESS: STREET 1: 500 W MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 5025801000 MAIL ADDRESS: STREET 1: 500 W. MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 FORMER COMPANY: FORMER CONFORMED NAME: EXTENDICARE INC DATE OF NAME CHANGE: 19740404 FORMER COMPANY: FORMER CONFORMED NAME: HERITAGE HOUSE OF AMERICA INC DATE OF NAME CHANGE: 19671129 10-Q 1 hum-20240930.htm 10-Q hum-20240930
0000049071--12-312024Q3false0.16670.1667http://fasb.org/us-gaap/2024#HealthCareMemberhttp://fasb.org/us-gaap/2024#HealthCareMemberhttp://fasb.org/us-gaap/2024#HealthCareMemberhttp://fasb.org/us-gaap/2024#HealthCareMemberP1Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purehum:positionhum:statehum:beneficiaryhum:option_periodhum:segment00000490712024-01-012024-09-3000000490712024-09-3000000490712023-12-3100000490712024-07-012024-09-3000000490712023-07-012023-09-3000000490712023-01-012023-09-300000049071us-gaap:CommonStockMember2024-06-300000049071us-gaap:AdditionalPaidInCapitalMember2024-06-300000049071us-gaap:RetainedEarningsMember2024-06-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000049071us-gaap:TreasuryStockCommonMember2024-06-300000049071us-gaap:ParentMember2024-06-300000049071us-gaap:NoncontrollingInterestMember2024-06-3000000490712024-06-300000049071us-gaap:RetainedEarningsMember2024-07-012024-09-300000049071us-gaap:ParentMember2024-07-012024-09-300000049071us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000049071us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000049071us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000049071us-gaap:CommonStockMember2024-09-300000049071us-gaap:AdditionalPaidInCapitalMember2024-09-300000049071us-gaap:RetainedEarningsMember2024-09-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000049071us-gaap:TreasuryStockCommonMember2024-09-300000049071us-gaap:ParentMember2024-09-300000049071us-gaap:NoncontrollingInterestMember2024-09-300000049071us-gaap:CommonStockMember2023-06-300000049071us-gaap:AdditionalPaidInCapitalMember2023-06-300000049071us-gaap:RetainedEarningsMember2023-06-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000049071us-gaap:TreasuryStockCommonMember2023-06-300000049071us-gaap:ParentMember2023-06-300000049071us-gaap:NoncontrollingInterestMember2023-06-3000000490712023-06-300000049071us-gaap:RetainedEarningsMember2023-07-012023-09-300000049071us-gaap:ParentMember2023-07-012023-09-300000049071us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000049071us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000049071us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000049071us-gaap:CommonStockMember2023-09-300000049071us-gaap:AdditionalPaidInCapitalMember2023-09-300000049071us-gaap:RetainedEarningsMember2023-09-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000049071us-gaap:TreasuryStockCommonMember2023-09-300000049071us-gaap:ParentMember2023-09-300000049071us-gaap:NoncontrollingInterestMember2023-09-3000000490712023-09-300000049071us-gaap:CommonStockMember2023-12-310000049071us-gaap:AdditionalPaidInCapitalMember2023-12-310000049071us-gaap:RetainedEarningsMember2023-12-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000049071us-gaap:TreasuryStockCommonMember2023-12-310000049071us-gaap:ParentMember2023-12-310000049071us-gaap:NoncontrollingInterestMember2023-12-310000049071us-gaap:RetainedEarningsMember2024-01-012024-09-300000049071us-gaap:ParentMember2024-01-012024-09-300000049071us-gaap:NoncontrollingInterestMember2024-01-012024-09-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000049071us-gaap:TreasuryStockCommonMember2024-01-012024-09-300000049071us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300000049071us-gaap:CommonStockMember2024-01-012024-09-300000049071us-gaap:CommonStockMember2022-12-310000049071us-gaap:AdditionalPaidInCapitalMember2022-12-310000049071us-gaap:RetainedEarningsMember2022-12-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000049071us-gaap:TreasuryStockCommonMember2022-12-310000049071us-gaap:ParentMember2022-12-310000049071us-gaap:NoncontrollingInterestMember2022-12-3100000490712022-12-310000049071us-gaap:RetainedEarningsMember2023-01-012023-09-300000049071us-gaap:ParentMember2023-01-012023-09-300000049071us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000049071us-gaap:TreasuryStockCommonMember2023-01-012023-09-300000049071us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000049071us-gaap:CommonStockMember2023-01-012023-09-300000049071hum:ValueCreationInitiativesMember2024-07-012024-09-300000049071hum:ValueCreationInitiativesMember2024-01-012024-09-300000049071hum:ValueCreationInitiativesMember2023-07-012023-09-300000049071hum:ValueCreationInitiativesMember2023-01-012023-09-300000049071us-gaap:ServiceMember2024-09-300000049071us-gaap:USTreasuryAndGovernmentMember2024-09-300000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-09-300000049071us-gaap:NontaxableMunicipalNotesMember2024-09-300000049071us-gaap:ResidentialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:CommercialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:AssetBackedSecuritiesMember2024-09-300000049071us-gaap:CorporateDebtSecuritiesMember2024-09-300000049071us-gaap:USTreasuryAndGovernmentMember2023-12-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000049071us-gaap:NontaxableMunicipalNotesMember2023-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:AssetBackedSecuritiesMember2023-12-310000049071us-gaap:CorporateDebtSecuritiesMember2023-12-310000049071us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhum:GentivaHospiceMember2024-09-300000049071us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhum:GentivaHospiceMember2023-12-310000049071srt:StandardPoorsAAMinusRatingMember2024-09-300000049071us-gaap:FairValueMeasurementsRecurringMember2024-09-300000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-09-300000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-09-300000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-09-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-09-300000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-09-300000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-09-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:NontaxableMunicipalNotesMember2024-09-300000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:NontaxableMunicipalNotesMember2024-09-300000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:NontaxableMunicipalNotesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:NontaxableMunicipalNotesMember2024-09-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000049071us-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:NontaxableMunicipalNotesMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:NontaxableMunicipalNotesMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:NontaxableMunicipalNotesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:NontaxableMunicipalNotesMember2023-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberhum:FairValueRiskMemberus-gaap:InvestmentsMember2024-01-012024-09-300000049071us-gaap:FairValueInputsLevel3Memberhum:FairValueRiskMemberus-gaap:InvestmentsMember2023-01-012023-12-310000049071us-gaap:InterestRateSwapMember2024-09-300000049071hum:A5875PercentSeniorNotesDueMarch2033Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:InterestRateSwapMaturing2033Memberus-gaap:InterestRateSwapMember2024-09-300000049071hum:InterestRateSwapMaturing2033Memberus-gaap:InterestRateSwapMember2023-12-310000049071hum:A5.950PercentSeniorNotesDueMarch2034Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:InterestRateSwapMaturing2034Memberus-gaap:InterestRateSwapMember2024-09-300000049071hum:InterestRateSwapMaturing2034Memberus-gaap:InterestRateSwapMember2023-12-310000049071hum:A395PercentSeniorNotesDueAugust2049Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:InterestRateSwapMaturing2049Memberus-gaap:InterestRateSwapMember2024-09-300000049071hum:InterestRateSwapMaturing2049Memberus-gaap:InterestRateSwapMember2023-12-310000049071hum:A550PercentSeniorNotesDueMarch2053Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:InterestRateSwapMaturing2053Memberus-gaap:InterestRateSwapMember2024-09-300000049071hum:InterestRateSwapMaturing2053Memberus-gaap:InterestRateSwapMember2023-12-310000049071hum:A4.625PercentSeniorNotesDueDecember2042Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:InterestRateSwapMaturing2042Memberus-gaap:InterestRateSwapMember2024-09-300000049071hum:InterestRateSwapMaturing2042Memberus-gaap:InterestRateSwapMember2023-12-310000049071hum:A4.95PercentSeniorNotesDueOctober2044Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:InterestRateSwapMaturing2044Memberus-gaap:InterestRateSwapMember2024-09-300000049071hum:InterestRateSwapMaturing2044Memberus-gaap:InterestRateSwapMember2023-12-310000049071hum:A5.750PercentSeniorNotesDueApril2054Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:InterestRateSwapMaturing2054Memberus-gaap:InterestRateSwapMember2024-09-300000049071hum:InterestRateSwapMaturing2054Memberus-gaap:InterestRateSwapMember2023-12-310000049071us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300000049071us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000049071us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000049071us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000049071us-gaap:CommercialPaperMember2024-09-300000049071us-gaap:CommercialPaperMember2023-12-310000049071us-gaap:PutOptionMember2024-09-300000049071us-gaap:CallOptionMember2024-09-300000049071us-gaap:PutOptionMember2023-12-310000049071us-gaap:CallOptionMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputOptionVolatilityMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputOptionVolatilityMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputOptionVolatilityMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputOptionVolatilityMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:CreditSpreadOptionMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:CreditSpreadOptionMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:CreditSpreadOptionMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:CreditSpreadOptionMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberhum:RevenueExitMultipleMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberhum:RevenueExitMultipleMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberhum:RevenueExitMultipleMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberhum:RevenueExitMultipleMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:OptionOnSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:OptionOnSecuritiesMember2023-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputLongTermRevenueGrowthRateMemberus-gaap:OptionOnSecuritiesMember2024-09-300000049071us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputLongTermRevenueGrowthRateMemberus-gaap:OptionOnSecuritiesMember2023-12-310000049071hum:RiskCorridorSettlementsMedicarePartDMember2024-09-300000049071hum:CmsSubsidiesOrDiscountsMember2024-09-300000049071hum:RiskCorridorSettlementsMedicarePartDMember2023-12-310000049071hum:CmsSubsidiesOrDiscountsMember2023-12-310000049071hum:InsuranceSegmentMember2023-12-310000049071hum:CenterWellSegmentMember2023-12-310000049071hum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:InsuranceSegmentMember2024-09-300000049071hum:CenterWellSegmentMember2024-09-300000049071hum:CertificateOfNeedMember2024-09-300000049071hum:CertificateOfNeedMember2023-12-310000049071us-gaap:LicensingAgreementsMember2024-09-300000049071us-gaap:LicensingAgreementsMember2023-12-310000049071us-gaap:CustomerContractsMember2024-09-300000049071us-gaap:CustomerContractsMember2023-12-310000049071us-gaap:TradeNamesMember2024-09-300000049071us-gaap:TradeNamesMember2023-12-310000049071us-gaap:ContractualRightsMember2024-09-300000049071us-gaap:ContractualRightsMember2023-12-310000049071hum:NoncompetesAndOtherMember2024-09-300000049071hum:NoncompetesAndOtherMember2023-12-310000049071us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000049071us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000049071us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000049071us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000049071us-gaap:RestrictedStockMember2024-07-012024-09-300000049071us-gaap:RestrictedStockMember2023-07-012023-09-300000049071us-gaap:RestrictedStockMember2024-01-012024-09-300000049071us-gaap:RestrictedStockMember2023-01-012023-09-3000000490712024-01-012024-03-3100000490712024-04-012024-06-300000049071srt:ScenarioForecastMember2024-10-012024-12-310000049071us-gaap:SubsequentEventMember2024-10-012024-10-300000049071hum:A2023ShareRepurchaseAuthorizationMember2024-02-160000049071hum:A2024ShareRepurchaseAuthorizationMember2024-02-160000049071hum:A2023And2024ShareRepurchaseAuthorizationMember2024-01-012024-09-300000049071hum:A2023ShareRepurchaseAuthorizationMember2023-01-012023-09-300000049071us-gaap:SubsequentEventMember2024-10-290000049071hum:A3.85PercentSeniorNotesDueOctober2024Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A3.85PercentSeniorNotesDueOctober2024Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A450PercentSeniorNotesDueApril2025Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A450PercentSeniorNotesDueApril2025Memberus-gaap:SeniorNotesMember2023-12-310000049071us-gaap:SeniorNotesMember2024-09-300000049071us-gaap:SeniorNotesMember2023-12-310000049071hum:A570PercentSeniorNotesDueMarch2026Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A570PercentSeniorNotesDueMarch2026Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A135PercentSeniorNotesDueFebruary2027Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A135PercentSeniorNotesDueFebruary2027Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A3.95PercentSeniorNotesDueMarch2027Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A3.95PercentSeniorNotesDueMarch2027Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A5750PercentSeniorNotesDueMarch2028Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A5750PercentSeniorNotesDueMarch2028Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A5.750PercentSeniorNotesDueDecember2028Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A5.750PercentSeniorNotesDueDecember2028Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A3700PercentSeniorNotesDueMarch2029Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A3700PercentSeniorNotesDueMarch2029Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A3125PercentSeniorNotesDueAugust2029Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A3125PercentSeniorNotesDueAugust2029Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A4875PercentSeniorNotesDueApril2030Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A4875PercentSeniorNotesDueApril2030Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A5.375PercentSeniorNotesDueApril2031Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A5.375PercentSeniorNotesDueApril2031Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A215PercentSeniorNotesDueFebruary2032Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A215PercentSeniorNotesDueFebruary2032Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A5875PercentSeniorNotesDueMarch2033Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A5.950PercentSeniorNotesDueMarch2034Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A8.15PercentSeniorNotesDueJune2038Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A8.15PercentSeniorNotesDueJune2038Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A4.625PercentSeniorNotesDueDecember2042Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A4.95PercentSeniorNotesDueOctober2044Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A4.80PercentSeniorNotesDueMarch2047Memberus-gaap:SeniorNotesMember2024-09-300000049071hum:A4.80PercentSeniorNotesDueMarch2047Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A395PercentSeniorNotesDueAugust2049Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A550PercentSeniorNotesDueMarch2053Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A5.750PercentSeniorNotesDueApril2054Memberus-gaap:SeniorNotesMember2023-12-310000049071hum:A5.375PercentSeniorNotesDueApril2031Memberus-gaap:SeniorNotesMember2024-03-310000049071hum:A5.750PercentSeniorNotesDueApril2054Memberus-gaap:SeniorNotesMember2024-03-310000049071hum:A5.375PercentSeniorNotesDueApril2031And5.750PercentSeniorNotesDueApril2054Memberus-gaap:SeniorNotesMember2024-03-012024-03-310000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2023-06-012023-06-300000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2023-06-300000049071hum:RevolvingCreditAgreementJune2021FiveYearMemberus-gaap:RevolvingCreditFacilityMember2021-06-012021-06-300000049071hum:RevolvingCreditAgreementJune2021FiveYearMemberus-gaap:RevolvingCreditFacilityMember2021-06-300000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2024-05-012024-05-310000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2024-05-310000049071hum:RevolvingCreditAgreementMay2024OneYearMemberus-gaap:RevolvingCreditFacilityMember2024-05-012024-05-310000049071hum:RevolvingCreditAgreementMay2024OneYearMemberus-gaap:RevolvingCreditFacilityMember2024-05-310000049071hum:RevolvingCreditAgreementJune2023OneYearMemberus-gaap:RevolvingCreditFacilityMember2023-06-012023-06-300000049071hum:RevolvingCreditAgreementJune2023OneYearMemberus-gaap:RevolvingCreditFacilityMember2023-06-300000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-09-300000049071hum:RevolvingCreditAgreementMay2024OneYearMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-09-300000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2024-01-012024-09-300000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2024-01-012024-09-300000049071hum:RevolvingCreditAgreementMay2024OneYearMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2024-01-012024-09-300000049071hum:RevolvingCreditAgreementMay2024OneYearMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2024-01-012024-09-300000049071us-gaap:RevolvingCreditFacilityMember2024-09-300000049071us-gaap:LoansPayableMember2024-09-300000049071us-gaap:LetterOfCreditMember2024-09-300000049071hum:RevolvingCreditAgreementJune2023FiveYearMemberus-gaap:RevolvingCreditFacilityMember2024-09-300000049071hum:RevolvingCreditAgreementMay2024OneYearMemberus-gaap:RevolvingCreditFacilityMember2024-09-300000049071us-gaap:CommercialPaperMember2024-01-012024-09-300000049071us-gaap:FederalHomeLoanBankAdvancesMember2024-09-300000049071hum:MedicareMember2024-01-012024-09-300000049071hum:MedicaidMember2024-01-012024-09-300000049071hum:MilitaryServiceMemberhum:TRICARE2017EastRegionContractMember2024-01-012024-09-300000049071hum:TRICARE2017EastRegionContractMember2024-09-300000049071hum:TRICARE2017EastRegionContractMember2024-01-012024-09-300000049071hum:TRICAREManagedCareSupportContractEffective2024Member2022-12-310000049071hum:TRICAREManagedCareSupportContractEffective2024Member2022-12-012022-12-310000049071hum:UnitedStatesOfAmericaExRel.StevenScottV.HumanaInc.Member2024-08-152024-08-150000049071hum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:MedicareAdvantageMemberus-gaap:ProductMember2024-07-012024-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:ProductMember2024-07-012024-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:ProductMember2024-07-012024-09-300000049071hum:MedicareMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:MedicareMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:MedicareMemberus-gaap:ProductMember2024-07-012024-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:ProductMember2024-07-012024-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:ProductMember2024-07-012024-09-300000049071hum:MedicareSupplementProductMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:MedicareSupplementProductMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:MedicareSupplementProductMemberus-gaap:ProductMember2024-07-012024-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMember2024-07-012024-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071us-gaap:ProductMember2024-07-012024-09-300000049071hum:HomeSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:HomeSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:HomeSolutionsMemberus-gaap:ServiceMember2024-07-012024-09-300000049071hum:PrimaryCareMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:PrimaryCareMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:PrimaryCareMemberus-gaap:ServiceMember2024-07-012024-09-300000049071hum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:PharmacySolutionsMemberus-gaap:ServiceMember2024-07-012024-09-300000049071hum:CommercialASOMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:CommercialASOMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:CommercialASOMemberus-gaap:ServiceMember2024-07-012024-09-300000049071hum:MilitaryAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:MilitaryAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:MilitaryAndOtherMemberus-gaap:ServiceMember2024-07-012024-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071us-gaap:ServiceMember2024-07-012024-09-300000049071us-gaap:OperatingSegmentsMemberhum:ExternalRevenuesMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071us-gaap:OperatingSegmentsMemberhum:ExternalRevenuesMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:ExternalRevenuesMember2024-07-012024-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2024-07-012024-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071us-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2024-07-012024-09-300000049071hum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071hum:CorporateAndEliminationsMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071us-gaap:IntersegmentEliminationMember2024-07-012024-09-300000049071us-gaap:OperatingSegmentsMemberhum:InsuranceSegmentMember2024-07-012024-09-300000049071us-gaap:OperatingSegmentsMemberhum:CenterWellSegmentMember2024-07-012024-09-300000049071hum:CorporateAndEliminationsMember2024-07-012024-09-300000049071hum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:MedicareAdvantageMemberus-gaap:ProductMember2023-07-012023-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:ProductMember2023-07-012023-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:ProductMember2023-07-012023-09-300000049071hum:MedicareMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:MedicareMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:MedicareMemberus-gaap:ProductMember2023-07-012023-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:ProductMember2023-07-012023-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:ProductMember2023-07-012023-09-300000049071hum:MedicareSupplementProductMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:MedicareSupplementProductMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:MedicareSupplementProductMemberus-gaap:ProductMember2023-07-012023-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMember2023-07-012023-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071us-gaap:ProductMember2023-07-012023-09-300000049071hum:HomeSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:HomeSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:HomeSolutionsMemberus-gaap:ServiceMember2023-07-012023-09-300000049071hum:PrimaryCareMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:PrimaryCareMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:PrimaryCareMemberus-gaap:ServiceMember2023-07-012023-09-300000049071hum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:PharmacySolutionsMemberus-gaap:ServiceMember2023-07-012023-09-300000049071hum:CommercialASOMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:CommercialASOMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:CommercialASOMemberus-gaap:ServiceMember2023-07-012023-09-300000049071hum:MilitaryAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:MilitaryAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:MilitaryAndOtherMemberus-gaap:ServiceMember2023-07-012023-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071us-gaap:ServiceMember2023-07-012023-09-300000049071us-gaap:OperatingSegmentsMemberhum:ExternalRevenuesMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071us-gaap:OperatingSegmentsMemberhum:ExternalRevenuesMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:ExternalRevenuesMember2023-07-012023-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2023-07-012023-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071us-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2023-07-012023-09-300000049071hum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071hum:CorporateAndEliminationsMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071us-gaap:IntersegmentEliminationMember2023-07-012023-09-300000049071us-gaap:OperatingSegmentsMemberhum:InsuranceSegmentMember2023-07-012023-09-300000049071us-gaap:OperatingSegmentsMemberhum:CenterWellSegmentMember2023-07-012023-09-300000049071hum:CorporateAndEliminationsMember2023-07-012023-09-300000049071hum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:MedicareAdvantageMemberus-gaap:ProductMember2024-01-012024-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:ProductMember2024-01-012024-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:ProductMember2024-01-012024-09-300000049071hum:MedicareMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:MedicareMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:MedicareMemberus-gaap:ProductMember2024-01-012024-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:ProductMember2024-01-012024-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:ProductMember2024-01-012024-09-300000049071hum:MedicareSupplementProductMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:MedicareSupplementProductMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:MedicareSupplementProductMemberus-gaap:ProductMember2024-01-012024-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMember2024-01-012024-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071us-gaap:ProductMember2024-01-012024-09-300000049071hum:HomeSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:HomeSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:HomeSolutionsMemberus-gaap:ServiceMember2024-01-012024-09-300000049071hum:PrimaryCareMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:PrimaryCareMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:PrimaryCareMemberus-gaap:ServiceMember2024-01-012024-09-300000049071hum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:PharmacySolutionsMemberus-gaap:ServiceMember2024-01-012024-09-300000049071hum:CommercialASOMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:CommercialASOMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:CommercialASOMemberus-gaap:ServiceMember2024-01-012024-09-300000049071hum:MilitaryAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:MilitaryAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:MilitaryAndOtherMemberus-gaap:ServiceMember2024-01-012024-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071us-gaap:ServiceMember2024-01-012024-09-300000049071us-gaap:OperatingSegmentsMemberhum:ExternalRevenuesMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071us-gaap:OperatingSegmentsMemberhum:ExternalRevenuesMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:ExternalRevenuesMember2024-01-012024-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2024-01-012024-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071us-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2024-01-012024-09-300000049071hum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071hum:CorporateAndEliminationsMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071us-gaap:IntersegmentEliminationMember2024-01-012024-09-300000049071us-gaap:OperatingSegmentsMemberhum:InsuranceSegmentMember2024-01-012024-09-300000049071us-gaap:OperatingSegmentsMemberhum:CenterWellSegmentMember2024-01-012024-09-300000049071hum:CorporateAndEliminationsMember2024-01-012024-09-300000049071hum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:MedicareAdvantageMemberus-gaap:ProductMember2023-01-012023-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:GroupMedicareAdvantageMemberus-gaap:ProductMember2023-01-012023-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:ProductMember2023-01-012023-09-300000049071hum:MedicareMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:MedicareMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:MedicareMemberus-gaap:ProductMember2023-01-012023-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:CommercialFullyInsuredMemberus-gaap:ProductMember2023-01-012023-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:SpecialtyBenefitsMemberus-gaap:ProductMember2023-01-012023-09-300000049071hum:MedicareSupplementProductMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:MedicareSupplementProductMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:MedicareSupplementProductMemberus-gaap:ProductMember2023-01-012023-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:StateBasedContractsAndOtherMemberus-gaap:ProductMember2023-01-012023-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071us-gaap:ProductMember2023-01-012023-09-300000049071hum:HomeSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:HomeSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:HomeSolutionsMemberus-gaap:ServiceMember2023-01-012023-09-300000049071hum:PrimaryCareMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:PrimaryCareMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:PrimaryCareMemberus-gaap:ServiceMember2023-01-012023-09-300000049071hum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:PharmacySolutionsMemberus-gaap:ServiceMember2023-01-012023-09-300000049071hum:CommercialASOMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:CommercialASOMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:CommercialASOMemberus-gaap:ServiceMember2023-01-012023-09-300000049071hum:MilitaryAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:MilitaryAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:MilitaryAndOtherMemberus-gaap:ServiceMember2023-01-012023-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071us-gaap:ServiceMember2023-01-012023-09-300000049071us-gaap:OperatingSegmentsMemberhum:ExternalRevenuesMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071us-gaap:OperatingSegmentsMemberhum:ExternalRevenuesMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:ExternalRevenuesMember2023-01-012023-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2023-01-012023-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071us-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2023-01-012023-09-300000049071hum:CorporateAndEliminationsMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071hum:CorporateAndEliminationsMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071us-gaap:IntersegmentEliminationMember2023-01-012023-09-300000049071us-gaap:OperatingSegmentsMemberhum:InsuranceSegmentMember2023-01-012023-09-300000049071us-gaap:OperatingSegmentsMemberhum:CenterWellSegmentMember2023-01-012023-09-300000049071hum:CorporateAndEliminationsMember2023-01-012023-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number 1-5975
HUMANA INC.
(Exact name of registrant as specified in its charter)
Delaware61-0647538
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
500 West Main Street
Louisville, Kentucky 40202
(Address of principal executive offices, including zip code)
(502) 580-1000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common stock, $0.16 2/3 par valueHUMNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.
Class of Common Stock
Outstanding at September 30, 2024
$0.16 2/3 par value120,411,343 shares

Humana Inc.
FORM 10-Q
SEPTEMBER 30, 2024
INDEX
 Page
Part I: Financial Information
Item 1.Financial Statements
Condensed Consolidated Balance Sheets (Unaudited) at September 30, 2024 and December 31, 2023
Condensed Consolidated Statements of Income (Unaudited) for the three and nine months ended September 30, 2024 and 2023
Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three and nine months ended September 30, 2024 and 2023
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the three and nine months ended September 30, 2024 and 2023
Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2024 and 2023
Notes to Condensed Consolidated Financial Statements (Unaudited)
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3.Quantitative and Qualitative Disclosures about Market Risk
Item 4.Controls and Procedures
Part II: Other Information
Item 1.Legal Proceedings
Item 1A.Risk Factors
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.Defaults Upon Senior Securities
Item 4.Mine Safety Disclosures
Item 5.Other Information
Item 6.Exhibits
Signatures
Certifications


Humana Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30,
2024		December 31, 2023
(in millions, except share amounts)
ASSETS
Current assets:
Cash and cash equivalents$5,116 $4,694 
Investment securities19,033 16,626 
Receivables, net of allowances of $93 in 2024
    and $88 in 2023
2,144 2,035 
Other current assets6,633 6,631 
Total current assets32,926 29,986 
Property and equipment, net2,693 3,030 
Long-term investment securities400 382 
Equity method investments729 740 
Goodwill9,590 9,550 
Other long-term assets3,669 3,377 
Total assets$50,007 $47,065 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Benefits payable$11,125 $10,241 
Trade accounts payable and accrued expenses5,915 6,569 
Book overdraft356 353 
Unearned revenues195 266 
Short-term debt1,136 1,443 
Total current liabilities18,727 18,872 
Long-term debt11,886 10,213 
Other long-term liabilities1,770 1,662 
Total liabilities32,383 30,747 
Commitments and Contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $1 par; 10,000,000 shares authorized; none issued
— — 
Common stock, $0.16 2/3 par; 300,000,000 shares authorized;
  198,718,810 shares issued at September 30, 2024 and 198,690,082 shares issued at December 31, 2023
33 33 
Capital in excess of par value3,471 3,346 
Retained earnings29,118 27,540 
Accumulated other comprehensive loss(653)(999)
Treasury stock, at cost, 78,307,467 shares at September 30, 2024 and
    76,465,862 shares at December 31, 2023
(14,404)(13,658)
Total stockholders' equity17,565 16,262 
Noncontrolling interests59 56 
Total equity17,624 16,318 
Total liabilities and equity$50,007 $47,065 

See accompanying notes to condensed consolidated financial statements.

3

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
 
Three months ended September 30,Nine months ended September 30,
 2024202320242023
 (in millions, except per share results)
Revenues:
Premiums$27,951 $25,099 $84,354 $76,144 
Services1,103 1,016 3,265 2,993 
Investment income343 308 929 775 
Total revenues29,397 26,423 88,548 79,912 
Operating expenses:
Benefits25,120 21,745 75,283 65,612 
Operating costs3,339 3,271 9,529 9,361 
Depreciation and amortization210 201 631 578 
Total operating expenses28,669 25,217 85,443 75,551 
Income from operations728 1,206 3,105 4,361 
Interest expense169 114 496 347 
Other (income) expense, net(92)(6)26 40 
Income before income taxes and equity in net losses651 1,098 2,583 3,974 
Provision for income taxes155 256 629 911 
Equity in net losses(16)(12)(57)(39)
Net income$480 $830 $1,897 $3,024 
Net loss attributable to noncontrolling interests— 2 3 6 
Net income attributable to Humana$480 $832 $1,900 $3,030 
Basic earnings per common share$3.99 $6.74 $15.76 $24.37 
Diluted earnings per common share$3.98 $6.71 $15.72 $24.26 
See accompanying notes to condensed consolidated financial statements.

4

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Three months ended September 30,Nine months ended September 30,
 2024202320242023
 (in millions)
Net income attributable to Humana$480 $832 $1,900 $3,030 
Other comprehensive income (loss):
Change in gross unrealized investment (losses) gains619 (365)458 (314)
Effect of income taxes(142)85 (104)73 
Total change in unrealized investment (losses) gains, net of tax477 (280)354 (241)
Reclassification adjustment for net realized losses (gains)(10)3 (10)56 
Effect of income taxes2 — 2 (14)
Total reclassification adjustment, net of tax(8)3 (8)42 
Other comprehensive (loss) income, net of tax469 (277)346 (199)
Comprehensive income attributable to Humana$949 $555 $2,246 $2,831 
See accompanying notes to condensed consolidated financial statements.

5

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
 Common StockCapital In
Excess of
Par Value		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Treasury
Stock		Total Stockholders' EquityNoncontrolling InterestsTotal
Equity
 Issued
Shares		Amount
(dollars in millions, share amounts in thousands)
Three months ended September 30, 2024
Balances, June 30, 2024198,719 $33 $3,420 $28,745 $(1,122)$(14,405)$16,671 $57 $16,728 
Net income480 480 — 480 
Distribution from noncontrolling interest holders, net2 2 
Other comprehensive income469 469 469 
Common stock repurchases— (1)(1)(1)
Dividends and dividend
   equivalents		— (107)(107)(107)
Stock-based compensation53 53 53 
Restricted stock unit vesting— — (2)2 — — 
Balances, September 30, 2024198,719 $33 $3,471 $29,118 $(653)$(14,404)$17,565 $59 $17,624 
Three months ended September 30, 2023
Balances, June 30, 2023198,690 $33 $3,313 $27,468 $(1,226)$(12,754)$16,834 $57 $16,891 
Net income832 832 (2)830 
Other comprehensive loss(277)(277)(277)
Common stock repurchases— (383)(383)(383)
Dividends and dividend
   equivalents		— (109)(109)(109)
Stock-based compensation53 53 53 
Restricted stock unit vesting— — (3)3 — — 
Stock option exercises— — (1)— (1)(1)
Balances, September 30, 2023198,690 $33 $3,362 $28,191 $(1,503)$(13,134)$16,949 $55 $17,004 
See accompanying notes to condensed consolidated financial statements.
















6

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY—(Continued)
(Unaudited)
 Common StockCapital In
Excess of
Par Value		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Treasury
Stock		Total Stockholders' EquityNoncontrolling InterestsTotal
Equity
 Issued
Shares		Amount
(dollars in millions, share amounts in thousands)
Nine months ended September 30, 2024
Balances, December 31, 2023198,690 $33 $3,346 $27,540 $(999)$(13,658)$16,262 $56 $16,318 
Net income1,900 1,900 (3)1,897 
Distribution from noncontrolling interest holders, net— 6 6 
Other comprehensive income346 346 346 
Common stock repurchases— (774)(774)(774)
Dividends and dividend
   equivalents		— (322)(322)(322)
Stock-based compensation153 153 153 
Restricted stock unit vesting29 — (28)28 — — 
Stock option exercises— — — — — — 
Balances, September 30, 2024198,719 $33 $3,471 $29,118 $(653)$(14,404)$17,565 $59 $17,624 
Nine months ended September 30, 2023
Balances, December 31, 2022198,667 $33 $3,246 $25,492 $(1,304)$(12,156)$15,311 $59 $15,370 
Net income3,030 3,030 (6)3,024 
Distribution from noncontrolling interest holders, net— 7 7 
Acquisition— (5)(5)
Other comprehensive loss(199)(199)(199)
Common stock repurchases— (1,011)(1,011)(1,011)
Dividends and dividend
   equivalents		— (331)(331)(331)
Stock-based compensation142 142 142 
Restricted stock unit vesting23 — (30)30 — — 
Stock option exercises— — 4 3 7 7 
Balances, September 30, 2023198,690 $33 $3,362 $28,191 $(1,503)$(13,134)$16,949 $55 $17,004 
See accompanying notes to condensed consolidated financial statements.    



7

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 For the nine months ended September 30,
 20242023
 (in millions)
Cash flows from operating activities
Net income$1,897 $3,024 
Adjustments to reconcile net income to net cash provided by operating activities:
(Gain) loss on investment securities, net(10)49 
Equity in net losses57 39 
Stock-based compensation153 142 
Depreciation682 628 
Amortization46 51 
Impairment of property and equipment129 31 
Changes in operating assets and liabilities, net of effect of
    businesses acquired and disposed:
Receivables(109)(126)
Other assets258 (935)
Benefits payable884 870 
Other liabilities(498)39 
Unearned revenues(71)7,250 
Other76 53 
Net cash provided by operating activities3,494 11,115 
Cash flows from investing activities
Acquisitions, net of cash and cash equivalents acquired(37)(223)
Purchases of property and equipment, net(421)(721)
Purchases of investment securities(6,403)(3,366)
Proceeds from maturities of investment securities2,214 885 
Proceeds from sales of investment securities1,758 815 
Net cash used in investing activities(2,889)(2,610)
Cash flows from financing activities
(Payments) receipts from contract deposits, net(638)2,481 
Proceeds from issuance of senior notes, net2,232 1,215 
Repayments of senior notes(48)(1,719)
(Repayments) issuance of commercial paper, net(895)1,618 
Repayment of term loan— (500)
Debt issue costs(7)(4)
Change in book overdraft3 (52)
Common stock repurchases(768)(1,002)
Dividends paid(323)(320)
Other261 (135)
Net cash (used in) provided by financing activities(183)1,582 
Increase in cash and cash equivalents422 10,087 
Cash and cash equivalents at beginning of period4,694 5,061 
Cash and cash equivalents at end of period$5,116 $15,148 
See accompanying notes to condensed consolidated financial statements.





8

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS—(Continued)
(Unaudited)
For the nine months ended September 30,
20242023
(in millions)
Supplemental cash flow disclosures:
Interest payments$416 $317 
Income tax payments, net$570 $957 
Details of businesses acquired in purchase transactions:
Fair value of assets acquired, net of cash and cash equivalents acquired$49 $454 
Less: Fair value of liabilities assumed(12)(236)
Less: Noncontrolling interests acquired— 5 
Cash paid for acquired businesses, net of cash and cash equivalents acquired$37 $223 
See accompanying notes to condensed consolidated financial statements.

9


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT EVENTS
The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.
The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.
Employer Group Commercial Medical Products Business Exit
In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. We anticipate the exit of this line of business to be finalized in the first half of 2025.

Value Creation Initiatives
Beginning in 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges, primarily in asset impairments, of $55 million and $151 million for the three and nine months ended September 30, 2024, respectively, and $52 million for the three and nine months ended September 30, 2023 within operating costs in the condensed consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024.




10


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
Revenue Recognition
Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
At September 30, 2024, accounts receivable related to services were $428 million. For the three and nine months ended September 30, 2024, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at September 30, 2024.
For the three and nine months ended September 30, 2024, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.

Investment Securities
We participate in a securities lending program to optimize investment income. We loan certain investment securities for short periods of time in exchange for collateral initially equal to at least 102% of the fair value of the investment securities on loan. The fair value of the loaned investment securities is monitored on a daily basis, with additional collateral obtained or refunded as the fair value of the loaned investment securities fluctuates. The collateral, which may be in the form of cash or U.S. Government securities, is deposited by the borrower with an independent lending agent. Any cash collateral, which is reinvested by the lending agent primarily in short-term, highly liquid investments, is recorded as a securities lending collateral asset within other current assets on our consolidated balance sheet at September 30, 2024. We record a corresponding liability to reflect our obligation to return the collateral within trade accounts payable and accrued expenses on our consolidated balance sheet at September 30, 2024. Collateral received in the form of securities is not recorded in our consolidated balance sheets because, absent default by the borrower, we do not have the right to sell, pledge or otherwise reinvest securities collateral. Loaned securities continue to be carried as investment securities on the consolidated balance sheet at September 30, 2024. Earnings on the invested cash collateral, net of expense, associated with the securities lending payable are recorded as investment income.
2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Accounting Pronouncements Effective in Future Periods
In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We do not believe the adoption of ASU 2023-07 will have a material impact on our consolidated financial statements or disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be

11


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.

3. ACQUISITIONS
During 2024 and 2023, respectively, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in 2024 and 2023, respectively, have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in 2024 and 2023, were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the quarter of acquisition, were not material for disclosure purposes.

12


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
4. INVESTMENT SECURITIES
Investment securities classified as current and long-term were as follows at September 30, 2024 and December 31, 2023, respectively:
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
 (in millions)
September 30, 2024
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$3,203 $13 $(33)$3,183 
Mortgage-backed securities4,501 33 (351)4,183 
Tax-exempt municipal securities602 — (18)584 
Mortgage-backed securities:
Residential555 1 (54)502 
Commercial1,292 2 (78)1,216 
Asset-backed securities1,533 11 (20)1,524 
Corporate debt securities8,593 92 (444)8,241 
Total debt securities$20,279 $152 $(998)$19,433 
December 31, 2023
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$2,717 $1 $(51)$2,667 
Mortgage-backed securities3,946 1 (425)3,522 
Tax-exempt municipal securities879 1 (22)858 
Mortgage-backed securities:
Residential465 1 (66)400 
Commercial1,471 — (126)1,345 
Asset-backed securities1,813 2 (44)1,771 
Corporate debt securities7,011 28 (594)6,445 
Total debt securities$18,302 $34 $(1,328)$17,008 
We own certain corporate debt securities of Gentiva Hospice. The book value and fair value are $381 million and $396 million, respectively, at September 30, 2024. The book value and fair value were $379 million and $398 million, respectively, at December 31, 2023.
We participate in a securities lending program where we loan certain investment securities for short periods of time in exchange for collateral, consisting of cash or U.S. Government securities, initially equal to at least 102% of the fair value of the investment securities on loan. Collateral with a fair value of $361 million was held at September 30, 2024. At September 30, 2024, collateral from lending our investment securities has been reinvested in short-term, highly liquid assets. In addition, we participated in non-cash securities lending with a fair value of $148 million at September 30, 2024.

13


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at September 30, 2024 and December 31, 2023, respectively:
 Less than 12 months12 months or moreTotal
 Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
 (in millions)
September 30, 2024
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$551 $(2)$518 $(31)$1,069 $(33)
Mortgage-backed securities330 (2)2,378 (349)2,708 (351)
Tax-exempt municipal securities77 — 417 (18)494 (18)
Mortgage-backed securities:
Residential57 (2)361 (52)418 (54)
Commercial26 (1)1,124 (77)1,150 (78)
Asset-backed securities218 (1)571 (19)789 (20)
Corporate debt securities290 (1)4,466 (443)4,756 (444)
Total debt securities$1,549 $(9)$9,835 $(989)$11,384 $(998)
December 31, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$1,899 $(12)$431 $(39)$2,330 $(51)
Mortgage-backed securities958 (12)2,269 (413)3,227 (425)
Tax-exempt municipal securities160 (1)523 (21)683 (22)
Mortgage-backed securities:
Residential— — 373 (66)373 (66)
Commercial18 — 1,303 (126)1,321 (126)
Asset-backed securities120 (1)1,364 (43)1,484 (44)
Corporate debt securities466 (2)4,783 (592)5,249 (594)
Total debt securities$3,621 $(28)$11,046 $(1,300)$14,667 $(1,328)

Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by Standard & Poor's Rating Service, or S&P, at September 30, 2024. Our remaining debt securities below investment-grade were primarily rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.
Our unrealized losses from all debt securities were generated from approximately 1,300 positions out of a total of approximately 2,290 positions at September 30, 2024. All issuers of debt securities we own that were trading at an unrealized loss at September 30, 2024 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At September 30,

14


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
2024, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three and nine months ended September 30, 2024 or 2023.
The detail of gains (losses) related to investment securities and included within investment income was as follows for the three and nine months ended September 30, 2024 and 2023:
 Three months ended September 30,Nine months ended September 30,
 2024202320242023
 (in millions)(in millions)
Gross gains on investment securities$14 $— $16 $15 
Gross losses on investment securities(4)(4)(6)(65)
Gross gains on equity securities— — — 1 
Gross losses on equity securities— — — — 
Net recognized gains (losses) on investment securities$10 $(4)$10 $(49)
The gains and losses related to equity securities for the three and nine months ended September 30, 2024 and 2023 was as follows:
Three months ended September 30,Nine Months Ended September 30,
2024202320242023
(in millions)(in millions)
Net gains recognized on equity securities during the period$— $— $— $1 
Less: Net gains recognized on equity securities sold during the period— — — — 
Unrealized gains (losses) recognized on equity securities still held at the end of the period$— $— $— $1 
The contractual maturities of debt securities available for sale at September 30, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.
Amortized
Cost		Fair
Value
 (in millions)
Due within one year$1,082 $1,079 
Due after one year through five years5,669 5,584 
Due after five years through ten years4,407 4,261 
Due after ten years1,240 1,084 
Mortgage and asset-backed securities7,881 7,425 
Total debt securities$20,279 $19,433 

For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.


15


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
5. FAIR VALUE
Financial Assets
The following table summarizes our fair value measurements at September 30, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:
 Fair Value Measurements Using
 Fair
Value		Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)
 (in millions)
September 30, 2024
Cash equivalents$4,941 $4,941 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations3,183 — 3,183 — 
Mortgage-backed securities4,183 — 4,183 — 
Tax-exempt municipal securities584 — 584 — 
Mortgage-backed securities:
Residential502 — 500 2 
Commercial1,216 — 1,216 — 
Asset-backed securities1,524 — 1,479 45 
Corporate debt securities8,241 — 7,997 244 
Total debt securities19,433 — 19,142 291 
Securities lending invested collateral361 361 — — 
Total invested assets$24,735 $5,302 $19,142 $291 
December 31, 2023
Cash equivalents$4,582 $4,582 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations2,667 — 2,667 — 
Mortgage-backed securities3,522 — 3,522 — 
Tax-exempt municipal securities858 — 858 — 
Mortgage-backed securities:
Residential400 — 396 4 
Commercial1,345 — 1,345 — 
Asset-backed securities1,771 — 1,733 38 
Corporate debt securities6,445 — 6,269 176 
Total debt securities$17,008 $— $16,790 $218 
Our Level 3 assets had a fair value of $291 million, or 1.2% of total invested assets, and $218 million, or 1.0% or total invested assets, at September 30, 2024 and December 31, 2023, respectively. During the nine months ended

16


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
September 30, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    
Private Placements
For the nine months ended September 30, 2024For the nine months ended September 30, 2023
(in millions)
Beginning balance at January 1$218 $101 
Total gains or losses:
Realized in earnings— — 
Unrealized in other comprehensive income6 (1)
Purchases72 13 
Maturities— (4)
Sales— — 
Settlements(5)— 
Transfer out— (4)
Balance at September 30$291 $105 
Interest Rate Swaps

We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on Secured Overnight Financing Rate (SOFR), to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our condensed consolidated balance sheets at fair value as of the reporting date. Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy. The cumulative, aggregate adjustment to the carrying value of the senior notes was approximately $117 million at September 30, 2024. The swap asset, included within other long-term assets on our condensed consolidated balance sheet was approximately $117 million at September 30, 2024. The swap asset, included within other long-term assets on our condensed consolidated balance sheets, was approximately $68 million at December 31, 2023. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three and nine months ended September 30, 2024 and 2023. The following table summarizes the notional amounts at September 30, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:

September 30, 2024December 31, 2023
(in millions)
$750 million, 5.875% due March 1, 2033
$650 $650 
$850 million, 5.950% due March 15, 2034
800 400 
$500 million, 3.950% due August 15, 2049
450 450 
$750 million, 5.500% due March 15, 2053
700 300 
$400 million, 4.625% due December 1, 2042
400 — 
$750 million, 4.950% due October 1, 2044
400 — 
$1,000 million, 5.750% due April 15, 2054
400 — 


17


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
Financial Liabilities
Our debt is recorded at carrying value in our condensed consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $13.0 billion at September 30, 2024 and $10.8 billion at December 31, 2023. The fair value of our senior notes debt was $12.9 billion at September 30, 2024 and $10.6 billion at December 31, 2023. The fair value of our senior notes debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our commercial paper borrowings. We had no outstanding commercial paper borrowings at September 30, 2024. The commercial paper borrowings were $0.9 billion at December 31, 2023.
Put and Call Options Measured at Fair Value
Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation.
The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $742 million and $24 million, respectively, at September 30, 2024. The put and call options fair values, derived from the Monte Carlo simulation, were $595 million and $18 million, respectively, at December 31, 2023. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets.
The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.
September 30, 2024December 31, 2023
Annualized volatility
16.5% - 18.3%
16.1% - 17.8%
Credit spread
0.8% - 1.4%
0.9% - 1.1%
Revenue exit multiple
1.5x - 2.5x
1.5x - 2.5x
Weighted average cost of capital
11.0% - 14.0%
11.0% - 12.5%
Long term growth rate3.0 %3.0 %
The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.
Other Assets and Liabilities Measured at Fair Value
Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2024 and 2023. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based primarily on the income approach. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing

18


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.
Other than the assets and liabilities acquired during 2024 and 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2024 and 2023.
For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
6. MEDICARE PART D
We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at September 30, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

 September 30, 2024December 31, 2023
Risk
Corridor
Settlement		CMS
Subsidies/
Discounts		Risk
Corridor
Settlement		CMS
Subsidies/
Discounts
 (in millions)
Other current assets$107 $846 $224 $514 
Trade accounts payable and accrued expenses(114)(1,594)(232)(1,825)
Net current liability(7)(748)(8)(1,311)
Other long-term assets298 — 17 — 
Other long-term liabilities(62)— (77)— 
Net long-term asset (liability)236 — (60)— 
Total net asset (liability)$229 $(748)$(68)$(1,311)

7. GOODWILL AND OTHER INTANGIBLE ASSETS
Changes in the carrying amount of goodwill for our reportable segments for the nine months ended September 30, 2024 were as follows:
InsuranceCenterWellTotal
 (in millions)
Balance at January 1, 2024$2,663 $6,887 $9,550 
Acquisitions— 40 40 
Balance at September 30, 2024$2,663 $6,927 $9,590 

19


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2024 and December 31, 2023:
 September 30, 2024December 31, 2023
Weighted
Average
Life		CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
 ($ in millions)
Other intangible assets:
Certificates of needIndefinite$1,092 $— $1,092 $1,092 $— $1,092 
Medicare licensesIndefinite288 — 288 288 — 288 
Customer contracts/
    relationships		9.4 years956 749 207 956 718 238 
Trade names and
    technology		6.7 years139 116 23 139 109 30 
Provider contracts11.9 years67 63 4 67 62 5 
Noncompetes and
    other		8.4 years85 49 36 84 44 40 
Total other intangible
    assets		9.2 years$2,627 $977 $1,650 $2,626 $933 $1,693 
    For the three months ended September 30, 2024 and 2023, amortization expense for other intangible assets was approximately $15 million and $17 million, respectively. For the nine months ended September 30, 2024 and 2023, amortization expense for other intangible assets was approximately $46 million and $51 million, respectively. The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at September 30, 2024:
 (in millions)
For the years ending December 31,
2024$15 
202558 
202643 
202733 
202829 
202927 
For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

20


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
8. BENEFITS PAYABLE
On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the nine months ended September 30, 2024 and 2023:
For the nine months ended September 30,
20242023
(in millions)
Balances, beginning of period$10,241 $9,264 
Acquisitions— 62 
Incurred related to:
Current year75,976 66,370 
Prior years(693)(758)
Total incurred75,283 65,612 
Paid related to:
Current year(65,282)(56,700)
Prior years(9,117)(8,042)
Total paid(74,399)(64,742)
Balances, end of period$11,125 $10,196 
The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At September 30, 2024, benefits payable included IBNR of approximately $7.2 billion, primarily associated with claims incurred in 2024.
Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).
Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.


21


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
9. EARNINGS PER COMMON SHARE COMPUTATION
Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and nine months ended September 30, 2024 and 2023:
Three months ended September 30,Nine months ended September 30,
2024202320242023
(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders$480 $832 $1,900 $3,030 
Weighted average outstanding shares of common stock
    used to compute basic earnings per common share		120,405 123,426 120,609 124,335 
Dilutive effect of:
Employee stock options3 26 4 31 
Restricted stock356 531 286 519 
Shares used to compute diluted earnings per common share120,764 123,983 120,899 124,885 
Basic earnings per common share$3.99 $6.74 $15.76 $24.37 
Diluted earnings per common share$3.98 $6.71 $15.72 $24.26 
Number of antidilutive stock options and restricted stock
    excluded from computation		361 137 759 251 

For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

10. STOCKHOLDERS’ EQUITY
Dividends
The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:
Record
Date		Payment
Date		Amount
per Share		Total
Amount
(in millions)
2024 payments
12/29/20231/26/2024$0.8850 $108 
3/29/20244/26/2024$0.8850 $107 
6/28/20247/26/2024$0.8850 $107 
9/30/202410/25/2024$0.8850 $107 
In October 2024, the Board declared a cash dividend of $0.885 per share payable on January 31, 2025 to stockholders of record as of the close of business on December 31, 2024. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.




22


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
Stock Repurchases
Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.
Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824 million remained unused) with a new share repurchase authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. During the nine months ended September 30, 2024, we repurchased 1.9 million shares in open market transactions for $750 million at an average price of $384.65 under the February 2023 and 2024 share repurchase authorizations. During the nine months ended September 30, 2023, we repurchased 2.0 million shares in open market transactions for $980 million at an average price of $478.20 under the February 2023 share repurchase authorization.

Our remaining repurchase authorization was $2.93 billion as of October 29, 2024.
In connection with employee stock plans, we acquired 0.05 million common shares for $18 million and 0.06 million common shares for $31 million during the nine months ended September 30, 2024 and 2023, respectively.
For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

11. INCOME TAXES
The effective income tax rate was 24.4% and 24.9% for the three and nine months ended September 30, 2024, respectively, and 23.5% and 23.1% for the three and nine months ended September 30, 2023, respectively. The year-over-year increase in the effective income tax rate is primarily due to a change in the mix of current year earnings between our Insurance segment and our CenterWell health services segment, as our CenterWell health services segment is subject to a higher effective tax rate than our Insurance segment. In addition, the prior year income tax rate was favorably impacted by the recognition of a non-taxable gain.

For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.



23


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
12.  DEBT
The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at September 30, 2024 and December 31, 2023:
September 30, 2024December 31, 2023
(in millions)
Short-term debt:
Commercial paper$— $871 
Senior notes:
$600 million, 3.850% due October 1, 2024
559 572 
$600 million, 4.500% due April 1, 2025
577 — 
Total senior notes1,136 572 
Total short-term debt$1,136 $1,443 
Long-term debt:
Senior notes:
$600 million, 4.500% due April 1, 2025
$— $598 
$500 million, 5.700% due March 13, 2026
499 498 
$750 million, 1.350% due February 3, 2027
689 688 
$600 million, 3.950% due March 15, 2027
537 537 
$500 million, 5.750% due March 1, 2028
489 495 
$500 million, 5.750% due December 1, 2028
495 495 
$750 million, 3.700% due March 23, 2029
585 590 
$500 million, 3.125% due August 15, 2029
433 433 
$500 million, 4.875% due April 1, 2030
496 496 
$1,250 million, 5.375% due April 15, 2031
1,239 — 
$750 million, 2.150% due February 3, 2032
744 743 
$750 million, 5.875% due March 1, 2033
762 750 
$850 million, 5.950% due March 15, 2034
853 840 
$250 million, 8.150% due June 15, 2038
260 261 
$400 million, 4.625% due December 1, 2042
390 396 
$750 million, 4.950% due October 1, 2044
738 740 
$400 million, 4.800% due March 15, 2047
396 396 
$500 million, 3.950% due August 15, 2049
534 529 
$750 million, 5.500% due March 15, 2053
745 728 
$1,000 million, 5.750% due April 15, 2054
1,002 — 
Total senior notes11,886 10,213 
Total long-term debt$11,886 $10,213 
Senior Notes
In March 2024, we issued $1.3 billion of 5.375% unsecured senior notes due April 15, 2031 and $1.0 billion of 5.750% unsecured senior notes due April 15, 2054. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $2.2 billion. We used the net proceeds for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.


24


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on Secured Overnight Financing Rate (SOFR), to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities, as further described in Note 5. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value caused by an increase or decrease in interest rates. The cumulative, aggregate decrease to the carrying value of the senior notes was approximately $117 million at September 30, 2024.

For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Revolving Credit Agreements
In June 2023, we entered into an amended and restated 5-year, $2.5 billion unsecured revolving credit agreement (replacing the 5-year, $2.5 billion unsecured revolving credit agreement entered in June 2021). In May 2024, we entered into an amendment to increase commitments $0.142 billion resulting in a $2.642 billion borrowing capacity.
In May 2024, we entered into a 364-day $2.1 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2023, which expired in accordance with its terms).
Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option.
The SOFR spread, currently 114.0 basis points under the 5-year revolving credit agreement and 116.0 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 11.0 basis points, under the 5-year revolving credit agreement and 9.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.
Our credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 42.3% as measured in accordance with the revolving credit agreements as of September 30, 2024.
At September 30, 2024, we had no borrowings and approximately $18 million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of September 30, 2024, we had $2.624 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $2.1 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750 million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement.
For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Commercial Paper
Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the nine

25


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
months ended September 30, 2024 was $2.7 billion, with no outstanding amount at September 30, 2024 compared to $0.9 billion outstanding at December 31, 2023.
For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Other Short-term Borrowings
We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At September 30, 2024 we had no outstanding short-term FHLB borrowings.
13. COMMITMENTS, GUARANTEES AND CONTINGENCIES
Government Contracts
Our Medicare products, which accounted for approximately 85% of our total premiums and services revenue for the nine months ended September 30, 2024, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.
CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, or BBA, and the Benefits Improvement and Protection Act of 2000, or BIPA, generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.
CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.
In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would

26


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.
In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”
We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.
On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.

Our state-based Medicaid business, which accounted for approximately 8% of our total premiums and services revenue for the nine months ended September 30, 2024 primarily consisted of serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states.
At September 30, 2024, our Military services business, which accounted for approximately 1% of our total premiums and services revenue for the nine months ended September 30, 2024, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the U.S. Department of Defense, or DoD, and is currently scheduled to expire on December 31, 2024, unless further extended.

27


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD.The T-5 East Region contract comprises 24 states, and Washington D.C., and covers approximately 4.6 million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is one transition year followed by eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years.
The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.
Legal Proceedings and Certain Regulatory Matters
As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020.
As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned United States of America ex rel. Steven Scott v. Humana Inc in United States District Court, Western District of Kentucky, Louisville division. The complaint alleged certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action sought damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening. During 2023, we accrued certain anticipated expenses in connection with this matter. On August 15, 2024, Humana settled the claims in this suit, and paid the United States $90 million.

On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. There is no assurance that we will prevail in the lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter.

In June 2024, a putative stockholder class action was filed against Humana Inc. and certain of our current and former executive officers under the federal securities laws in the United States District Court for the District of Delaware. The case, now captioned In re Humana Stockholders Litigation., alleges that between July 2022 and January 2024, Humana made false or misleading statements in its periodic SEC filings and statements to the financial markets about our financial performance and the medical costs in our Medicare Advantage business. In July 2024 and October 2024, parallel stockholder derivative action captioned Silva v. Broussard and Spikes v. Broussard, respectively, were filed in the United States District Court for the Western District of Kentucky alleging that the same claimed acts and omissions underlying the federal securities law case also constitute a breach of fiduciary duty by certain of our current and former directors and executive officers. We will vigorously defend against the allegations in all cases.


28


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
On October 18, 2024, Humana Inc., along with co-plaintiff Americans for Beneficiary Choice, filed suit against the United States Department of Health and Human Services, Centers for Medicare and Medicaid Services, Xavier Becerra in his official capacity as Secretary, and Chiquita Brooks-LaSure, in her official capacity as Administrator, in the United States District Court, Northern District of Texas, Fort Worth Division, seeking a determination that they violated the Administrative Procedure Act in administering the Medicare Advantage and Part D Star Ratings program. We seek to set aside and vacate Humana’s 2025 Star Ratings and remand the matter to CMS for recalculation and to declare that CMS’s policy refusing to disclose all relevant data and information is arbitrary, capricious, and unlawful. There is no assurance that we will prevail in the lawsuit. For additional information on this matter, refer to Part II, Item 1A, "Risk Factors" of this Form 10-Q.
Other Lawsuits and Regulatory Matters
Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider and vendor contracting and oversight, risk adjustment, competitive practices, commission payments, marketing payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.
We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, personal injury nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.
As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.
A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.
We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be

29


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.
The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.
14. SEGMENT INFORMATION
Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.
The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.
The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.
Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics.
In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.
We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $5.6 billion and $5.7 billion for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, these amounts were $14.1 billion and $14.7 billion respectively. In

30


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $32 million and $35 million for the three months ended September 30, 2024 and 2023, respectively, and $96 million and $102 million for the nine months ended September 30, 2024 and 2023, respectively.
Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.


































31


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
Our segment results were as follows for the three and nine months ended September 30, 2024 and 2023:
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended September 30, 2024(in millions)
External revenues
Premiums:
Individual Medicare Advantage$21,856 $— $— $21,856 
Group Medicare Advantage1,913 — — 1,913 
Medicare stand-alone PDP721 — — 721 
Total Medicare24,490 — — 24,490 
Commercial fully-insured85 — — 85 
Specialty benefits238 — — 238 
Medicare Supplement217 — — 217 
State-based contracts and other2,921 — — 2,921 
Total premiums27,951 — — 27,951 
Services revenue:
Home solutions— 326 — 326 
Primary care— 319 — 319 
Pharmacy solutions— 232 — 232 
Commercial ASO12 — — 12 
Military services and other214 — — 214 
Total services revenue226 877 — 1,103 
Total external revenues 28,177 877 — 29,054 
Intersegment revenues
Services1 1,463 (1,464)— 
Products— 2,701 (2,701)— 
Total intersegment revenues1 4,164 (4,165)— 
Investment income192 — 151 343 
Total revenues28,370 5,041 (4,014)29,397 
Operating expenses:
Benefits25,319 — (199)25,120 
Operating costs2,595 4,602 (3,858)3,339 
Depreciation and amortization182 57 (29)210 
Total operating expenses28,096 4,659 (4,086)28,669 
Income from operations274 382 72 728 
Interest expense— 2 167 169 
Other income, net— — (92)(92)
Income (loss) before income taxes and equity in net earnings 274 380 (3)651 
Equity in net losses(1)(15)— (16)
Segment earnings (loss)$273 $365 $(3)$635 
Net loss attributable to noncontrolling interests— — — — 
Segment earnings (loss) attributable to Humana$273 $365 $(3)$635 

32


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended September 30, 2023(in millions)
External revenues
Premiums:
Individual Medicare Advantage$19,637 $— $— $19,637 
Group Medicare Advantage1,695 — — 1,695 
Medicare stand-alone PDP493 — — 493 
Total Medicare21,825 — — 21,825 
Commercial fully-insured842 — — 842 
Specialty benefits252 — — 252 
Medicare Supplement185 — — 185 
State-based contracts and other1,995 — — 1,995 
Total premiums25,099 — — 25,099 
Services revenue:
Home solutions— 342 — 342 
Primary care— 214 — 214 
Pharmacy solutions— 203 — 203 
Commercial ASO55 — — 55 
Military services and other202 — — 202 
Total services revenue257 759 — 1,016 
Total external revenues 25,356 759 — 26,115 
Intersegment revenues
Services1 1,307 (1,308)— 
Products— 2,594 (2,594)— 
Total intersegment revenues1 3,901 (3,902)— 
Investment income 154 — 154 308 
Total revenues25,511 4,660 (3,748)26,423 
Operating expenses:
Benefits21,976 — (231)21,745 
Operating costs2,634 4,207 (3,570)3,271 
Depreciation and amortization179 53 (31)201 
Total operating expenses24,789 4,260 (3,832)25,217 
Income from operations722 400 84 1,206 
Interest expense— 1 113 114 
Other income, net— — (6)(6)
Income (loss) before income taxes and equity in net earnings 722 399 (23)1,098 
Equity in net losses— (12)— (12)
Segment earnings (loss)$722 $387 $(23)$1,086 
Net loss (income) attributable to noncontrolling interests3 (1)— 2 
Segment earnings (loss) attributable to Humana$725 $386 $(23)$1,088 

33


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
InsuranceCenterWellEliminations/
Corporate		Consolidated
Nine months ended September 30, 2024(in millions)
External revenues
Premiums:
Individual Medicare Advantage$66,519 $— $— $66,519 
Group Medicare Advantage5,840 — — 5,840 
Medicare stand-alone PDP2,409 — — 2,409 
Total Medicare74,768 — — 74,768 
Commercial fully-insured493 — — 493 
Specialty benefits717 — — 717 
Medicare Supplement620 — — 620 
State-based contracts and other7,756 — — 7,756 
Total premiums84,354 — — 84,354 
Services revenue:
Home solutions— 996 — 996 
Primary care— 882 — 882 
Pharmacy solutions— 672 — 672 
Commercial ASO44 — — 44 
Military services and other671 — — 671 
Total services revenue715 2,550 — 3,265 
Total external revenues 85,069 2,550 — 87,619 
Intersegment revenues
Services3 4,293 (4,296)— 
Products— 7,963 (7,963)— 
Total intersegment revenues3 12,256 (12,259)— 
Investment income522 — 407 929 
Total revenues85,594 14,806 (11,852)88,548 
Operating expenses:
Benefits75,752 — (469)75,283 
Operating costs7,354 13,638 (11,463)9,529 
Depreciation and amortization553 166 (88)631 
Total operating expenses83,659 13,804 (12,020)85,443 
Income from operations1,935 1,002 168 3,105 
Interest expense— 4 492 496 
Other expense, net— — 26 26 
Income (loss) before income taxes and equity in net losses 1,935 998 (350)2,583 
Equity in net losses(2)(55)— (57)
Segment earnings (loss)$1,933 $943 $(350)$2,526 
Net loss attributable to noncontrolling interests3 — — 3 
Segment earnings (loss) attributable to Humana$1,936 $943 $(350)$2,529 



34


Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
InsuranceCenterWellEliminations/
Corporate		Consolidated
Nine Months Ended September 30, 2023(in millions)
External Revenues
Premiums:
Individual Medicare Advantage$59,195 $— $— $59,195 
Group Medicare Advantage5,192 — — 5,192 
Medicare stand-alone PDP1,677 — — 1,677 
Total Medicare66,064 — — 66,064 
Commercial fully-insured2,810 — — 2,810 
Specialty benefits758 — — 758 
Medicare Supplement546 — — 546 
State-based contracts and other5,966 — — 5,966 
Total premiums76,144 — — 76,144 
Services revenue:
Home solutions— 997 — 997 
Primary care— 605 — 605 
Pharmacy solutions— 661 — 661 
Commercial ASO190 — — 190 
Military services and other540 — — 540 
Total services revenue730 2,263 — 2,993 
Total external revenues 76,874 2,263 — 79,137 
Intersegment revenues
Services30 3,584 (3,614)— 
Products— 7,848 (7,848)— 
Total intersegment revenues30 11,432 (11,462)— 
Investment income385 — 390 775 
Total revenues77,289 13,695 (11,072)79,912 
Operating expenses:
Benefits66,096 — (484)65,612 
Operating costs7,597 12,526 (10,762)9,361 
Depreciation and amortization516 152 (90)578 
Total operating expenses74,209 12,678 (11,336)75,551 
Income from operations3,080 1,017 264 4,361 
Interest expense— 2 345 347 
Other expense, net— — 40 40 
Income (loss) before income taxes and equity in net losses3,080 1,015 (121)3,974 
Equity in net losses(2)(37)— (39)
Segment earnings (loss)$3,078 $978 $(121)$3,935 
Net loss (income) attributable to noncontrolling interests7 (1)— 6 
Segment earnings (loss) attributable to Humana$3,085 $977 $(121)$3,941 

35


Humana Inc.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The condensed consolidated financial statements of Humana Inc. in this document present the Company’s financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the Securities and Exchange Commission, or SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like “believes,” “expects,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward–looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. – Risk Factors in our 2023 Form 10-K, as modified by any changes to those risk factors included in this document and in other reports we filed subsequent to February 15, 2024, in each case incorporated by reference herein. In making these statements, we are not undertaking to address or update such forward-looking statements in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward–looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.
Executive Overview
General
Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large.
Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking
total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.
Employer Group Commercial Medical Products Business Exit
In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. We anticipate the exit of this line of business to be finalized in the first half of 2025.
Value Creation Initiatives
Beginning in 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges, primarily in asset impairments, of $55 million and $151 million for the three and nine months ended September 30, 2024, respectively, and $52 million for the three and nine months ended September 30, 2023 within operating costs in the condensed consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024.


36
Business Segments
Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.
The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.
The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.
The results of each segment are measured by income (loss) from operations. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.
Seasonality
One of the product offerings of our Insurance segment is Medicare stand-alone prescription drug plans, or PDP, under the Medicare Part D program. Our quarterly Insurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.
The Insurance segment also experiences seasonality in the commercial fully-insured product offering. The effect on the Insurance segment benefit ratio is opposite of the Medicare stand-alone PDP impact, with the benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses. The Employer Group Commercial Fully-Insured business increased the Insurance segment benefit ratio by 10 basis points and increased the Insurance segment benefit ratio by 20 basis points for the three months ended September 30, 2024 and 2023, respectively. The Employer Group Commercial Fully-Insured business did not impact the Insurance segment benefit ratio for the nine months ended September 30, 2024 and 2023.

37
The Insurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare marketing season. The Insurance segment may experience adverse impacts in the operating cost ratio as a result of our Employer Group Commercial Medical Products exit. The Employer Group Commercial Fully-Insured business increased the Insurance segment operating cost ratio by 10 basis points for the three months ended September 30, 2024 and increased the Insurance segment operating cost ratio by 40 basis points for the three months ended September 30, 2023. The Employer Group Commercial Fully-Insured business did not impact the Insurance segment operating cost ratio for the nine months ended September 30, 2024 and increased the Insurance segment operating cost ratio by 40 basis points for the nine months ended September 30, 2023.
2024 Highlights
•Our strategy offers our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At September 30, 2024, approximately 3,984,900 members, or 70%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 3,727,500 members, or 69%, at September 30, 2023.
•Net income attributable to Humana was $0.5 billion, or $3.98 per diluted common share, and $0.8 billion, or $6.71 per diluted common share, for the three months ended September 30, 2024 and 2023, respectively. Net income attributable to Humana was $1.9 billion, or $15.72 per diluted common share, and $3.0 billion, or $24.26 per diluted common share, for the nine months ended September 30, 2024, and 2023, respectively. These comparisons were significantly impacted by put/call valuation adjustments associated with non-consolidating minority interest investments, charges associated with value creation initiatives, transaction and integration costs and an accrual related to certain anticipated litigation expenses. The impact of these adjustments to our consolidated income before income taxes and equity in net earnings and diluted earnings per common share was as follows for the 2024 and 2023 quarter and period:

38
For the three months ended September 30,For the nine months ended September 30,
2024202320242023
(in millions)
Consolidated income before income taxes and equity in net earnings:
Put/call valuation adjustments associated with our non consolidating minority interest investments$(59)$35 $141 $141 
Transaction and integration costs— — — (47)
Value creation initiatives55 52 151 52 
Accrual related to certain anticipated litigation expenses— 15 — 105 
Total$(4)$102 $292 $251 
For the three months ended September 30,For the nine months ended September 30,
2024202320242023
Diluted earnings per common share:
Put/call valuation adjustments associated with our non consolidating minority interest investments$(0.49)$0.28 $1.17 $1.13 
Transaction and integration costs— — — (0.38)
Value creation initiatives0.45 0.42 1.25 0.42 
Accrual related to certain anticipated litigation expenses— 0.12 — 0.84 
Net tax impact of transactions0.01 (0.18)(0.56)(0.57)
Total$(0.03)$0.64 $1.86 $1.44 

































39
Regulatory Environment

We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Health Care Reform Law, the Families First Act, the CARES Act, and the Inflation Reduction Act, and related regulations, are examples of laws which have enacted significant reforms to various aspects of the U.S. health insurance industry, including, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with insurance products, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, and the introduction of plan designs based on set actuarial values, and changes to the Part D prescription drug benefit design.
It is reasonably possible that these laws and regulations, as well as other current or future legislative, judicial or regulatory changes including restrictions on our ability to manage our provider network, manage and sell our products, or otherwise operate our business, or restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, increases in regulation of our prescription drug benefit businesses, or changes to the Part D prescription drug benefit design (and uncertainty arising from the implementation of these changes) in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows.
In March 2024, the United States Securities and Exchange Commission issued its final regulation on climate-related disclosures. The regulation requires certain disclosures in registration statements and annual reports, including financial impact and climate-related impact metrics. On April 4, 2024, the SEC exercised its discretion to stay the Final Rules pending the completion of judicial review. The new regulation is effective for us beginning with the annual report for the year ended December 31, 2025. We are evaluating the final rule and its impact on our disclosures.

We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home solutions, to our Insurance segment customers and are described in Note 14 to the condensed consolidated financial statements included in this report.


40
Comparison of Results of Operations for 2024 and 2023
The following discussion primarily deals with our results of operations for the three months ended September 30, 2024, or the 2024 quarter, the three months ended September 30, 2023, or the 2023 quarter, the nine months ended September 30, 2024, or the 2024 period, and the nine months ended September 30, 2023, or the 2023 period.
Change
Three months ended September 30,Nine months ended September 30,Three months ended September 30, 2024 vs 2023Nine months ended September 30, 2024 vs 2023
2024202320242023$%$%
($ in millions, except per common share results)
Revenues:
Insurance premiums$27,951 $25,099 $84,354 $76,144 $2,852 11.4 %$8,210 10.8 %
Services:
Insurance226 257 715 730 (31)(12.1)%(15)(2.1)%
CenterWell877 759 2,550 2,263 118 15.5 %287 12.7 %
Total services revenue1,103 1,016 3,265 2,993 87 8.6 %272 9.1 %
Investment income343 308 929 775 35 11.4 %154 19.9 %
Total revenues29,397 26,423 88,548 79,912 2,974 11.3 %8,636 10.8 %
Operating expenses:
Benefits25,120 21,745 75,283 65,612 3,375 15.5 %9,671 14.7 %
Operating costs3,339 3,271 9,529 9,361 68 2.1 %168 1.8 %
Depreciation and amortization210 201 631 578 9 4.5 %53 9.2 %
Total operating expenses28,669 25,217 85,443 75,551 3,452 13.7 %9,892 13.1 %
Income from operations728 1,206 3,105 4,361 (478)(39.6)%(1,256)(28.8)%
Interest expense169 114 496 347 55 48.2 %149 42.9 %
Other (income) expense, net(92)(6)26 40 86 1,433.3 %(14)(35.0)%
Income before income taxes and equity in net earnings651 1,098 2,583 3,974 (447)(40.7)%(1,391)(35.0)%
Provision for income taxes155 256 629 911 (101)(39.5)%(282)(31.0)%
Equity in net losses(16)(12)(57)(39)4 33.3 %18 46.2 %
Net income$480 $830 $1,897 $3,024 $(350)(42.2)%$(1,127)(37.3)%
Diluted earnings per common share$3.98 $6.71 $15.72 $24.26 $(2.73)(40.7)%$(8.54)(35.2)%
Benefit ratio (a)89.9 %86.6 %89.2 %86.2 %3.3 %3.0 %
Operating cost ratio (b)11.5 %12.5 %10.9 %11.8 %(1.0)%(0.9)%
Effective tax rate24.4 %23.5 %24.9 %23.1 %0.9 %1.8 %
(a)Represents benefits expense as a percentage of premiums revenue.
(b)Represents operating costs as a percentage of total revenues less investment income.

Premiums Revenue

Consolidated premiums revenue increased $2.9 billion, or 11.4%, from $25.1 billion in the 2023 quarter to $28.0 billion in the 2024 quarter and increased $8.2 billion, or 10.8%, from $76.1 billion in the 2023 period to $84.4

41
billion in the 2024 period primarily due to higher per member Medicare premiums as well as Medicare Advantage and state-based contracts membership growth. These factors were partially offset by the continued decline in our group commercial medical and stand-alone PDP membership.

Services Revenue
Consolidated services revenue increased $87 million, or 8.6%, from $1.0 billion in the 2023 quarter to $1.1 billion in the 2024 quarter and increased $272 million, or 9.1%, from $3.0 billion in the 2023 period to $3.3 billion in the 2024 period primarily due to higher revenues associated with growth in the primary care business, partially offset by the impact of the v28 risk model revision.
Investment Income
Investment income increased $35 million, or 11.4%, from $308 million in the 2023 quarter to $343 million in the 2024 quarter and increased $154 million, or 19.9%, from $775 million in the 2023 period to $929 million in the 2024 period primarily due to increase in interest income on our debt securities.
Benefit Expense    
Consolidated benefits expense increased $3.4 billion, or 15.5%, from $21.7 billion in the 2023 quarter to $25.1 billion in the 2024 quarter and increased $9.7 billion, or 14.7%, from $65.6 billion in the 2023 period to $75.3 billion in the 2024 period. The consolidated benefit ratio increased 330 basis points from 86.6% for the 2023 quarter to 89.9% for the 2024 quarter and increased 300 basis points from 86.2% for the 2023 period to 89.2% for the 2024 period primarily due to the continued impact of elevated Medicare Advantage and state-based contracts medical cost trends in the 2024 quarter and period. The elevated medical cost trend was partially offset by the impact of the pricing and benefit design of our 2024 Medicare Advantage products, which included a reduction in member benefits in response to the net impact of the 2024 final rate notice and the initial emergence of increased medical cost trends in 2023. Further, the year-over-year comparisons continue to reflect a shift in line of business mix, with growth in Medicare Advantage and state-based contracts and other membership, which can carry a higher benefit ratio.
Consolidated benefits expense included $24 million of favorable prior-period medical claims reserve development in the 2024 quarter and $4 million of favorable prior-period medical claims development in the 2023 quarter. Consolidated benefits expense included $693 million of favorable prior-period medical claims reserve development in the 2024 period and $758 million of favorable prior-period medical claims reserve development in the 2023 period. Prior-period medical claims reserve development decreased the consolidated benefit ratio by approximately 10 basis points in the 2024 quarter and did not impact the consolidated benefit ratio in the 2023 quarter. Prior-period medical claims reserve development decreased the consolidated benefit ratio by approximately 80 basis points in the 2024 period and decreased the consolidated benefit ratio by approximately 100 basis points in the 2023 period.
Operating Costs
Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.
Consolidated operating costs increased $68 million, or 2.1%, from $3.3 billion in the 2023 quarter to $3.3 billion in the 2024 quarter and increased $168 million, or 1.8%, from $9.4 billion in the 2023 period to $9.5 billion in the 2024 period. The consolidated operating cost ratio decreased 100 basis points from 12.5% for the 2023 quarter to 11.5% for the 2024 quarter and decreased 90 basis points from 11.8% for the 2023 period to 10.9% for the 2024 period primarily due to scale efficiencies associated with growth in our Medicare Advantage membership, administrative cost efficiencies resulting from our value creation initiatives, lower impact of commission expense for brokers in 2024 compared to 2023 as a result of significant individual Medicare Advantage membership growth in 2023, and the impact of the accrued charge related to certain anticipated litigation expenses included in the 2023

42
quarter and period results. These factors were partially offset by the impact from charges related to value creation initiatives in the 2024 quarter and period.
Depreciation and Amortization
Depreciation and amortization increased $9 million, or 4.5%, from $201 million in the 2023 quarter to $210 million in the 2024 quarter and increased $53 million, or 9.2%, from $578 million in the 2023 period to $631 million in the 2024 period primarily due to capital expenditures.
Interest Expense
Interest expense increased $55 million, or 48.2%, from $114 million in the 2023 quarter to $169 million in the 2024 quarter and increased $149 million, or 42.9%, from $347 million in the 2023 period to $496 million in the 2024 period primarily due to increase in interest rates and higher average debt balances.
Income Taxes
The effective income tax rate was 24.4% and 23.5% for the three months ended September 30, 2024, and 2023, respectively, and 24.9% and 23.1% for the nine months ended September 30, 2024 and 2023, respectively. The year-over-year increase in the effective income tax rate is primarily due to a change in the mix of current year earnings between our Insurance segment and our CenterWell health services segment, as our CenterWell health services segment is subject to a higher effective tax rate than our Insurance segment. In addition, the prior year income tax rate was favorably impacted by the recognition of a non-taxable gain.



































43
Insurance Segment
 September 30,Change
 20242023Members%
Membership:
Individual Medicare Advantage5,659,200 5,374,400 284,800 5.3 %
Group Medicare Advantage546,700 510,300 36,400 7.1 %
Medicare stand-alone PDP2,315,700 2,885,800 (570,100)(19.8)%
Total Medicare8,521,600 8,770,500 (248,900)(2.8)%
Medicare Supplement357,300 299,400 57,900 19.3 %
Commercial fully-insured25,900 409,300 (383,400)(93.7)%
State-based contracts and other1,446,100 1,264,600 181,500 14.4 %
Military services 5,984,800 5,935,400 49,400 0.8 %
Commercial ASO22,400 284,300 (261,900)(92.1)%
Total Medical Membership16,358,100 16,963,500 (605,400)(3.6)%
Total Specialty Membership (a)
4,566,800 4,964,300 (397,500)(8.0)%
(a) We provide a full range of insured specialty products including dental, vision, and life insurance benefits marketed to individuals and groups. Members included in these products may not be unique to each product since members have the ability to enroll in a medical product and one or more specialty products.
Change
Three months ended September 30,Nine months ended September 30,Three months ended September 30, 2024 vs 2023Nine months ended September 30, 2024 vs 2023
2024202320242023$%$%
($ in millions)
Premiums and Services Revenue:
Premiums:
Individual Medicare Advantage$21,856 $19,637 $66,519 $59,195 $2,219 11.3 %$7,324 12.4 %
Group Medicare Advantage1,913 1,695 5,840 5,192 218 12.9 %648 12.5 %
Medicare stand-alone PDP721 493 2,409 1,677 228 46.2 %732 43.6 %
Total Medicare24,490 21,825 74,768 66,064 2,665 12.2 %8,704 13.2 %
Commercial fully-insured 85 842 493 2,810 (757)(89.9)%(2,317)(82.5)%
Specialty benefits238 252 717 758 (14)(5.6)%(41)(5.4)%
Medicare Supplement217 185 620 546 32 17.3 %74 13.6 %
State-based contracts and other2,921 1,995 7,756 5,966 926 46.4 %1,790 30.0 %
Total premiums revenue27,951 25,099 84,354 76,144 2,852 11.4 %8,210 10.8 %
Commercial ASO 12 55 44 190 (43)(78.2)%(146)(76.8)%
Military services and other214 202 671 540 12 5.9 %131 24.3 %
Services revenue226 257 715 730 (31)(12.1)%(15)(2.1)%
Total premiums and services revenue$28,177 $25,356 $85,069 $76,874 $2,821 11.1 %$8,195 10.7 %
Income from operations$274 $722 $1,935 $3,080 $(448)(62.0)%$(1,145)(37.2)%
Benefit ratio90.6 %87.6 %89.8 %86.8 %3.0 %3.0 %
Operating cost ratio9.2 %10.4 %8.6 %9.9 %(1.2)%(1.3)%


44
Income from operations
Insurance segment income from operations decreased $0.4 billion, or 62.0%, from $0.7 billion in the 2023 quarter to $0.3 billion in the 2024 quarter and decreased $1.1 billion, or 37.2%, from $3.1 billion in the 2023 period to $1.9 billion in the 2024 period primarily due to the same factors impacting the segment's higher benefit ratio partially offset by the lower operating cost ratio as more fully described below.
Enrollment
Individual Medicare Advantage membership increased 284,800 members, or 5.3%, from September 30, 2023 to September 30, 2024 primarily due to membership additions associated with the previous Annual Election Period, or AEP. Individual Medicare Advantage membership includes 939,600 D-SNP members as of September 30, 2024, a net increase of 71,600 D-SNP members, or 8.2%, from 868,000 D-SNP members as of September 30, 2023.
Group Medicare Advantage membership increased 36,400 members, or 7.1%, from September 30, 2023 to September 30, 2024 primarily due to growth in small and medium group accounts.
Medicare stand-alone PDP membership decreased 570,100 members, or 19.8%, from September 30, 2023 to September 30, 2024 primarily due to continued intensified competition for Medicare stand-alone PDP offerings.
State-based contracts and other membership increased 181,500 members, or 14.4%, from September 30, 2023 to September 30, 2024 primarily reflecting the impact of membership additions associated with the implementation of new contracts partially offset with membership loss as a result of the public health of emergency unwind.

Commercial fully-insured medical membership decreased 383,400 members, or 93.7%, from September 30, 2023 to September 30, 2024 and commercial ASO medical membership decreased 261,900 members, or 92.1%, from September 30, 2023 to September 30, 2024. These decreases reflect our planned exit of the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. We anticipate the exit of this line of business to be finalized in the first half of 2025.
Specialty membership decreased 397,500 members, or 8.0%, from September 30, 2023 to September 30, 2024 primarily due to non-renewal of dental and vision plans as a result of exit from the Employer Group Commercial Medical Products business partially offset by growth in dental and vision plans as a result of Medicare Advantage enrollment.

Premiums Revenue
Insurance segment premiums revenue increased $2.9 billion, or 11.4%, from $25.1 billion in the 2023 quarter to $28.0 billion in the 2024 quarter and increased $8.2 billion, or 10.8%, from $76.1 billion in the 2023 period to $84.4 billion in the 2024 period primarily due to higher per member Medicare premiums as well as Medicare Advantage and state-based contracts membership growth. These factors were partially offset by the continued decline in our group commercial medical and stand-alone PDP membership.
Services Revenue
Insurance segment services revenue decreased $31 million, or 12.1%, from $257 million in the 2023 quarter to $226 million in the 2024 quarter and decreased $15 million, or 2.1%, from $730 million in the 2023 period to $715 million in the 2024 period.





45
Benefits Expense
The Insurance segment benefit ratio increased 300 basis points from 87.6% for the 2023 quarter to 90.6% for the 2024 quarter and increased 300 basis points from 86.8% for the 2023 period to 89.8% for the 2024 period primarily due to the continued impact of elevated Medicare Advantage and state-based contracts medical cost trends in the 2024 quarter and period. The elevated medical cost trend was partially offset by the impact of the pricing and benefit design of our 2024 Medicare Advantage products, which included a reduction in member benefits in response to the net impact of the 2024 final rate notice and the initial emergence of increased medical cost trends in 2023. Further, the year-over-year comparisons continue to reflect a shift in line of business mix, with growth in Medicare Advantage and state-based contracts and other membership, which can carry a higher benefit ratio.
Operating Costs
The Insurance segment operating cost ratio decreased 120 basis points from 10.4% for the 2023 quarter to 9.2% for the 2024 quarter and decreased 130 basis points from 9.9% for the 2023 period to 8.6% for the 2024 period primarily due to scale efficiencies associated with growth in our individual Medicare Advantage membership, administrative cost efficiencies resulting from our value creation initiatives, lower impact of commission expense for brokers in 2024 compared to 2023 as a result of significant individual Medicare Advantage membership growth in 2023, and the impact of the accrued charge related to certain anticipated litigation expenses included in the 2023 quarter and period results.




















46
CenterWell Segment
Change
Three months ended September 30,Nine months ended September 30,Three months ended September 30, 2024 vs 2023Nine months ended September 30, 2024 vs 2023
2024202320242023$%$%
($ in millions)
Revenues:
Services:
Home solutions$326 $342 $996 $997 $(16)(4.7)%$(1)(0.1)%
Pharmacy solutions232 203 672 661 29 14.3 %11 1.7 %
Primary care319 214 882 605 105 49.1 %277 45.8 %
Total services revenue877 759 2,550 2,263 118 15.5 %287 12.7 %
Intersegment revenues:
Home solutions525 453 1,509 1,088 72 15.9 %421 38.7 %
Pharmacy solutions2,701 2,594 7,963 7,848 107 4.1 %115 1.5 %
Primary care938 854 2,784 2,496 84 9.8 %288 11.5 %
Total intersegment revenues4,164 3,901 12,256 11,432 263 6.7 %824 7.2 %
Total services and intersegment revenues$5,041 $4,660 $14,806 $13,695 $381 8.2 %$1,111 8.1 %
Income from operations$382 $400 $1,002 $1,017 $(18)(4.5)%$(15)(1.5)%
Operating cost ratio91.3 %90.3 %92.1 %91.5 %1.0 %0.6 %

Income from operations
CenterWell income from operations decreased $18 million, or 4.5%, from $400 million in the 2023 quarter to $382 million in the 2024 quarter and decreased $0.02 billion, or 1.5%, from $1.02 billion in the 2023 period to $1.00 billion in the 2024 period primarily due to the same factors impacting the segment's operating cost ratio as more fully described below.
Services Revenue
CenterWell services revenue increased $118 million, or 15.5%, from $759 million in the 2023 quarter to $877 million in the 2024 quarter and increased $0.3 billion, or 12.7%, from $2.3 billion in the 2023 period to $2.6 billion in the 2024 period primarily due to higher revenues associated with growth in the primary care business, partially offset by the impact of the v28 risk model revision.
Intersegment Revenue
CenterWell intersegment revenues increased $0.3 billion, or 6.7%, from $3.9 billion in the 2023 quarter to $4.2 billion in the 2024 quarter and increased $0.8 billion, or 7.2%, from $11.4 billion in the 2023 period to $12.3 billion in the 2024 period primarily due to greater intersegment revenues associated with the home solutions business in the 2024 quarter and period as compared to the 2023 quarter and period as a result of the expansion of the value-based home care model, higher revenues associated with growth in the primary care business, partially offset by the impact of the v28 risk model revision, as well as an increase in pharmacy solutions revenues resulting from growth in the specialty pharmacy business, driven by increased penetration of Humana health plan members and payor agnostic consumers.

47
Operating Costs
The CenterWell segment operating cost ratio increased 100 basis points from 90.3% for the 2023 quarter to 91.3% for the 2024 quarter and increased 60 basis points from 91.5% for the 2023 period to 92.1% for the 2024 period primarily due to the unfavorable impact of the v28 risk model revision to the primary care business partially offset by administrative cost efficiencies resulting from our value creation initiatives and positive prior-period medical claims reserve development within the Primary Care Organization.
Liquidity
Historically, our primary sources of cash have included receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities, and borrowings. Our primary uses of cash historically have included disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. As premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including premiums receivable, benefits payable, and other receivables and payables. Our cash flows are impacted by the timing of payments to and receipts from CMS associated with Medicare Part D subsidies for which we do not assume risk. The use of cash flows may be limited by regulatory requirements of state departments of insurance (or comparable state regulators) which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of cash flows derived from our non-insurance subsidiaries, such as in our CenterWell segment, is generally not restricted by state departments of insurance (or comparable state regulators).
For additional information regarding our liquidity risk, refer to Part I, Item 1A, "Risk Factors" in our 2023 Form 10-K and Part II, Item 1A, "Risk Factors" of this Form 10-Q.
Cash and cash equivalents increased to approximately $5.1 billion at September 30, 2024 from $4.7 billion at December 31, 2023. The change in cash and cash equivalents for the nine months ended September 30, 2024 and 2023 is summarized as follows:
Nine Months Ended
20242023
 (in millions)
Net cash provided by operating activities$3,494 $11,115 
Net cash used in investing activities(2,889)(2,610)
Net cash provided by financing activities(183)1,582 
Increase in cash and cash equivalents$422 $10,087 
Cash Flow from Operating Activities
Cash flows provided by operations of $3.5 billion in the 2024 period decreased $7.6 billion from cash flows provided by operations of $11.1 billion in the 2023 period. Our operating cash flows for the 2023 period were significantly impacted by the early receipt of the Medicare premium remittance of $7.1 billion in September 2023 because the payment date for October 2023 fell on a weekend. Generally, when the first day of a month falls on a weekend or holiday, with the exception of January 1 (New Year's Day), we receive this payment at the end of the previous month. This also resulted in an increase to unearned revenues in our condensed consolidated balance sheet at September 30, 2023. The 2024 period does not include an early receipt of the Medicare premium remittance. Our operating cash flows for the 2024 period also reflect lower earnings compared to the 2023 period, partially offset by the favorable impact of working capital items in the 2024 period.
The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. Benefits expense includes claim payments, capitation payments, pharmacy costs

48
net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
The detail of total net receivables at September 30, 2024 and December 31, 2023 and reconciliation to cash flow for the nine months ended September 30, 2024 and 2023 was as follows:
September 30, 2024December 31, 20232024 Period Change2023 Period Change
 (in millions)
Medicare$1,289 $1,426 $(137)$33 
Commercial and other753 549 204 96 
Military services195 148 47 24 
Allowances(93)(88)(5)(3)
Total net receivables$2,144 $2,035 $109 $150 
Reconciliation to cash flow statement:
Receivables acquired— (24)
Change in receivables per cash flow statement $109 $126 

The changes in Medicare receivables for both the 2024 period and the 2023 period reflect individual Medicare Advantage membership growth and the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model. Significant collections occur with the mid-year and final settlements with CMS in the second and third quarter.
Cash Flow from Investing Activities
During the 2024 period and 2023 period, we acquired various businesses for approximately $37 million and $223 million, net of cash and cash equivalents received, respectively.
Our ongoing capital expenditures primarily relate to our information technology initiatives, support of services in our primary care operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination, regulatory compliance and customer service. Total net capital expenditures, excluding acquisitions, were $421 million in the 2024 period and $721 million in the 2023 period.
Net purchases of investment securities were $2.4 billion and $1.7 billion in the 2024 period and 2023 period, respectively.
Cash Flow from Financing Activities
Claim payments were higher than receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk by $0.6 billion in the 2024 period and receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk were higher than claim payments by $2.5 billion in the 2023 period.
Under our administrative services only TRICARE contracts, health care costs payments for which we do not assume risk exceeded reimbursements from the federal government by $75 million and $28 million in the 2024 and 2023 periods, respectively.
In March 2024, we issued $1.25 billion of 5.375% unsecured senior notes due April 15, 2031 and $1.00 billion of 5.750% unsecured senior notes due April 15, 2054. Our net proceeds, reduced for the underwriters' discounts and

49
commissions paid, were $2.23 billion. We used the net proceeds for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.
In August 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $750 million aggregate principal amount of 1.350% senior notes maturing in February 2027, our $600 million aggregate principal amount of 3.950% senior notes maturing in March 2027, our $750 million aggregate principal amount of 3.700% senior notes maturing in March 2029, and our $500 million aggregate principal amount of 3.125% senior notes maturing in August 2029 during the period beginning on August 7, 2023 and ending on November 15, 2023. For the nine months ended September 30, 2023, we repurchased $213 million principal amount of these senior notes for approximately $196 million cash.
In March 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $1.5 billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600 million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the period beginning on March 13, 2023 and ending on July 21, 2023. For the nine months ended September 30, 2023, we repurchased $361 million principal amount of these senior notes for approximately $358 million cash. In August 2023, we repaid the remaining $1.2 billion aggregate principal amount of our 0.650% senior notes due on their maturity date of August 3, 2023.
In March 2023, we issued $500 million of 5.700% unsecured senior notes due March 13, 2026 and $750 million of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2 billion. We used the net proceeds to repay outstanding amounts under our $500 million Delayed Draw Term Loan. The remaining net proceeds will be used for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program
Net repayments from the issuance of commercial paper were $895 million in the 2024 period and net proceeds from the issuance of commercial paper were $1.6 billion in the 2023 period. The maximum principal amount outstanding at any one time during the 2024 period was $2.7 billion.
We repurchased common shares for $750 million and $980 million in the 2024 period and 2023 period, respectively, under share repurchase plans authorized by the Board of Directors. We also acquired common shares in connection with employee stock plans for $18 million and $31 million in the 2024 period and 2023 period, respectively.
We paid dividends to stockholders of $323 million and $320 million during the 2024 period and 2023 period, respectively.

Future Sources and Uses of Liquidity
Dividends
For additional information regarding our dividends to stockholders, refer to Note 10 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Stock Repurchases
For additional information regarding stock repurchases, refer to Note 10 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Debt
For additional information regarding debt, including our senior notes, term loans, revolving credit agreements, commercial paper program and other short-term borrowings, refer to Note 12 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

50
Acquisitions
For additional information regarding acquisitions, refer to Note 3 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Liquidity Requirements
We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement and our commercial paper program or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares.
Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at September 30, 2024 was BBB according to Standard & Poor’s Rating Services, or S&P, and Baa2 according to Moody’s Investors Services, Inc., or Moody’s. A downgrade by S&P to BB+ or by Moody’s to Ba1 triggers an interest rate increase of 25 basis points with respect to $250 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis points, or annual interest expense by $1 million, up to a maximum 100 basis points, or annual interest expense by $3 million.
In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent company were $609 million at September 30, 2024 compared to $510 million at December 31, 2023. This increase primarily reflects working capital changes, net proceeds from the issuance of senior notes and commercial paper, proceeds from the sale and maturities of investment securities, dividends from insurance subsidiaries and cash from certain non-insurance subsidiaries within our CenterWell segment partially offset by common stock repurchases, repayment of maturing senior notes, repayment of borrowings under the commercial paper program, purchases of investment securities, capital expenditures, capital contributions to certain subsidiaries, cash dividends to shareholders and acquisitions. Our use of operating cash derived from our non-insurance subsidiaries, such as our CenterWell segment, is generally not restricted by departments of insurance (or comparable state regulators).
Regulatory Requirements
Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity’s level of statutory income and statutory capital and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required.
Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Based on the most recently filed statutory financial statements as of June 30, 2024, our state regulated subsidiaries had aggregate statutory capital and surplus of approximately $13.5 billion, which exceeded aggregate minimum regulatory requirements of $10.6 billion. The amount of ordinary dividends paid to our parent company was approximately $0.5 billion during the nine months ended September 30, 2024. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.


51
Item 3.    Quantitative and Qualitative Disclosures about Market Risk
Our earnings and financial position are exposed to financial market risk, including those resulting from changes in interest rates.
Interest rate risk also represents a market risk factor affecting our consolidated financial position due to our significant investment portfolio, consisting primarily of fixed maturity securities of investment-grade quality with a weighted average S&P credit rating of AA- at September 30, 2024. Our net unrealized position decreased $448 million from a net unrealized loss position of $1,294 million at December 31, 2023 to a net unrealized loss position of $846 million at September 30, 2024. At September 30, 2024, we had gross unrealized losses of $998 million on our investment portfolio primarily due to an increase in market interest rates since the time the securities were purchased. There were no material credit allowances during the nine months ended September 30, 2024. While we believe that these securities in an unrealized loss will recover in value over time and we currently do not have the intent to sell such securities, given the current market conditions and the significant judgments involved, there is a continuing risk that future declines in fair value may occur and material realized losses from sales or credit allowances may be recorded in future periods.
Duration is the time-weighted average of the present value of the bond portfolio’s cash flow. Duration is indicative of the relationship between changes in fair value and changes in interest rates, providing a general indication of the sensitivity of the fair values of our fixed maturity securities to changes in interest rates. However, actual fair values may differ significantly from estimates based on duration. The average duration of our investment portfolio, including cash and cash equivalents, was approximately 3.3 years as of September 30, 2024 and 3.0 years as of December 31, 2023. Based on the duration, including cash equivalents, a 1% increase in interest rates would generally decrease the fair value of our securities by approximately $803 million at September 30, 2024.
Item 4.    Controls and Procedures
Under the supervision and with the participation of our Chief Executive Officer, or CEO, our Chief Financial Officer, or CFO, and our Principal Accounting Officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for the quarter ended September 30, 2024.
Based on our evaluation, our CEO, CFO, and our Principal Accounting Officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information the Company is required to disclose in its reports under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including, without limitation, ensuring that such information is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
There have been no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.


52
Part II. Other Information

Item 1.     Legal Proceedings
For additional information regarding legal proceedings pending against us and certain other pending or threatened litigation, investigations or other matters, refer to “Legal Proceedings and Certain Regulatory Matters” in Note 13 to the unaudited Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.

Item 1A. Risk Factors
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and the risk factor set forth below.
The number of our Medicare Advantage plans rated 4-star or higher are expected to significantly decline in 2025. We have filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of our Medicare Advantage plans, but there is no assurance that we will prevail in this lawsuit. If we are not successful the decline in our Star Ratings may negatively impact our 2026 quality bonus payments from CMS and may also significantly adversely affect our revenues, operating results, and cash flows.
Based on 2025 Medicare Advantage Star Ratings released by CMS in October 2024, approximately 25% of our Medicare Advantage members are currently enrolled in plans rated 4-star or higher for 2025, as compared to 94% based on our 2024 Star Ratings. We have filed a lawsuit that, among other things, seeks to set aside and vacate the 2025 Star Ratings for our Medicare Advantage plans, but there is no assurance that we will prevail in the lawsuit. If we are not successful the decline in our Star Ratings performance for 2025 may negatively impact our 2026 quality bonus payments from CMS and may also significantly adversely affect our revenues, operating results, and cash flows. Please see “Legal Proceedings and Certain Regulatory Matters” in Note 13 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q for a description of the lawsuit.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
(a)None.
(b)N/A
(c)The following table provides information about our purchases of equity securities that are registered by us pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, during the three months ended September 30, 2024:
PeriodTotal Number
of Shares
Purchased (1)(2)		Average
Price Paid
per Share		Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs (1)(2)		Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs (1) (2)
July 20241,148 $375.21 1,148 $2,926,243,841 
August 2024— — — 2,926,243,841 
September 2024— — — 2,926,243,841 
Total1,148 $375.21 1,148 

53
(1)Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824 million remained unused) with a new share repurchase authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. Our remaining repurchase authorization was $2.93 billion as of October 29, 2024.
(2)Excludes 0.05 million shares repurchased in connection with employee stock plans.
Item 3.     Defaults Upon Senior Securities
None.

Item 4.     Mine Safety Disclosures
Not applicable.

Item 5.     Other Information
a.None.
b.None.
c.During the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.


54
Item 6:     Exhibits
Restated Certificate of Incorporation of Humana Inc. filed with the Secretary of State of Delaware on November 9, 1989, as restated to incorporate the amendment of January 9, 1992, the correction of March 23, 1992, and the amendment dated April 24, 2024 (incorporated herein by reference to Exhibit 3(i) to Humana Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024).
Humana Inc. Amended and Restated By-laws, effective as of December 7, 2023 (incorporated herein by reference to Exhibit 3(b) to Humana Inc.’s Current Report on Form 8-K filed on December 7, 2023).
Principal Executive Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.
Principal Financial Officer certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.
Principal Executive Officer and Principal Financial Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101The following materials from Humana Inc.'s Quarterly Report on Form 10-Q formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets (Unaudited) at September 30, 2024 and December 31, 2023; (ii) the Condensed Consolidated Statements of Income (Unaudited) for the three and nine months ended September 30, 2024 and 2023; (iii) the Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three and nine months ended September 30, 2024 and 2023; (iv) the Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the three and nine months ended September 30, 2024 and 2023; (v) the Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2024 and 2023; and (vi) Notes to Condensed Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.

55
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HUMANA INC.
(Registrant)
Date:October 30, 2024By:/s/ JOHN-PAUL W. FELTER
John-Paul W. Felter
Senior Vice President, Chief Accounting Officer and Controller (Principal Accounting Officer)

56
 EX-31.1 2 hum-20240930xex31x1.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002
I, James A. Rechtin, principal executive officer of Humana Inc., certify that:
1. I have reviewed this Report of Humana Inc. (the "Company") on Form 10-Q for the period ending September 30, 2024;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:October 30, 2024
Signature:/s/ James A. Rechtin
James A. Rechtin
Principal Executive Officer

 EX-31.2 3 hum-20240930xex31x2.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002
I, Susan M. Diamond, principal financial officer of Humana Inc., certify that:
1. I have reviewed this Report of Humana Inc. (the "Company") on Form 10-Q for the period ending September 30, 2024;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: October 30, 2024
Signature: /s/ Susan M. Diamond
 Susan M. Diamond
Principal Financial Officer

 EX-32 4 hum-20240930xex32.htm EX-32 Document

Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Report of Humana Inc. (the "Company") on Form 10-Q for the period ending September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, in their capacity as an officer of Humana Inc., that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
/s/ James A. Rechtin
James A. Rechtin
Principal Executive Officer
October 30, 2024
/s/ Susan M. Diamond
Susan M. Diamond
Principal Financial Officer
October 30, 2024
A signed original of this written statement required by Section 906 has been provided to Humana Inc. and will be retained by Humana Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.SCH 5 hum-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - INVESTMENT SECURITIES link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - MEDICARE PART D link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - BENEFITS PAYABLE link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - INVESTMENT SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - MEDICARE PART D (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - BENEFITS PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - INVESTMENT SECURITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - FAIR VALUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - FAIR VALUE - Fair Value of Swap Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - FAIR VALUE - Put and Call Options Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - MEDICARE PART D (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - BENEFITS PAYABLE - Activity in Benefits Payable (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - STOCKHOLDERS' EQUITY - Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - DEBT - Debt Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - DEBT - Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - DEBT - Revolving Credit Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - DEBT - Commercial Paper and Other Short-term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - SEGMENT INFORMATION - Segment Results (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hum-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 hum-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 hum-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Acquisitions Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Remaining authorized amount Share Repurchase Program, Remaining Authorized, Amount Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Cover [Abstract] Cover [Abstract] 5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 [Member] 5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Weighted average cost of capital Measurement Input, Discount Rate [Member] Schedule of Indefinite-Lived Intangible Assets [Table] Intangible Asset, Indefinite-Lived [Table] Gross losses on equity securities Equity Securities, FV-NI, Realized Loss T2017 East Region TRICARE 2017 East Region Contract [Member] TRICARE 2017 East Region Contract Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Less: Net gains recognized on equity securities sold during the period Equity Securities, FV-NI, Realized Gain (Loss) All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Details Supporting Computation of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income tax payments, net Income Taxes Paid, Net Medicare stand-alone PDP Medicare Stand Alone Prescription Drug Plan [Member] Medicare Stand Alone Prescription Drug Plan [Member] Receivables, net of allowances Accounts Receivable, Allowance for Credit Loss, Current T-5, Effective 2024 TRICARE Managed Care Support Contract, Effective 2024 [Member] TRICARE Managed Care Support Contract, Effective 2024 Disposal Group Name [Domain] Disposal Group Name [Domain] Equity method investments Equity Method Investments Pay vs Performance Disclosure [Line Items] Line of Credit Facility [Table] Line of Credit Facility [Table] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Residential Residential Mortgage-Backed Securities [Member] Net gains recognized on equity securities during the period Equity Securities, FV-NI, Gain (Loss) BASIS OF PRESENTATION AND SIGNIFICANT EVENTS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] FAIR VALUE Fair Value Disclosures [Text Block] Total change in unrealized investment (losses) gains, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] $750 million, 1.350% due February 3, 2027 1.35 Percent Senior Notes Due February 2027 [Member] 1.35 Percent Senior Notes Due February 2027 Member co-share amounts and government subsidies Government And Health Plan Member Subsidies Amount Amount of member co-share amounts and government subsidies that are excluded from benefits expense because the health plans do not bear responsibility. Other Performance Measure, Amount Other Performance Measure, Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Net loss (income) attributable to noncontrolling interests Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Noncontrolling Interest Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Noncontrolling Interest Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Acquisition Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Unearned revenues Contract with Customer, Liability, Current Term Loan Loans Payable [Member] Other long-term assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Amortizable intangible assets, cost Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Stock repurchases (in shares) Treasury Stock, Shares, Acquired Settled the claims in this suit Payments for Legal Settlements Operating segments Operating Segments [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities $500 million, 4.875% due April 1, 2030 4.875 Percent Senior Notes Due April 2030 [Member] A 4.875 Percent Senior Notes Due April 2030 [Member] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Stock Treasury Stock, Common [Member] (Payments) receipts from contract deposits, net Payments For Proceeds From Contract Deposits Payments For Proceeds From Contract Deposits Intersegment Eliminations Intersegment Eliminations [Member] Less: Fair value of liabilities assumed Liabilities Assumed $500 million, 3.950% due August 15, 2049 3.95 Percent Senior Notes Due August 2049 [Member] 3.95 Percent Senior Notes Due August 2049 [Member] Equity Components [Axis] Equity Components [Axis] Options Option on Securities [Member] Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] $500 million, 3.125% due August 15, 2029 3.125 Percent Senior Notes Due August 2029 [Member] A 3.125 Percent Senior Notes Due August 2029 [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value Fair value Fair Value Total debt securities Debt Securities, Available-for-Sale Trade names and technology Trade Names [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Beginning balance at January 1 Balance at September 30 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $600 million, 3.850% due October 1, 2024 3.85 Percent Senior Notes Due October 2024 [Member] 3.85 Percent Senior Notes Due October 2024 [Member] Adjustment to Compensation, Amount Adjustment to Compensation Amount Capital in excess of par value Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Acquisitions Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions $400 million, 4.625% due December 1, 2042 4.625 Percent Senior Notes Due December 2042 [Member] 4.625 Percent Senior Notes Due December 2042 [Member] Gross gains on investment securities Debt And Equity Securities, Realized Gain Debt And Equity Securities, Realized Gain Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Military services Military Service [Member] Military Service [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Financing Receivable, Credit Quality Indicator [Line Items] Financing Receivable, Credit Quality Indicator [Line Items] Proceeds from maturities of investment securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Debt issue costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Investment income Investment Income, Interest and Dividend Unobservable Inputs (Level 3) Level 3 fair value measurement Fair Value, Inputs, Level 3 [Member] Receivables, net of allowances of $93 in 2024 and $88 in 2023 Receivables, Net, Current Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Number of antidilutive stock options and restricted stock excluded from computation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Prior years Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years State-based contracts and other State-Based Contracts and Other [Member] State-Based Contracts and Other Amortized Cost Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract] Total Debt Securities, Available-for-Sale, Unrealized Loss Position Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts and Financing Receivables [Table] Benefits payable Balances, beginning of period Balances, end of period Liability for Claims and Claims Adjustment Expense Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Current assets: Assets, Current [Abstract] Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Share repurchase authorization Share Repurchase Program, Authorized, Amount Commercial ASO Commercial ASO [Member] Commercial ASO Treasury stock, shares (in shares) Treasury Stock, Common, Shares Customer contracts/ relationships Customer Contracts [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee stock options Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Goodwill Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation Depreciation Prior years Prior Year Claims and Claims Adjustment Expense Other Proceeds from (Payments for) Other Financing Activities Comprehensive income attributable to Humana Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total gains or losses: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) [Abstract] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Security Exchange Name Security Exchange Name Number of TRICARE managed care support contract beneficiaries Number Of TRICARE Managed Care Support Contract Beneficiaries Number Of TRICARE Managed Care Support Contract Beneficiaries Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Schedule of Contractual Maturity of Debt Securities Available for Sale Investments Classified by Contractual Maturity Date [Table Text Block] Change in gross unrealized investment (losses) gains OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Award Type [Axis] Award Type [Axis] $850 million, 5.950% due March 15, 2034 5.950 Percent Senior Notes Due March 2034 [Member] 5.950 Percent Senior Notes Due March 2034 Financing Receivable, Credit Quality Indicator [Table] Financing Receivable, Credit Quality Indicator [Table] Corporate debt securities Corporate debt securities Corporate Debt Securities [Member] Securities, number of positions Debt, Securities, Available-For-Sale, Securities, Number Of Positions Debt Securities, Available-for-sale, Securities, Number Of Positions Property and equipment, net Property, Plant and Equipment, Net Depreciation and amortization classified as benefit expense Depreciation And Amortization Classified As Benefit Expense Depreciation and amortization expense that has been reclassified to be included with benefit expenses. The reclassification is the result of depreciation and amortization expense associated primarily from the delivery of pharmacy services by our wholly-owned pharmacy business included in our Healthcare Services segment. Total liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Amount per Share (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Debt to capitalization percentage, maximum Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum Short-term debt Short-term debt outstanding Short-Term Debt Gross Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract] Common stock, par (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Revolving credit facility Revolving Credit Facility [Member] Schedule of Gross Unrealized Losses and Fair Value of Securities Unrealized Gain (Loss) on Investments [Table Text Block] Expiration Date Trading Arrangement Expiration Date Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Interest Rate Swap Maturing 2053 Interest Rate Swap Maturing 2053 [Member] Interest Rate Swap Maturing 2053 Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Due after ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Transfer out Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Concentration risk (percent) Concentration Risk, Percentage Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Restructuring and impairment charge Restructuring Costs and Asset Impairment Charges Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Mortgage-backed securities Mortgage-Backed Security, Issued by US Government-Sponsored Enterprise [Member] Common shares acquired in connection with employee stock plans, amount Share Repurchases Related To Employee Stock Based Compensation Awards Value Cost of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares. Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Eliminations/ Corporate Corporate And Eliminations [Member] Corporate And Eliminations [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Tax-exempt municipal securities Nontaxable Municipal Notes [Member] Acquisitions, net of cash and cash equivalents acquired Cash paid for acquired businesses, net of cash and cash equivalents acquired Payments to Acquire Businesses, Net of Cash Acquired Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Shares used to compute diluted earnings per common share (in shares) Weighted Average Number of Shares Outstanding, Diluted Insurance [Abstract] Insurance [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] $500 million, 5.700% due March 13, 2026 5.70 Percent Senior Notes Due March 2026 [Member] 5.70 Percent Senior Notes Due March 2026 Total stockholders' equity Equity, Attributable to Parent Total external revenues External Revenues [Member] External Revenues TRICARE Contract [Domain] TRICARE Contract [Domain] TRICARE Contract [Domain] Due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Litigation Case [Axis] Litigation Case [Axis] Interest expense Interest Expense, Nonoperating Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments Schedule of Goodwill [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Mortgage and asset-backed securities Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost Operating costs Selling, General and Administrative Expense Other comprehensive (loss) income, net of tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Short-term debt Total short-term debt Debt, Current Recurring Basis Fair Value, Recurring [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current $600 million, 3.950% due March 15, 2027 3.95 Percent Senior Notes Due March 2027 [Member] 3.95 Percent Senior Notes Due March 2027 [Member] Products Product [Member] 12 months or more Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Actual debt to capitalization percentage Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual Other liabilities Increase (Decrease) in Other Operating Liabilities 364-day unsecured revolving credit agreement May 2024 Revolving Credit Agreement May 2024 One Year [Member] Revolving Credit Agreement May 2024 One Year Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus $600 million, 4.500% due April 1, 2025 4.50 Percent Senior Notes Due April 2025 [Member] A 4.50 Percent Senior Notes Due April 2025 [Member] All Executive Categories All Executive Categories [Member] Dilutive effect of employee stock options and restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Fair value of assets acquired, net of cash and cash equivalents acquired Fair Value of Assets Acquired 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Document Type Document Type Facility fee (percent) Line of Credit Facility, Commitment Fee Percentage Derivative Contract [Domain] Derivative Contract [Domain] Number of states comprising TRICARE beneficiaries Number Of States Comprising TRICARE Beneficiaries Number Of States Comprising TRICARE Beneficiaries Commercial paper Commercial Paper [Member] Restricted stock unit vesting Stock Issued During Period, Value, Restricted Stock Award, Gross Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] (Repayments) issuance of commercial paper, net Proceeds from (Repayments of) Commercial Paper Schedule of Segment Results Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Stock repurchase average price (in dollars per share) Shares Acquired, Average Cost Per Share Restricted stock unit vesting (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income Schedule of Realized Gain (Loss) [Table Text Block] Common shares acquired in connection with employee stock plans (in shares) Share Repurchases Related To Employee Stock Based Compensation Awards Shares Number of shares of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares. Amortized Cost Book value Debt Securities, Available-for-Sale, Amortized Cost Schedule of Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Total Stockholders' Equity Parent [Member] Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Amortization Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Amortizable intangible assets, net Finite-Lived Intangible Assets, Net Schedule of Activity in Benefits Payable Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Revenues: Revenues [Abstract] ACQUISITIONS Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Investment securities Short-Term Investments Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Segment earnings (loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Medicare licenses Licensing Agreements [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Weighted average life (in years) Finite-Lived Intangible Asset, Useful Life Paid related to: Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] Capital In Excess of Par Value Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] $750 million, 3.700% due March 23, 2029 3.700 Percent Senior Notes Due March 2029 [Member] 3.700 Percent Senior Notes Due March 2029 Subsequent Event Type [Domain] Subsequent Event Type [Domain] Short-term Debt [Line Items] Short-Term Debt [Line Items] Accounting Pronouncements Effective in Future Periods New Accounting Pronouncements, Policy [Policy Text Block] Forecast Forecast [Member] Diluted earnings per common share (in dollars per share) Earnings Per Share, Diluted Fair Value Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Amortizable intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Credit spread Credit Spread Option [Member] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Unearned revenues Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from sales of investment securities Proceeds from Sale of Debt Securities, Available-for-Sale Impairment of property and equipment Tangible Asset Impairment Charges Book overdraft Book Overdraft Liability Book Overdraft Liability Benefits Policyholder Benefits and Claims Incurred, Net Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] External Credit Rating, Standard & Poor's [Domain] External Credit Rating, Standard & Poor's [Domain] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Asset-backed securities Asset-backed securities Asset-Backed Securities [Member] Receivables Increase (Decrease) in Receivables Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Realized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings BENEFITS PAYABLE Insurance Disclosure [Text Block] Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net long-term asset (liability) Net Noncurrent Asset (Liability) Net Noncurrent Asset (Liability) Fair value of non-cash securities lending Securities Received as Collateral Provision for income taxes Income Tax Expense (Benefit) Stated interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Derivative, notional amount Derivative, Notional Amount Repayments of senior notes Repayments of Senior Debt Supplemental cash flow disclosures: Supplemental Cash Flow Information [Abstract] Services Service [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Number of states comprising of TRICARE managed care support contract beneficiaries Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Credit Rating, Standard & Poor's [Axis] Credit Rating, Standard & Poor's [Axis] 2023 Share Repurchase Authorization 2023 Share Repurchase Authorization [Member] 2023 Share Repurchase Authorization Effective income tax rate (percent) Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Income from operations Operating Income (Loss) Number of reportable segments Number of Reportable Segments Change in book overdraft Increase (Decrease) in Book Overdrafts Total liabilities and equity Liabilities and Equity Other Other Operating Activities, Cash Flow Statement Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Dividends paid Payments of Dividends Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Dispositions Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Scenario [Domain] Scenario [Domain] Measurement Input Type [Axis] Measurement Input Type [Axis] Individual: Individual [Axis] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Fair Value Risk Fair Value Risk [Member] Fair Value Risk CMS Subsidies/ Discounts Cms Subsidies Or Discounts [Member] CMS Subsidies Or Discounts [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Receivables and Other [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Annualized volatility Measurement Input, Option Volatility [Member] $750 million, 2.150% due February 3, 2032 2.15 Percent Senior Notes Due February 2032 [Member] 2.15 Percent Senior Notes Due February 2032 Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Fair Value Estimate of Fair Value Measurement [Member] Investment income Net Investment Income Long-term investment securities Debt Securities, Available-for-Sale, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Schedule of Investment Securities Classified as Current and Long-Term Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Due after five years through ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] $1,250 million, 5.375% due April 15, 2031 5.375 Percent Senior Notes Due April 2031 [Member] 5.375 Percent Senior Notes Due April 2031 Outstanding borrowings Line of Credit, Current Individual Medicare Advantage Medicare Advantage [Member] Medicare Advantage [Member] Segments [Axis] Segments [Axis] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] FHLB borrowings Federal Home Loan Bank Advances [Member] Exercise Price Award Exercise Price Fair value of financial liability Financial Liabilities Fair Value Disclosure EARNINGS PER COMMON SHARE COMPUTATION Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Stock option exercises Stock Issued During Period, Value, Stock Options Exercised GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Current year Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Debt instrument term (in years) Debt Instrument, Term 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Repayment of term loan Repayments of Unsecured Debt PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Debt outstanding Debt Instrument, Fair Value Disclosure Name Trading Arrangement, Individual Name Other (income) expense, net Other expense (income), net Other Nonoperating Income (Expense) Percentage of debt securities considered to be of investment-grade (percent) Percentage Of Total Debt Securities, Investment Grade Quality Percentage Of Total Debt Securities, Investment Grade Quality Total other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] $750 million, 5.500% due March 15, 2053 5.50 Percent Senior Notes Due March 2053 [Member] 5.50 Percent Senior Notes Due March 2053 Effect of income taxes Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax Disposal Group Name [Axis] Disposal Group Name [Axis] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Maturities Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Maturities Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Maturities Fair value of financial asset Financial Assets, Fair Value Disclosure Financial Assets, Fair Value Disclosure Percentage of premiums and services revenue Percentage Of Total Premium And Services Revenues Percentage Of Total Premium And Services Revenues Equity in net losses Equity in net losses Equity in net losses Income (Loss) from Equity Method Investments Treasury stock, at cost, 78,307,467 shares at September 30, 2024 and 76,465,862 shares at December 31, 2023 Treasury Stock, Common, Value COMMITMENTS, GUARANTEES AND CONTINGENCIES Commitments Contingencies and Guarantees [Text Block] Income (loss) before income taxes and equity in net losses Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Contract base term TRICARE Managed Care Support Contract, Base Term TRICARE Managed Care Support Contract, Base Term Call option Call Option [Member] Cumulative, aggregate adjustment Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Maximum individual state general bond obligation as a percentage of total debt securities (percent) Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Incurred related to: Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract] Interest Rate Swap Maturing 2033 Interest Rate Swap Maturing 2033 [Member] Interest Rate Swap Maturing 2033 Maximum amount outstanding during period Short-Term Debt, Maximum Amount Outstanding During Period Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Fair Value Debt Securities, Available-for-Sale, Unrealized Gain (Loss) [Abstract] Trade accounts payable and accrued expenses Trade accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Proceeds from issuance of senior notes, net Proceeds from Issuance of Senior Long-Term Debt Local Phone Number Local Phone Number Pharmacy solutions Pharmacy Solutions [Member] Pharmacy Solutions Total other intangible assets, cost Intangible Assets, Gross (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Securities in unrealized loss positions, number of positions Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Home solutions Home Solutions [Member] Home Solutions Other assets Increase (Decrease) in Other Operating Assets Changes in operating assets and liabilities, net of effect of businesses acquired and disposed: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount 364-day unsecured revolving credit agreement June 2023 Revolving Credit Agreement June 2023 One Year [Member] Revolving Credit Agreement June 2023 One Year Share Repurchase Program [Domain] Share Repurchase Program [Domain] Interest Rate Swap Maturing 2054 Interest Rate Swap Maturing 2054 [Member] Interest Rate Swap Maturing 2054 Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Schedule of Balance Sheet Amounts Associated With Medicare Part D Balance Sheet Account Associated With Medicare Part D Table [Table Text Block] Balance Sheet Account Associated With Medicare Part D 2024 Share Repurchase Authorization 2024 Share Repurchase Authorization [Member] 2024 Share Repurchase Authorization Scenario [Axis] Scenario [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Total incurred Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount MEDICARE PART D Medicare Part D Disclosure [Text Block] Balance sheet amounts associated with Medicare Part D. STOCKHOLDERS' EQUITY Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Total senior notes Long-Term Debt, Current Maturities SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Swap asset Interest Rate Fair Value Hedge Asset at Fair Value Class of Treasury Stock [Table] Class of Treasury Stock [Table] Benefits payable Increase (Decrease) in Health Care Insurance Liabilities Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restricted stock Restricted Stock [Member] Entity Shell Company Entity Shell Company Measurement Basis [Axis] Measurement Basis [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Details of Dividend Payments Dividends Declared [Table Text Block] Other intangible assets: Intangible Assets, Net (Excluding Goodwill) [Abstract] Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Interest Rate Swap Maturing 2049 Interest Rate Swap Maturing 2049 [Member] Interest Rate Swap Maturing 2049 Measurement Frequency [Domain] Measurement Frequency [Domain] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Consolidation Items [Domain] Consolidation Items [Domain] For the years ending December 31, Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Investments Investments [Member] Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Interest payments Interest Paid, Excluding Capitalized Interest, Operating Activities Segment earnings (loss) attributable to Humana Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Parent Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Parent Specialty benefits Specialty Benefits [Member] Specialty [Member] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Revenue Recognition Revenue [Policy Text Block] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Details of businesses acquired in purchase transactions: Noncash Investing and Financing Items [Abstract] Number of TRICARE beneficiaries Number Of TRICARE Beneficiaries Number Of TRICARE Beneficiaries Increase commitments Line Of Credit Facility, Maximum Borrowing Capacity Increase (Decrease) Line Of Credit Facility, Maximum Borrowing Capacity Increase (Decrease) $400 million, 4.800% due March 15, 2047 4.80 Percent Senior Notes Due March 2047 [Member] 4.80 Percent Senior Notes Due March 2047 [Member] Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Common stock repurchases Payments for Repurchase of Common Stock Noncompetes and other Noncompetes And Other [Member] Noncompetes and Other [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Reclassification adjustment for net realized losses (gains) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Assumptions Used For Inputs In Fair Value Measurement Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Due after five years through ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Subsequent Event Type [Axis] Subsequent Event Type [Axis] Insurance Insurance Segment [Member] Insurance Segment Total paid Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid INCOME TAXES Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Contract term with exercises TRICARE Managed Care Support Contract, Term With Option Exercises TRICARE Managed Care Support Contract, Term With Option Exercises Provider contracts Contractual Rights [Member] Schedule of Carrying Value of Debt Outstanding Schedule of Debt [Table Text Block] Unrealized gains (losses) recognized on equity securities still held at the end of the period Equity Securities, FV-NI, Unrealized Gain (Loss) Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Unrealized in other comprehensive income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount INVESTMENT SECURITIES Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Risk Corridor Settlement Risk Corridor Settlements Medicare Part D [Member] Risk Corridor Settlements - Medicare Part D [Member] Medicare Total Medicare Medicare [Member] Medicare [Member] Credit Facility [Axis] Credit Facility [Axis] Gentiva Hospice Gentiva Hospice [Member] Gentiva Hospice Dividends and dividend equivalents Dividends, Common Stock, Cash Long term growth rate Measurement Input, Long-Term Revenue Growth Rate [Member] S&P AA- rating Standard & Poor's, AA- Rating [Member] Amendment Flag Amendment Flag Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table] Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table] Carrying Value Reported Value Measurement [Member] Entity Registrant Name Entity Registrant Name Commercial Commercial Mortgage-Backed Securities [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Less: Noncontrolling interests acquired Noncash or Part Noncash Acquisition, Noncontrolling Interest Acquired Noncash or Part Noncash Acquisition, Noncontrolling Interest Acquired $250 million, 8.150% due June 15, 2038 8.15 Percent Senior Notes Due June 2038 [Member] 8.15 Percent Senior Notes Due June 2038 [Member] Securities lending invested collateral Securities Loaned, Fair Value of Collateral Fair Value as of Grant Date Award Grant Date Fair Value Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Uncommitted incremental loan facility Line Of Credit Facility, Uncommitted Incremental Capacity Line Of Credit Facility, Uncommitted Incremental Capacity Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Due within one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One DEBT Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of Other Intangible Assets, Indefinite-Lived Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Aggregate principal Debt Instrument, Face Amount Entity Address, Postal Zip Code Entity Address, Postal Zip Code Interest Rate Swap Interest Rate Swap [Member] Restatement Determination Date: Restatement Determination Date [Axis] United States Of America Ex Rel. Steven Scott V. Humana Inc. United States Of America Ex Rel. Steven Scott V. Humana Inc. [Member] United States Of America Ex Rel. Steven Scott V. Humana Inc. Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,718,810 shares issued at September 30, 2024 and 198,690,082 shares issued at December 31, 2023 Common Stock, Value, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Value Creation Initiatives Value Creation Initiatives [Member] Value Creation Initiatives Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Acquired Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, $1 par; 10,000,000 shares authorized; none issued Preferred Stock, Value, Issued $500 million, 5.750% due December 1, 2028 5.750 Percent Senior Notes Due December 2028 [Member] 5.750 Percent Senior Notes Due December 2028 Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Fair Value Measurement [Domain] Fair Value Measurement [Domain] Basic earnings per common share (in dollars per share) Earnings Per Share, Basic Schedule of Short-term Debt [Table] Short-Term Debt [Table] Primary care Primary Care [Member] Primary Care Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Group Medicare Advantage Group Medicare Advantage [Member] Group Medicare Advantage Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Schedule of Goodwill [Table] Goodwill [Table] Amortization Amortization Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] 5-year unsecured revolving credit agreement June 2021 Revolving Credit Agreement June 2021 Five Year [Member] Revolving Credit Agreement June 2021 Five Year Share Repurchase Program [Axis] Share Repurchase Program [Axis] Total assets Assets (Gain) loss on investment securities, net Net recognized gains (losses) on investment securities Debt and Equity Securities, Gain (Loss) 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Military services and other Military And Other [Member] Military And Other U.S. Treasury and agency obligations US Treasury and Government [Member] Schedule of Financial Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Purchases of property and equipment, net Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other long-term liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and Contingencies (Note 13) Commitments and Contingencies Gross losses on investment securities Debt And Equity Securities, Realized Loss Debt And Equity Securities, Realized Loss Total reclassification adjustment, net of tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax $750 million, 4.950% due October 1, 2044 4.95 Percent Senior Notes Due October 2044 [Member] 4.95 Percent Senior Notes Due October 2044 [Member] Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total revenues Revenues Interest Rate Swap Maturing 2044 Interest Rate Swap Maturing 2044 [Member] Interest Rate Swap Maturing 2044 Interest Rate Swap Maturing 2034 Interest Rate Swap Maturing 2034 [Member] Interest Rate Swap Maturing 2034 Entity Address, City or Town Entity Address, City or Town Due after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Debt Instrument [Axis] Debt Instrument [Axis] Net income attributable to Humana Net income attributable to Humana Net income available for common stockholders Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Services Services revenue Revenue from Contract with Customer, Including Assessed Tax Certificates of need Certificate Of Need [Member] Certificate Of Need Total IBNR included in benefits payable Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Other Intangible Assets, Amortizable Schedule of Finite-Lived Intangible Assets [Table Text Block] Total net asset (liability) Net Asset (Liability) Net Asset (Liability) Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Due after ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Investment Securities, Available-for-sale Amortized Cost to Fair Value Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Total operating expenses Benefits, Losses and Expenses Entity File Number Entity File Number 5-year unsecured revolving credit agreement June 2023 Revolving Credit Agreement June 2023 Five Year [Member] Revolving Credit Agreement June 2023 Five Year Document Fiscal Year Focus Document Fiscal Year Focus Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One CenterWell CenterWell Segment [Member] CenterWell Segment Common stock repurchases Stock repurchases Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Total Amount Dividends, Common Stock Total invested assets Assets, Fair Value Disclosure Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date 2023 And 2024 Share Repurchase Authorization 2023 And 2024 Share Repurchase Authorization [Member] 2023 And 2024 Share Repurchase Authorization Put option Put Option [Member] Investment Securities Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Medicare Supplement Medicare Supplement Product [Member] Medicare Supplement Product Mortgage and asset-backed securities Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value Gross gains on equity securities Equity Securities, FV-NI, Realized Gain TRICARE Contract [Axis] TRICARE Contract [Axis] TRICARE Contract Insider Trading Arrangements [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Significant unobservable inputs Derivative Asset (Liability) Net, Measurement Input Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Net current liability Net Current (Liability) Asset Net current (liability) asset Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Medicaid Medicaid [Member] Medicaid [Member] Minimum collateral as percentage of fair value of investment securities Securities Loaned, Minimum Collateral As Percentage Of Fair Value Of Investment Securities Securities Loaned, Minimum Collateral As Percentage Of Fair Value Of Investment Securities PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Revenue exit multiple Revenue Exit Multiple [Member] Revenue Exit Multiple Adjustment to Compensation: Adjustment to Compensation [Axis] Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items] Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Current year Current Year Claims and Claims Adjustment Expense Due after one year through five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five $1,000 million, 5.750% due April 15, 2054 5.750 Percent Senior Notes Due April 2054 [Member] 5.750 Percent Senior Notes Due April 2054 Litigation Case [Domain] Litigation Case [Domain] Customer [Domain] Customer [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Schedule of Gain (Loss) on Equity Securities Gain (Loss) on Securities [Table Text Block] Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Distributions from (to) noncontrolling interest holders, net Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions From Noncontrolling Interest Holders Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions From Noncontrolling Interest Holders Weighted average outstanding shares of common stock used to compute basic earnings per common share (in shares) Weighted Average Number of Shares Outstanding, Basic $750 million, 5.875% due March 1, 2033 5.875 Percent Senior Notes Due March 2033 [Member] 5.875 Percent Senior Notes Due March 2033 Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Effect of income taxes OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Premiums Premiums Earned, Net 12 months or more Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name $500 million, 5.750% due March 1, 2028 5.750 Percent Senior Notes Due March 2028 [Member] 5.750 Percent Senior Notes Due March 2028 Annual option periods TRICARE Managed Care Support Contract, Number Of Option Periods TRICARE Managed Care Support Contract, Number Of Option Periods Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Entity Filer Category Entity Filer Category Purchases of investment securities Payments to Acquire Debt Securities, Available-for-Sale Loss Contingencies [Line Items] Loss Contingencies [Line Items] Letter of credit Letter of Credit [Member] Interest Rate Swap Maturing 2042 Interest Rate Swap Maturing 2042 [Member] Interest Rate Swap Maturing 2042 Company Selected Measure Name Company Selected Measure Name Commercial fully-insured Commercial Fully-Insured [Member] Commercial Fully-Insured Health Care [Member] EX-101.PRE 9 hum-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover
 9 Months Ended
Sep. 30, 2024
shares
Cover [Abstract]  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Sep. 30, 2024
Document Transition Report false
Entity File Number 1-5975
Entity Registrant Name HUMANA INC
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 61-0647538
Entity Address, Address Line One 500 West Main Street
Entity Address, City or Town Louisville
Entity Address, State or Province KY
Entity Address, Postal Zip Code 40202
City Area Code 502
Local Phone Number 580-1000
Title of 12(b) Security Common stock, $0.16 2/3 par value
Trading Symbol HUM
Security Exchange Name NYSE
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 120,411,343
Entity Central Index Key 0000049071
Current Fiscal Year End Date --12-31
Document Fiscal Year Focus 2024
Document Fiscal Period Focus Q3
Amendment Flag false
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 5,116 $ 4,694
Investment securities 19,033 16,626
Receivables, net of allowances of $93 in 2024 and $88 in 2023 2,144 2,035
Other current assets 6,633 6,631
Total current assets 32,926 29,986
Property and equipment, net 2,693 3,030
Long-term investment securities 400 382
Equity method investments 729 740
Goodwill 9,590 9,550
Other long-term assets 3,669 3,377
Total assets 50,007 47,065
Current liabilities:    
Benefits payable 11,125 10,241
Trade accounts payable and accrued expenses 5,915 6,569
Book overdraft 356 353
Unearned revenues 195 266
Short-term debt 1,136 1,443
Total current liabilities 18,727 18,872
Long-term debt 11,886 10,213
Other long-term liabilities 1,770 1,662
Total liabilities 32,383 30,747
Commitments and Contingencies (Note 13)
Stockholders’ equity:    
Preferred stock, $1 par; 10,000,000 shares authorized; none issued 0 0
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,718,810 shares issued at September 30, 2024 and 198,690,082 shares issued at December 31, 2023 33 33
Capital in excess of par value 3,471 3,346
Retained earnings 29,118 27,540
Accumulated other comprehensive loss (653) (999)
Treasury stock, at cost, 78,307,467 shares at September 30, 2024 and 76,465,862 shares at December 31, 2023 (14,404) (13,658)
Total stockholders' equity 17,565 16,262
Noncontrolling interests 59 56
Total equity 17,624 16,318
Total liabilities and equity $ 50,007 $ 47,065
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Receivables, net of allowances $ 93 $ 88
Preferred stock, par (in dollars per share) $ 1 $ 1
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par (in dollars per share) $ 0.1667 $ 0.1667
Common stock, shares authorized (in shares) 300,000,000 300,000,000
Common stock, shares issued (in shares) 198,718,810 198,690,082
Treasury stock, shares (in shares) 78,307,467 76,465,862
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues:        
Premiums $ 27,951 $ 25,099 $ 84,354 $ 76,144
Services 1,103 1,016 3,265 2,993
Investment income 343 308 929 775
Total revenues 29,397 26,423 88,548 79,912
Operating expenses:        
Benefits 25,120 21,745 75,283 65,612
Operating costs 3,339 3,271 9,529 9,361
Depreciation and amortization 210 201 631 578
Total operating expenses 28,669 25,217 85,443 75,551
Income from operations 728 1,206 3,105 4,361
Interest expense 169 114 496 347
Other (income) expense, net (92) (6) 26 40
Income (loss) before income taxes and equity in net losses 651 1,098 2,583 3,974
Provision for income taxes 155 256 629 911
Equity in net losses (16) (12) (57) (39)
Net income 480 830 1,897 3,024
Net loss attributable to noncontrolling interests 0 2 3 6
Net income attributable to Humana $ 480 $ 832 $ 1,900 $ 3,030
Basic earnings per common share (in dollars per share) $ 3.99 $ 6.74 $ 15.76 $ 24.37
Diluted earnings per common share (in dollars per share) $ 3.98 $ 6.71 $ 15.72 $ 24.26
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Health Care [Member] Health Care [Member] Health Care [Member] Health Care [Member]
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Comprehensive Income [Abstract]        
Net income attributable to Humana $ 480 $ 832 $ 1,900 $ 3,030
Other comprehensive income (loss):        
Change in gross unrealized investment (losses) gains 619 (365) 458 (314)
Effect of income taxes (142) 85 (104) 73
Total change in unrealized investment (losses) gains, net of tax 477 (280) 354 (241)
Reclassification adjustment for net realized losses (gains) (10) 3 (10) 56
Effect of income taxes 2 0 2 (14)
Total reclassification adjustment, net of tax (8) 3 (8) 42
Other comprehensive (loss) income, net of tax 469 (277) 346 (199)
Comprehensive income attributable to Humana $ 949 $ 555 $ 2,246 $ 2,831
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($)
shares in Thousands, $ in Millions
Total
Total Stockholders' Equity
Common Stock
Capital In Excess of Par Value
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury Stock
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2022     198,667          
Beginning balance at Dec. 31, 2022 $ 15,370 $ 15,311 $ 33 $ 3,246 $ 25,492 $ (1,304) $ (12,156) $ 59
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 3,024 3,030     3,030     (6)
Distributions from (to) noncontrolling interest holders, net 7             7
Acquisition (5)             (5)
Other comprehensive income (loss) (199) (199)       (199)    
Common stock repurchases (1,011) (1,011)         (1,011)  
Dividends and dividend equivalents (331) (331)     (331)      
Stock-based compensation 142 142   142        
Restricted stock unit vesting (in shares)     23          
Restricted stock unit vesting 0     (30)     30  
Stock option exercises 7 7   4     3  
Ending balance (in shares) at Sep. 30, 2023     198,690          
Ending balance at Sep. 30, 2023 17,004 16,949 $ 33 3,362 28,191 (1,503) (13,134) 55
Beginning balance (in shares) at Jun. 30, 2023     198,690          
Beginning balance at Jun. 30, 2023 16,891 16,834 $ 33 3,313 27,468 (1,226) (12,754) 57
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 830 832     832     (2)
Other comprehensive income (loss) (277) (277)       (277)    
Common stock repurchases (383) (383)         (383)  
Dividends and dividend equivalents (109) (109)     (109)      
Stock-based compensation 53 53   53        
Restricted stock unit vesting 0     (3)     3  
Stock option exercises (1) (1)   (1)        
Ending balance (in shares) at Sep. 30, 2023     198,690          
Ending balance at Sep. 30, 2023 17,004 16,949 $ 33 3,362 28,191 (1,503) (13,134) 55
Beginning balance (in shares) at Dec. 31, 2023     198,690          
Beginning balance at Dec. 31, 2023 16,318 16,262 $ 33 3,346 27,540 (999) (13,658) 56
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 1,897 1,900     1,900     (3)
Distributions from (to) noncontrolling interest holders, net 6             6
Other comprehensive income (loss) 346 346       346    
Common stock repurchases (774) (774)         (774)  
Dividends and dividend equivalents (322) (322)     (322)      
Stock-based compensation 153 153   153        
Restricted stock unit vesting (in shares)     29          
Restricted stock unit vesting 0     (28)     28  
Ending balance (in shares) at Sep. 30, 2024     198,719          
Ending balance at Sep. 30, 2024 17,624 17,565 $ 33 3,471 29,118 (653) (14,404) 59
Beginning balance (in shares) at Jun. 30, 2024     198,719          
Beginning balance at Jun. 30, 2024 16,728 16,671 $ 33 3,420 28,745 (1,122) (14,405) 57
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 480 480     480      
Distributions from (to) noncontrolling interest holders, net 2             2
Other comprehensive income (loss) 469 469       469    
Common stock repurchases (1) (1)         (1)  
Dividends and dividend equivalents (107) (107)     (107)      
Stock-based compensation 53 53   53        
Restricted stock unit vesting 0     (2)     2  
Ending balance (in shares) at Sep. 30, 2024     198,719          
Ending balance at Sep. 30, 2024 $ 17,624 $ 17,565 $ 33 $ 3,471 $ 29,118 $ (653) $ (14,404) $ 59
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities    
Net income $ 1,897 $ 3,024
Adjustments to reconcile net income to net cash provided by operating activities:    
(Gain) loss on investment securities, net (10) 49
Equity in net losses 57 39
Stock-based compensation 153 142
Depreciation 682 628
Amortization 46 51
Impairment of property and equipment 129 31
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:    
Receivables (109) (126)
Other assets 258 (935)
Benefits payable 884 870
Other liabilities (498) 39
Unearned revenues (71) 7,250
Other 76 53
Net cash provided by operating activities 3,494 11,115
Cash flows from investing activities    
Acquisitions, net of cash and cash equivalents acquired (37) (223)
Purchases of property and equipment, net (421) (721)
Purchases of investment securities (6,403) (3,366)
Proceeds from maturities of investment securities 2,214 885
Proceeds from sales of investment securities 1,758 815
Net cash used in investing activities (2,889) (2,610)
Cash flows from financing activities    
(Payments) receipts from contract deposits, net (638) 2,481
Proceeds from issuance of senior notes, net 2,232 1,215
Repayments of senior notes (48) (1,719)
(Repayments) issuance of commercial paper, net (895) 1,618
Repayment of term loan 0 (500)
Debt issue costs (7) (4)
Change in book overdraft 3 (52)
Common stock repurchases (768) (1,002)
Dividends paid (323) (320)
Other 261 (135)
Net cash (used in) provided by financing activities (183) 1,582
Increase in cash and cash equivalents 422 10,087
Cash and cash equivalents at beginning of period 4,694 5,061
Cash and cash equivalents at end of period 5,116 15,148
Supplemental cash flow disclosures:    
Interest payments 416 317
Income tax payments, net 570 957
Details of businesses acquired in purchase transactions:    
Fair value of assets acquired, net of cash and cash equivalents acquired 49 454
Less: Fair value of liabilities assumed (12) (236)
Less: Noncontrolling interests acquired 0 5
Cash paid for acquired businesses, net of cash and cash equivalents acquired $ 37 $ 223
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS BASIS OF PRESENTATION AND SIGNIFICANT EVENTS
The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.
The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.
Employer Group Commercial Medical Products Business Exit
In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. We anticipate the exit of this line of business to be finalized in the first half of 2025.

Value Creation Initiatives
Beginning in 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges, primarily in asset impairments, of $55 million and $151 million for the three and nine months ended September 30, 2024, respectively, and $52 million for the three and nine months ended September 30, 2023 within operating costs in the condensed consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024.
Revenue Recognition
Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
At September 30, 2024, accounts receivable related to services were $428 million. For the three and nine months ended September 30, 2024, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at September 30, 2024.
For the three and nine months ended September 30, 2024, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.

Investment Securities
We participate in a securities lending program to optimize investment income. We loan certain investment securities for short periods of time in exchange for collateral initially equal to at least 102% of the fair value of the investment securities on loan. The fair value of the loaned investment securities is monitored on a daily basis, with additional collateral obtained or refunded as the fair value of the loaned investment securities fluctuates. The collateral, which may be in the form of cash or U.S. Government securities, is deposited by the borrower with an independent lending agent. Any cash collateral, which is reinvested by the lending agent primarily in short-term, highly liquid investments, is recorded as a securities lending collateral asset within other current assets on our consolidated balance sheet at September 30, 2024. We record a corresponding liability to reflect our obligation to return the collateral within trade accounts payable and accrued expenses on our consolidated balance sheet at September 30, 2024. Collateral received in the form of securities is not recorded in our consolidated balance sheets because, absent default by the borrower, we do not have the right to sell, pledge or otherwise reinvest securities collateral. Loaned securities continue to be carried as investment securities on the consolidated balance sheet at September 30, 2024. Earnings on the invested cash collateral, net of expense, associated with the securities lending payable are recorded as investment income.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
 9 Months Ended
Sep. 30, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]  
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Accounting Pronouncements Effective in Future Periods
In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We do not believe the adoption of ASU 2023-07 will have a material impact on our consolidated financial statements or disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be
effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3
ACQUISITIONS
 9 Months Ended
Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
ACQUISITIONS ACQUISITIONS
During 2024 and 2023, respectively, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in 2024 and 2023, respectively, have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in 2024 and 2023, were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the quarter of acquisition, were not material for disclosure purposes.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3
INVESTMENT SECURITIES
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
INVESTMENT SECURITIES INVESTMENT SECURITIES
Investment securities classified as current and long-term were as follows at September 30, 2024 and December 31, 2023, respectively:
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
 (in millions)
September 30, 2024
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$3,203 $13 $(33)$3,183 
Mortgage-backed securities4,501 33 (351)4,183 
Tax-exempt municipal securities602 — (18)584 
Mortgage-backed securities:
Residential555 1 (54)502 
Commercial1,292 2 (78)1,216 
Asset-backed securities1,533 11 (20)1,524 
Corporate debt securities8,593 92 (444)8,241 
Total debt securities$20,279 $152 $(998)$19,433 
December 31, 2023
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$2,717 $1 $(51)$2,667 
Mortgage-backed securities3,946 1 (425)3,522 
Tax-exempt municipal securities879 1 (22)858 
Mortgage-backed securities:
Residential465 1 (66)400 
Commercial1,471 — (126)1,345 
Asset-backed securities1,813 2 (44)1,771 
Corporate debt securities7,011 28 (594)6,445 
Total debt securities$18,302 $34 $(1,328)$17,008 
We own certain corporate debt securities of Gentiva Hospice. The book value and fair value are $381 million and $396 million, respectively, at September 30, 2024. The book value and fair value were $379 million and $398 million, respectively, at December 31, 2023.
We participate in a securities lending program where we loan certain investment securities for short periods of time in exchange for collateral, consisting of cash or U.S. Government securities, initially equal to at least 102% of the fair value of the investment securities on loan. Collateral with a fair value of $361 million was held at September 30, 2024. At September 30, 2024, collateral from lending our investment securities has been reinvested in short-term, highly liquid assets. In addition, we participated in non-cash securities lending with a fair value of $148 million at September 30, 2024.
Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at September 30, 2024 and December 31, 2023, respectively:
 Less than 12 months12 months or moreTotal
 Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
 (in millions)
September 30, 2024
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$551 $(2)$518 $(31)$1,069 $(33)
Mortgage-backed securities330 (2)2,378 (349)2,708 (351)
Tax-exempt municipal securities77 — 417 (18)494 (18)
Mortgage-backed securities:
Residential57 (2)361 (52)418 (54)
Commercial26 (1)1,124 (77)1,150 (78)
Asset-backed securities218 (1)571 (19)789 (20)
Corporate debt securities290 (1)4,466 (443)4,756 (444)
Total debt securities$1,549 $(9)$9,835 $(989)$11,384 $(998)
December 31, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$1,899 $(12)$431 $(39)$2,330 $(51)
Mortgage-backed securities958 (12)2,269 (413)3,227 (425)
Tax-exempt municipal securities160 (1)523 (21)683 (22)
Mortgage-backed securities:
Residential— — 373 (66)373 (66)
Commercial18 — 1,303 (126)1,321 (126)
Asset-backed securities120 (1)1,364 (43)1,484 (44)
Corporate debt securities466 (2)4,783 (592)5,249 (594)
Total debt securities$3,621 $(28)$11,046 $(1,300)$14,667 $(1,328)

Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by Standard & Poor's Rating Service, or S&P, at September 30, 2024. Our remaining debt securities below investment-grade were primarily rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.
Our unrealized losses from all debt securities were generated from approximately 1,300 positions out of a total of approximately 2,290 positions at September 30, 2024. All issuers of debt securities we own that were trading at an unrealized loss at September 30, 2024 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At September 30,
2024, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three and nine months ended September 30, 2024 or 2023.
The detail of gains (losses) related to investment securities and included within investment income was as follows for the three and nine months ended September 30, 2024 and 2023:
 Three months ended September 30,Nine months ended September 30,
 2024202320242023
 (in millions)(in millions)
Gross gains on investment securities$14 $— $16 $15 
Gross losses on investment securities(4)(4)(6)(65)
Gross gains on equity securities— — — 1 
Gross losses on equity securities— — — — 
Net recognized gains (losses) on investment securities$10 $(4)$10 $(49)
The gains and losses related to equity securities for the three and nine months ended September 30, 2024 and 2023 was as follows:
Three months ended September 30,Nine Months Ended September 30,
2024202320242023
(in millions)(in millions)
Net gains recognized on equity securities during the period$— $— $— $1 
Less: Net gains recognized on equity securities sold during the period— — — — 
Unrealized gains (losses) recognized on equity securities still held at the end of the period$— $— $— $1 
The contractual maturities of debt securities available for sale at September 30, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.
Amortized
Cost		Fair
Value
 (in millions)
Due within one year$1,082 $1,079 
Due after one year through five years5,669 5,584 
Due after five years through ten years4,407 4,261 
Due after ten years1,240 1,084 
Mortgage and asset-backed securities7,881 7,425 
Total debt securities$20,279 $19,433 
For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3
FAIR VALUE
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE FAIR VALUE
Financial Assets
The following table summarizes our fair value measurements at September 30, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:
 Fair Value Measurements Using
 Fair
Value		Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)
 (in millions)
September 30, 2024
Cash equivalents$4,941 $4,941 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations3,183 — 3,183 — 
Mortgage-backed securities4,183 — 4,183 — 
Tax-exempt municipal securities584 — 584 — 
Mortgage-backed securities:
Residential502 — 500 2 
Commercial1,216 — 1,216 — 
Asset-backed securities1,524 — 1,479 45 
Corporate debt securities8,241 — 7,997 244 
Total debt securities19,433 — 19,142 291 
Securities lending invested collateral361 361 — — 
Total invested assets$24,735 $5,302 $19,142 $291 
December 31, 2023
Cash equivalents$4,582 $4,582 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations2,667 — 2,667 — 
Mortgage-backed securities3,522 — 3,522 — 
Tax-exempt municipal securities858 — 858 — 
Mortgage-backed securities:
Residential400 — 396 4 
Commercial1,345 — 1,345 — 
Asset-backed securities1,771 — 1,733 38 
Corporate debt securities6,445 — 6,269 176 
Total debt securities$17,008 $— $16,790 $218 
Our Level 3 assets had a fair value of $291 million, or 1.2% of total invested assets, and $218 million, or 1.0% or total invested assets, at September 30, 2024 and December 31, 2023, respectively. During the nine months ended
September 30, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    
Private Placements
For the nine months ended September 30, 2024For the nine months ended September 30, 2023
(in millions)
Beginning balance at January 1$218 $101 
Total gains or losses:
Realized in earnings— — 
Unrealized in other comprehensive income6 (1)
Purchases72 13 
Maturities— (4)
Sales— — 
Settlements(5)— 
Transfer out— (4)
Balance at September 30$291 $105 
Interest Rate Swaps

We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on Secured Overnight Financing Rate (SOFR), to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our condensed consolidated balance sheets at fair value as of the reporting date. Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy. The cumulative, aggregate adjustment to the carrying value of the senior notes was approximately $117 million at September 30, 2024. The swap asset, included within other long-term assets on our condensed consolidated balance sheet was approximately $117 million at September 30, 2024. The swap asset, included within other long-term assets on our condensed consolidated balance sheets, was approximately $68 million at December 31, 2023. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three and nine months ended September 30, 2024 and 2023. The following table summarizes the notional amounts at September 30, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:

September 30, 2024December 31, 2023
(in millions)
$750 million, 5.875% due March 1, 2033
$650 $650 
$850 million, 5.950% due March 15, 2034
800 400 
$500 million, 3.950% due August 15, 2049
450 450 
$750 million, 5.500% due March 15, 2053
700 300 
$400 million, 4.625% due December 1, 2042
400 — 
$750 million, 4.950% due October 1, 2044
400 — 
$1,000 million, 5.750% due April 15, 2054
400 — 
Financial Liabilities
Our debt is recorded at carrying value in our condensed consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $13.0 billion at September 30, 2024 and $10.8 billion at December 31, 2023. The fair value of our senior notes debt was $12.9 billion at September 30, 2024 and $10.6 billion at December 31, 2023. The fair value of our senior notes debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our commercial paper borrowings. We had no outstanding commercial paper borrowings at September 30, 2024. The commercial paper borrowings were $0.9 billion at December 31, 2023.
Put and Call Options Measured at Fair Value
Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation.
The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $742 million and $24 million, respectively, at September 30, 2024. The put and call options fair values, derived from the Monte Carlo simulation, were $595 million and $18 million, respectively, at December 31, 2023. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets.
The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.
September 30, 2024December 31, 2023
Annualized volatility
16.5% - 18.3%
16.1% - 17.8%
Credit spread
0.8% - 1.4%
0.9% - 1.1%
Revenue exit multiple
1.5x - 2.5x
1.5x - 2.5x
Weighted average cost of capital
11.0% - 14.0%
11.0% - 12.5%
Long term growth rate3.0 %3.0 %
The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.
Other Assets and Liabilities Measured at Fair Value
Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2024 and 2023. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based primarily on the income approach. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing
of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.
Other than the assets and liabilities acquired during 2024 and 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2024 and 2023.
For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3
MEDICARE PART D
 9 Months Ended
Sep. 30, 2024
Insurance [Abstract]  
MEDICARE PART D MEDICARE PART D
We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at September 30, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.

 September 30, 2024December 31, 2023
Risk
Corridor
Settlement		CMS
Subsidies/
Discounts		Risk
Corridor
Settlement		CMS
Subsidies/
Discounts
 (in millions)
Other current assets$107 $846 $224 $514 
Trade accounts payable and accrued expenses(114)(1,594)(232)(1,825)
Net current liability(7)(748)(8)(1,311)
Other long-term assets298 — 17 — 
Other long-term liabilities(62)— (77)— 
Net long-term asset (liability)236 — (60)— 
Total net asset (liability)$229 $(748)$(68)$(1,311)
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Changes in the carrying amount of goodwill for our reportable segments for the nine months ended September 30, 2024 were as follows:
InsuranceCenterWellTotal
 (in millions)
Balance at January 1, 2024$2,663 $6,887 $9,550 
Acquisitions— 40 40 
Balance at September 30, 2024$2,663 $6,927 $9,590 
The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2024 and December 31, 2023:
 September 30, 2024December 31, 2023
Weighted
Average
Life		CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
 ($ in millions)
Other intangible assets:
Certificates of needIndefinite$1,092 $— $1,092 $1,092 $— $1,092 
Medicare licensesIndefinite288 — 288 288 — 288 
Customer contracts/
    relationships		9.4 years956 749 207 956 718 238 
Trade names and
    technology		6.7 years139 116 23 139 109 30 
Provider contracts11.9 years67 63 4 67 62 5 
Noncompetes and
    other		8.4 years85 49 36 84 44 40 
Total other intangible
    assets		9.2 years$2,627 $977 $1,650 $2,626 $933 $1,693 
    For the three months ended September 30, 2024 and 2023, amortization expense for other intangible assets was approximately $15 million and $17 million, respectively. For the nine months ended September 30, 2024 and 2023, amortization expense for other intangible assets was approximately $46 million and $51 million, respectively. The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at September 30, 2024:
 (in millions)
For the years ending December 31,
2024$15 
202558 
202643 
202733 
202829 
202927 
For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3
BENEFITS PAYABLE
 9 Months Ended
Sep. 30, 2024
Insurance [Abstract]  
BENEFITS PAYABLE BENEFITS PAYABLE
On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the nine months ended September 30, 2024 and 2023:
For the nine months ended September 30,
20242023
(in millions)
Balances, beginning of period$10,241 $9,264 
Acquisitions— 62 
Incurred related to:
Current year75,976 66,370 
Prior years(693)(758)
Total incurred75,283 65,612 
Paid related to:
Current year(65,282)(56,700)
Prior years(9,117)(8,042)
Total paid(74,399)(64,742)
Balances, end of period$11,125 $10,196 
The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At September 30, 2024, benefits payable included IBNR of approximately $7.2 billion, primarily associated with claims incurred in 2024.
Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).
Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3
EARNINGS PER COMMON SHARE COMPUTATION
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE COMPUTATION EARNINGS PER COMMON SHARE COMPUTATION
Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and nine months ended September 30, 2024 and 2023:
Three months ended September 30,Nine months ended September 30,
2024202320242023
(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders$480 $832 $1,900 $3,030 
Weighted average outstanding shares of common stock
    used to compute basic earnings per common share		120,405 123,426 120,609 124,335 
Dilutive effect of:
Employee stock options3 26 4 31 
Restricted stock356 531 286 519 
Shares used to compute diluted earnings per common share120,764 123,983 120,899 124,885 
Basic earnings per common share$3.99 $6.74 $15.76 $24.37 
Diluted earnings per common share$3.98 $6.71 $15.72 $24.26 
Number of antidilutive stock options and restricted stock
    excluded from computation		361 137 759 251 
For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Dividends
The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:
Record
Date		Payment
Date		Amount
per Share		Total
Amount
(in millions)
2024 payments
12/29/20231/26/2024$0.8850 $108 
3/29/20244/26/2024$0.8850 $107 
6/28/20247/26/2024$0.8850 $107 
9/30/202410/25/2024$0.8850 $107 
In October 2024, the Board declared a cash dividend of $0.885 per share payable on January 31, 2025 to stockholders of record as of the close of business on December 31, 2024. Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.
Stock Repurchases
Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.
Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824 million remained unused) with a new share repurchase authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. During the nine months ended September 30, 2024, we repurchased 1.9 million shares in open market transactions for $750 million at an average price of $384.65 under the February 2023 and 2024 share repurchase authorizations. During the nine months ended September 30, 2023, we repurchased 2.0 million shares in open market transactions for $980 million at an average price of $478.20 under the February 2023 share repurchase authorization.

Our remaining repurchase authorization was $2.93 billion as of October 29, 2024.
In connection with employee stock plans, we acquired 0.05 million common shares for $18 million and 0.06 million common shares for $31 million during the nine months ended September 30, 2024 and 2023, respectively.
For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3
INCOME TAXES
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The effective income tax rate was 24.4% and 24.9% for the three and nine months ended September 30, 2024, respectively, and 23.5% and 23.1% for the three and nine months ended September 30, 2023, respectively. The year-over-year increase in the effective income tax rate is primarily due to a change in the mix of current year earnings between our Insurance segment and our CenterWell health services segment, as our CenterWell health services segment is subject to a higher effective tax rate than our Insurance segment. In addition, the prior year income tax rate was favorably impacted by the recognition of a non-taxable gain.

For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at September 30, 2024 and December 31, 2023:
September 30, 2024December 31, 2023
(in millions)
Short-term debt:
Commercial paper$— $871 
Senior notes:
$600 million, 3.850% due October 1, 2024
559 572 
$600 million, 4.500% due April 1, 2025
577 — 
Total senior notes1,136 572 
Total short-term debt$1,136 $1,443 
Long-term debt:
Senior notes:
$600 million, 4.500% due April 1, 2025
$— $598 
$500 million, 5.700% due March 13, 2026
499 498 
$750 million, 1.350% due February 3, 2027
689 688 
$600 million, 3.950% due March 15, 2027
537 537 
$500 million, 5.750% due March 1, 2028
489 495 
$500 million, 5.750% due December 1, 2028
495 495 
$750 million, 3.700% due March 23, 2029
585 590 
$500 million, 3.125% due August 15, 2029
433 433 
$500 million, 4.875% due April 1, 2030
496 496 
$1,250 million, 5.375% due April 15, 2031
1,239 — 
$750 million, 2.150% due February 3, 2032
744 743 
$750 million, 5.875% due March 1, 2033
762 750 
$850 million, 5.950% due March 15, 2034
853 840 
$250 million, 8.150% due June 15, 2038
260 261 
$400 million, 4.625% due December 1, 2042
390 396 
$750 million, 4.950% due October 1, 2044
738 740 
$400 million, 4.800% due March 15, 2047
396 396 
$500 million, 3.950% due August 15, 2049
534 529 
$750 million, 5.500% due March 15, 2053
745 728 
$1,000 million, 5.750% due April 15, 2054
1,002 — 
Total senior notes11,886 10,213 
Total long-term debt$11,886 $10,213 
Senior Notes
In March 2024, we issued $1.3 billion of 5.375% unsecured senior notes due April 15, 2031 and $1.0 billion of 5.750% unsecured senior notes due April 15, 2054. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $2.2 billion. We used the net proceeds for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.
We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on Secured Overnight Financing Rate (SOFR), to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities, as further described in Note 5. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value caused by an increase or decrease in interest rates. The cumulative, aggregate decrease to the carrying value of the senior notes was approximately $117 million at September 30, 2024.

For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Revolving Credit Agreements
In June 2023, we entered into an amended and restated 5-year, $2.5 billion unsecured revolving credit agreement (replacing the 5-year, $2.5 billion unsecured revolving credit agreement entered in June 2021). In May 2024, we entered into an amendment to increase commitments $0.142 billion resulting in a $2.642 billion borrowing capacity.
In May 2024, we entered into a 364-day $2.1 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2023, which expired in accordance with its terms).
Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option.
The SOFR spread, currently 114.0 basis points under the 5-year revolving credit agreement and 116.0 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 11.0 basis points, under the 5-year revolving credit agreement and 9.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.
Our credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 42.3% as measured in accordance with the revolving credit agreements as of September 30, 2024.
At September 30, 2024, we had no borrowings and approximately $18 million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of September 30, 2024, we had $2.624 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $2.1 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750 million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement.
For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Commercial Paper
Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the nine
months ended September 30, 2024 was $2.7 billion, with no outstanding amount at September 30, 2024 compared to $0.9 billion outstanding at December 31, 2023.
For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
Other Short-term Borrowings
We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. At September 30, 2024 we had no outstanding short-term FHLB borrowings.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENTS, GUARANTEES AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS, GUARANTEES AND CONTINGENCIES COMMITMENTS, GUARANTEES AND CONTINGENCIES
Government Contracts
Our Medicare products, which accounted for approximately 85% of our total premiums and services revenue for the nine months ended September 30, 2024, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.
CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, or BBA, and the Benefits Improvement and Protection Act of 2000, or BIPA, generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.
CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.
In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would
be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.
In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”
We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.
On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.

Our state-based Medicaid business, which accounted for approximately 8% of our total premiums and services revenue for the nine months ended September 30, 2024 primarily consisted of serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states.
At September 30, 2024, our Military services business, which accounted for approximately 1% of our total premiums and services revenue for the nine months ended September 30, 2024, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the U.S. Department of Defense, or DoD, and is currently scheduled to expire on December 31, 2024, unless further extended.
In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD.The T-5 East Region contract comprises 24 states, and Washington D.C., and covers approximately 4.6 million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is one transition year followed by eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years.
The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.
Legal Proceedings and Certain Regulatory Matters
As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020.
As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned United States of America ex rel. Steven Scott v. Humana Inc in United States District Court, Western District of Kentucky, Louisville division. The complaint alleged certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action sought damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening. During 2023, we accrued certain anticipated expenses in connection with this matter. On August 15, 2024, Humana settled the claims in this suit, and paid the United States $90 million.

On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. There is no assurance that we will prevail in the lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter.

In June 2024, a putative stockholder class action was filed against Humana Inc. and certain of our current and former executive officers under the federal securities laws in the United States District Court for the District of Delaware. The case, now captioned In re Humana Stockholders Litigation., alleges that between July 2022 and January 2024, Humana made false or misleading statements in its periodic SEC filings and statements to the financial markets about our financial performance and the medical costs in our Medicare Advantage business. In July 2024 and October 2024, parallel stockholder derivative action captioned Silva v. Broussard and Spikes v. Broussard, respectively, were filed in the United States District Court for the Western District of Kentucky alleging that the same claimed acts and omissions underlying the federal securities law case also constitute a breach of fiduciary duty by certain of our current and former directors and executive officers. We will vigorously defend against the allegations in all cases.
On October 18, 2024, Humana Inc., along with co-plaintiff Americans for Beneficiary Choice, filed suit against the United States Department of Health and Human Services, Centers for Medicare and Medicaid Services, Xavier Becerra in his official capacity as Secretary, and Chiquita Brooks-LaSure, in her official capacity as Administrator, in the United States District Court, Northern District of Texas, Fort Worth Division, seeking a determination that they violated the Administrative Procedure Act in administering the Medicare Advantage and Part D Star Ratings program. We seek to set aside and vacate Humana’s 2025 Star Ratings and remand the matter to CMS for recalculation and to declare that CMS’s policy refusing to disclose all relevant data and information is arbitrary, capricious, and unlawful. There is no assurance that we will prevail in the lawsuit. For additional information on this matter, refer to Part II, Item 1A, "Risk Factors" of this Form 10-Q.
Other Lawsuits and Regulatory Matters
Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider and vendor contracting and oversight, risk adjustment, competitive practices, commission payments, marketing payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.
We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, personal injury nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.
As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.
A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.
We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be
exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.
The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.
The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business.
The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.
Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics.
In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.
We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $5.6 billion and $5.7 billion for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, these amounts were $14.1 billion and $14.7 billion respectively. In
addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $32 million and $35 million for the three months ended September 30, 2024 and 2023, respectively, and $96 million and $102 million for the nine months ended September 30, 2024 and 2023, respectively.
Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.
Our segment results were as follows for the three and nine months ended September 30, 2024 and 2023:
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended September 30, 2024(in millions)
External revenues
Premiums:
Individual Medicare Advantage$21,856 $— $— $21,856 
Group Medicare Advantage1,913 — — 1,913 
Medicare stand-alone PDP721 — — 721 
Total Medicare24,490 — — 24,490 
Commercial fully-insured85 — — 85 
Specialty benefits238 — — 238 
Medicare Supplement217 — — 217 
State-based contracts and other2,921 — — 2,921 
Total premiums27,951 — — 27,951 
Services revenue:
Home solutions— 326 — 326 
Primary care— 319 — 319 
Pharmacy solutions— 232 — 232 
Commercial ASO12 — — 12 
Military services and other214 — — 214 
Total services revenue226 877 — 1,103 
Total external revenues 28,177 877 — 29,054 
Intersegment revenues
Services1 1,463 (1,464)— 
Products— 2,701 (2,701)— 
Total intersegment revenues1 4,164 (4,165)— 
Investment income192 — 151 343 
Total revenues28,370 5,041 (4,014)29,397 
Operating expenses:
Benefits25,319 — (199)25,120 
Operating costs2,595 4,602 (3,858)3,339 
Depreciation and amortization182 57 (29)210 
Total operating expenses28,096 4,659 (4,086)28,669 
Income from operations274 382 72 728 
Interest expense— 2 167 169 
Other income, net— — (92)(92)
Income (loss) before income taxes and equity in net earnings 274 380 (3)651 
Equity in net losses(1)(15)— (16)
Segment earnings (loss)$273 $365 $(3)$635 
Net loss attributable to noncontrolling interests— — — — 
Segment earnings (loss) attributable to Humana$273 $365 $(3)$635 
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended September 30, 2023(in millions)
External revenues
Premiums:
Individual Medicare Advantage$19,637 $— $— $19,637 
Group Medicare Advantage1,695 — — 1,695 
Medicare stand-alone PDP493 — — 493 
Total Medicare21,825 — — 21,825 
Commercial fully-insured842 — — 842 
Specialty benefits252 — — 252 
Medicare Supplement185 — — 185 
State-based contracts and other1,995 — — 1,995 
Total premiums25,099 — — 25,099 
Services revenue:
Home solutions— 342 — 342 
Primary care— 214 — 214 
Pharmacy solutions— 203 — 203 
Commercial ASO55 — — 55 
Military services and other202 — — 202 
Total services revenue257 759 — 1,016 
Total external revenues 25,356 759 — 26,115 
Intersegment revenues
Services1 1,307 (1,308)— 
Products— 2,594 (2,594)— 
Total intersegment revenues1 3,901 (3,902)— 
Investment income 154 — 154 308 
Total revenues25,511 4,660 (3,748)26,423 
Operating expenses:
Benefits21,976 — (231)21,745 
Operating costs2,634 4,207 (3,570)3,271 
Depreciation and amortization179 53 (31)201 
Total operating expenses24,789 4,260 (3,832)25,217 
Income from operations722 400 84 1,206 
Interest expense— 1 113 114 
Other income, net— — (6)(6)
Income (loss) before income taxes and equity in net earnings 722 399 (23)1,098 
Equity in net losses— (12)— (12)
Segment earnings (loss)$722 $387 $(23)$1,086 
Net loss (income) attributable to noncontrolling interests3 (1)— 2 
Segment earnings (loss) attributable to Humana$725 $386 $(23)$1,088 
InsuranceCenterWellEliminations/
Corporate		Consolidated
Nine months ended September 30, 2024(in millions)
External revenues
Premiums:
Individual Medicare Advantage$66,519 $— $— $66,519 
Group Medicare Advantage5,840 — — 5,840 
Medicare stand-alone PDP2,409 — — 2,409 
Total Medicare74,768 — — 74,768 
Commercial fully-insured493 — — 493 
Specialty benefits717 — — 717 
Medicare Supplement620 — — 620 
State-based contracts and other7,756 — — 7,756 
Total premiums84,354 — — 84,354 
Services revenue:
Home solutions— 996 — 996 
Primary care— 882 — 882 
Pharmacy solutions— 672 — 672 
Commercial ASO44 — — 44 
Military services and other671 — — 671 
Total services revenue715 2,550 — 3,265 
Total external revenues 85,069 2,550 — 87,619 
Intersegment revenues
Services3 4,293 (4,296)— 
Products— 7,963 (7,963)— 
Total intersegment revenues3 12,256 (12,259)— 
Investment income522 — 407 929 
Total revenues85,594 14,806 (11,852)88,548 
Operating expenses:
Benefits75,752 — (469)75,283 
Operating costs7,354 13,638 (11,463)9,529 
Depreciation and amortization553 166 (88)631 
Total operating expenses83,659 13,804 (12,020)85,443 
Income from operations1,935 1,002 168 3,105 
Interest expense— 4 492 496 
Other expense, net— — 26 26 
Income (loss) before income taxes and equity in net losses 1,935 998 (350)2,583 
Equity in net losses(2)(55)— (57)
Segment earnings (loss)$1,933 $943 $(350)$2,526 
Net loss attributable to noncontrolling interests3 — — 3 
Segment earnings (loss) attributable to Humana$1,936 $943 $(350)$2,529 
InsuranceCenterWellEliminations/
Corporate		Consolidated
Nine Months Ended September 30, 2023(in millions)
External Revenues
Premiums:
Individual Medicare Advantage$59,195 $— $— $59,195 
Group Medicare Advantage5,192 — — 5,192 
Medicare stand-alone PDP1,677 — — 1,677 
Total Medicare66,064 — — 66,064 
Commercial fully-insured2,810 — — 2,810 
Specialty benefits758 — — 758 
Medicare Supplement546 — — 546 
State-based contracts and other5,966 — — 5,966 
Total premiums76,144 — — 76,144 
Services revenue:
Home solutions— 997 — 997 
Primary care— 605 — 605 
Pharmacy solutions— 661 — 661 
Commercial ASO190 — — 190 
Military services and other540 — — 540 
Total services revenue730 2,263 — 2,993 
Total external revenues 76,874 2,263 — 79,137 
Intersegment revenues
Services30 3,584 (3,614)— 
Products— 7,848 (7,848)— 
Total intersegment revenues30 11,432 (11,462)— 
Investment income385 — 390 775 
Total revenues77,289 13,695 (11,072)79,912 
Operating expenses:
Benefits66,096 — (484)65,612 
Operating costs7,597 12,526 (10,762)9,361 
Depreciation and amortization516 152 (90)578 
Total operating expenses74,209 12,678 (11,336)75,551 
Income from operations3,080 1,017 264 4,361 
Interest expense— 2 345 347 
Other expense, net— — 40 40 
Income (loss) before income taxes and equity in net losses3,080 1,015 (121)3,974 
Equity in net losses(2)(37)— (39)
Segment earnings (loss)$3,078 $978 $(121)$3,935 
Net loss (income) attributable to noncontrolling interests7 (1)— 6 
Segment earnings (loss) attributable to Humana$3,085 $977 $(121)$3,941 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure        
Net income attributable to Humana $ 480 $ 832 $ 1,900 $ 3,030
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies)
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.
The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.
Employer Group Commercial Medical Products Business Exit
In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. We anticipate the exit of this line of business to be finalized in the first half of 2025.
Revenue Recognition
Revenue Recognition
Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.
Investment Securities
Investment Securities
We participate in a securities lending program to optimize investment income. We loan certain investment securities for short periods of time in exchange for collateral initially equal to at least 102% of the fair value of the investment securities on loan. The fair value of the loaned investment securities is monitored on a daily basis, with additional collateral obtained or refunded as the fair value of the loaned investment securities fluctuates. The collateral, which may be in the form of cash or U.S. Government securities, is deposited by the borrower with an independent lending agent. Any cash collateral, which is reinvested by the lending agent primarily in short-term, highly liquid investments, is recorded as a securities lending collateral asset within other current assets on our consolidated balance sheet at September 30, 2024. We record a corresponding liability to reflect our obligation to return the collateral within trade accounts payable and accrued expenses on our consolidated balance sheet at September 30, 2024. Collateral received in the form of securities is not recorded in our consolidated balance sheets because, absent default by the borrower, we do not have the right to sell, pledge or otherwise reinvest securities collateral. Loaned securities continue to be carried as investment securities on the consolidated balance sheet at September 30, 2024. Earnings on the invested cash collateral, net of expense, associated with the securities lending payable are recorded as investment income.
Accounting Pronouncements Effective in Future Periods
Accounting Pronouncements Effective in Future Periods
In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We do not believe the adoption of ASU 2023-07 will have a material impact on our consolidated financial statements or disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be
effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.

There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3
INVESTMENT SECURITIES (Tables)
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investment Securities Classified as Current and Long-Term
Investment securities classified as current and long-term were as follows at September 30, 2024 and December 31, 2023, respectively:
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
 (in millions)
September 30, 2024
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$3,203 $13 $(33)$3,183 
Mortgage-backed securities4,501 33 (351)4,183 
Tax-exempt municipal securities602 — (18)584 
Mortgage-backed securities:
Residential555 1 (54)502 
Commercial1,292 2 (78)1,216 
Asset-backed securities1,533 11 (20)1,524 
Corporate debt securities8,593 92 (444)8,241 
Total debt securities$20,279 $152 $(998)$19,433 
December 31, 2023
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations$2,717 $1 $(51)$2,667 
Mortgage-backed securities3,946 1 (425)3,522 
Tax-exempt municipal securities879 1 (22)858 
Mortgage-backed securities:
Residential465 1 (66)400 
Commercial1,471 — (126)1,345 
Asset-backed securities1,813 2 (44)1,771 
Corporate debt securities7,011 28 (594)6,445 
Total debt securities$18,302 $34 $(1,328)$17,008 
Schedule of Gross Unrealized Losses and Fair Value of Securities
Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at September 30, 2024 and December 31, 2023, respectively:
 Less than 12 months12 months or moreTotal
 Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
 (in millions)
September 30, 2024
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$551 $(2)$518 $(31)$1,069 $(33)
Mortgage-backed securities330 (2)2,378 (349)2,708 (351)
Tax-exempt municipal securities77 — 417 (18)494 (18)
Mortgage-backed securities:
Residential57 (2)361 (52)418 (54)
Commercial26 (1)1,124 (77)1,150 (78)
Asset-backed securities218 (1)571 (19)789 (20)
Corporate debt securities290 (1)4,466 (443)4,756 (444)
Total debt securities$1,549 $(9)$9,835 $(989)$11,384 $(998)
December 31, 2023
U.S. Treasury and other U.S. government corporations and agencies:
U.S. Treasury and agency obligations$1,899 $(12)$431 $(39)$2,330 $(51)
Mortgage-backed securities958 (12)2,269 (413)3,227 (425)
Tax-exempt municipal securities160 (1)523 (21)683 (22)
Mortgage-backed securities:
Residential— — 373 (66)373 (66)
Commercial18 — 1,303 (126)1,321 (126)
Asset-backed securities120 (1)1,364 (43)1,484 (44)
Corporate debt securities466 (2)4,783 (592)5,249 (594)
Total debt securities$3,621 $(28)$11,046 $(1,300)$14,667 $(1,328)
Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income
The detail of gains (losses) related to investment securities and included within investment income was as follows for the three and nine months ended September 30, 2024 and 2023:
 Three months ended September 30,Nine months ended September 30,
 2024202320242023
 (in millions)(in millions)
Gross gains on investment securities$14 $— $16 $15 
Gross losses on investment securities(4)(4)(6)(65)
Gross gains on equity securities— — — 1 
Gross losses on equity securities— — — — 
Net recognized gains (losses) on investment securities$10 $(4)$10 $(49)
Schedule of Gain (Loss) on Equity Securities
The gains and losses related to equity securities for the three and nine months ended September 30, 2024 and 2023 was as follows:
Three months ended September 30,Nine Months Ended September 30,
2024202320242023
(in millions)(in millions)
Net gains recognized on equity securities during the period$— $— $— $1 
Less: Net gains recognized on equity securities sold during the period— — — — 
Unrealized gains (losses) recognized on equity securities still held at the end of the period$— $— $— $1 
Schedule of Contractual Maturity of Debt Securities Available for Sale
The contractual maturities of debt securities available for sale at September 30, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.
Amortized
Cost		Fair
Value
 (in millions)
Due within one year$1,082 $1,079 
Due after one year through five years5,669 5,584 
Due after five years through ten years4,407 4,261 
Due after ten years1,240 1,084 
Mortgage and asset-backed securities7,881 7,425 
Total debt securities$20,279 $19,433 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3
FAIR VALUE (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Measured at Fair Value on Recurring Basis
The following table summarizes our fair value measurements at September 30, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:
 Fair Value Measurements Using
 Fair
Value		Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)
 (in millions)
September 30, 2024
Cash equivalents$4,941 $4,941 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations3,183 — 3,183 — 
Mortgage-backed securities4,183 — 4,183 — 
Tax-exempt municipal securities584 — 584 — 
Mortgage-backed securities:
Residential502 — 500 2 
Commercial1,216 — 1,216 — 
Asset-backed securities1,524 — 1,479 45 
Corporate debt securities8,241 — 7,997 244 
Total debt securities19,433 — 19,142 291 
Securities lending invested collateral361 361 — — 
Total invested assets$24,735 $5,302 $19,142 $291 
December 31, 2023
Cash equivalents$4,582 $4,582 $— $— 
Debt securities:
U.S. Treasury and other U.S. government
    corporations and agencies:
U.S. Treasury and agency obligations2,667 — 2,667 — 
Mortgage-backed securities3,522 — 3,522 — 
Tax-exempt municipal securities858 — 858 — 
Mortgage-backed securities:
Residential400 — 396 4 
Commercial1,345 — 1,345 — 
Asset-backed securities1,771 — 1,733 38 
Corporate debt securities6,445 — 6,269 176 
Total debt securities$17,008 $— $16,790 $218 
Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation During the nine months ended
September 30, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    
Private Placements
For the nine months ended September 30, 2024For the nine months ended September 30, 2023
(in millions)
Beginning balance at January 1$218 $101 
Total gains or losses:
Realized in earnings— — 
Unrealized in other comprehensive income6 (1)
Purchases72 13 
Maturities— (4)
Sales— — 
Settlements(5)— 
Transfer out— (4)
Balance at September 30$291 $105 
Schedule of Notional Amounts of Outstanding Derivative Positions The following table summarizes the notional amounts at September 30, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:
September 30, 2024December 31, 2023
(in millions)
$750 million, 5.875% due March 1, 2033
$650 $650 
$850 million, 5.950% due March 15, 2034
800 400 
$500 million, 3.950% due August 15, 2049
450 450 
$750 million, 5.500% due March 15, 2053
700 300 
$400 million, 4.625% due December 1, 2042
400 — 
$750 million, 4.950% due October 1, 2044
400 — 
$1,000 million, 5.750% due April 15, 2054
400 — 
Schedule of Assumptions Used For Inputs In Fair Value Measurement The table below presents the assumptions used for each reporting period.
September 30, 2024December 31, 2023
Annualized volatility
16.5% - 18.3%
16.1% - 17.8%
Credit spread
0.8% - 1.4%
0.9% - 1.1%
Revenue exit multiple
1.5x - 2.5x
1.5x - 2.5x
Weighted average cost of capital
11.0% - 14.0%
11.0% - 12.5%
Long term growth rate3.0 %3.0 %
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3
MEDICARE PART D (Tables)
 9 Months Ended
Sep. 30, 2024
Insurance [Abstract]  
Schedule of Balance Sheet Amounts Associated With Medicare Part D The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at September 30, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.
 September 30, 2024December 31, 2023
Risk
Corridor
Settlement		CMS
Subsidies/
Discounts		Risk
Corridor
Settlement		CMS
Subsidies/
Discounts
 (in millions)
Other current assets$107 $846 $224 $514 
Trade accounts payable and accrued expenses(114)(1,594)(232)(1,825)
Net current liability(7)(748)(8)(1,311)
Other long-term assets298 — 17 — 
Other long-term liabilities(62)— (77)— 
Net long-term asset (liability)236 — (60)— 
Total net asset (liability)$229 $(748)$(68)$(1,311)
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments
Changes in the carrying amount of goodwill for our reportable segments for the nine months ended September 30, 2024 were as follows:
InsuranceCenterWellTotal
 (in millions)
Balance at January 1, 2024$2,663 $6,887 $9,550 
Acquisitions— 40 40 
Balance at September 30, 2024$2,663 $6,927 $9,590 
Schedule of Other Intangible Assets, Indefinite-Lived
The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2024 and December 31, 2023:
 September 30, 2024December 31, 2023
Weighted
Average
Life		CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
 ($ in millions)
Other intangible assets:
Certificates of needIndefinite$1,092 $— $1,092 $1,092 $— $1,092 
Medicare licensesIndefinite288 — 288 288 — 288 
Customer contracts/
    relationships		9.4 years956 749 207 956 718 238 
Trade names and
    technology		6.7 years139 116 23 139 109 30 
Provider contracts11.9 years67 63 4 67 62 5 
Noncompetes and
    other		8.4 years85 49 36 84 44 40 
Total other intangible
    assets		9.2 years$2,627 $977 $1,650 $2,626 $933 $1,693 
Schedule of Other Intangible Assets, Amortizable
The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2024 and December 31, 2023:
 September 30, 2024December 31, 2023
Weighted
Average
Life		CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
 ($ in millions)
Other intangible assets:
Certificates of needIndefinite$1,092 $— $1,092 $1,092 $— $1,092 
Medicare licensesIndefinite288 — 288 288 — 288 
Customer contracts/
    relationships		9.4 years956 749 207 956 718 238 
Trade names and
    technology		6.7 years139 116 23 139 109 30 
Provider contracts11.9 years67 63 4 67 62 5 
Noncompetes and
    other		8.4 years85 49 36 84 44 40 
Total other intangible
    assets		9.2 years$2,627 $977 $1,650 $2,626 $933 $1,693 
Schedule of Estimated Amortization Expense The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at September 30, 2024:
 (in millions)
For the years ending December 31,
2024$15 
202558 
202643 
202733 
202829 
202927 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3
BENEFITS PAYABLE (Tables)
 9 Months Ended
Sep. 30, 2024
Insurance [Abstract]  
Schedule of Activity in Benefits Payable
On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the nine months ended September 30, 2024 and 2023:
For the nine months ended September 30,
20242023
(in millions)
Balances, beginning of period$10,241 $9,264 
Acquisitions— 62 
Incurred related to:
Current year75,976 66,370 
Prior years(693)(758)
Total incurred75,283 65,612 
Paid related to:
Current year(65,282)(56,700)
Prior years(9,117)(8,042)
Total paid(74,399)(64,742)
Balances, end of period$11,125 $10,196 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3
EARNINGS PER COMMON SHARE COMPUTATION (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Details Supporting Computation of Earnings Per Share
Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and nine months ended September 30, 2024 and 2023:
Three months ended September 30,Nine months ended September 30,
2024202320242023
(dollars in millions, except per common share results; number of shares in thousands)
Net income available for common stockholders$480 $832 $1,900 $3,030 
Weighted average outstanding shares of common stock
    used to compute basic earnings per common share		120,405 123,426 120,609 124,335 
Dilutive effect of:
Employee stock options3 26 4 31 
Restricted stock356 531 286 519 
Shares used to compute diluted earnings per common share120,764 123,983 120,899 124,885 
Basic earnings per common share$3.99 $6.74 $15.76 $24.37 
Diluted earnings per common share$3.98 $6.71 $15.72 $24.26 
Number of antidilutive stock options and restricted stock
    excluded from computation		361 137 759 251 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of Details of Dividend Payments
The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:
Record
Date		Payment
Date		Amount
per Share		Total
Amount
(in millions)
2024 payments
12/29/20231/26/2024$0.8850 $108 
3/29/20244/26/2024$0.8850 $107 
6/28/20247/26/2024$0.8850 $107 
9/30/202410/25/2024$0.8850 $107 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Carrying Value of Debt Outstanding
The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at September 30, 2024 and December 31, 2023:
September 30, 2024December 31, 2023
(in millions)
Short-term debt:
Commercial paper$— $871 
Senior notes:
$600 million, 3.850% due October 1, 2024
559 572 
$600 million, 4.500% due April 1, 2025
577 — 
Total senior notes1,136 572 
Total short-term debt$1,136 $1,443 
Long-term debt:
Senior notes:
$600 million, 4.500% due April 1, 2025
$— $598 
$500 million, 5.700% due March 13, 2026
499 498 
$750 million, 1.350% due February 3, 2027
689 688 
$600 million, 3.950% due March 15, 2027
537 537 
$500 million, 5.750% due March 1, 2028
489 495 
$500 million, 5.750% due December 1, 2028
495 495 
$750 million, 3.700% due March 23, 2029
585 590 
$500 million, 3.125% due August 15, 2029
433 433 
$500 million, 4.875% due April 1, 2030
496 496 
$1,250 million, 5.375% due April 15, 2031
1,239 — 
$750 million, 2.150% due February 3, 2032
744 743 
$750 million, 5.875% due March 1, 2033
762 750 
$850 million, 5.950% due March 15, 2034
853 840 
$250 million, 8.150% due June 15, 2038
260 261 
$400 million, 4.625% due December 1, 2042
390 396 
$750 million, 4.950% due October 1, 2044
738 740 
$400 million, 4.800% due March 15, 2047
396 396 
$500 million, 3.950% due August 15, 2049
534 529 
$750 million, 5.500% due March 15, 2053
745 728 
$1,000 million, 5.750% due April 15, 2054
1,002 — 
Total senior notes11,886 10,213 
Total long-term debt$11,886 $10,213 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Results
Our segment results were as follows for the three and nine months ended September 30, 2024 and 2023:
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended September 30, 2024(in millions)
External revenues
Premiums:
Individual Medicare Advantage$21,856 $— $— $21,856 
Group Medicare Advantage1,913 — — 1,913 
Medicare stand-alone PDP721 — — 721 
Total Medicare24,490 — — 24,490 
Commercial fully-insured85 — — 85 
Specialty benefits238 — — 238 
Medicare Supplement217 — — 217 
State-based contracts and other2,921 — — 2,921 
Total premiums27,951 — — 27,951 
Services revenue:
Home solutions— 326 — 326 
Primary care— 319 — 319 
Pharmacy solutions— 232 — 232 
Commercial ASO12 — — 12 
Military services and other214 — — 214 
Total services revenue226 877 — 1,103 
Total external revenues 28,177 877 — 29,054 
Intersegment revenues
Services1 1,463 (1,464)— 
Products— 2,701 (2,701)— 
Total intersegment revenues1 4,164 (4,165)— 
Investment income192 — 151 343 
Total revenues28,370 5,041 (4,014)29,397 
Operating expenses:
Benefits25,319 — (199)25,120 
Operating costs2,595 4,602 (3,858)3,339 
Depreciation and amortization182 57 (29)210 
Total operating expenses28,096 4,659 (4,086)28,669 
Income from operations274 382 72 728 
Interest expense— 2 167 169 
Other income, net— — (92)(92)
Income (loss) before income taxes and equity in net earnings 274 380 (3)651 
Equity in net losses(1)(15)— (16)
Segment earnings (loss)$273 $365 $(3)$635 
Net loss attributable to noncontrolling interests— — — — 
Segment earnings (loss) attributable to Humana$273 $365 $(3)$635 
InsuranceCenterWellEliminations/
Corporate		Consolidated
Three months ended September 30, 2023(in millions)
External revenues
Premiums:
Individual Medicare Advantage$19,637 $— $— $19,637 
Group Medicare Advantage1,695 — — 1,695 
Medicare stand-alone PDP493 — — 493 
Total Medicare21,825 — — 21,825 
Commercial fully-insured842 — — 842 
Specialty benefits252 — — 252 
Medicare Supplement185 — — 185 
State-based contracts and other1,995 — — 1,995 
Total premiums25,099 — — 25,099 
Services revenue:
Home solutions— 342 — 342 
Primary care— 214 — 214 
Pharmacy solutions— 203 — 203 
Commercial ASO55 — — 55 
Military services and other202 — — 202 
Total services revenue257 759 — 1,016 
Total external revenues 25,356 759 — 26,115 
Intersegment revenues
Services1 1,307 (1,308)— 
Products— 2,594 (2,594)— 
Total intersegment revenues1 3,901 (3,902)— 
Investment income 154 — 154 308 
Total revenues25,511 4,660 (3,748)26,423 
Operating expenses:
Benefits21,976 — (231)21,745 
Operating costs2,634 4,207 (3,570)3,271 
Depreciation and amortization179 53 (31)201 
Total operating expenses24,789 4,260 (3,832)25,217 
Income from operations722 400 84 1,206 
Interest expense— 1 113 114 
Other income, net— — (6)(6)
Income (loss) before income taxes and equity in net earnings 722 399 (23)1,098 
Equity in net losses— (12)— (12)
Segment earnings (loss)$722 $387 $(23)$1,086 
Net loss (income) attributable to noncontrolling interests3 (1)— 2 
Segment earnings (loss) attributable to Humana$725 $386 $(23)$1,088 
InsuranceCenterWellEliminations/
Corporate		Consolidated
Nine months ended September 30, 2024(in millions)
External revenues
Premiums:
Individual Medicare Advantage$66,519 $— $— $66,519 
Group Medicare Advantage5,840 — — 5,840 
Medicare stand-alone PDP2,409 — — 2,409 
Total Medicare74,768 — — 74,768 
Commercial fully-insured493 — — 493 
Specialty benefits717 — — 717 
Medicare Supplement620 — — 620 
State-based contracts and other7,756 — — 7,756 
Total premiums84,354 — — 84,354 
Services revenue:
Home solutions— 996 — 996 
Primary care— 882 — 882 
Pharmacy solutions— 672 — 672 
Commercial ASO44 — — 44 
Military services and other671 — — 671 
Total services revenue715 2,550 — 3,265 
Total external revenues 85,069 2,550 — 87,619 
Intersegment revenues
Services3 4,293 (4,296)— 
Products— 7,963 (7,963)— 
Total intersegment revenues3 12,256 (12,259)— 
Investment income522 — 407 929 
Total revenues85,594 14,806 (11,852)88,548 
Operating expenses:
Benefits75,752 — (469)75,283 
Operating costs7,354 13,638 (11,463)9,529 
Depreciation and amortization553 166 (88)631 
Total operating expenses83,659 13,804 (12,020)85,443 
Income from operations1,935 1,002 168 3,105 
Interest expense— 4 492 496 
Other expense, net— — 26 26 
Income (loss) before income taxes and equity in net losses 1,935 998 (350)2,583 
Equity in net losses(2)(55)— (57)
Segment earnings (loss)$1,933 $943 $(350)$2,526 
Net loss attributable to noncontrolling interests3 — — 3 
Segment earnings (loss) attributable to Humana$1,936 $943 $(350)$2,529 
InsuranceCenterWellEliminations/
Corporate		Consolidated
Nine Months Ended September 30, 2023(in millions)
External Revenues
Premiums:
Individual Medicare Advantage$59,195 $— $— $59,195 
Group Medicare Advantage5,192 — — 5,192 
Medicare stand-alone PDP1,677 — — 1,677 
Total Medicare66,064 — — 66,064 
Commercial fully-insured2,810 — — 2,810 
Specialty benefits758 — — 758 
Medicare Supplement546 — — 546 
State-based contracts and other5,966 — — 5,966 
Total premiums76,144 — — 76,144 
Services revenue:
Home solutions— 997 — 997 
Primary care— 605 — 605 
Pharmacy solutions— 661 — 661 
Commercial ASO190 — — 190 
Military services and other540 — — 540 
Total services revenue730 2,263 — 2,993 
Total external revenues 76,874 2,263 — 79,137 
Intersegment revenues
Services30 3,584 (3,614)— 
Products— 7,848 (7,848)— 
Total intersegment revenues30 11,432 (11,462)— 
Investment income385 — 390 775 
Total revenues77,289 13,695 (11,072)79,912 
Operating expenses:
Benefits66,096 — (484)65,612 
Operating costs7,597 12,526 (10,762)9,361 
Depreciation and amortization516 152 (90)578 
Total operating expenses74,209 12,678 (11,336)75,551 
Income from operations3,080 1,017 264 4,361 
Interest expense— 2 345 347 
Other expense, net— — 40 40 
Income (loss) before income taxes and equity in net losses3,080 1,015 (121)3,974 
Equity in net losses(2)(37)— (39)
Segment earnings (loss)$3,078 $978 $(121)$3,935 
Net loss (income) attributable to noncontrolling interests7 (1)— 6 
Segment earnings (loss) attributable to Humana$3,085 $977 $(121)$3,941 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Receivables and Other [Line Items]        
Minimum collateral as percentage of fair value of investment securities 102.00%   102.00%  
Services        
Receivables and Other [Line Items]        
Accounts receivable $ 428   $ 428  
Value Creation Initiatives        
Receivables and Other [Line Items]        
Restructuring and impairment charge $ 55 $ 52 $ 151 $ 52
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3
INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost $ 20,279 $ 18,302
Gross Unrealized Gains 152 34
Gross Unrealized Losses (998) (1,328)
Fair Value 19,433 17,008
U.S. Treasury and agency obligations    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 3,203 2,717
Gross Unrealized Gains 13 1
Gross Unrealized Losses (33) (51)
Fair Value 3,183 2,667
Mortgage-backed securities    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 4,501 3,946
Gross Unrealized Gains 33 1
Gross Unrealized Losses (351) (425)
Fair Value 4,183 3,522
Tax-exempt municipal securities    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 602 879
Gross Unrealized Gains 0 1
Gross Unrealized Losses (18) (22)
Fair Value 584 858
Residential    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 555 465
Gross Unrealized Gains 1 1
Gross Unrealized Losses (54) (66)
Fair Value 502 400
Commercial    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 1,292 1,471
Gross Unrealized Gains 2 0
Gross Unrealized Losses (78) (126)
Fair Value 1,216 1,345
Asset-backed securities    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 1,533 1,813
Gross Unrealized Gains 11 2
Gross Unrealized Losses (20) (44)
Fair Value 1,524 1,771
Corporate debt securities    
Investment Securities, Available-for-sale Amortized Cost to Fair Value    
Amortized Cost 8,593 7,011
Gross Unrealized Gains 92 28
Gross Unrealized Losses (444) (594)
Fair Value $ 8,241 $ 6,445
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3
INVESTMENT SECURITIES - Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
position
Dec. 31, 2023
USD ($)
Financing Receivable, Credit Quality Indicator [Line Items]    
Book value $ 20,279 $ 18,302
Fair value $ 19,433 17,008
Minimum collateral as percentage of fair value of investment securities 102.00%  
Securities lending invested collateral $ 361  
Fair value of non-cash securities lending $ 148  
Maximum individual state general bond obligation as a percentage of total debt securities (percent) 1.00%  
Securities in unrealized loss positions, number of positions | position 1,300  
Securities, number of positions | position 2,290  
S&P AA- rating    
Financing Receivable, Credit Quality Indicator [Line Items]    
Percentage of debt securities considered to be of investment-grade (percent) 97.00%  
Dispositions | Gentiva Hospice    
Financing Receivable, Credit Quality Indicator [Line Items]    
Book value $ 381 379
Fair value $ 396 $ 398
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3
INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Fair Value    
Less than 12 months $ 1,549 $ 3,621
12 months or more 9,835 11,046
Total 11,384 14,667
Gross Unrealized Losses    
Less than 12 months (9) (28)
12 months or more (989) (1,300)
Total (998) (1,328)
U.S. Treasury and agency obligations    
Fair Value    
Less than 12 months 551 1,899
12 months or more 518 431
Total 1,069 2,330
Gross Unrealized Losses    
Less than 12 months (2) (12)
12 months or more (31) (39)
Total (33) (51)
Mortgage-backed securities    
Fair Value    
Less than 12 months 330 958
12 months or more 2,378 2,269
Total 2,708 3,227
Gross Unrealized Losses    
Less than 12 months (2) (12)
12 months or more (349) (413)
Total (351) (425)
Tax-exempt municipal securities    
Fair Value    
Less than 12 months 77 160
12 months or more 417 523
Total 494 683
Gross Unrealized Losses    
Less than 12 months 0 (1)
12 months or more (18) (21)
Total (18) (22)
Residential    
Fair Value    
Less than 12 months 57 0
12 months or more 361 373
Total 418 373
Gross Unrealized Losses    
Less than 12 months (2) 0
12 months or more (52) (66)
Total (54) (66)
Commercial    
Fair Value    
Less than 12 months 26 18
12 months or more 1,124 1,303
Total 1,150 1,321
Gross Unrealized Losses    
Less than 12 months (1) 0
12 months or more (77) (126)
Total (78) (126)
Asset-backed securities    
Fair Value    
Less than 12 months 218 120
12 months or more 571 1,364
Total 789 1,484
Gross Unrealized Losses    
Less than 12 months (1) (1)
12 months or more (19) (43)
Total (20) (44)
Corporate debt securities    
Fair Value    
Less than 12 months 290 466
12 months or more 4,466 4,783
Total 4,756 5,249
Gross Unrealized Losses    
Less than 12 months (1) (2)
12 months or more (443) (592)
Total $ (444) $ (594)
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3
INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]        
Gross gains on investment securities $ 14 $ 0 $ 16 $ 15
Gross losses on investment securities (4) (4) (6) (65)
Gross gains on equity securities 0 0 0 1
Gross losses on equity securities 0 0 0 0
Net recognized gains (losses) on investment securities $ 10 $ (4) $ 10 $ (49)
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3
INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]        
Net gains recognized on equity securities during the period $ 0 $ 0 $ 0 $ 1
Less: Net gains recognized on equity securities sold during the period 0 0 0 0
Unrealized gains (losses) recognized on equity securities still held at the end of the period $ 0 $ 0 $ 0 $ 1
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3
INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Amortized Cost    
Due within one year $ 1,082  
Due after one year through five years 5,669  
Due after five years through ten years 4,407  
Due after ten years 1,240  
Mortgage and asset-backed securities 7,881  
Amortized Cost 20,279 $ 18,302
Fair Value    
Due within one year 1,079  
Due after one year through five years 5,584  
Due after five years through ten years 4,261  
Due after ten years 1,084  
Mortgage and asset-backed securities 7,425  
Fair Value $ 19,433 $ 17,008
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3
FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities $ 19,433 $ 17,008
Securities lending invested collateral 361  
U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 3,183 2,667
Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 4,183 3,522
Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 584 858
Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 502 400
Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,216 1,345
Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,524 1,771
Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 8,241 6,445
Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 4,941 4,582
Total debt securities 19,433 17,008
Securities lending invested collateral 361  
Total invested assets 24,735  
Recurring Basis | U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 3,183 2,667
Recurring Basis | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 4,183 3,522
Recurring Basis | Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 584 858
Recurring Basis | Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 502 400
Recurring Basis | Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,216 1,345
Recurring Basis | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,524 1,771
Recurring Basis | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 8,241 6,445
Recurring Basis | Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 4,941 4,582
Total debt securities 0 0
Securities lending invested collateral 361  
Total invested assets 5,302  
Recurring Basis | Quoted Prices in Active Markets (Level 1) | U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Quoted Prices in Active Markets (Level 1) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Total debt securities 19,142 16,790
Securities lending invested collateral 0  
Total invested assets 19,142  
Recurring Basis | Other Observable Inputs (Level 2) | U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 3,183 2,667
Recurring Basis | Other Observable Inputs (Level 2) | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 4,183 3,522
Recurring Basis | Other Observable Inputs (Level 2) | Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 584 858
Recurring Basis | Other Observable Inputs (Level 2) | Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 500 396
Recurring Basis | Other Observable Inputs (Level 2) | Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,216 1,345
Recurring Basis | Other Observable Inputs (Level 2) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 1,479 1,733
Recurring Basis | Other Observable Inputs (Level 2) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 7,997 6,269
Recurring Basis | Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Total debt securities 291 218
Securities lending invested collateral 0  
Total invested assets 291 218
Recurring Basis | Unobservable Inputs (Level 3) | U.S. Treasury and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Unobservable Inputs (Level 3) | Mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Unobservable Inputs (Level 3) | Tax-exempt municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Unobservable Inputs (Level 3) | Residential    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 2 4
Recurring Basis | Unobservable Inputs (Level 3) | Commercial    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 0 0
Recurring Basis | Unobservable Inputs (Level 3) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities 45 38
Recurring Basis | Unobservable Inputs (Level 3) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total debt securities $ 244 $ 176
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3
FAIR VALUE - Narrative (Details) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Swap asset $ 117,000,000 $ 68,000,000
Interest Rate Swap    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cumulative, aggregate adjustment 117,000,000  
Put option    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of financial liability 742,000,000 595,000,000
Call option    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Fair value of financial asset 24,000,000 18,000,000
Commercial paper    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Short-term debt 0 871,000,000
Carrying Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt outstanding 13,000,000,000.0 10,800,000,000
Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt outstanding 12,900,000,000 10,600,000,000
Recurring Basis    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total invested assets 24,735,000,000  
Unobservable Inputs (Level 3) | Recurring Basis    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Total invested assets $ 291,000,000 $ 218,000,000
Investments | Fair Value Risk | Unobservable Inputs (Level 3)    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Concentration risk (percent) 1.20% 1.00%
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3
FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance at January 1 $ 218 $ 101
Total gains or losses:    
Realized in earnings 0 0
Unrealized in other comprehensive income 6 (1)
Purchases 72 13
Maturities 0 (4)
Sales 0 0
Settlements (5) 0
Transfer out 0 (4)
Balance at September 30 $ 291 $ 105
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.3
FAIR VALUE - Fair Value of Swap Agreements (Details) - USD ($)
Sep. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Interest Rate Swap Maturing 2033 | Interest Rate Swap      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Derivative, notional amount $ 650,000,000   $ 650,000,000
Interest Rate Swap Maturing 2034 | Interest Rate Swap      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Derivative, notional amount 800,000,000   400,000,000
Interest Rate Swap Maturing 2049 | Interest Rate Swap      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Derivative, notional amount 450,000,000   450,000,000
Interest Rate Swap Maturing 2053 | Interest Rate Swap      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Derivative, notional amount 700,000,000   300,000,000
Interest Rate Swap Maturing 2042 | Interest Rate Swap      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Derivative, notional amount 400,000,000   0
Interest Rate Swap Maturing 2044 | Interest Rate Swap      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Derivative, notional amount 400,000,000   0
Interest Rate Swap Maturing 2054 | Interest Rate Swap      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Derivative, notional amount 400,000,000   $ 0
$750 million, 5.875% due March 1, 2033 | Senior Notes      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Aggregate principal $ 750,000,000    
Stated interest rate (percent) 5.875%    
$850 million, 5.950% due March 15, 2034 | Senior Notes      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Aggregate principal $ 850,000,000    
Stated interest rate (percent) 5.95%    
$500 million, 3.950% due August 15, 2049 | Senior Notes      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Aggregate principal $ 500,000,000    
Stated interest rate (percent) 3.95%    
$750 million, 5.500% due March 15, 2053 | Senior Notes      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Aggregate principal $ 750,000,000    
Stated interest rate (percent) 5.50%    
$400 million, 4.625% due December 1, 2042 | Senior Notes      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Aggregate principal $ 400,000,000    
Stated interest rate (percent) 4.625%    
$750 million, 4.950% due October 1, 2044 | Senior Notes      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Aggregate principal $ 750,000,000    
Stated interest rate (percent) 4.95%    
$1,000 million, 5.750% due April 15, 2054 | Senior Notes      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Aggregate principal $ 1,000,000,000 $ 1,000,000,000  
Stated interest rate (percent) 5.75% 5.75%  
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.3
FAIR VALUE - Put and Call Options Measured at Fair Value (Details) - Options - Level 3 fair value measurement
Sep. 30, 2024
Dec. 31, 2023
Annualized volatility | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.165 0.161
Annualized volatility | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.183 0.178
Credit spread | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.008 0.009
Credit spread | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.014 0.011
Revenue exit multiple | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 1.5 1.5
Revenue exit multiple | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 2.5 2.5
Weighted average cost of capital | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.110 0.110
Weighted average cost of capital | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.140 0.125
Long term growth rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Significant unobservable inputs 0.030 0.030
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.3
MEDICARE PART D (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Other current assets $ 6,633 $ 6,631
Trade accounts payable and accrued expenses (5,915) (6,569)
Other long-term assets 3,669 3,377
Other long-term liabilities (1,770) (1,662)
Risk Corridor Settlement    
Segment Reporting Information [Line Items]    
Other current assets 107 224
Trade accounts payable and accrued expenses (114) (232)
Net current liability (7) (8)
Other long-term assets 298 17
Other long-term liabilities (62) (77)
Net long-term asset (liability) 236 (60)
Total net asset (liability) 229 (68)
CMS Subsidies/ Discounts    
Segment Reporting Information [Line Items]    
Other current assets 846 514
Trade accounts payable and accrued expenses (1,594) (1,825)
Net current liability (748) (1,311)
Other long-term assets 0 0
Other long-term liabilities 0 0
Net long-term asset (liability) 0 0
Total net asset (liability) $ (748) $ (1,311)
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
Goodwill  
Goodwill, beginning balance $ 9,550
Acquisitions 40
Goodwill, ending balance 9,590
Insurance  
Goodwill  
Goodwill, beginning balance 2,663
Acquisitions 0
Goodwill, ending balance 2,663
CenterWell  
Goodwill  
Goodwill, beginning balance 6,887
Acquisitions 40
Goodwill, ending balance $ 6,927
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Other intangible assets:    
Weighted average life (in years) 9 years 2 months 12 days  
Total other intangible assets, cost $ 2,627 $ 2,626
Amortizable intangible assets, accumulated amortization 977 933
Total other intangible assets, net 1,650 1,693
Certificates of need    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 1,092 1,092
Medicare licenses    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets $ 288 288
Customer contracts/ relationships    
Other intangible assets:    
Weighted average life (in years) 9 years 4 months 24 days  
Amortizable intangible assets, cost $ 956 956
Amortizable intangible assets, accumulated amortization 749 718
Amortizable intangible assets, net $ 207 238
Trade names and technology    
Other intangible assets:    
Weighted average life (in years) 6 years 8 months 12 days  
Amortizable intangible assets, cost $ 139 139
Amortizable intangible assets, accumulated amortization 116 109
Amortizable intangible assets, net $ 23 30
Provider contracts    
Other intangible assets:    
Weighted average life (in years) 11 years 10 months 24 days  
Amortizable intangible assets, cost $ 67 67
Amortizable intangible assets, accumulated amortization 63 62
Amortizable intangible assets, net $ 4 5
Noncompetes and other    
Other intangible assets:    
Weighted average life (in years) 8 years 4 months 24 days  
Amortizable intangible assets, cost $ 85 84
Amortizable intangible assets, accumulated amortization 49 44
Amortizable intangible assets, net $ 36 $ 40
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization $ 15 $ 17 $ 46 $ 51
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details)
$ in Millions
Sep. 30, 2024
USD ($)
For the years ending December 31,  
2024 $ 15
2025 58
2026 43
2027 33
2028 29
2029 $ 27
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3
BENEFITS PAYABLE - Activity in Benefits Payable (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]    
Balances, beginning of period $ 10,241 $ 9,264
Acquisitions 0 62
Incurred related to:    
Current year 75,976 66,370
Prior years (693) (758)
Total incurred 75,283 65,612
Paid related to:    
Current year (65,282) (56,700)
Prior years (9,117) (8,042)
Total paid (74,399) (64,742)
Balances, end of period 11,125 $ 10,196
Total IBNR included in benefits payable $ 7,200  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.3
EARNINGS PER COMMON SHARE COMPUTATION (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Net income available for common stockholders $ 480 $ 832 $ 1,900 $ 3,030
Weighted average outstanding shares of common stock used to compute basic earnings per common share (in shares) 120,405 123,426 120,609 124,335
Shares used to compute diluted earnings per common share (in shares) 120,764 123,983 120,899 124,885
Basic earnings per common share (in dollars per share) $ 3.99 $ 6.74 $ 15.76 $ 24.37
Diluted earnings per common share (in dollars per share) $ 3.98 $ 6.71 $ 15.72 $ 24.26
Number of antidilutive stock options and restricted stock excluded from computation (in shares) 361 137 759 251
Employee stock options        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Dilutive effect of employee stock options and restricted stock (in shares) 3 26 4 31
Restricted stock        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Dilutive effect of employee stock options and restricted stock (in shares) 356 531 286 519
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' EQUITY - Dividends (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Equity, Class of Treasury Stock [Line Items]        
Amount per Share (in dollars per share)   $ 0.8850 $ 0.8850 $ 0.8850
Total Amount   $ 107 $ 107 $ 108
Forecast        
Equity, Class of Treasury Stock [Line Items]        
Amount per Share (in dollars per share) $ 0.8850      
Total Amount $ 107      
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Oct. 29, 2024
Feb. 16, 2024
Equity, Class of Treasury Stock [Line Items]              
Stock repurchases   $ 1 $ 383 $ 774 $ 1,011    
Common shares acquired in connection with employee stock plans (in shares)       50 60    
Common shares acquired in connection with employee stock plans, amount       $ 18 $ 31    
Subsequent Event              
Equity, Class of Treasury Stock [Line Items]              
Dividends declared (in dollars per share) $ 0.885            
Remaining authorized amount           $ 2,930  
2023 And 2024 Share Repurchase Authorization              
Equity, Class of Treasury Stock [Line Items]              
Stock repurchases (in shares)       1,900      
Stock repurchases       $ 750      
Stock repurchase average price (in dollars per share)       $ 384.65      
2023 Share Repurchase Authorization              
Equity, Class of Treasury Stock [Line Items]              
Remaining authorized amount             $ 824
Stock repurchases (in shares)         2,000    
Stock repurchases         $ 980    
Stock repurchase average price (in dollars per share)         $ 478.20    
2024 Share Repurchase Authorization              
Equity, Class of Treasury Stock [Line Items]              
Share repurchase authorization             $ 3,000
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3
INCOME TAXES (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Tax Disclosure [Abstract]        
Effective income tax rate (percent) 24.40% 23.50% 24.90% 23.10%
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT - Debt Outstanding (Details) - USD ($)
Sep. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]      
Total short-term debt $ 1,136,000,000   $ 1,443,000,000
Total long-term debt 11,886,000,000   10,213,000,000
Senior Notes      
Debt Instrument [Line Items]      
Total senior notes 1,136,000,000   572,000,000
Total long-term debt 11,886,000,000   10,213,000,000
Senior Notes | $600 million, 3.850% due October 1, 2024      
Debt Instrument [Line Items]      
Aggregate principal $ 600,000,000    
Stated interest rate (percent) 3.85%    
Total senior notes $ 559,000,000   572,000,000
Senior Notes | $600 million, 4.500% due April 1, 2025      
Debt Instrument [Line Items]      
Aggregate principal $ 600,000,000    
Stated interest rate (percent) 4.50%    
Total senior notes $ 577,000,000   0
Total long-term debt 0   598,000,000
Senior Notes | $500 million, 5.700% due March 13, 2026      
Debt Instrument [Line Items]      
Aggregate principal $ 500,000,000    
Stated interest rate (percent) 5.70%    
Total long-term debt $ 499,000,000   498,000,000
Senior Notes | $750 million, 1.350% due February 3, 2027      
Debt Instrument [Line Items]      
Aggregate principal $ 750,000,000    
Stated interest rate (percent) 1.35%    
Total long-term debt $ 689,000,000   688,000,000
Senior Notes | $600 million, 3.950% due March 15, 2027      
Debt Instrument [Line Items]      
Aggregate principal $ 600,000,000    
Stated interest rate (percent) 3.95%    
Total long-term debt $ 537,000,000   537,000,000
Senior Notes | $500 million, 5.750% due March 1, 2028      
Debt Instrument [Line Items]      
Aggregate principal $ 500,000,000    
Stated interest rate (percent) 5.75%    
Total long-term debt $ 489,000,000   495,000,000
Senior Notes | $500 million, 5.750% due December 1, 2028      
Debt Instrument [Line Items]      
Aggregate principal $ 500,000,000    
Stated interest rate (percent) 5.75%    
Total long-term debt $ 495,000,000   495,000,000
Senior Notes | $750 million, 3.700% due March 23, 2029      
Debt Instrument [Line Items]      
Aggregate principal $ 750,000,000    
Stated interest rate (percent) 3.70%    
Total long-term debt $ 585,000,000   590,000,000
Senior Notes | $500 million, 3.125% due August 15, 2029      
Debt Instrument [Line Items]      
Aggregate principal $ 500,000,000    
Stated interest rate (percent) 3.125%    
Total long-term debt $ 433,000,000   433,000,000
Senior Notes | $500 million, 4.875% due April 1, 2030      
Debt Instrument [Line Items]      
Aggregate principal $ 500,000,000    
Stated interest rate (percent) 4.875%    
Total long-term debt $ 496,000,000   496,000,000
Senior Notes | $1,250 million, 5.375% due April 15, 2031      
Debt Instrument [Line Items]      
Aggregate principal $ 1,250,000,000 $ 1,300,000,000  
Stated interest rate (percent) 5.375% 5.375%  
Total long-term debt $ 1,239,000,000   0
Senior Notes | $750 million, 2.150% due February 3, 2032      
Debt Instrument [Line Items]      
Aggregate principal $ 750,000,000    
Stated interest rate (percent) 2.15%    
Total long-term debt $ 744,000,000   743,000,000
Senior Notes | $750 million, 5.875% due March 1, 2033      
Debt Instrument [Line Items]      
Aggregate principal $ 750,000,000    
Stated interest rate (percent) 5.875%    
Total long-term debt $ 762,000,000   750,000,000
Senior Notes | $850 million, 5.950% due March 15, 2034      
Debt Instrument [Line Items]      
Aggregate principal $ 850,000,000    
Stated interest rate (percent) 5.95%    
Total long-term debt $ 853,000,000   840,000,000
Senior Notes | $250 million, 8.150% due June 15, 2038      
Debt Instrument [Line Items]      
Aggregate principal $ 250,000,000    
Stated interest rate (percent) 8.15%    
Total long-term debt $ 260,000,000   261,000,000
Senior Notes | $400 million, 4.625% due December 1, 2042      
Debt Instrument [Line Items]      
Aggregate principal $ 400,000,000    
Stated interest rate (percent) 4.625%    
Total long-term debt $ 390,000,000   396,000,000
Senior Notes | $750 million, 4.950% due October 1, 2044      
Debt Instrument [Line Items]      
Aggregate principal $ 750,000,000    
Stated interest rate (percent) 4.95%    
Total long-term debt $ 738,000,000   740,000,000
Senior Notes | $400 million, 4.800% due March 15, 2047      
Debt Instrument [Line Items]      
Aggregate principal $ 400,000,000    
Stated interest rate (percent) 4.80%    
Total long-term debt $ 396,000,000   396,000,000
Senior Notes | $500 million, 3.950% due August 15, 2049      
Debt Instrument [Line Items]      
Aggregate principal $ 500,000,000    
Stated interest rate (percent) 3.95%    
Total long-term debt $ 534,000,000   529,000,000
Senior Notes | $750 million, 5.500% due March 15, 2053      
Debt Instrument [Line Items]      
Aggregate principal $ 750,000,000    
Stated interest rate (percent) 5.50%    
Total long-term debt $ 745,000,000   728,000,000
Senior Notes | $1,000 million, 5.750% due April 15, 2054      
Debt Instrument [Line Items]      
Aggregate principal $ 1,000,000,000 $ 1,000,000,000  
Stated interest rate (percent) 5.75% 5.75%  
Total long-term debt $ 1,002,000,000   0
Commercial paper      
Debt Instrument [Line Items]      
Short-term debt $ 0   $ 871,000,000
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT - Senior Notes (Details) - USD ($)
 1 Months Ended 9 Months Ended
Mar. 31, 2024
Sep. 30, 2024
Sep. 30, 2023
Debt Instrument [Line Items]      
Proceeds from issuance of senior notes, net   $ 2,232,000,000 $ 1,215,000,000
Interest Rate Swap      
Debt Instrument [Line Items]      
Cumulative, aggregate adjustment   117,000,000  
5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 | Senior Notes      
Debt Instrument [Line Items]      
Proceeds from issuance of senior notes, net $ 2,200,000,000    
$1,250 million, 5.375% due April 15, 2031 | Senior Notes      
Debt Instrument [Line Items]      
Aggregate principal $ 1,300,000,000 $ 1,250,000,000  
Stated interest rate (percent) 5.375% 5.375%  
$1,000 million, 5.750% due April 15, 2054 | Senior Notes      
Debt Instrument [Line Items]      
Aggregate principal $ 1,000,000,000 $ 1,000,000,000  
Stated interest rate (percent) 5.75% 5.75%  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT - Revolving Credit Agreements (Details) - USD ($)
 1 Months Ended 9 Months Ended
May 31, 2024
Jun. 30, 2023
Jun. 30, 2021
Sep. 30, 2024
Term Loan        
Line of Credit Facility [Line Items]        
Actual debt to capitalization percentage       42.30%
Revolving credit facility        
Line of Credit Facility [Line Items]        
Debt to capitalization percentage, maximum       60.00%
Outstanding borrowings       $ 0
Uncommitted incremental loan facility       $ 750,000,000
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023        
Line of Credit Facility [Line Items]        
Debt instrument term (in years)   5 years   5 years
Maximum borrowing capacity $ 2,642,000,000 $ 2,500,000,000    
Increase commitments $ 142,000,000      
Basis spread on variable rate (percent)       1.14%
Facility fee (percent)       0.11%
Remaining borrowing capacity       $ 2,624,000,000
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | Minimum        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (percent)       0.92%
Facility fee (percent)       0.08%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2023 | Maximum        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (percent)       1.30%
Facility fee (percent)       0.20%
Revolving credit facility | 5-year unsecured revolving credit agreement June 2021        
Line of Credit Facility [Line Items]        
Debt instrument term (in years)     5 years  
Maximum borrowing capacity     $ 2,500,000,000  
Revolving credit facility | 364-day unsecured revolving credit agreement May 2024        
Line of Credit Facility [Line Items]        
Debt instrument term (in years) 364 days     364 days
Maximum borrowing capacity $ 2,100,000,000      
Basis spread on variable rate (percent)       1.16%
Facility fee (percent)       0.09%
Remaining borrowing capacity       $ 2,100,000,000
Revolving credit facility | 364-day unsecured revolving credit agreement May 2024 | Minimum        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (percent)       0.94%
Facility fee (percent)       0.06%
Revolving credit facility | 364-day unsecured revolving credit agreement May 2024 | Maximum        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (percent)       1.35%
Facility fee (percent)       0.15%
Revolving credit facility | 364-day unsecured revolving credit agreement June 2023        
Line of Credit Facility [Line Items]        
Debt instrument term (in years)   364 days    
Maximum borrowing capacity   $ 1,500,000,000    
Letter of credit        
Line of Credit Facility [Line Items]        
Outstanding borrowings       $ 18,000,000
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.3
DEBT - Commercial Paper and Other Short-term Borrowings (Details) - USD ($)
 9 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Commercial paper    
Short-term Debt [Line Items]    
Maximum amount outstanding during period $ 2,700,000,000  
Short-term debt outstanding 0 $ 871,000,000
FHLB borrowings    
Short-term Debt [Line Items]    
Short-term debt outstanding $ 0  
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)
$ in Millions
 1 Months Ended 9 Months Ended
Aug. 15, 2024
USD ($)
Dec. 31, 2022
state
beneficiary
option_period
Sep. 30, 2024
state
beneficiary
United States Of America Ex Rel. Steven Scott V. Humana Inc.      
Loss Contingencies [Line Items]      
Settled the claims in this suit | $ $ 90    
T2017 East Region      
Loss Contingencies [Line Items]      
Number of states comprising TRICARE beneficiaries | state     32
Number of TRICARE beneficiaries | beneficiary     6,000,000
T-5, Effective 2024      
Loss Contingencies [Line Items]      
Number of TRICARE managed care support contract beneficiaries | beneficiary   4,600,000  
Number of states comprising of TRICARE managed care support contract beneficiaries | state   24  
Contract base term   1 year  
Annual option periods | option_period   8  
Contract term with exercises   9 years  
Medicare      
Loss Contingencies [Line Items]      
Percentage of premiums and services revenue     85.00%
Medicaid      
Loss Contingencies [Line Items]      
Percentage of premiums and services revenue     8.00%
Military services | T2017 East Region      
Loss Contingencies [Line Items]      
Percentage of premiums and services revenue     1.00%
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT INFORMATION - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2023
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | segment     2  
Member co-share amounts and government subsidies $ 5,600 $ 5,700 $ 14,100 $ 14,700
Depreciation and amortization classified as benefit expense $ 32 $ 35 $ 96 $ 102
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT INFORMATION - Segment Results (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Premiums $ 27,951 $ 25,099 $ 84,354 $ 76,144
Services revenue 1,103 1,016 3,265 2,993
Total revenues 29,397 26,423 88,548 79,912
Investment income 343 308 929 775
Benefits 25,120 21,745 75,283 65,612
Operating costs 3,339 3,271 9,529 9,361
Depreciation and amortization 210 201 631 578
Total operating expenses 28,669 25,217 85,443 75,551
Income from operations 728 1,206 3,105 4,361
Interest expense 169 114 496 347
Other expense (income), net (92) (6) 26 40
Income (loss) before income taxes and equity in net losses 651 1,098 2,583 3,974
Equity in net losses (16) (12) (57) (39)
Segment earnings (loss) 635 1,086 2,526 3,935
Net loss (income) attributable to noncontrolling interests 0 2 3 6
Segment earnings (loss) attributable to Humana 635 1,088 2,529 3,941
Products        
Segment Reporting Information [Line Items]        
Premiums 27,951 25,099 84,354 76,144
Products | Total Medicare        
Segment Reporting Information [Line Items]        
Premiums 24,490 21,825 74,768 66,064
Products | Individual Medicare Advantage        
Segment Reporting Information [Line Items]        
Premiums 21,856 19,637 66,519 59,195
Products | Group Medicare Advantage        
Segment Reporting Information [Line Items]        
Premiums 1,913 1,695 5,840 5,192
Products | Medicare stand-alone PDP        
Segment Reporting Information [Line Items]        
Premiums 721 493 2,409 1,677
Products | Commercial fully-insured        
Segment Reporting Information [Line Items]        
Premiums 85 842 493 2,810
Products | Specialty benefits        
Segment Reporting Information [Line Items]        
Premiums 238 252 717 758
Products | Medicare Supplement        
Segment Reporting Information [Line Items]        
Premiums 217 185 620 546
Products | State-based contracts and other        
Segment Reporting Information [Line Items]        
Premiums 2,921 1,995 7,756 5,966
Services        
Segment Reporting Information [Line Items]        
Services revenue 1,103 1,016 3,265 2,993
Services | Home solutions        
Segment Reporting Information [Line Items]        
Services revenue 326 342 996 997
Services | Primary care        
Segment Reporting Information [Line Items]        
Services revenue 319 214 882 605
Services | Pharmacy solutions        
Segment Reporting Information [Line Items]        
Services revenue 232 203 672 661
Services | Commercial ASO        
Segment Reporting Information [Line Items]        
Services revenue 12 55 44 190
Services | Military services and other        
Segment Reporting Information [Line Items]        
Services revenue 214 202 671 540
Total external revenues        
Segment Reporting Information [Line Items]        
Total revenues 29,054 26,115 87,619 79,137
Operating segments | Insurance        
Segment Reporting Information [Line Items]        
Total revenues 28,370 25,511 85,594 77,289
Investment income 192 154 522 385
Benefits 25,319 21,976 75,752 66,096
Operating costs 2,595 2,634 7,354 7,597
Depreciation and amortization 182 179 553 516
Total operating expenses 28,096 24,789 83,659 74,209
Income from operations 274 722 1,935 3,080
Interest expense 0 0 0 0
Other expense (income), net 0 0 0 0
Income (loss) before income taxes and equity in net losses 274 722 1,935 3,080
Equity in net losses (1) 0 (2) (2)
Segment earnings (loss) 273 722 1,933 3,078
Net loss (income) attributable to noncontrolling interests 0 3 3 7
Segment earnings (loss) attributable to Humana 273 725 1,936 3,085
Operating segments | Insurance | Products        
Segment Reporting Information [Line Items]        
Premiums 27,951 25,099 84,354 76,144
Operating segments | Insurance | Products | Total Medicare        
Segment Reporting Information [Line Items]        
Premiums 24,490 21,825 74,768 66,064
Operating segments | Insurance | Products | Individual Medicare Advantage        
Segment Reporting Information [Line Items]        
Premiums 21,856 19,637 66,519 59,195
Operating segments | Insurance | Products | Group Medicare Advantage        
Segment Reporting Information [Line Items]        
Premiums 1,913 1,695 5,840 5,192
Operating segments | Insurance | Products | Medicare stand-alone PDP        
Segment Reporting Information [Line Items]        
Premiums 721 493 2,409 1,677
Operating segments | Insurance | Products | Commercial fully-insured        
Segment Reporting Information [Line Items]        
Premiums 85 842 493 2,810
Operating segments | Insurance | Products | Specialty benefits        
Segment Reporting Information [Line Items]        
Premiums 238 252 717 758
Operating segments | Insurance | Products | Medicare Supplement        
Segment Reporting Information [Line Items]        
Premiums 217 185 620 546
Operating segments | Insurance | Products | State-based contracts and other        
Segment Reporting Information [Line Items]        
Premiums 2,921 1,995 7,756 5,966
Operating segments | Insurance | Services        
Segment Reporting Information [Line Items]        
Services revenue 226 257 715 730
Operating segments | Insurance | Services | Home solutions        
Segment Reporting Information [Line Items]        
Services revenue 0 0 0 0
Operating segments | Insurance | Services | Primary care        
Segment Reporting Information [Line Items]        
Services revenue 0 0 0 0
Operating segments | Insurance | Services | Pharmacy solutions        
Segment Reporting Information [Line Items]        
Services revenue 0 0 0 0
Operating segments | Insurance | Services | Commercial ASO        
Segment Reporting Information [Line Items]        
Services revenue 12 55 44 190
Operating segments | Insurance | Services | Military services and other        
Segment Reporting Information [Line Items]        
Services revenue 214 202 671 540
Operating segments | Insurance | Total external revenues        
Segment Reporting Information [Line Items]        
Total revenues 28,177 25,356 85,069 76,874
Operating segments | CenterWell        
Segment Reporting Information [Line Items]        
Total revenues 5,041 4,660 14,806 13,695
Investment income 0 0 0 0
Benefits 0 0 0 0
Operating costs 4,602 4,207 13,638 12,526
Depreciation and amortization 57 53 166 152
Total operating expenses 4,659 4,260 13,804 12,678
Income from operations 382 400 1,002 1,017
Interest expense 2 1 4 2
Other expense (income), net 0 0 0 0
Income (loss) before income taxes and equity in net losses 380 399 998 1,015
Equity in net losses (15) (12) (55) (37)
Segment earnings (loss) 365 387 943 978
Net loss (income) attributable to noncontrolling interests 0 (1) 0 (1)
Segment earnings (loss) attributable to Humana 365 386 943 977
Operating segments | CenterWell | Products        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Operating segments | CenterWell | Products | Total Medicare        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Operating segments | CenterWell | Products | Individual Medicare Advantage        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Operating segments | CenterWell | Products | Group Medicare Advantage        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Operating segments | CenterWell | Products | Medicare stand-alone PDP        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Operating segments | CenterWell | Products | Commercial fully-insured        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Operating segments | CenterWell | Products | Specialty benefits        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Operating segments | CenterWell | Products | Medicare Supplement        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Operating segments | CenterWell | Products | State-based contracts and other        
Segment Reporting Information [Line Items]        
Premiums 0 0 0 0
Operating segments | CenterWell | Services        
Segment Reporting Information [Line Items]        
Services revenue 877 759 2,550 2,263
Operating segments | CenterWell | Services | Home solutions        
Segment Reporting Information [Line Items]        
Services revenue 326 342 996 997
Operating segments | CenterWell | Services | Primary care        
Segment Reporting Information [Line Items]        
Services revenue 319 214 882 605
Operating segments | CenterWell | Services | Pharmacy solutions        
Segment Reporting Information [Line Items]        
Services revenue 232 203 672 661
Operating segments | CenterWell | Services | Commercial ASO        
Segment Reporting Information [Line Items]        
Services revenue 0 0 0 0
Operating segments | CenterWell | Services | Military services and other        
Segment Reporting Information [Line Items]        
Services revenue 0 0 0 0
Operating segments | CenterWell | Total external revenues        
Segment Reporting Information [Line Items]        
Total revenues 877 759 2,550 2,263
Eliminations/ Corporate        
Segment Reporting Information [Line Items]        
Total revenues (4,014) (3,748) (11,852) (11,072)
Investment income 151 154 407 390
Benefits (199) (231) (469) (484)
Operating costs (3,858) (3,570) (11,463) (10,762)
Depreciation and amortization (29) (31) (88) (90)
Total operating expenses (4,086) (3,832) (12,020) (11,336)
Income from operations 72 84 168 264
Interest expense 167 113 492 345
Other expense (income), net (92) (6) 26 40
Income (loss) before income taxes and equity in net losses (3) (23) (350) (121)
Equity in net losses 0 0 0 0
Segment earnings (loss) (3) (23) (350) (121)
Net loss (income) attributable to noncontrolling interests 0 0 0 0
Segment earnings (loss) attributable to Humana (3) (23) (350) (121)
Eliminations/ Corporate | Insurance        
Segment Reporting Information [Line Items]        
Total revenues 1 1 3 30
Eliminations/ Corporate | Insurance | Products        
Segment Reporting Information [Line Items]        
Total revenues 0 0 0 0
Eliminations/ Corporate | Insurance | Services        
Segment Reporting Information [Line Items]        
Total revenues 1 1 3 30
Eliminations/ Corporate | CenterWell        
Segment Reporting Information [Line Items]        
Total revenues 4,164 3,901 12,256 11,432
Eliminations/ Corporate | CenterWell | Products        
Segment Reporting Information [Line Items]        
Total revenues 2,701 2,594 7,963 7,848
Eliminations/ Corporate | CenterWell | Services        
Segment Reporting Information [Line Items]        
Total revenues 1,463 1,307 4,293 3,584
Intersegment Eliminations        
Segment Reporting Information [Line Items]        
Total revenues (4,165) (3,902) (12,259) (11,462)
Intersegment Eliminations | Products        
Segment Reporting Information [Line Items]        
Total revenues (2,701) (2,594) (7,963) (7,848)
Intersegment Eliminations | Services        
Segment Reporting Information [Line Items]        
Total revenues $ (1,464) $ (1,308) $ (4,296) $ (3,614)
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 566 307 1 false 117 0 false 9 false false R1.htm 0000001 - Document - Cover Sheet http://www.humana.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited) Statements 6 false false R7.htm 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 9952157 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS Sheet http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTS BASIS OF PRESENTATION AND SIGNIFICANT EVENTS Notes 8 false false R9.htm 9952158 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://www.humana.com/role/RECENTLYISSUEDACCOUNTINGPRONOUNCEMENTS RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Notes 9 false false R10.htm 9952159 - Disclosure - ACQUISITIONS Sheet http://www.humana.com/role/ACQUISITIONS ACQUISITIONS Notes 10 false false R11.htm 9952160 - Disclosure - INVESTMENT SECURITIES Sheet http://www.humana.com/role/INVESTMENTSECURITIES INVESTMENT SECURITIES Notes 11 false false R12.htm 9952161 - Disclosure - FAIR VALUE Sheet http://www.humana.com/role/FAIRVALUE FAIR VALUE Notes 12 false false R13.htm 9952162 - Disclosure - MEDICARE PART D Sheet http://www.humana.com/role/MEDICAREPARTD MEDICARE PART D Notes 13 false false R14.htm 9952163 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 14 false false R15.htm 9952164 - Disclosure - BENEFITS PAYABLE Sheet http://www.humana.com/role/BENEFITSPAYABLE BENEFITS PAYABLE Notes 15 false false R16.htm 9952165 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION Sheet http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION EARNINGS PER COMMON SHARE COMPUTATION Notes 16 false false R17.htm 9952166 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.humana.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 17 false false R18.htm 9952167 - Disclosure - INCOME TAXES Sheet http://www.humana.com/role/INCOMETAXES INCOME TAXES Notes 18 false false R19.htm 9952168 - Disclosure - DEBT Sheet http://www.humana.com/role/DEBT DEBT Notes 19 false false R20.htm 9952169 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES Sheet http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES COMMITMENTS, GUARANTEES AND CONTINGENCIES Notes 20 false false R21.htm 9952170 - Disclosure - SEGMENT INFORMATION Sheet http://www.humana.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies) Sheet http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies) Policies 24 false false R25.htm 9954472 - Disclosure - INVESTMENT SECURITIES (Tables) Sheet http://www.humana.com/role/INVESTMENTSECURITIESTables INVESTMENT SECURITIES (Tables) Tables http://www.humana.com/role/INVESTMENTSECURITIES 25 false false R26.htm 9954473 - Disclosure - FAIR VALUE (Tables) Sheet http://www.humana.com/role/FAIRVALUETables FAIR VALUE (Tables) Tables http://www.humana.com/role/FAIRVALUE 26 false false R27.htm 9954474 - Disclosure - MEDICARE PART D (Tables) Sheet http://www.humana.com/role/MEDICAREPARTDTables MEDICARE PART D (Tables) Tables http://www.humana.com/role/MEDICAREPARTD 27 false false R28.htm 9954475 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 28 false false R29.htm 9954476 - Disclosure - BENEFITS PAYABLE (Tables) Sheet http://www.humana.com/role/BENEFITSPAYABLETables BENEFITS PAYABLE (Tables) Tables http://www.humana.com/role/BENEFITSPAYABLE 29 false false R30.htm 9954477 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Tables) Sheet http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables EARNINGS PER COMMON SHARE COMPUTATION (Tables) Tables http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION 30 false false R31.htm 9954478 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.humana.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.humana.com/role/STOCKHOLDERSEQUITY 31 false false R32.htm 9954479 - Disclosure - DEBT (Tables) Sheet http://www.humana.com/role/DEBTTables DEBT (Tables) Tables http://www.humana.com/role/DEBT 32 false false R33.htm 9954480 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.humana.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://www.humana.com/role/SEGMENTINFORMATION 33 false false R34.htm 9954481 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details) Sheet http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details) Details http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies 34 false false R35.htm 9954482 - Disclosure - INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details) Details 35 false false R36.htm 9954483 - Disclosure - INVESTMENT SECURITIES - Narrative (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails INVESTMENT SECURITIES - Narrative (Details) Details 36 false false R37.htm 9954484 - Disclosure - INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) Details 37 false false R38.htm 9954485 - Disclosure - INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details) Details 38 false false R39.htm 9954486 - Disclosure - INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details) Details 39 false false R40.htm 9954487 - Disclosure - INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) Sheet http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) Details 40 false false R41.htm 9954488 - Disclosure - FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) Sheet http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) Details 41 false false R42.htm 9954489 - Disclosure - FAIR VALUE - Narrative (Details) Sheet http://www.humana.com/role/FAIRVALUENarrativeDetails FAIR VALUE - Narrative (Details) Details 42 false false R43.htm 9954490 - Disclosure - FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) Sheet http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) Details 43 false false R44.htm 9954491 - Disclosure - FAIR VALUE - Fair Value of Swap Agreements (Details) Sheet http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails FAIR VALUE - Fair Value of Swap Agreements (Details) Details 44 false false R45.htm 9954492 - Disclosure - FAIR VALUE - Put and Call Options Measured at Fair Value (Details) Sheet http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails FAIR VALUE - Put and Call Options Measured at Fair Value (Details) Details 45 false false R46.htm 9954493 - Disclosure - MEDICARE PART D (Details) Sheet http://www.humana.com/role/MEDICAREPARTDDetails MEDICARE PART D (Details) Details http://www.humana.com/role/MEDICAREPARTDTables 46 false false R47.htm 9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details) Details 47 false false R48.htm 9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details) Details 48 false false R49.htm 9954496 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Details 49 false false R50.htm 9954497 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details) Sheet http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details) Details 50 false false R51.htm 9954498 - Disclosure - BENEFITS PAYABLE - Activity in Benefits Payable (Details) Sheet http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails BENEFITS PAYABLE - Activity in Benefits Payable (Details) Details 51 false false R52.htm 9954499 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Details) Sheet http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails EARNINGS PER COMMON SHARE COMPUTATION (Details) Details http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables 52 false false R53.htm 9954500 - Disclosure - STOCKHOLDERS' EQUITY - Dividends (Details) Sheet http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails STOCKHOLDERS' EQUITY - Dividends (Details) Details 53 false false R54.htm 9954501 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) Sheet http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS' EQUITY - Narrative (Details) Details 54 false false R55.htm 9954502 - Disclosure - INCOME TAXES (Details) Sheet http://www.humana.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.humana.com/role/INCOMETAXES 55 false false R56.htm 9954503 - Disclosure - DEBT - Debt Outstanding (Details) Sheet http://www.humana.com/role/DEBTDebtOutstandingDetails DEBT - Debt Outstanding (Details) Details 56 false false R57.htm 9954504 - Disclosure - DEBT - Senior Notes (Details) Notes http://www.humana.com/role/DEBTSeniorNotesDetails DEBT - Senior Notes (Details) Details 57 false false R58.htm 9954505 - Disclosure - DEBT - Revolving Credit Agreements (Details) Sheet http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails DEBT - Revolving Credit Agreements (Details) Details 58 false false R59.htm 9954506 - Disclosure - DEBT - Commercial Paper and Other Short-term Borrowings (Details) Sheet http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails DEBT - Commercial Paper and Other Short-term Borrowings (Details) Details 59 false false R60.htm 9954507 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details) Sheet http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details) Details http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES 60 false false R61.htm 9954508 - Disclosure - SEGMENT INFORMATION - Narrative (Details) Sheet http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails SEGMENT INFORMATION - Narrative (Details) Details 61 false false R62.htm 9954509 - Disclosure - SEGMENT INFORMATION - Segment Results (Details) Sheet http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails SEGMENT INFORMATION - Segment Results (Details) Details 62 false false All Reports Book All Reports hum-20240930.htm hum-20240930.xsd hum-20240930_cal.xml hum-20240930_def.xml hum-20240930_lab.xml hum-20240930_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hum-20240930.htm": { "nsprefix": "hum", "nsuri": "http://www.humana.com/20240930", "dts": { "inline": { "local": [ "hum-20240930.htm" ] }, "schema": { "local": [ "hum-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "hum-20240930_cal.xml" ] }, "definitionLink": { "local": [ "hum-20240930_def.xml" ] }, "labelLink": { "local": [ "hum-20240930_lab.xml" ] }, "presentationLink": { "local": [ "hum-20240930_pre.xml" ] } }, "keyStandard": 272, "keyCustom": 35, "axisStandard": 30, "axisCustom": 1, "memberStandard": 51, "memberCustom": 66, "hidden": { "total": 12, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 6, "http://www.humana.com/20240930": 1 }, "contextCount": 566, "entityCount": 1, "segmentCount": 117, "elementCount": 673, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1541, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.humana.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R5": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R6": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-64", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-64", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R8": { "role": "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTS", "longName": "9952157 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.humana.com/role/RECENTLYISSUEDACCOUNTINGPRONOUNCEMENTS", "longName": "9952158 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS", "shortName": "RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.humana.com/role/ACQUISITIONS", "longName": "9952159 - Disclosure - ACQUISITIONS", "shortName": "ACQUISITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.humana.com/role/INVESTMENTSECURITIES", "longName": "9952160 - Disclosure - INVESTMENT SECURITIES", "shortName": "INVESTMENT SECURITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.humana.com/role/FAIRVALUE", "longName": "9952161 - Disclosure - FAIR VALUE", "shortName": "FAIR VALUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.humana.com/role/MEDICAREPARTD", "longName": "9952162 - Disclosure - MEDICARE PART D", "shortName": "MEDICARE PART D", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "hum:MedicarePartDDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hum:MedicarePartDDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "longName": "9952163 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.humana.com/role/BENEFITSPAYABLE", "longName": "9952164 - Disclosure - BENEFITS PAYABLE", "shortName": "BENEFITS PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InsuranceDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InsuranceDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION", "longName": "9952165 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION", "shortName": "EARNINGS PER COMMON SHARE COMPUTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.humana.com/role/STOCKHOLDERSEQUITY", "longName": "9952166 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.humana.com/role/INCOMETAXES", "longName": "9952167 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.humana.com/role/DEBT", "longName": "9952168 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES", "longName": "9952169 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES", "shortName": "COMMITMENTS, GUARANTEES AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.humana.com/role/SEGMENTINFORMATION", "longName": "9952170 - Disclosure - SEGMENT INFORMATION", "shortName": "SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies", "longName": "9954471 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies)", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESTables", "longName": "9954472 - Disclosure - INVESTMENT SECURITIES (Tables)", "shortName": "INVESTMENT SECURITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.humana.com/role/FAIRVALUETables", "longName": "9954473 - Disclosure - FAIR VALUE (Tables)", "shortName": "FAIR VALUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.humana.com/role/MEDICAREPARTDTables", "longName": "9954474 - Disclosure - MEDICARE PART D (Tables)", "shortName": "MEDICARE PART D (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "hum:BalanceSheetAccountAssociatedWithMedicarePartDTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hum:BalanceSheetAccountAssociatedWithMedicarePartDTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "longName": "9954475 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.humana.com/role/BENEFITSPAYABLETables", "longName": "9954476 - Disclosure - BENEFITS PAYABLE (Tables)", "shortName": "BENEFITS PAYABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables", "longName": "9954477 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Tables)", "shortName": "EARNINGS PER COMMON SHARE COMPUTATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYTables", "longName": "9954478 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.humana.com/role/DEBTTables", "longName": "9954479 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.humana.com/role/SEGMENTINFORMATIONTables", "longName": "9954480 - Disclosure - SEGMENT INFORMATION (Tables)", "shortName": "SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails", "longName": "9954481 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details)", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-2", "name": "hum:SecuritiesLoanedMinimumCollateralAsPercentageOfFairValueOfInvestmentSecurities", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-79", "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R35": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails", "longName": "9954482 - Disclosure - INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details)", "shortName": "INVESTMENT SECURITIES - Securities Classified as Current and Long-Term (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R36": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails", "longName": "9954483 - Disclosure - INVESTMENT SECURITIES - Narrative (Details)", "shortName": "INVESTMENT SECURITIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:SecuritiesReceivedAsCollateral", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R37": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "longName": "9954484 - Disclosure - INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details)", "shortName": "INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails", "longName": "9954485 - Disclosure - INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details)", "shortName": "INVESTMENT SECURITIES - Gains (Losses) Within Investment Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-4", "name": "hum:DebtAndEquitySecuritiesRealizedGain", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealizedGainLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "hum:DebtAndEquitySecuritiesRealizedGain", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealizedGainLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails", "longName": "9954486 - Disclosure - INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details)", "shortName": "INVESTMENT SECURITIES - Gains and Losses Related to Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails", "longName": "9954487 - Disclosure - INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details)", "shortName": "INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "longName": "9954488 - Disclosure - FAIR VALUE - Financial Assets Measured on Recurring Basis (Details)", "shortName": "FAIR VALUE - Financial Assets Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-101", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R42": { "role": "http://www.humana.com/role/FAIRVALUENarrativeDetails", "longName": "9954489 - Disclosure - FAIR VALUE - Narrative (Details)", "shortName": "FAIR VALUE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:InterestRateFairValueHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:InterestRateFairValueHedgeAssetAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details", "longName": "9954490 - Disclosure - FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details)", "shortName": "FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "longName": "9954491 - Disclosure - FAIR VALUE - Fair Value of Swap Agreements (Details)", "shortName": "FAIR VALUE - Fair Value of Swap Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-169", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-169", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails", "longName": "9954492 - Disclosure - FAIR VALUE - Put and Call Options Measured at Fair Value (Details)", "shortName": "FAIR VALUE - Put and Call Options Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-199", "name": "us-gaap:DerivativeAssetLiabilityNetMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-199", "name": "us-gaap:DerivativeAssetLiabilityNetMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.humana.com/role/MEDICAREPARTDDetails", "longName": "9954493 - Disclosure - MEDICARE PART D (Details)", "shortName": "MEDICARE PART D (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-217", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R47": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "longName": "9954494 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Goodwill by Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfGoodwillTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfGoodwillTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R48": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails", "longName": "9954495 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Other Intangible Assets Subject to Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "longName": "9954496 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails", "longName": "9954497 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization and Estimated Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails", "longName": "9954498 - Disclosure - BENEFITS PAYABLE - Activity in Benefits Payable (Details)", "shortName": "BENEFITS PAYABLE - Activity in Benefits Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-71", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R52": { "role": "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "longName": "9954499 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Details)", "shortName": "EARNINGS PER COMMON SHARE COMPUTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R53": { "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails", "longName": "9954500 - Disclosure - STOCKHOLDERS' EQUITY - Dividends (Details)", "shortName": "STOCKHOLDERS' EQUITY - Dividends (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "longName": "9954501 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)", "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R55": { "role": "http://www.humana.com/role/INCOMETAXESDetails", "longName": "9954502 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.humana.com/role/DEBTDebtOutstandingDetails", "longName": "9954503 - Disclosure - DEBT - Debt Outstanding (Details)", "shortName": "DEBT - Debt Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:DebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-260", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R57": { "role": "http://www.humana.com/role/DEBTSeniorNotesDetails", "longName": "9954504 - Disclosure - DEBT - Senior Notes (Details)", "shortName": "DEBT - Senior Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-295", "name": "us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } }, "R58": { "role": "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "longName": "9954505 - Disclosure - DEBT - Revolving Credit Agreements (Details)", "shortName": "DEBT - Revolving Credit Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-313", "name": "hum:DebtInstrumentCovenantDebtToCapitalizationPercentageActual", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-313", "name": "hum:DebtInstrumentCovenantDebtToCapitalizationPercentageActual", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "longName": "9954506 - Disclosure - DEBT - Commercial Paper and Other Short-term Borrowings (Details)", "shortName": "DEBT - Commercial Paper and Other Short-term Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-317", "name": "us-gaap:ShorttermDebtMaximumAmountOutstandingDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-317", "name": "us-gaap:ShorttermDebtMaximumAmountOutstandingDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails", "longName": "9954507 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-326", "name": "us-gaap:PaymentsForLegalSettlements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-326", "name": "us-gaap:PaymentsForLegalSettlements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails", "longName": "9954508 - Disclosure - SEGMENT INFORMATION - Narrative (Details)", "shortName": "SEGMENT INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails", "longName": "9954509 - Disclosure - SEGMENT INFORMATION - Segment Results (Details)", "shortName": "SEGMENT INFORMATION - Segment Results (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:NetInvestmentIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hum-20240930.htm", "unique": true } } }, "tag": { "hum_A135PercentSeniorNotesDueFebruary2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A135PercentSeniorNotesDueFebruary2027Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750\u00a0million, 1.350% due February 3, 2027", "label": "1.35 Percent Senior Notes Due February 2027 [Member]", "documentation": "1.35 Percent Senior Notes Due February 2027" } } }, "auth_ref": [] }, "hum_A2023And2024ShareRepurchaseAuthorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A2023And2024ShareRepurchaseAuthorizationMember", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 And 2024 Share Repurchase Authorization", "label": "2023 And 2024 Share Repurchase Authorization [Member]", "documentation": "2023 And 2024 Share Repurchase Authorization" } } }, "auth_ref": [] }, "hum_A2023ShareRepurchaseAuthorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A2023ShareRepurchaseAuthorizationMember", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Share Repurchase Authorization", "label": "2023 Share Repurchase Authorization [Member]", "documentation": "2023 Share Repurchase Authorization" } } }, "auth_ref": [] }, "hum_A2024ShareRepurchaseAuthorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A2024ShareRepurchaseAuthorizationMember", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Share Repurchase Authorization", "label": "2024 Share Repurchase Authorization [Member]", "documentation": "2024 Share Repurchase Authorization" } } }, "auth_ref": [] }, "hum_A215PercentSeniorNotesDueFebruary2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A215PercentSeniorNotesDueFebruary2032Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750\u00a0million, 2.150% due February 3, 2032", "label": "2.15 Percent Senior Notes Due February 2032 [Member]", "documentation": "2.15 Percent Senior Notes Due February 2032" } } }, "auth_ref": [] }, "hum_A3.85PercentSeniorNotesDueOctober2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A3.85PercentSeniorNotesDueOctober2024Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$600 million, 3.850% due October 1, 2024", "label": "3.85 Percent Senior Notes Due October 2024 [Member]", "documentation": "3.85 Percent Senior Notes Due October 2024 [Member]" } } }, "auth_ref": [] }, "hum_A3.95PercentSeniorNotesDueMarch2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A3.95PercentSeniorNotesDueMarch2027Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$600\u00a0million, 3.950% due March 15, 2027", "label": "3.95 Percent Senior Notes Due March 2027 [Member]", "documentation": "3.95 Percent Senior Notes Due March 2027 [Member]" } } }, "auth_ref": [] }, "hum_A3125PercentSeniorNotesDueAugust2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A3125PercentSeniorNotesDueAugust2029Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500\u00a0million, 3.125% due August 15, 2029", "label": "3.125 Percent Senior Notes Due August 2029 [Member]", "documentation": "A 3.125 Percent Senior Notes Due August 2029 [Member]" } } }, "auth_ref": [] }, "hum_A3700PercentSeniorNotesDueMarch2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A3700PercentSeniorNotesDueMarch2029Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750 million, 3.700% due March 23, 2029", "label": "3.700 Percent Senior Notes Due March 2029 [Member]", "documentation": "3.700 Percent Senior Notes Due March 2029" } } }, "auth_ref": [] }, "hum_A395PercentSeniorNotesDueAugust2049Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A395PercentSeniorNotesDueAugust2049Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million, 3.950% due August 15, 2049", "label": "3.95 Percent Senior Notes Due August 2049 [Member]", "documentation": "3.95 Percent Senior Notes Due August 2049 [Member]" } } }, "auth_ref": [] }, "hum_A4.625PercentSeniorNotesDueDecember2042Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A4.625PercentSeniorNotesDueDecember2042Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$400\u00a0million, 4.625% due December\u00a01, 2042", "label": "4.625 Percent Senior Notes Due December 2042 [Member]", "documentation": "4.625 Percent Senior Notes Due December 2042 [Member]" } } }, "auth_ref": [] }, "hum_A4.80PercentSeniorNotesDueMarch2047Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A4.80PercentSeniorNotesDueMarch2047Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$400\u00a0million, 4.800% due March 15, 2047", "label": "4.80 Percent Senior Notes Due March 2047 [Member]", "documentation": "4.80 Percent Senior Notes Due March 2047 [Member]" } } }, "auth_ref": [] }, "hum_A4.95PercentSeniorNotesDueOctober2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A4.95PercentSeniorNotesDueOctober2044Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750\u00a0million, 4.950% due October 1, 2044", "label": "4.95 Percent Senior Notes Due October 2044 [Member]", "documentation": "4.95 Percent Senior Notes Due October 2044 [Member]" } } }, "auth_ref": [] }, "hum_A450PercentSeniorNotesDueApril2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A450PercentSeniorNotesDueApril2025Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$600\u00a0million, 4.500% due April 1, 2025", "label": "4.50 Percent Senior Notes Due April 2025 [Member]", "documentation": "A 4.50 Percent Senior Notes Due April 2025 [Member]" } } }, "auth_ref": [] }, "hum_A4875PercentSeniorNotesDueApril2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A4875PercentSeniorNotesDueApril2030Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500\u00a0million, 4.875% due April 1, 2030", "label": "4.875 Percent Senior Notes Due April 2030 [Member]", "documentation": "A 4.875 Percent Senior Notes Due April 2030 [Member]" } } }, "auth_ref": [] }, "hum_A5.375PercentSeniorNotesDueApril2031And5.750PercentSeniorNotesDueApril2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A5.375PercentSeniorNotesDueApril2031And5.750PercentSeniorNotesDueApril2054Member", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054", "label": "5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054 [Member]", "documentation": "5.375 Percent Senior Notes Due April 2031 And 5.750 Percent Senior Notes Due April 2054" } } }, "auth_ref": [] }, "hum_A5.375PercentSeniorNotesDueApril2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A5.375PercentSeniorNotesDueApril2031Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$1,250 million, 5.375% due April 15, 2031", "label": "5.375 Percent Senior Notes Due April 2031 [Member]", "documentation": "5.375 Percent Senior Notes Due April 2031" } } }, "auth_ref": [] }, "hum_A5.750PercentSeniorNotesDueApril2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A5.750PercentSeniorNotesDueApril2054Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$1,000 million, 5.750% due April 15, 2054", "label": "5.750 Percent Senior Notes Due April 2054 [Member]", "documentation": "5.750 Percent Senior Notes Due April 2054" } } }, "auth_ref": [] }, "hum_A5.750PercentSeniorNotesDueDecember2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A5.750PercentSeniorNotesDueDecember2028Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million, 5.750% due December 1, 2028", "label": "5.750 Percent Senior Notes Due December 2028 [Member]", "documentation": "5.750 Percent Senior Notes Due December 2028" } } }, "auth_ref": [] }, "hum_A5.950PercentSeniorNotesDueMarch2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A5.950PercentSeniorNotesDueMarch2034Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$850 million, 5.950% due March 15, 2034", "label": "5.950 Percent Senior Notes Due March 2034 [Member]", "documentation": "5.950 Percent Senior Notes Due March 2034" } } }, "auth_ref": [] }, "hum_A550PercentSeniorNotesDueMarch2053Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A550PercentSeniorNotesDueMarch2053Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750 million, 5.500% due March 15, 2053", "label": "5.50 Percent Senior Notes Due March 2053 [Member]", "documentation": "5.50 Percent Senior Notes Due March 2053" } } }, "auth_ref": [] }, "hum_A570PercentSeniorNotesDueMarch2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A570PercentSeniorNotesDueMarch2026Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million, 5.700% due March 13, 2026", "label": "5.70 Percent Senior Notes Due March 2026 [Member]", "documentation": "5.70 Percent Senior Notes Due March 2026" } } }, "auth_ref": [] }, "hum_A5750PercentSeniorNotesDueMarch2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A5750PercentSeniorNotesDueMarch2028Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$500 million, 5.750% due March 1, 2028", "label": "5.750 Percent Senior Notes Due March 2028 [Member]", "documentation": "5.750 Percent Senior Notes Due March 2028" } } }, "auth_ref": [] }, "hum_A5875PercentSeniorNotesDueMarch2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A5875PercentSeniorNotesDueMarch2033Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$750 million, 5.875% due March 1, 2033", "label": "5.875 Percent Senior Notes Due March 2033 [Member]", "documentation": "5.875 Percent Senior Notes Due March 2033" } } }, "auth_ref": [] }, "hum_A8.15PercentSeniorNotesDueJune2038Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "A8.15PercentSeniorNotesDueJune2038Member", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$250\u00a0million, 8.150% due June\u00a015, 2038", "label": "8.15 Percent Senior Notes Due June 2038 [Member]", "documentation": "8.15 Percent Senior Notes Due June 2038 [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables and Other [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r304", "r1009" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetCurrentLiabilityAsset", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable and accrued expenses", "negatedLabel": "Trade accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r73", "r74" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1008" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r16", "r17", "r91", "r197", "r657", "r710", "r713" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r12", "r17", "r540", "r543", "r594", "r706", "r707", "r983", "r984", "r985", "r996", "r997", "r998", "r1000" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r916" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r85" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Capital\u00a0In Excess\u00a0of Par Value", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r727", "r996", "r997", "r998", "r1000", "r1076", "r1142" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r929" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r929" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r929" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r929" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r8" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r47", "r48", "r474" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r962" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r888", "r898", "r908", "r940" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r891", "r901", "r911", "r943" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r963" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r929" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r936" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r892", "r902", "r912", "r936", "r944", "r948", "r956" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r954" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables, net of allowances", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r198", "r305", "r348" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r377", "r384", "r824" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of antidilutive stock options and restricted stock excluded from computation (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r263" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed securities", "verboseLabel": "Asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r834", "r856", "r1014", "r1020", "r1021" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r124", "r140", "r193", "r228", "r267", "r273", "r291", "r295", "r343", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r416", "r417", "r532", "r536", "r579", "r653", "r752", "r814", "r815", "r855", "r879", "r1066", "r1067", "r1096" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r186", "r200", "r228", "r343", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r416", "r417", "r532", "r536", "r579", "r855", "r1066", "r1067", "r1096" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total invested assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r553", "r554", "r843" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r314" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r315" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails", "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "terseLabel": "Book value", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r311", "r354", "r652" ] }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r356", "r822" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1017" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r320", "r647" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1016" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r319", "r646" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after ten years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1018" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after ten years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r321", "r648" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1015" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r318", "r645" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage and asset-backed securities", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping." } } }, "auth_ref": [ "r1013", "r1014" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage and asset-backed securities", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping." } } }, "auth_ref": [ "r317", "r644", "r1013" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails", "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value", "terseLabel": "Fair value", "totalLabel": "Fair Value", "netLabel": "Total debt securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r312", "r354", "r553", "r639", "r843", "r847", "r1010", "r1080", "r1081", "r1082" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investment securities", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r189", "r308", "r354" ] }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Securities, Available-for-sale Amortized Cost to Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss) [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r951" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r952" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r947" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r947" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r947" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r947" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r947" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r947" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r950" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r949" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r948" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r948" ] }, "hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.humana.com/20240930", "localname": "BalanceSheetAccountAssociatedWithMedicarePartDTableTableTextBlock", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Balance Sheet Amounts Associated With Medicare Part D", "label": "Balance Sheet Account Associated With Medicare Part D Table [Table Text Block]", "documentation": "Balance Sheet Account Associated With Medicare Part D" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BenefitsLossesAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BenefitsLossesAndExpenses", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Benefits, Losses and Expenses", "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs." } } }, "auth_ref": [ "r678" ] }, "hum_BookOverdraftLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "BookOverdraftLiability", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Book overdraft", "label": "Book Overdraft Liability", "documentation": "Book Overdraft Liability" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/ACQUISITIONS" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUISITIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r117", "r528" ] }, "us-gaap_CallOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CallOptionMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Call option", "label": "Call Option [Member]", "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option." } } }, "auth_ref": [ "r789", "r790" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r24", "r188", "r804" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1078", "r1079" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r24", "r104", "r225" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r104" ] }, "hum_CenterWellSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "CenterWellSegmentMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CenterWell", "label": "CenterWell Segment [Member]", "documentation": "CenterWell Segment" } } }, "auth_ref": [] }, "hum_CertificateOfNeedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "CertificateOfNeedMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of need", "label": "Certificate Of Need [Member]", "documentation": "Certificate Of Need" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r927" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r924" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r922" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails", "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Treasury Stock [Table]", "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r43", "r44", "r45", "r46" ] }, "hum_CmsSubsidiesOrDiscountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "CmsSubsidiesOrDiscountsMember", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CMS Subsidies/ Discounts", "label": "Cms Subsidies Or Discounts [Member]", "documentation": "CMS Subsidies Or Discounts [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r928" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r928" ] }, "hum_CommercialASOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "CommercialASOMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial ASO", "label": "Commercial ASO [Member]", "documentation": "Commercial ASO" } } }, "auth_ref": [] }, "hum_CommercialFullyInsuredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "CommercialFullyInsuredMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial fully-insured", "label": "Commercial Fully-Insured [Member]", "documentation": "Commercial Fully-Insured" } } }, "auth_ref": [] }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialMortgageBackedSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial", "label": "Commercial Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by commercial real estate mortgage loans." } } }, "auth_ref": [ "r843", "r845", "r847", "r1014", "r1020", "r1021", "r1071" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r112", "r406", "r871", "r872", "r873", "r876" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 13)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r80", "r128", "r654", "r739" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsContingenciesAndGuaranteesTextBlock", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS, GUARANTEES AND CONTINGENCIES", "label": "Commitments Contingencies and Guarantees [Text Block]", "documentation": "The entire disclosure for commitments, contingencies, and guarantees." } } }, "auth_ref": [ "r109", "r110", "r1059" ] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount per Share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r116" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r116" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r867", "r868", "r869", "r871", "r872", "r873", "r876", "r996", "r997", "r1000", "r1076", "r1141", "r1142" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r83" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r83", "r740" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r83" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r83", "r740", "r758", "r1142", "r1143" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,718,810 shares issued at September\u00a030, 2024 and 198,690,082 shares issued at December 31, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r83", "r656", "r855" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r933" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r932" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r934" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r931" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Humana", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r208", "r210", "r215", "r640", "r671", "r672" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r32", "r33", "r66", "r67", "r301", "r797" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r32", "r33", "r66", "r67", "r301", "r716", "r797" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r32", "r33", "r66", "r67", "r301", "r797", "r969" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r32", "r33", "r66", "r67", "r301" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r32", "r33", "r66", "r67", "r301", "r797" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r138", "r155", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r230", "r267", "r275", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r407", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r814", "r815", "r978", "r979", "r1066", "r1067" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r138", "r155", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r230", "r267", "r275", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r407", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r416", "r814", "r815", "r978", "r979", "r1066", "r1067" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unearned revenues", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r460", "r461", "r464" ] }, "us-gaap_ContractualRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualRightsMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provider contracts", "label": "Contractual Rights [Member]", "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements)." } } }, "auth_ref": [ "r51", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1050", "r1052", "r1053", "r1054" ] }, "hum_CorporateAndEliminationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "CorporateAndEliminationsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eliminations/ Corporate", "label": "Corporate And Eliminations [Member]", "documentation": "Corporate And Eliminations [Member]" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "verboseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r834", "r836", "r843", "r856", "r865", "r1138" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r406", "r1064" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r406", "r1064", "r1065" ] }, "srt_CreditRatingStandardPoorsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CreditRatingStandardPoorsAxis", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Rating, Standard & Poor's [Axis]", "label": "Credit Rating, Standard & Poor's [Axis]", "documentation": "Information by Standard and Poor's rating." } } }, "auth_ref": [ "r141", "r142", "r143", "r820", "r1029", "r1075" ] }, "us-gaap_CreditSpreadOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditSpreadOptionMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit spread", "label": "Credit Spread Option [Member]", "documentation": "An option on the yield spread on a bond." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerContractsMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer contracts/ relationships", "label": "Customer Contracts [Member]", "documentation": "Entity's established relationships with its customers through contracts." } } }, "auth_ref": [ "r50", "r1043", "r1044", "r1045", "r1046", "r1048", "r1050", "r1053", "r1054" ] }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndEquitySecuritiesGainLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 }, "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) loss on investment securities, net", "totalLabel": "Net recognized gains (losses) on investment securities", "label": "Debt and Equity Securities, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": [ "r98", "r99" ] }, "hum_DebtAndEquitySecuritiesRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "DebtAndEquitySecuritiesRealizedGain", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross gains on investment securities", "label": "Debt And Equity Securities, Realized Gain", "documentation": "Debt And Equity Securities, Realized Gain" } } }, "auth_ref": [] }, "hum_DebtAndEquitySecuritiesRealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "DebtAndEquitySecuritiesRealizedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross losses on investment securities", "label": "Debt And Equity Securities, Realized Loss", "documentation": "Debt And Equity Securities, Realized Loss" } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.humana.com/role/DEBTDebtOutstandingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "totalLabel": "Total short-term debt", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r195" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r111", "r226", "r392", "r393", "r394", "r395", "r396", "r405", "r406", "r418", "r424", "r425", "r426", "r427", "r428", "r429", "r434", "r441", "r442", "r444", "r587" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r15", "r73", "r74", "r126", "r127", "r230", "r419", "r420", "r421", "r422", "r423", "r425", "r430", "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r826", "r827", "r828", "r829", "r830", "r854", "r994", "r1055", "r1056", "r1057", "r1094", "r1095" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate (percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240930", "localname": "DebtInstrumentCovenantDebtToCapitalizationPercentageActual", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual debt to capitalization percentage", "label": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual", "documentation": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual" } } }, "auth_ref": [] }, "hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240930", "localname": "DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt to capitalization percentage, maximum", "label": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum", "documentation": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r419", "r587", "r588", "r827", "r828", "r854" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt outstanding", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r432", "r578", "r827", "r828", "r1079", "r1080", "r1081", "r1082", "r1089" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate (percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r76", "r420" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r230", "r419", "r420", "r421", "r422", "r423", "r425", "r430", "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r443", "r826", "r827", "r828", "r829", "r830", "r854", "r994", "r1094", "r1095" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r15", "r230", "r419", "r420", "r421", "r422", "r423", "r425", "r430", "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r826", "r827", "r828", "r829", "r830", "r854", "r994", "r1055", "r1056", "r1057", "r1094", "r1095" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r15", "r41", "r42", "r68", "r114", "r115", "r230", "r419", "r420", "r421", "r422", "r423", "r425", "r430", "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r443", "r826", "r827", "r828", "r829", "r830", "r854", "r994", "r1094", "r1095" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument term (in years)", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "12 months or more", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r147", "r360", "r822" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "12 months or more", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r147", "r360" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r147", "r360", "r822" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r147", "r360" ] }, "hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240930", "localname": "DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities, number of positions", "label": "Debt, Securities, Available-For-Sale, Securities, Number Of Positions", "documentation": "Debt Securities, Available-for-sale, Securities, Number Of Positions" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r144", "r357", "r822" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r145", "r358" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r356", "r822" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities in unrealized loss positions, number of positions", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r146", "r359" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r38" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r8", "r38" ] }, "hum_DepreciationAndAmortizationClassifiedAsBenefitExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "DepreciationAndAmortizationClassifiedAsBenefitExpense", "crdr": "debit", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization classified as benefit expense", "label": "Depreciation And Amortization Classified As Benefit Expense", "documentation": "Depreciation and amortization expense that has been reclassified to be included with benefit expenses. The reclassification is the result of depreciation and amortization expense associated primarily from the delivery of pharmacy services by our wholly-owned pharmacy business included in our Healthcare Services segment." } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetLiabilityNetMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetLiabilityNetMeasurementInput", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs", "label": "Derivative Asset (Liability) Net, Measurement Input", "documentation": "Value of input used to measure net derivative asset (liability)." } } }, "auth_ref": [ "r1080", "r1081", "r1082" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r729", "r731", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r766", "r767", "r768", "r769", "r772", "r773", "r774", "r775", "r790", "r791", "r792", "r793", "r867", "r869", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1090", "r1091" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r59", "r60", "r61", "r122", "r729", "r731", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r766", "r767", "r768", "r769", "r772", "r773", "r774", "r775", "r790", "r791", "r792", "r793", "r805", "r867", "r869", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1090", "r1091" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1073", "r1074" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r184" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dispositions", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r9", "r14" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r837", "r838" ] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Amount", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r4", "r116" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends and dividend equivalents", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r116" ] }, "us-gaap_DividendsDeclaredTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDeclaredTableTextBlock", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Details of Dividend Payments", "label": "Dividends Declared [Table Text Block]", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r883" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r915" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r926" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r216", "r240", "r241", "r242", "r243", "r244", "r245", "r252", "r254", "r260", "r261", "r262", "r266", "r526", "r530", "r550", "r551", "r641", "r673", "r807" ] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r254", "r258", "r260" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r216", "r240", "r241", "r242", "r243", "r244", "r245", "r254", "r260", "r261", "r262", "r266", "r526", "r530", "r550", "r551", "r641", "r673", "r807" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER COMMON SHARE COMPUTATION", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r251", "r263", "r264", "r265" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.humana.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate (percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r506", "r840" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r881" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r881" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r881" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r965" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r881" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r881" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r881" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r881" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r920" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r961" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r961" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r961" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails", "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Class of Treasury Stock [Line Items]", "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r180", "r211", "r212", "r213", "r231", "r232", "r233", "r237", "r244", "r246", "r248", "r268", "r344", "r347", "r390", "r459", "r514", "r515", "r521", "r522", "r523", "r527", "r529", "r530", "r539", "r540", "r541", "r542", "r543", "r545", "r549", "r580", "r581", "r582", "r583", "r584", "r585", "r589", "r591", "r594", "r667", "r706", "r707", "r708", "r727", "r778" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r267", "r283", "r295", "r342", "r981", "r1027" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net gains recognized on equity securities during the period", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r677", "r1026" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGain", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross gains on equity securities", "label": "Equity Securities, FV-NI, Realized Gain", "documentation": "Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r1026" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net gains recognized on equity securities sold during the period", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r675", "r1026" ] }, "us-gaap_EquitySecuritiesFvNiRealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedLoss", "crdr": "debit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails": { "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesWithinInvestmentIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross losses on equity securities", "label": "Equity Securities, FV-NI, Realized Loss", "documentation": "Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r1026" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESGainsandLossesRelatedtoEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) recognized on equity securities still held at the end of the period", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r676", "r1026" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r930" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r888", "r898", "r908", "r940" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r885", "r895", "r905", "r937" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r432", "r578", "r827", "r828" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r936" ] }, "srt_ExternalCreditRatingStandardPoorsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ExternalCreditRatingStandardPoorsMember", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "External Credit Rating, Standard & Poor's [Domain]", "label": "External Credit Rating, Standard & Poor's [Domain]", "documentation": "Credit-ratings as used by Standard & Poor's. Contact Standard & Poor's for a complete list of ratings and their definitions." } } }, "auth_ref": [] }, "hum_ExternalRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "ExternalRevenuesMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total external revenues", "label": "External Revenues [Member]", "documentation": "External Revenues" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r553", "r554", "r567", "r843" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r553", "r554", "r567", "r843" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r555", "r556", "r557", "r847" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r555", "r556", "r557", "r847" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions Used For Inputs In Fair Value Measurement", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r555", "r556", "r847" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1078", "r1079" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r558", "r563", "r568", "r845" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r432", "r466", "r467", "r468", "r469", "r470", "r471", "r552", "r554", "r555", "r556", "r557", "r566", "r567", "r569", "r601", "r602", "r603", "r827", "r828", "r834", "r835", "r836", "r843", "r847" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r432", "r827", "r828" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r553", "r554", "r555", "r557", "r843", "r1081", "r1092" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r432", "r827", "r828" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUE" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r562", "r564", "r565", "r566", "r569", "r570", "r571", "r572", "r573", "r637", "r843", "r848" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted\u00a0Prices in Active Markets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r432", "r466", "r471", "r554", "r567", "r601", "r834", "r835", "r836", "r843" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r432", "r466", "r471", "r554", "r555", "r567", "r602", "r827", "r828", "r834", "r835", "r836", "r843" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable Inputs (Level 3)", "verboseLabel": "Level 3 fair value measurement", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r432", "r466", "r467", "r468", "r469", "r470", "r471", "r554", "r555", "r556", "r557", "r567", "r603", "r827", "r828", "r834", "r835", "r836", "r843", "r847" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r553", "r554", "r555", "r557", "r843", "r1081", "r1092" ] }, "hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.humana.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Total gains or losses:", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) [Abstract]", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Realized in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r559", "r568", "r845", "r846" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized in other comprehensive income", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r560", "r568", "r845" ] }, "hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetMaturities", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Maturities", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Maturities", "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Maturities" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r561", "r568", "r845" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r561", "r568", "r845" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r561", "r568", "r845" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transfer out", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r562", "r568", "r845" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance at January\u00a01", "periodEndLabel": "Balance at September 30", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r558", "r568", "r845" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r432", "r466", "r467", "r468", "r469", "r470", "r471", "r552", "r554", "r555", "r556", "r557", "r566", "r567", "r569", "r601", "r602", "r603", "r827", "r828", "r834", "r835", "r836", "r843", "r847" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring Basis", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r843", "r1078", "r1079", "r1080", "r1081", "r1082", "r1092" ] }, "us-gaap_FairValueOfAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfAssetsAcquired", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of assets acquired, net of cash and cash equivalents acquired", "label": "Fair Value of Assets Acquired", "documentation": "The fair value of assets acquired in noncash investing or financing activities." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "hum_FairValueRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "FairValueRiskMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Risk", "label": "Fair Value Risk [Member]", "documentation": "Fair Value Risk" } } }, "auth_ref": [] }, "us-gaap_FederalHomeLoanBankAdvancesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalHomeLoanBankAdvancesMember", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FHLB borrowings", "label": "Federal Home Loan Bank Advances [Member]", "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans." } } }, "auth_ref": [ "r125" ] }, "hum_FinancialAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "FinancialAssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial asset", "label": "Financial Assets, Fair Value Disclosure", "documentation": "Financial Assets, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r349", "r350", "r351", "r352", "r353", "r355", "r361", "r362", "r443", "r457", "r546", "r574", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r668", "r822", "r843", "r845", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r856", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r1022", "r1023", "r1024", "r1025", "r1077", "r1080", "r1081", "r1082", "r1089", "r1092" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial liability", "label": "Financial Liabilities Fair Value Disclosure", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [ "r1078", "r1079", "r1089" ] }, "us-gaap_FinancingReceivableRecordedInvestmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentLineItems", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Credit Quality Indicator [Line Items]", "label": "Financing Receivable, Credit Quality Indicator [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r142", "r821", "r1029" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average life (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 }, "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizable intangible assets, accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r191", "r363", "r383", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r800", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1144" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r800", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r800", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r800", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r800", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r376", "r378", "r379", "r380", "r382", "r383", "r387", "r388", "r632", "r636", "r800" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSAmortizationandEstimatedFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "For the years ending December 31,", "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizable intangible assets, cost", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r363", "r383", "r636", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r376", "r383", "r387", "r388", "r389", "r632", "r800", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r376", "r378", "r379", "r380", "r382", "r383", "r387", "r388", "r800" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortizable intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r632", "r1050" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r892", "r902", "r912", "r944" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r892", "r902", "r912", "r944" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r892", "r902", "r912", "r944" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r892", "r902", "r912", "r944" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r892", "r902", "r912", "r944" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r925" ] }, "us-gaap_GainLossOnInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestmentsTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gain (Loss) on Equity Securities", "label": "Gain (Loss) on Securities [Table Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": [ "r986", "r987" ] }, "hum_GentivaHospiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "GentivaHospiceMember", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gentiva Hospice", "label": "Gentiva Hospice [Member]", "documentation": "Gentiva Hospice" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning balance", "periodEndLabel": "Goodwill, ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r190", "r364", "r638", "r815", "r823", "r844", "r855", "r1032", "r1039" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r367", "r823" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1030", "r1042" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r823" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "hum_GovernmentAndHealthPlanMemberSubsidiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "GovernmentAndHealthPlanMemberSubsidiesAmount", "crdr": "debit", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Member co-share amounts and government subsidies", "label": "Government And Health Plan Member Subsidies Amount", "documentation": "Amount of member co-share amounts and government subsidies that are excluded from benefits expense because the health plans do not bear responsibility." } } }, "auth_ref": [] }, "hum_GroupMedicareAdvantageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "GroupMedicareAdvantageMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Group Medicare Advantage", "label": "Group Medicare Advantage [Member]", "documentation": "Group Medicare Advantage" } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative, aggregate adjustment", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r538" ] }, "hum_HomeSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "HomeSolutionsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Home solutions", "label": "Home Solutions [Member]", "documentation": "Home Solutions" } } }, "auth_ref": [] }, "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss (income) attributable to noncontrolling interests", "label": "Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Noncontrolling Interest", "documentation": "Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Noncontrolling Interest" } } }, "auth_ref": [] }, "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent", "crdr": "credit", "calculation": { "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Segment earnings (loss) attributable to Humana", "label": "Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Parent", "documentation": "Income (Loss) From Continuing Operations Before Income Taxes, Attributable To Parent" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Segment earnings (loss)", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r92", "r134", "r139", "r642", "r663", "r809", "r814", "r1002", "r1004", "r1005", "r1006", "r1007" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes and equity in net losses", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r139", "r679", "r809", "r1002", "r1004", "r1005", "r1006", "r1007" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in net losses", "negatedTerseLabel": "Equity in net losses", "verboseLabel": "Equity in net losses", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r8", "r93", "r133", "r267", "r280", "r295", "r342", "r662" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r837", "r838" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r229", "r504", "r506", "r507", "r508", "r509", "r510", "r511", "r516", "r518", "r519", "r520", "r724", "r840" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r148", "r150", "r247", "r248", "r267", "r281", "r295", "r505", "r506", "r517", "r680", "r840" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax payments, net", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r25", "r224", "r512", "r513" ] }, "us-gaap_IncreaseDecreaseInBookOverdrafts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInBookOverdrafts", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in book overdraft", "label": "Increase (Decrease) in Book Overdrafts", "documentation": "The increase (decrease) in cash during the period due to the net increase or decrease in book overdrafts." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unearned revenues", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r630", "r992" ] }, "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Benefits payable", "label": "Increase (Decrease) in Health Care Insurance Liabilities", "documentation": "The increase (decrease) in health care insurance liability balances during the period." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Receivables", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of employee stock options and restricted stock (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r255", "r256", "r257", "r262", "r475" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r376", "r381", "r386", "r824" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r376", "r386", "r389", "r824" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r363", "r386", "r824" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r376", "r381", "r386", "r824" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r892", "r902", "r912", "r936", "r944", "r948", "r956" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r954" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r884", "r960" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r884", "r960" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r884", "r960" ] }, "us-gaap_InsuranceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceAbstract", "lang": { "en-us": { "role": { "terseLabel": "Insurance [Abstract]", "label": "Insurance [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InsuranceDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLE" ], "lang": { "en-us": { "role": { "terseLabel": "BENEFITS PAYABLE", "label": "Insurance Disclosure [Text Block]", "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items." } } }, "auth_ref": [ "r650", "r651", "r698", "r699" ] }, "hum_InsuranceSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "InsuranceSegmentMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance", "label": "Insurance Segment [Member]", "documentation": "Insurance Segment" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other intangible assets, cost", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r190" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r376", "r1050", "r1052" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets:", "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r277", "r988" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest payments", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r219", "r222", "r223" ] }, "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateFairValueHedgeAssetAtFairValue", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swap asset", "label": "Interest Rate Fair Value Hedge Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments." } } }, "auth_ref": [ "r122" ] }, "hum_InterestRateSwapMaturing2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "InterestRateSwapMaturing2033Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2033", "label": "Interest Rate Swap Maturing 2033 [Member]", "documentation": "Interest Rate Swap Maturing 2033" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "InterestRateSwapMaturing2034Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2034", "label": "Interest Rate Swap Maturing 2034 [Member]", "documentation": "Interest Rate Swap Maturing 2034" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2042Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "InterestRateSwapMaturing2042Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2042", "label": "Interest Rate Swap Maturing 2042 [Member]", "documentation": "Interest Rate Swap Maturing 2042" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "InterestRateSwapMaturing2044Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2044", "label": "Interest Rate Swap Maturing 2044 [Member]", "documentation": "Interest Rate Swap Maturing 2044" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2049Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "InterestRateSwapMaturing2049Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2049", "label": "Interest Rate Swap Maturing 2049 [Member]", "documentation": "Interest Rate Swap Maturing 2049" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2053Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "InterestRateSwapMaturing2053Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2053", "label": "Interest Rate Swap Maturing 2053 [Member]", "documentation": "Interest Rate Swap Maturing 2053" } } }, "auth_ref": [] }, "hum_InterestRateSwapMaturing2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "InterestRateSwapMaturing2054Member", "presentation": [ "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Maturing 2054", "label": "Interest Rate Swap Maturing 2054 [Member]", "documentation": "Interest Rate Swap Maturing 2054" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r802", "r874", "r875" ] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intersegment Eliminations", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r138", "r267", "r275", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r814" ] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r96", "r97" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Securities", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r674", "r719", "r720", "r721", "r722", "r784", "r785" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contractual Maturity of Debt Securities Available for Sale", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTMENT SECURITIES", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r136", "r154", "r306", "r309", "r575", "r576", "r1104" ] }, "us-gaap_InvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments [Member]", "documentation": "Assets held for their financial return, rather than for the entity's operations." } } }, "auth_ref": [] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r15", "r73", "r74", "r75", "r78", "r79", "r80", "r81", "r228", "r343", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r416", "r417", "r533", "r536", "r537", "r579", "r738", "r808", "r879", "r1066", "r1096", "r1097" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r89", "r130", "r660", "r855", "r995", "r1028", "r1093" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAssumed1", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Fair value of liabilities assumed", "label": "Liabilities Assumed", "documentation": "The fair value of liabilities assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r75", "r187", "r228", "r343", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r416", "r417", "r533", "r536", "r537", "r579", "r855", "r1066", "r1096", "r1097" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Benefits payable", "periodStartLabel": "Balances, beginning of period", "periodEndLabel": "Balances, end of period", "label": "Liability for Claims and Claims Adjustment Expense", "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date." } } }, "auth_ref": [ "r860", "r864", "r1105", "r1111" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions", "crdr": "credit", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions", "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported." } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paid related to:", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "crdr": "credit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Current year", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs." } } }, "auth_ref": [ "r702", "r860" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "crdr": "credit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Prior years", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs." } } }, "auth_ref": [ "r702", "r860" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount", "crdr": "credit", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total IBNR included in benefits payable", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount", "documentation": "Estimated costs as of the balance sheet date of settling insured claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance company for reimbursement." } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "crdr": "debit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total incurred", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process." } } }, "auth_ref": [ "r860", "r1109" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incurred related to:", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare licenses", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r52", "r503", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1050", "r1052", "r1053", "r1054", "r1072" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility fee (percent)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r406", "r994", "r1064" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r72", "r77" ] }, "hum_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease", "crdr": "debit", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase commitments", "label": "Line Of Credit Facility, Maximum Borrowing Capacity Increase (Decrease)", "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Increase (Decrease)" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r72", "r77", "r406" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r72", "r77", "r406", "r994", "r1064" ] }, "hum_LineOfCreditFacilityUncommittedIncrementalCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "LineOfCreditFacilityUncommittedIncrementalCapacity", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncommitted incremental loan facility", "label": "Line Of Credit Facility, Uncommitted Incremental Capacity", "documentation": "Line Of Credit Facility, Uncommitted Incremental Capacity" } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding borrowings", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r73", "r126" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/DEBTDebtOutstandingDetails": { "parentTag": "us-gaap_DebtCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total senior notes", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r194" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/DEBTDebtOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r196" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r15", "r1055", "r1056", "r1057" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r15", "r39", "r1055", "r1056", "r1057" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r399", "r400", "r401", "r404", "r502", "r825", "r1060", "r1061" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r399", "r400", "r401", "r404", "r502", "r825", "r1060", "r1061" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r301", "r833", "r858", "r863", "r1070", "r1108", "r1112", "r1113", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1139", "r1140" ] }, "hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240930", "localname": "MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum individual state general bond obligation as a percentage of total debt securities (percent)", "label": "Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities", "documentation": "Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r178", "r179", "r400", "r401", "r402", "r403", "r472", "r502", "r557", "r629", "r704", "r705", "r714", "r730", "r731", "r783", "r786", "r787", "r788", "r794", "r798", "r799", "r819", "r831", "r839", "r847", "r848", "r852", "r853", "r859", "r1068", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r928" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r928" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average cost of capital", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1080", "r1081", "r1082" ] }, "us-gaap_MeasurementInputLongTermRevenueGrowthRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputLongTermRevenueGrowthRateMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term growth rate", "label": "Measurement Input, Long-Term Revenue Growth Rate [Member]", "documentation": "Measurement input using compounded annualized rate of long-term growth in revenue." } } }, "auth_ref": [ "r1080", "r1081", "r1082" ] }, "us-gaap_MeasurementInputOptionVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputOptionVolatilityMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annualized volatility", "label": "Measurement Input, Option Volatility [Member]", "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns." } } }, "auth_ref": [ "r1080", "r1081", "r1082" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r555", "r556", "r557", "r847" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r555", "r556", "r557", "r847" ] }, "hum_MedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "MedicaidMember", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicaid", "label": "Medicaid [Member]", "documentation": "Medicaid [Member]" } } }, "auth_ref": [] }, "hum_MedicareAdvantageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "MedicareAdvantageMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Individual Medicare Advantage", "label": "Medicare Advantage [Member]", "documentation": "Medicare Advantage [Member]" } } }, "auth_ref": [] }, "hum_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "MedicareMember", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Medicare", "terseLabel": "Total Medicare", "label": "Medicare [Member]", "documentation": "Medicare [Member]" } } }, "auth_ref": [] }, "hum_MedicarePartDDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.humana.com/20240930", "localname": "MedicarePartDDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/MEDICAREPARTD" ], "lang": { "en-us": { "role": { "terseLabel": "MEDICARE PART D", "label": "Medicare Part D Disclosure [Text Block]", "documentation": "Balance sheet amounts associated with Medicare Part D." } } }, "auth_ref": [] }, "hum_MedicareStandAlonePrescriptionDrugPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "MedicareStandAlonePrescriptionDrugPlanMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare stand-alone PDP", "label": "Medicare Stand Alone Prescription Drug Plan [Member]", "documentation": "Medicare Stand Alone Prescription Drug Plan [Member]" } } }, "auth_ref": [] }, "hum_MedicareSupplementProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "MedicareSupplementProductMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare Supplement", "label": "Medicare Supplement Product [Member]", "documentation": "Medicare Supplement Product" } } }, "auth_ref": [] }, "hum_MilitaryAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "MilitaryAndOtherMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Military services and other", "label": "Military And Other [Member]", "documentation": "Military And Other" } } }, "auth_ref": [] }, "hum_MilitaryServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "MilitaryServiceMember", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Military services", "label": "Military Service [Member]", "documentation": "Military Service [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r178", "r179", "r400", "r401", "r402", "r403", "r472", "r502", "r557", "r629", "r704", "r705", "r714", "r730", "r731", "r783", "r786", "r787", "r788", "r794", "r798", "r799", "r819", "r831", "r839", "r847", "r848", "r852", "r859", "r1068", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r88", "r129", "r228", "r343", "r407", "r410", "r411", "r412", "r416", "r417", "r579", "r659", "r742" ] }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)." } } }, "auth_ref": [ "r55", "r116", "r120" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r947" ] }, "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Mortgage-backed securities", "label": "Mortgage-Backed Security, Issued by US Government-Sponsored Enterprise [Member]", "documentation": "Debt security collateralized by real estate mortgage loan issued by U.S. government-sponsored enterprise (GSE), including, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and Federal Home Loan Bank (FHLBank)." } } }, "auth_ref": [ "r1014", "r1020", "r1021", "r1071" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r955" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r301", "r833", "r858", "r863", "r1070", "r1108", "r1112", "r1113", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1139", "r1140" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r929" ] }, "hum_NetAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NetAssetLiability", "crdr": "debit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net asset (liability)", "label": "Net Asset (Liability)", "documentation": "Net Asset (Liability)" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r221" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r221" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r104", "r105", "r106" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "hum_NetCurrentLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NetCurrentLiabilityAsset", "crdr": "debit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetAssetLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net current liability", "label": "Net Current (Liability) Asset", "documentation": "Net current (liability) asset" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Humana", "terseLabel": "Net income attributable to Humana", "verboseLabel": "Net income available for common stockholders", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r94", "r106", "r135", "r185", "r206", "r209", "r213", "r228", "r236", "r240", "r241", "r242", "r243", "r244", "r247", "r248", "r259", "r343", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r416", "r417", "r526", "r530", "r551", "r579", "r666", "r760", "r776", "r777", "r877", "r1066" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net loss attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r57", "r121", "r206", "r209", "r244", "r247", "r248", "r665", "r985" ] }, "us-gaap_NetInvestmentIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentIncome", "crdr": "credit", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Investment income", "label": "Net Investment Income", "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments." } } }, "auth_ref": [ "r149", "r669", "r670", "r763", "r877" ] }, "hum_NetNoncurrentAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NetNoncurrentAssetLiability", "crdr": "debit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetAssetLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net long-term asset (liability)", "label": "Net Noncurrent Asset (Liability)", "documentation": "Net Noncurrent Asset (Liability)" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.humana.com/role/RECENTLYISSUEDACCOUNTINGPRONOUNCEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r153", "r182", "r234", "r235", "r238", "r239", "r249", "r250", "r302", "r345", "r346", "r524", "r525", "r527", "r530", "r544", "r548", "r593", "r595", "r596", "r633", "r634", "r635", "r709", "r710", "r711", "r712", "r713" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Pronouncements Effective in Future Periods", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r928" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r892", "r902", "r912", "r936", "r944" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r919" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r918" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r936" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r955" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r955" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Details of businesses acquired in purchase transactions:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Noncontrolling interests acquired", "label": "Noncash or Part Noncash Acquisition, Noncontrolling Interest Acquired", "documentation": "Noncash or Part Noncash Acquisition, Noncontrolling Interest Acquired" } } }, "auth_ref": [] }, "hum_NoncompetesAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NoncompetesAndOtherMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncompetes and other", "label": "Noncompetes And Other [Member]", "documentation": "Noncompetes and Other [Member]" } } }, "auth_ref": [] }, "hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsFromNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsFromNoncontrollingInterestHolders", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions from (to) noncontrolling interest holders, net", "label": "Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions From Noncontrolling Interest Holders", "documentation": "Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions From Noncontrolling Interest Holders" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r53", "r459", "r996", "r997", "r998", "r1000", "r1142" ] }, "us-gaap_NontaxableMunicipalNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NontaxableMunicipalNotesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax-exempt municipal securities", "label": "Nontaxable Municipal Notes [Member]", "documentation": "Short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments that are not taxable." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r810", "r818", "r1003" ] }, "hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states comprising of TRICARE managed care support contract beneficiaries", "label": "Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries", "documentation": "Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries" } } }, "auth_ref": [] }, "hum_NumberOfStatesComprisingTRICAREBeneficiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NumberOfStatesComprisingTRICAREBeneficiaries", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states comprising TRICARE beneficiaries", "label": "Number Of States Comprising TRICARE Beneficiaries", "documentation": "Number Of States Comprising TRICARE Beneficiaries" } } }, "auth_ref": [] }, "hum_NumberOfTRICAREBeneficiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NumberOfTRICAREBeneficiaries", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of TRICARE beneficiaries", "label": "Number Of TRICARE Beneficiaries", "documentation": "Number Of TRICARE Beneficiaries" } } }, "auth_ref": [] }, "hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240930", "localname": "NumberOfTRICAREManagedCareSupportContractBeneficiaries", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of TRICARE managed care support contract beneficiaries", "label": "Number Of TRICARE Managed Care Support Contract Beneficiaries", "documentation": "Number Of TRICARE Managed Care Support Contract Beneficiaries" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r139", "r809", "r1002", "r1004", "r1005", "r1006", "r1007" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r289", "r290", "r291", "r292", "r293", "r296", "r814", "r815" ] }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityEquityAxis", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Indexed to Issuer's Equity [Axis]", "label": "Option Indexed to Issuer's Equity [Axis]", "documentation": "Information by type of options indexed to an issuer's equity." } } }, "auth_ref": [ "r40", "r62", "r63", "r123" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OptionOnSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionOnSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Option on Securities [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PRESENTATION AND SIGNIFICANT EVENTS", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r69", "r118", "r717", "r718" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetCurrentLiabilityAsset", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r199", "r855" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetNoncurrentAssetLiability", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r192" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive (loss) income, net of tax", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r5", "r12", "r119", "r207", "r210", "r244" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification adjustment for net realized losses (gains)", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax", "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r3", "r91", "r205", "r341" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total reclassification adjustment, net of tax", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r3", "r91", "r205", "r341" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of income taxes", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r2" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in gross unrealized investment (losses) gains", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r202", "r204", "r341" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total change in unrealized investment (losses) gains, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r202", "r204", "r341" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Effect of income taxes", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax", "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r2", "r203" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.humana.com/role/MEDICAREPARTDDetails": { "parentTag": "hum_NetNoncurrentAssetLiability", "weight": -1.0, "order": 2.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "negatedTerseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r79" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other (income) expense, net", "negatedLabel": "Other expense (income), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r928" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r890", "r900", "r910", "r942" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r893", "r903", "r913", "r945" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r893", "r903", "r913", "r945" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total Stockholders' Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r917" ] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled the claims in this suit", "label": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLossesAndLossAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total paid", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process." } } }, "auth_ref": [ "r6", "r860", "r1110" ] }, "hum_PaymentsForProceedsFromContractDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "PaymentsForProceedsFromContractDeposits", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Payments) receipts from contract deposits, net", "label": "Payments For Proceeds From Contract Deposits", "documentation": "Payments For Proceeds From Contract Deposits" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Common stock repurchases", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r102" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt issue costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r23" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r102" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investment securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r20", "r217", "r307" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions, net of cash and cash equivalents acquired", "verboseLabel": "Cash paid for acquired businesses, net of cash and cash equivalents acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r21" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment, net", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r101" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r927" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r927" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r919" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r936" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r929" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r918" ] }, "hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240930", "localname": "PercentageOfTotalDebtSecuritiesInvestmentGradeQuality", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of debt securities considered to be of investment-grade (percent)", "label": "Percentage Of Total Debt Securities, Investment Grade Quality", "documentation": "Percentage Of Total Debt Securities, Investment Grade Quality" } } }, "auth_ref": [] }, "hum_PercentageOfTotalPremiumAndServicesRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240930", "localname": "PercentageOfTotalPremiumAndServicesRevenues", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of premiums and services revenue", "label": "Percentage Of Total Premium And Services Revenues", "documentation": "Percentage Of Total Premium And Services Revenues" } } }, "auth_ref": [] }, "hum_PharmacySolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "PharmacySolutionsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharmacy solutions", "label": "Pharmacy Solutions [Member]", "documentation": "Pharmacy Solutions" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r920" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r964" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r919" ] }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderBenefitsAndClaimsIncurredNet", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefits", "label": "Policyholder Benefits and Claims Incurred, Net", "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred." } } }, "auth_ref": [ "r1107" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r577" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r82", "r446" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r82", "r740" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r82", "r446" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $1 par; 10,000,000 shares authorized; none issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r82", "r655", "r855" ] }, "us-gaap_PremiumsEarnedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumsEarnedNet", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Premiums", "label": "Premiums Earned, Net", "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned." } } }, "auth_ref": [ "r151", "r152", "r696", "r715" ] }, "hum_PrimaryCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "PrimaryCareMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Primary care", "label": "Primary Care [Member]", "documentation": "Primary Care" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.humana.com/role/DEBTSeniorNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of senior notes, net", "label": "Proceeds from Issuance of Senior Long-Term Debt", "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of investment securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r217", "r218", "r1011" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r968", "r989" ] }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfCommercialPaper", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "(Repayments) issuance of commercial paper, net", "label": "Proceeds from (Repayments of) Commercial Paper", "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper." } } }, "auth_ref": [ "r990", "r991", "r993" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of investment securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r19", "r217", "r307", "r340" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r832" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r161", "r162", "r163", "r164", "r165", "r166", "r176", "r298", "r631", "r692", "r693", "r694", "r695", "r696", "r697", "r703", "r803", "r832", "r857", "r859", "r861", "r864", "r866", "r980", "r1062", "r1063", "r1070", "r1108", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1139", "r1140" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r161", "r162", "r163", "r164", "r165", "r166", "r176", "r298", "r631", "r692", "r693", "r694", "r695", "r696", "r697", "r703", "r803", "r832", "r857", "r859", "r861", "r864", "r866", "r980", "r1062", "r1063", "r1070", "r1108", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1139", "r1140" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r185", "r206", "r209", "r220", "r228", "r236", "r244", "r247", "r248", "r343", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r416", "r417", "r526", "r530", "r531", "r534", "r535", "r551", "r579", "r642", "r664", "r726", "r760", "r776", "r777", "r841", "r842", "r878", "r985", "r1066" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r592", "r649", "r661", "r855" ] }, "us-gaap_PutOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PutOptionMember", "presentation": [ "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Put option", "label": "Put Option [Member]", "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option." } } }, "auth_ref": [ "r789", "r790" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r917" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r917" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r178", "r179", "r400", "r401", "r402", "r403", "r465", "r472", "r498", "r499", "r500", "r502", "r557", "r604", "r613", "r629", "r704", "r705", "r714", "r730", "r731", "r783", "r786", "r787", "r788", "r794", "r798", "r799", "r819", "r831", "r839", "r847", "r848", "r852", "r853", "r859", "r869", "r1058", "r1068", "r1081", "r1099", "r1100", "r1101", "r1102", "r1103" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r178", "r179", "r400", "r401", "r402", "r403", "r465", "r472", "r498", "r499", "r500", "r502", "r557", "r604", "r613", "r629", "r704", "r705", "r714", "r730", "r731", "r783", "r786", "r787", "r788", "r794", "r798", "r799", "r819", "r831", "r839", "r847", "r848", "r852", "r853", "r859", "r869", "r1058", "r1068", "r1081", "r1099", "r1100", "r1101", "r1102", "r1103" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables, net of allowances of $93 in 2024 and $88 in 2023", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r855" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r885", "r895", "r905", "r937" ] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of senior notes", "label": "Repayments of Senior Debt", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": [ "r103" ] }, "us-gaap_RepaymentsOfUnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfUnsecuredDebt", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of term loan", "label": "Repayments of Unsecured Debt", "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt." } } }, "auth_ref": [ "r103" ] }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResidentialMortgageBackedSecuritiesMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Residential", "label": "Residential Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by residential real estate mortgage loans." } } }, "auth_ref": [ "r843", "r845", "r847", "r1012", "r1014", "r1019", "r1020", "r1021", "r1071" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r886", "r896", "r906", "r938" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r887", "r897", "r907", "r939" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r894", "r904", "r914", "r946" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r30" ] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and impairment charge", "label": "Restructuring Costs and Asset Impairment Charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r86", "r116", "r658", "r709", "r713", "r723", "r741", "r855" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r180", "r231", "r232", "r233", "r237", "r244", "r246", "r248", "r344", "r347", "r390", "r514", "r515", "r521", "r522", "r523", "r527", "r529", "r530", "r539", "r541", "r542", "r545", "r549", "r589", "r591", "r706", "r708", "r727", "r1142" ] }, "hum_RevenueExitMultipleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "RevenueExitMultipleMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue exit multiple", "label": "Revenue Exit Multiple [Member]", "documentation": "Revenue Exit Multiple" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Services", "verboseLabel": "Services revenue", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r137", "r138", "r267", "r274", "r275", "r289", "r295", "r298", "r300", "r301", "r462", "r463", "r631" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer." } } }, "auth_ref": [ "r832" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r761", "r801", "r806" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r137", "r138", "r214", "r228", "r267", "r274", "r275", "r289", "r295", "r298", "r300", "r301", "r343", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r416", "r417", "r579", "r642", "r814", "r1066" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "hum_RevolvingCreditAgreementJune2021FiveYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "RevolvingCreditAgreementJune2021FiveYearMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5-year unsecured revolving credit agreement June 2021", "label": "Revolving Credit Agreement June 2021 Five Year [Member]", "documentation": "Revolving Credit Agreement June 2021 Five Year" } } }, "auth_ref": [] }, "hum_RevolvingCreditAgreementJune2023FiveYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "RevolvingCreditAgreementJune2023FiveYearMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5-year unsecured revolving credit agreement June 2023", "label": "Revolving Credit Agreement June 2023 Five Year [Member]", "documentation": "Revolving Credit Agreement June 2023 Five Year" } } }, "auth_ref": [] }, "hum_RevolvingCreditAgreementJune2023OneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "RevolvingCreditAgreementJune2023OneYearMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "364-day unsecured revolving credit agreement June 2023", "label": "Revolving Credit Agreement June 2023 One Year [Member]", "documentation": "Revolving Credit Agreement June 2023 One Year" } } }, "auth_ref": [] }, "hum_RevolvingCreditAgreementMay2024OneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "RevolvingCreditAgreementMay2024OneYearMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "364-day unsecured revolving credit agreement May 2024", "label": "Revolving Credit Agreement May 2024 One Year [Member]", "documentation": "Revolving Credit Agreement May 2024 One Year" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "hum_RiskCorridorSettlementsMedicarePartDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "RiskCorridorSettlementsMedicarePartDMember", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk Corridor Settlement", "label": "Risk Corridor Settlements Medicare Part D [Member]", "documentation": "Risk Corridor Settlements - Medicare Part D [Member]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r955" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r955" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r473", "r977", "r999" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r177", "r249", "r473", "r966", "r999" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": [ "r84", "r90", "r304", "r1009" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment Securities Classified as Current and Long-Term", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.humana.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Value of Debt Outstanding", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Details Supporting Computation of Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1001" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r29", "r31", "r254", "r258", "r260" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]", "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Credit Quality Indicator [Table]", "label": "Financing Receivable, Credit Quality Indicator [Table]", "documentation": "Disclosure of information about credit quality indicator for financing receivable." } } }, "auth_ref": [ "r142", "r821", "r1029" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r376", "r383", "r387", "r388", "r389", "r632", "r800", "r824" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Intangible Assets, Amortizable", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r824", "r1049" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r823" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r823", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": [ "r376", "r386", "r389", "r824" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Intangible Assets, Indefinite-Lived", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r824", "r1052" ] }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity in Benefits Payable", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims." } } }, "auth_ref": [ "r700" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.humana.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ScheduleOfRealizedGainLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRealizedGainLossTableTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income", "label": "Schedule of Realized Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Results", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-term Debt [Table]", "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r824", "r1051" ] }, "us-gaap_SecuritiesLoanedFairValueOfCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesLoanedFairValueOfCollateral", "crdr": "debit", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities lending invested collateral", "label": "Securities Loaned, Fair Value of Collateral", "documentation": "Fair value of the securities pledged as collateral against securities loaned." } } }, "auth_ref": [ "r201" ] }, "hum_SecuritiesLoanedMinimumCollateralAsPercentageOfFairValueOfInvestmentSecurities": { "xbrltype": "percentItemType", "nsuri": "http://www.humana.com/20240930", "localname": "SecuritiesLoanedMinimumCollateralAsPercentageOfFairValueOfInvestmentSecurities", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails", "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum collateral as percentage of fair value of investment securities", "label": "Securities Loaned, Minimum Collateral As Percentage Of Fair Value Of Investment Securities", "documentation": "Securities Loaned, Minimum Collateral As Percentage Of Fair Value Of Investment Securities" } } }, "auth_ref": [] }, "us-gaap_SecuritiesReceivedAsCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesReceivedAsCollateral", "crdr": "debit", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of non-cash securities lending", "label": "Securities Received as Collateral", "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability." } } }, "auth_ref": [ "r11" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r880" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r882" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r137", "r138", "r139", "r140", "r267", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r301", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r389", "r397", "r398", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r811", "r814", "r815", "r823", "r862", "r1108", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1139", "r1140" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r140", "r267", "r269", "r270", "r271", "r272", "r273", "r285", "r287", "r288", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r301", "r810", "r812", "r813", "r814", "r816", "r817", "r818" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.humana.com/role/MEDICAREPARTDDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating costs", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r95" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Services", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r832" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r1069" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r1069" ] }, "hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.humana.com/20240930", "localname": "ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares acquired in connection with employee stock plans (in shares)", "label": "Share Repurchases Related To Employee Stock Based Compensation Awards Shares", "documentation": "Number of shares of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares." } } }, "auth_ref": [] }, "hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.humana.com/20240930", "localname": "ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue", "crdr": "debit", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares acquired in connection with employee stock plans, amount", "label": "Share Repurchases Related To Employee Stock Based Compensation Awards Value", "documentation": "Cost of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.humana.com/role/DEBTDebtOutstandingDetails": { "parentTag": "us-gaap_DebtCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt", "verboseLabel": "Short-term debt outstanding", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r71", "r126", "r855", "r1106" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt [Line Items]", "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r73", "r1055", "r1056", "r1057" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails", "http://www.humana.com/role/DEBTDebtOutstandingDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r71", "r1055", "r1056", "r1057" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment securities", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r131", "r132", "r982" ] }, "us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShorttermDebtMaximumAmountOutstandingDuringPeriod", "crdr": "credit", "presentation": [ "http://www.humana.com/role/DEBTCommercialPaperandOtherShorttermBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount outstanding during period", "label": "Short-Term Debt, Maximum Amount Outstanding During Period", "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, the maximum amount borrowed at any time during the period." } } }, "auth_ref": [] }, "hum_SpecialtyBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "SpecialtyBenefitsMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty benefits", "label": "Specialty Benefits [Member]", "documentation": "Specialty [Member]" } } }, "auth_ref": [] }, "srt_StandardPoorsAAMinusRatingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StandardPoorsAAMinusRatingMember", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "S&P AA- rating", "label": "Standard & Poor's, AA- Rating [Member]", "documentation": "AA- credit rating as defined by the external credit rating agency, Standard & Poor's." } } }, "auth_ref": [] }, "hum_StateBasedContractsAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "StateBasedContractsAndOtherMember", "presentation": [ "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State-based contracts and other", "label": "State-Based Contracts and Other [Member]", "documentation": "State-Based Contracts and Other" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSGoodwillbySegmentsDetails", "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r137", "r138", "r139", "r140", "r183", "r267", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r301", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r389", "r391", "r397", "r398", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r811", "r814", "r815", "r823", "r862", "r1108", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1139", "r1140" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r83", "r87", "r88", "r180", "r211", "r212", "r213", "r231", "r232", "r233", "r237", "r244", "r246", "r248", "r268", "r344", "r347", "r390", "r459", "r514", "r515", "r521", "r522", "r523", "r527", "r529", "r530", "r539", "r540", "r541", "r542", "r543", "r545", "r549", "r580", "r581", "r582", "r583", "r584", "r585", "r589", "r591", "r594", "r667", "r706", "r707", "r708", "r727", "r778" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r231", "r232", "r233", "r268", "r591", "r631", "r719", "r728", "r732", "r733", "r734", "r735", "r736", "r737", "r740", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r759", "r761", "r762", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r778", "r870" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r177", "r249", "r473", "r966", "r967", "r999" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r231", "r232", "r233", "r268", "r303", "r591", "r631", "r719", "r728", "r732", "r733", "r734", "r735", "r736", "r737", "r740", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r759", "r761", "r762", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r778", "r870" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r889", "r899", "r909", "r941" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock unit vesting (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r13", "r116" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock unit vesting", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r13", "r82", "r83", "r116" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option exercises", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r13", "r83", "r87", "r88", "r116" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share repurchase authorization", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1069" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining authorized amount", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r83", "r87", "r88", "r107", "r742", "r758", "r779", "r780", "r855", "r879", "r995", "r1028", "r1093", "r1142" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r53", "r54", "r56", "r180", "r181", "r212", "r231", "r232", "r233", "r237", "r244", "r246", "r344", "r347", "r390", "r459", "r514", "r515", "r521", "r522", "r523", "r527", "r529", "r530", "r539", "r540", "r541", "r542", "r543", "r545", "r549", "r580", "r581", "r585", "r590", "r594", "r707", "r708", "r725", "r742", "r758", "r779", "r780", "r795", "r878", "r995", "r1028", "r1093", "r1142" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r113", "r227", "r445", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r459", "r547", "r781", "r782", "r796" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r586", "r597" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r586", "r597" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r586", "r597" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow disclosures:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current year", "label": "Current Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs." } } }, "auth_ref": [ "r701", "r860" ] }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior years", "label": "Prior Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs." } } }, "auth_ref": [ "r701", "r860" ] }, "hum_TRICARE2017EastRegionContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "TRICARE2017EastRegionContractMember", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "T2017 East Region", "label": "TRICARE 2017 East Region Contract [Member]", "documentation": "TRICARE 2017 East Region Contract" } } }, "auth_ref": [] }, "hum_TRICAREContractAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.humana.com/20240930", "localname": "TRICAREContractAxis", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TRICARE Contract [Axis]", "label": "TRICARE Contract [Axis]", "documentation": "TRICARE Contract" } } }, "auth_ref": [] }, "hum_TRICAREContractDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "TRICAREContractDomain", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TRICARE Contract [Domain]", "label": "TRICARE Contract [Domain]", "documentation": "TRICARE Contract [Domain]" } } }, "auth_ref": [] }, "hum_TRICAREManagedCareSupportContractBaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.humana.com/20240930", "localname": "TRICAREManagedCareSupportContractBaseTerm", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract base term", "label": "TRICARE Managed Care Support Contract, Base Term", "documentation": "TRICARE Managed Care Support Contract, Base Term" } } }, "auth_ref": [] }, "hum_TRICAREManagedCareSupportContractEffective2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "TRICAREManagedCareSupportContractEffective2024Member", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "T-5, Effective 2024", "label": "TRICARE Managed Care Support Contract, Effective 2024 [Member]", "documentation": "TRICARE Managed Care Support Contract, Effective 2024" } } }, "auth_ref": [] }, "hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods": { "xbrltype": "integerItemType", "nsuri": "http://www.humana.com/20240930", "localname": "TRICAREManagedCareSupportContractNumberOfOptionPeriods", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual option periods", "label": "TRICARE Managed Care Support Contract, Number Of Option Periods", "documentation": "TRICARE Managed Care Support Contract, Number Of Option Periods" } } }, "auth_ref": [] }, "hum_TRICAREManagedCareSupportContractTermWithOptionExercises": { "xbrltype": "durationItemType", "nsuri": "http://www.humana.com/20240930", "localname": "TRICAREManagedCareSupportContractTermWithOptionExercises", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract term with exercises", "label": "TRICARE Managed Care Support Contract, Term With Option Exercises", "documentation": "TRICARE Managed Care Support Contract, Term With Option Exercises" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r935" ] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of property and equipment", "label": "Tangible Asset Impairment Charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r70", "r108" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r927" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r934" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [ "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSOtherIntangibleAssetsSubjecttoAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade names and technology", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r49", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1050", "r1052", "r1053", "r1054" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r954" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r956" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.humana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.humana.com/role/DEBTSeniorNotesDetails", "http://www.humana.com/role/FAIRVALUEFairValueofSwapAgreementsDetails", "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/FAIRVALUENarrativeDetails", "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r443", "r457", "r546", "r574", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r668", "r843", "r845", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r856", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r1022", "r1023", "r1024", "r1025", "r1077", "r1080", "r1081", "r1082", "r1089", "r1092" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r957" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r958" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r958" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r956" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r956" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r959" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r957" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase average price (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r43" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r43" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r43" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost, 78,307,467 shares at September\u00a030, 2024 and 76,465,862 shares at December 31, 2023", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r43", "r46", "r87" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchases (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r13", "r83", "r116" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.humana.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock repurchases", "terseLabel": "Stock repurchases", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r13", "r43", "r116" ] }, "us-gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryAndGovernmentMember", "presentation": [ "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails", "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails", "http://www.humana.com/role/INVESTMENTSECURITIESSecuritiesClassifiedasCurrentandLongTermDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury and agency obligations", "label": "US Treasury and Government [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r643", "r834", "r856", "r865", "r1138" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r953" ] }, "hum_UnitedStatesOfAmericaExRel.StevenScottV.HumanaInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "UnitedStatesOfAmericaExRel.StevenScottV.HumanaInc.Member", "presentation": [ "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States Of America Ex Rel. Steven Scott V. Humana Inc.", "label": "United States Of America Ex Rel. Steven Scott V. Humana Inc. [Member]", "documentation": "United States Of America Ex Rel. Steven Scott V. Humana Inc." } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "presentation": [ "http://www.humana.com/role/INVESTMENTSECURITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gross Unrealized Losses and Fair Value of Securities", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "documentation": "Tabular disclosure of unrealized gains and losses on investments." } } }, "auth_ref": [] }, "hum_ValueCreationInitiativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.humana.com/20240930", "localname": "ValueCreationInitiativesMember", "presentation": [ "http://www.humana.com/role/BASISOFPRESENTATIONANDSIGNIFICANTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value Creation Initiatives", "label": "Value Creation Initiatives [Member]", "documentation": "Value Creation Initiatives" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r923" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Shares used to compute diluted earnings per common share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r253", "r262" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average outstanding shares of common stock used to compute basic earnings per common share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r252", "r262" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r921" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)", "SubTopic": "30", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-24" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "460", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/460/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13)(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "220", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(1))", "SubTopic": "220", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(c))", "SubTopic": "220", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/944/tableOfContent" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479838/944-20-50-7" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(4)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(4)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-15" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-7" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r966": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r967": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 81 0000049071-24-000055-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000049071-24-000055-xbrl.zip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

A!ACJ/A9Z M=EE,$!0=376W :!OM#MHO>GFN]N(N37DW6H!VV:3KY5@1?W546Y8.XNB^3+' M@M PILJT!C'#Q)<)SDDHL? I3QA-:!)(6+_)H[1&MJU=RO6A@G9H0YM/'@?, MS#]R! /,9G:)GBGE?IV)-1A=#LZ4"2A?F_F;?=A8=*<07IAEN>4XLB+,DP899@F<8BY[WLR2CF7 ML&.2"=&15;\3B^CTWC]UV$0?B&96P#4T,'-@BXK]4 D#,5W/DN@C^6-&2!B M<'1RA,F[=J;ADE9E43XME,=QKR,(O]!%P1[3- @C(AEF0N@*CBS%>:R''[,X M]6(_SJ0/JFD[2&5DY:]I(-%21J_*G65M];QF 7TJ2L3GLYG.C-._K/\5.&+S M,'IF1N!D3&!:OR*GO7Y4$SQ#-4EW^MXKD2,%/TQC4HWN%7-7A?L?/G7(R_VS M\A$>1/6B6US7TQ64X^Y'N60!CJ2>Y,*4]YY%:8H#=7KB'HNH1ZC=))=]8B-K M<'>X2$T0<>!KVMBA=:?5PH"[$*=69!%!%.<))*Y8[SV,-9DD98:3"5 MF7+1"3$Z@!]8HJ@>>QM'X/AJ.1)DD%O&QJA-"V+R.*^=.;1PY.D MM(L0=J5U$P$\*D1/E&__G4?9[4;KCC\$S]8XY__],+\5.!ACFXO;[:F%IVA+_/YLIPO#:U 'PS]ML 1 C"+8"J\XU&N M!K):)2@<6W.R_(,!H;KI!4./6JB?3E%Y>'GZ5KX6^K@-5\!C"XRM@IHN>BA> M=-+,M^O;J\ZL,(#:'17?0/%<2 Y4O1ZAQU"W(0GM%.[HJM.IW)!@6THW^##< M\?VUFK^]?A.\T+[B.7^GRE%Y6GM(7L#\R">Z0;W$)&<2T] +DQL"^>Y_UMB[$>[PL'.I09_ M#4#NM8EL/9YV[^N3.=TF0G3];Z/G+7R!IZ?E;;DHE9>QN']G%XLE+#'ZV/MC M>P+KX8JWR@G5-[P;#W6![D7U7C"A?-3%\<&#YE 8N 4.4 !Z!<8 .$XH'A+5 MSCTXMNATWL& 6%O.P="SI\:Z?YW/^?=B-FNBM3H/T(LXQ9&4$28I)SCW X%I M)'T:QCGG$>B&Z@B="2/<*[JGAK:W<8)&M:VE!_H&IL*>$,D^*(KS(/8VE1\4 MOSXHZO'0]>''[11T8V&_S*NMC"A*\LR3L8\]+THQB6B$\R2F6,J8A2*1@8R, MIDT-4AI[6[7.%SN.C9E:.I$8N(6:" M6RD%!'*GE<3J3*N:@N+NJ.?R"1>.J M^%S^CFJ55 M5A.@IY0A5,,^[P@HP?07 M (@3*@_'8-G@QI3-?."2;T5O,FX*NG-3@OQ.+B MK:J4F7G,LR@0N9_@3.@>O>HO.*49P[$?>+E/O22@XG$Y7]*9V>:\3P)D"=:$ MC+_H#_H5Q!I::+8A;]=;O .-V=Y\FL PI>[0.D,M-?<=O? MWA?P6$/M T_"-^#?%\ORZ?/R8!'L>:E4?5,+"PLO@1<>>5/^72R6^AZF'A5L M4O^M"P]^;PJ[=TK!S?=L.+K#N_>HP,)4WB&FCF-=UB!9;?9P:I-M^]9 =!T M^T7@=VUWXGT^>U??J@OUU2B6YT^5J%/__^NM% IT_TOQ+O07IM47R3*?;I7'!@]FD-1^H802=[\.$-#.&9N=4Y,PO_L9#T.XJ M$(:DFPM".PQZK@R!"TYVB6@G:/=:T7(%F$5>5,O'NB3@3KRJK\DS78C;:OY4 MT9>Z;WXHHM17IE8=R[P$DR1)<<[#$/NIQQ(>I;GTC/)_^\F,?;]15]IL**.6 M-&C@P !0_?;3G?@P6VDKN;%*FPG6=X)3*W1.;^IO&\]K8/%)5-E,P)7:&CYM M><=1=Y-\9 $)99QG6/!87VCH@CA*$IPD,?7S5,2!5DGSF$FS["1Q$EJ3 MY> M-%(;7E6 90'>2_0+ +^1V.+7U?5#L^BT=PU;@NQ=+&S_UK9/1+Y49Y'FW-E. M7"_$XE=:E%_G"Z47,LUI1!,AJ]VSQ9J9,U0*PT0:4R")ETA? M>!&6H]\NS1U]$G3/UZ4;-&)PTA29]TX M^JE-W)'#2/3]KAQFKSD?HM&]!EY/;_QC^?!=S-[%MWFY?%X\9B*14>#[.)&I MP$1D(::A#+!,_2R,A3(@L&+?T]@9^3"AOEZ1LT$:)NB:&8_I,(/9EM[A&V?U MG%BFH\7;'8#JR,U-Z7 *MAM\QI_48<+,GV6&!P XP'0/R*KPZ/,W?;%&JP]E M3-L[[CJ(Q](DH;%D. ^8.E0Q&2GG41VO A[R+/ SX@GC&H_#)$8V2RNBRH>I M\XN;PG M$B>,>9C(+,'4CSCV&8F)\+PDSD YXKW41K8RO_U\_S-:D6_:&#Z)DGV@>3XK MGNIO,?#HU(^=F>_C#!&8$?KM?AN*#66'=]T@&1VY)_VT)O4^C,3>=2[,7CJQ MB6'CK+0IDC/* M/6G7T-"0@;'O5CJU(^W\$#I;S;=:,8?H=%$W)_YBNBD!PCG98A*YC.9Z"?M2UB _S M=HKH;35_%=7RXU9]"U=AIE?]B')>XL3C-,"Q[G=/N,]Q[BLW1D;2YWGN)W[@ MPX+JYL1'CZ_?ME=T"VV\7ELVZJUH9N1L'4*N>7$X^ (LOZMY&.:$IQV3 09D;WH&? 4[4U,?LCKYS-=*PC;! MG1+!HC!0IH7IU)(P#W!*,H:3V ND"((P2T&.T7%2([M 3?QA-B^?FLZ0UE4 M/6 %/,EX)#@6OD*,1+Z'J?03G/" ^J$7"!EZ*SO\,!EFV\;WX<\)G9F1=?/M M@1G51OJMLHH-67?VR@U;\U!.#E)NP M9DE[5YHIU'*%%%MGJ&D?;EYI 4:S7^_'!A)XX!L%0U!!A2T85O448&*3E5/8 MPM"MIK!>P\['NIB_O!1-=QGEN5W,2UVR(TJF[-AC0D44I&&*B:3J_";"&&<1 MC3'Q19B'7I0+"9I6WT-K9#/3H5P?-+9HHT]Z/!'R0V#G_#[HS/P&1X# S$4O M%NX@=]3'TGXN1-TIO/8ZK0RW6$H)CS# 6OE:,[I8%+)@S>2R32L;)=SYS<65R ?ZQV.4YZ'P2(ZS6+=QRW4>4!Q&.)8>#47,!&%L;4C-$Y]'8]C&!-O6 M;%0[C"*ZYK0.CNN3R9+^81&N&>6C!$1[?M@GCY+N]#3F#B[C%R-PN?T@:\QX3X8-QN5 MH,4L;_)S%AT<77O#EO-ZO_\//_;^LA[FK7EKAWFWW#2SO D!3*4& #OL2X\$%\RH M:AZ.#Z!>(:4YL9GB#< +,,-['-SLO&V7^,$&><-1Z!OC#5AMNB'>Z@HUZEABJ;ZYZ:;A['0H!N#7L&LK@4.KSA9[+]7H&Z O_]!)XFEZBC=N8\\ MD!&F'KB>E]56@MC7HJQ'\RX>(Y[FJ1=$. QYB$GJ"TQIG&-*,AHPGF9QEIR0 M=7H:=V-?2.YG3^H@>8?A(]F4^JDNUZOT2LTXJCFW'=;MY#,U.]K^L$\*>./Y M(SZD4[-?W8 Y3FKLB;S]R+Q9-[ .)-4Z(F)GW._$NRC?]'UL&G,OR3C.8UUG M2)1QSG(NL!_S+&2ASX. 07HKK!8&F53[4&!##&8$U[*;V2\;B6"FYVY(#+"9 MV.79D8:OEYU4.7>%V=6KO=_#0S17I=K6Q6)YI]RF^^_T]1M=OFF=ZQR(\S!E M?IQD."(\PB064BF*S'$0\Y"$DR1K!A F@.D64 K'H Q& /D MAD,O;O& *=\0%!9Q%@-,S,,K;K&QBZI8?UU (11S27LB)P:+3!8P,1>H&RXYRE3'D$F8=3P2E.@T#(G'E)ZD>G&[KPSV#H0B>&+G1A MZ&SP<&GH0K>&+G1IZ&RP&IA_5]] 07POR$,FB,;-(:JJ@E>X8T804+TJ3-5+; M@Y/Z87->ZEMS$J4T$&JEB2:/6K:'?:?%3!>"M]?JFTMUG9K5:+O^V[E46G!3 MBH?G:O[V]+SJ(KU8QTL>69#F-,@%#M-8*2V)/9S'-,=2S[,D*4MH".KGYHRS MD55=WUE2S0/2M1AU=_YEPPJ2.MU&_PNT>ZVS#\4L>O)#H(;9ESI#LYMXM.89 MRWF%-==GJ!L>;KG^4$_.:L/2SAFY5YO73*Q_7=]LG;4?X*J!'&H%K-O8.^S; MZQIF5ZU_G?$U;?=@UW#N-2!V3L"^A_%5N5A6M;-<-XZ/1)0E"1.8D5A@XLL0 MY[KA0I0R+XX%20BL#'J?Q-A64^OSAB*HJ7X/+F;V[C1I+0R7N:!677$/R^*P M$>X.@M5AN,A,?HSCCS&,4!T2Y-41$,$Y(!+J%V5I]Y*L8G:9;-'F_=+FLBOQM67?_6<[17]]>:$EAFK<-3)ZF5&9A MCD60*L\O\Q-,O4@HB^0Q2<,DEU$,,4;VP,#MT+C 1%&F2\4*G-5>6&>"JW]ZF9=HL9RS?S[/9TJC@![N M-DYF5MM:=IC!UD)OI^4UHR.C*M0WM>4'>/8 8&RVNXV#'$R5'8(& MW@3A\CO:(0&$)]T^X8#L[JT6*YR4J*8KM'0G [WBWXKE\\6;4A8##MGC(RFU6EDA>2V@/<$1-PF08(X^!'YDC80 M'4FMM%H*GIQT(:IE4YTK;N2U$+S-(4E2&N72\[#,F, D]1C.]/17P;,@(UE MN7)S#3.2CM 8V5YWJ-:]?4M%V#S-YA@N_3;$D;0P&]$AB&XDTB0M\HJ."6R> M3.1 <+L,H@, N$D:&I"H)U/HV)N3I0<-L-[-"1IZU,Z)7-59?'R95[^5K[3@ M%S-:O-3ML9H?UJT V@%/5TV[3?[+V_)ZOKP3K_-J*?C5+]=W[0MUH\/'1(9Q M[/D4QT3&39^6C,A !ZJ#/(]RCS!0-[NQ&!T[_%178VBB.J:KM@2E]46)X^CTX+'\V_?7 M>C;)9A2+83A_[\613>HM_4#O"]W*0BGS"U6?+_I<+-ALKJL$S]"#N3T]+/9P MD/\DB6&6ZX"P8XR0Z97**NJ_O]ID@?^C@G1C_\O5'$K" MD#3&5&=6$Z'#10')<<)DF,4DHH(8'=#ZR8RL<9KH3A/?YDL(#-\?P\2':X\Y_.P$31Z;&AH-)[= )$.T:J5.6@@> K\6R7G%] M<'A,)0VEYZ4Z!9EB0GR!LR2A.*"QDZ2T"^["I 6%=X]*TQ/8 MW7]GLI#N47:[P=SC#\$/[I?_6GZSNM5HJ:W3_]O)2 M?>BNKXME^9#/VML"PY,]?.61O94V*>;\.U5,=<)URD?1[#6WJ\W@VG68KBCK M3LRB7#1-]8#Q 0MTAP,(XP(+LU.6F"I?\0"N#EN'GH:35]X0_&*^6#XR+Z \CAA.B1=B$G*.J604>WF8Y5%$4A$% MHY6X'F1I9"NWJ6U=BG+T2M;#H)N=PJ:%$F;7C&I7U[P@S%)Q:O_*<$?O\SOGBYOJ9OE<75;ET^*6WY1K@WZ]U/_^ M?7$G9TQ;\X?E3)MRQ>?%>\7_7L$\/P>DQC:2Q7O!1:EFG"^;![\7"^W+R)E@K3/3G$>WW!E]47RA9P*J)_2G:.XQNOB8 MAEW(B3\AH.V=^,-Q['8ZQ-;*#W5!?S+'U"%874_5Y;*N7==UBX&'^99MK_O0 MKBM0O$!0[D<)YI'G8Q*%!&>$Y#B4(4EEFH74#]WXK4;\C&R/-V4//4[70L\R MVO:Y=&GGIH.(*S_7[!,ZU+#:U_U>YQ;4AE59U6)9 M#]X;I>;($9ZC^[9FW/Q)'%L0=.9>+6Q9.SO[2YL+^;4>(*KKI9J,I\4C\9*4 MIS['*0L23&)&<"Z\",M<2C]CJ1]F(:3WPU%*DUQWS%]%1?6=-A(M69BU.XZ3 MF1US(CW,0JU(GJ&&:%/9."0]V*(,2N;(5ARG,ZD5&!1W5[^'7[#M(OFEF(GK MMZ8414J>I(1BRD.EK(&?XXR'.8X$R1(F0A8)HZ+F0XN/?:W0M%'4]%!#$-HM MLH-#OS*>*ATPMF\NF$57R'T)3F@'V5ELXCZ0^V+L-X \\ S\#O].O,]G[VH# M:#RL\Z=*U(T;_NNM% J1<-7";%72$V4RE(F/918$F(1$ZD;3'O9%$E!/!-0G M1G.!X*1'5K<(U_T:W\IZ.KCR1:L5=X@UOB==\8DFC<$.@YX8VM. MYOX,"-7U@H8>/34EN_&R_E9P<576A2[:G'=*["__4#I0TMFJO'[QR\=M->=O MK!X6MNI1T903,)9X"?>9;F_B8>+%(:< MM >*2,81EX3@)&:ZX%2/E//2C,@D)[D7@6[,^HB-;("W2:,5;6C#UCZT MS.RC*PQ@9NZ(^ [OZ2'RN>KJVD=JVB:O!D+O]7PU><>V]:7N)7NO#N'U,6U] MO\I"Y@=ADN!4I 23S,LPC3V)@S0* R$ES40*ZW-YD,[H-]MU6^(UV1.Z5QZ& MR4R1'0@/TV$;N2T:4/9*Y:S;Y&$J$[>6[!5UOX]D_^,G#OYJ__A:E,)_3.)< M)H2F.,H2BDD:>9A&7/V5YQF/@CBCQ$A1>ZE,QG( V!9. MIG<[)TIO=Q?)[S1T)R$OA,X-C+A>Y< M3'&>13D.0T&2/ U]GL6/I7C2Y2\/YNZY"6VC;V76?"OW.##_9G8FI:!*O*K' MGBDXX3/5C,.5RR<-?G+#1?N3D00F1T=CXQ(3GI6@H"P>W "O>MB-N U M?1&?YR^T*!^E](C/B514F 4Z:\MYAZ@3I'Q7XL0;6JQPB-?7N\/3[O M#&G*Z!\-[9/F!7:P,C,!+A" J;VE\"?.$-R7;)1)@ATR/W">X+ZP_5,%#SQO MJ;BKPK3&0ZA-Q&/*.4GS(,5>W4F'!P'.TT!@R6.>,1KE229 2GN R,@*VV28 M#[2@-4?$4#5/E!.HEBMJ>M^MW;N:H$-][!''E2X>(C&M'O8(N:>#?<]:UM35 M7;'6526;OJV//(C#5/IJJQ3,QR03.)Z!JN6.4)M'$HJZ& MT\T#:C: 96U'03+32R>BPY1SU2FP4VVV(>NP=&Q(,E=%84?I3%ON-23N7B'7 MX NVHZ;T3LQT=X/RZ59]\JT+E_EQ3"1-<X$T[T1/JY*KAUGTYX?A]\>.T]&D3!OK7%$P'[]FA%4,^1X-J=>E/.0:_,H$85_6)9]9XXLN1D[23Z1>IVB!AXTFZGZ^GENNJ" MK.](V@+*.A%:/?L8ABG/N618TCS') X9IMSSL! D#_W E]0'S56T8V-D757? MDPRV(5JB:;9?CH\14.?[.C^?U67/=4N;+G-G;:6">L?=EGL:,(YV9$LF)MVP M3P-J=S\_<37[ZJ5;415S?EERW97ND9$X%3Y+,&-QK [2*<%I3#,L.8D849]3 M'$MH[=(6A;%CSZM2GH8H4E3K=GOPNJ5M7/J-BA-I@0$MJ*!6%4L'A3FI7FE[ MQ%YR#<;],ZV4Q[&Z&3U_6S[/JU:QV\2-V(OR M/% .@(PBVJ3MT-P+L,RB."72$ZDT2F*'DQY_^P^18D97QQ)4LX,V_* MALSS M7X#H]FOQN)C!U!L"ET7>$! W\W2B\?"SRS)R\K4#Y1_9(="3E@1<<+)L)3M! MNTE,EBO8GD$V6!F3XO54!JAV.>(%(Z.++NK3WH6.2+:[B'C MV&.VA3NKIHVW\UG!/CJ3KZ(P]C)",,_33)?N,)Q3]1_"24"BQ/=% (KL'Z4T MLI8=;$L)+=LY!I*9ZCD1'::$&Y)GJ"&*_M'^.7IV_E:W%1+GC%O\SHDVFP__#;(RMC310]%"_ZONG;]>V5 MGJ^X*+CNXVQ^"7!$\.%+@--EAFEAG[CH'YJVHW[5_8)970,<67*R:X!^D;K7 M -/PL_[WP0OF')E[]]>7V=U[5U;"[\Z2F4)I8ER-DE.U(:HA]JGB<\QRV4< M9KF7B]AH**0!K9'U<44=;=]F G\0'OR_&1V^' M@-B=M7N <7.T-I2PYRP]M,)DAV=#4;JG9=-7QAVU]+="'<-/8K0DTS$&19,*!.7<5T@Y*OC=1XKQS_+8B\!%;6X8VULBSBOED_T2=3- M=NKLWLYB^-ZP>F<)D,#U@M!%, MYB!./(K)@+$_2>=Z6T!M1S,!*-C9X6:P3:>'_OMU<2?H3/?._[4N$LK],/#U M&#L2)\J+#".FOH(\V .UME*JHC"S1(;E*[8BK\KK4P M?@]^?GRXN[HXO[N\T,V6*%N>_U$L'HE/0Y+("'NYGV$B&,4II3D6-,YH0%,A MAENUYBK LC:6..?A0@8T2NTLL#4HWQE^>\U2AI@E:HD!0%?]<[V-+\$T" M #4"2U'-:1:-(ILCPRX6W9QFK1_A5'C:S%.5X]RF39'U3YC6C>CW'R$6"HH= M[ HWE4HWE8N?4HYA&'B^ZX24HU@ISJE$;>85K/XX-VE7[K\CK_;5&LA.S4FU M)A$]/3Y+&-KNJ1*3EGS3<5J+.J9*;!][I6HOF=:L*++OPC_XWN0D?\XPJ(XIM3W(DCB)!7NJO@/X?)=! Y!)XII[51V1JEF$F02E&YWK0#1W%\"['8[W MX(N\R]## FHP-JMB:$O 6J$,=0F+$I\P5Z7!ZA@1+=75[ZTJR +:T 7KCK!ZU&90 M--/A*1L,ZZFFY+4E>; FUV0M\*P>KK+!NUG,JC_?[]9[&>!1&6@%L*:8&XEB M#;ZZ6"AK"GP_GC7YK.$=ZNX@[7>\EEW%[Y\XK_ZKV&Q?A%'[E.7B;QE>[RJ; M7^$ZH;G<[YY3[''F\0#&A% 8T,"!<S5X^]PGA'%.'NJU+8U2TZ GDE=1O;Z5[@M"YSX2Q[ MK=N2\%Y=\+8UKFE.:L:Z1DG"4W13%D,2)8XL-^%"C&("/9<*SRUU$B=2/DX\ M''KN_*J6F&YVY8[S:;?,G!\]R]'1,"WM2X/5E>]UE4+Q6[:_(J:;M#3#Q$T;N+>;#CT#N:0%+^=<7]OALE1M]1O-TEFEOX-)DMKR9A'GB-+ MCF6"BRU9\PBJO^3-1$'_N.&.;RYIM<7K]<\[L01KGC6GNXRWHJ )) M]KRCA0$)3)\KG,^\WEIP'M]:QPCCK!F=(0P,N=@!PCA+_=.#B2?UW=*V2?#' M'UEULUU7V90ARHG'5#W,02HSJV/7 M>IL+PN"YI:SN70P+9]J+L\*RGA)VW$J:H"-JL'T=9EO=/[+"OIFKOA5IN# M->P_-0H8'' YO5@;,ZAG'H9YF\J%URM6<(H;LQH%!R,M5YK@% ,'%0E./F!V MEO:%5TTCX,^;LKRLJB(CVTHFK#UL3C?T7KDX)'Z$8NABV9".QF)=)C&#$?=I MXL6I'R)NT-Q/&XC2AWIVIS]Y'+R6]\]P#Y+\?O/##O19BTHSPT]?_&H'8O-( MTSBIH&WU_4ZB>0\NCT1YB ATD.R==AE+P]+QEC[]1<^SC,5S?(!E/I#MB@3R M"DV6;S?;\H^\:*_=25!WFS*3*\XN:-"U/5]%,4JB@&+(XYC#@.,0QBA"T'<" M1E.&?<_3*O9G$=O,/L?$9?FROBR_APHD5M"!/2,WP.;LJ5G%-YH3/7NI5+O@ MO.FP6*[ 6'"SURO01_:+%"PP%JEZQ0)S$N95Y!\*G#>C?^4OFZ):Q3RA#,6! M\!QE(7D/89@@Y$)&HI1%Q E2IE0"): MTSCI,VQ457Z(H[,*R[\:=/':\D-LG2HO/_BLN0K^]Q87XBM?_VR_,"14D#BA M T/'#6 0HA F3A)!+W)HR*C/?5?I!N8(C:44<$?66/^.A:.N?F>P;*A]RMP: M*=\ /V?IWO&8BZO> %.G-&_H4;--RKX8&UY?Y\*%>ZYC7F)-OBLV+[RH?E[A M#/K.9Z"XU_!10]#8I"\Z>VA[F MUYP3/3O634?=FZJA7A?$:W_L!8I;*/9V,LN+S])&9T'@B^Z#EI^0XVW2&R"8 MMP#G92IPW>;\X:G8;!^?9!SB+N!>NVZF& M[1>)A)TA5M/JG7I$#)J]H?^(D-/F+][S/-L47S:50+'EER]%MO8<%+3)+ES8 M8 ?Y'DQ26239%;OS./$CF/C4I4'(8^Q[RHW>E,G.;'E_M M61DNW681FEGVE+#Q+O=RT61_KXZ8^V'(]W+09/.C?IO^VGDTMBVKU65CN MQ_HK$8XZ?Q #-)WN5TZ"4U>XMS!BPG@&H8-@@B(.G2")0^Y@SPN5NF:/$9G9 M7N[) DD7?&NH*FK\J'3&C:$MGO5,GS:[RLJJPL^8+R;>[_EAXK>]#S8Z]"** MJL)7_NF'SZS+DK;%#YG7=D5L;%IR["QV_RKW/H4LOY3SKYL\J+[]7=<9N6# MW".MB.=@@GD*"6,)#&*.((F"%#+*?0=Y/N,Q,2J06\@C_QO,R^\WWFZQ=>W:8/^,G/;"Q[:,!&P@&TCZ=.F]>,H6O*5S%*/I_4],Q= M7V U$G Y3!+_D)6PI7E(P0DBR%L,UG8"E)K4E\V#&TFFE>!9L-A]+.Z/N95 M5OULCQ^;5!5A[&1YJ&VYH\(:MR,V1:!G,$RYU\KZ4F'-*/5K=.#%\K]4V.LG M@2D]?^;^K%<26W:+^Z-7)[XND5T*3T9P)APZ$U_,$RYYN:(^ M"CG'+J0T1C!(J-1QA*%/W92'#D]Q%!AMU2R"G-E([.@8;LAL3H?FWNR-A&R^ M3>M7YI=M,T$?Y=F$^#8;OAF$ M/+CWFX.6F1V7_?ND#W>;[PL.E0_\1_6[$-)?JX#[;L)2LRPQ&! M#O-\+Z4QCR.MFX3CY&:VK??TB;/MNBYD)X%T=W@W.7C5B%+/_$Y(426&Y^PC M+G)A9IK\BE>+M6C5>+*DKP-$%M73<4:/]7/B:8."?7F97[(_R_OO M]*JLVL].M5S?B7?GWK?(H)"L3K?+$R_%2E)\SRBODV UZO2=8GQ6;K< &R(\!O*LV[X<*#X&G!M4%R+5Z]2PTO^/&Z!>=-3W[ M-E#&Z )T/(!W'1?O@<0)#A@!MP4XG//ZF8%10?KT9-^P9]4O- MO%XOJF7G8*RUU4)(ENN4M:QH#QIO+4S:; O]/SQ[?*HXN_S."_S(OVREKW*; MWC]A0:/7IU!&\.@JH*%+4I1"''C"0Z!N ). 4^BZA"+?:U MOL,"< ,&;'I-,LL:D0S TJDBVW% 9$X >]VL2]- M/D;]O!P O,O:G\KW>MMYO6E2V^7/)GR])7LG]Q8':(!(63=00 _+17UZ0>V% M!8R$8"E:H$=[T2""D5B.8PMF@YCA&'"&8(DB5R*PS!)(R7[I45U9KOUF[QKU;O+)U U=_EJ&,"55_E\7^=V MFJHTI_<3L\A(S[S4 AF^B]8(20(QNLBG_.%IW..;062FU_@416?K&I\FYZ.W M^%3'6O 2GR9[AW?X=%_6C]S>5W_=%?2V>"B+CV65-14X;GCUM&'[(T'%2*[* M6'.?FM8>VETA0YOBNWVX_PKV4$"#13VZJR2V6YO*!MV7X%4[BJ%2[8_MMT?JU\662G^Z<-69G0( M6Y0)7/C'*DG\E"+N0!\QL2>,&8/$=WWH^[%#(AXEQ'6Z6O1JN\(94"KIU&&A M>CUK\S%-.:V:5H-U!GF%?^AF8\PQ.VI;P;>2N)$5N[VZO@"Z%9I;_/W\F0M MN'B6]P[#+NQF^L\H5DM;T#D0+KI1G5'$Q]O9.4F9F?.[@C]GV^=2'MYS]H57 M*Q01$OI(* &N,Y%=88R9YT$2!\REH>N[2*EAUR"%N8_C6WIZAO.U'-3,WEG< M:1Z\MZ1 0ZN^663/T PR8LE,O!Y_424?9.]818=-_LB+WK4D^=B*)QPY./0A\5 JS]L1)$Z (/62V.,I3ZD7&W3Q MF16T@2-ET/'']?Q^ZF:IO 1>1MR9S.BW51T[R(V(_-_#)$#4N-RQA+FP?49.<+ M+W&]E7[AG;S'MLF56HSYL>>'PF&#+/+%KAIQ%R9Q&$$W1HPCFGH)25?5IL)K MM47!#BPM[V\'3MGX/,A7 *_A:98(MR/UF#&6N)[,%_=E7[T$P812#@E%4>PS MPHB#5R^U]WY?X:+Z565_#%%Y!G[GCUDN#Z\!P6M99?E-I@&Q "*]-@ MJA/ &E2@A;5\\T.[HK)5S=X.J&4KU5L5Y*LJ]'9'-W,@CC/$KO/7L+X*BL+; M^1L7;$4XH4X0>Q!% 8$!$<8RH1&'<> $'D)1ZNL5N-&D/W- Z%3V9I:#/J1_ M[VY!?I.P0(M+LS*8KM353.2,LM2SA3.(4=L(&@K#DK73I;ZH63,4S;'],AU& M/U?@XP^Q_:JR[_Q*;)L>-\5/G6;N)U^>V8[L:(*.J$8S]]/+3:U'V4&Z-S^],C+G90/\I0_V1^_$%][;F4VE=>K3>E<")N\I?L0U;2ZYS) MHJ2J2C0VQLRZ)$FH*\\HL],Z9(M//55JJ(*:K%PH'[+G>J=P\^7N6MX3H>(? MMH6,CPHHV?>,;?$:C,I%2]54F#;2N-&!%U,\%?;Z^J?TO$G>\%!=_#:ISHN[ M-B!>$D6<->K),, MJRK-<:6?349Z%F"BAT67_.K%1GG#JJ+2R1N>062SM/_8B\Y6WK FYZ-YPZIC M+9@WK,G>8=ZP[LOZ9O3AZ_75Y=>/-SC'CYQ=X8++;GZ;HJKOM6%:=1<_;E_D M9]0DOY0KE,1!$E(*@Y03&+C"NL:A3Z&3T"A #*.(*57'-(I:VQ0-:0$ B BTDT&&ZZ*Z%W::@P07N%I*HN@V> M7[)F!GDN"6N9Z?.$,V*S#0=>S("?QWC?FI\YTEOD0'WF9?GPA'>'[L?)-'Y M$X_Z :0^"V"0R"X7GDLACDD:N1&.68P7SX&: +U,#I0$ 2J! NRRH9;,@IJ: M.+4 ^-O/PQMG01W,8L/%KYL%I2CO7R(+:@KK_Z,L*$6QV\V"4B5J6A/_4[;F M11D2IF=' ^',?'C0UX&N2N]BZ M;MW[0X&,FT\+;&H>'6AQ:%#;_B0?9Y2T/QQOX4KV)YEY7<#^]&.&5SWPSZ9T MZN:2_N\V*_AX,^55B*GG1C&"G,@"R([#('$="AF._9AC%[M)J'=R%3//B^4AB>,3'P9! MFD#,_12&Q.$>36A$(Z5NH].D9E[X:V?^@#+X)FF#FKAFBM&(P-1LB1TQZ)D- M4PEHFX=IYBQ9@A%"BRK]-,/'^JWPAJ$J\ZJ28:.K@K.L*UV<Q3)+OG$92DR,%Z5=1/$9E;?6N2==6VFJBFOIZ2BJ*FGLFKIH[NV&SH MS5 ]?8PA6WIYBL2R&CG"Y"M=''M6_PRMRQW^*OS@^[_QRPVNZIOBGA-X[9<7 M<=_#2<"A$R6)6%2=!)*8>#!Q'!PE+DY9H'Q>-DUN9LW<%5*5"("$ #H,0()0 M/]11D-RXSMJ7AY[V3HG"(+] 02;JAUIV96-V@&7\N6B=4*ES.G(:I3#(8B=/ MZ@SU3YDTWM)/?;S:W/,UIV*WW_:2TLEY//GRS)9*%OS N6RQU%#NNJ^-9_LI M\CUNF:RPK&>,S+C5RFTOWS.J][<+<&'H5A$,5."I.8R3TX(9 $PGL@;D*I'T1^%"AU0)LB-+_ZM:1! M*FG#K"&NOAB.2FG:-;#%N[8>=FS79&%+U\ 9&.5?W0VP)0 M1I;\T=<76^Q5F.@O\TK/F\43_L7QNGJ2^2E:N^;CU^93KX92DP=E?[,\Q(>E MC?*KX1?=) \Q=[Q!'GQNZ)/JR_^S^.F?_^C^(OY#<,G_^8__ U!+ P04 M" N&UL[+W9 M=ELYDBY\WT^1?YW;'Y68AU[=?98LRYE:;4LN2:[J.C=<& (VNRC235+.=#_] M"9 :J<$+=\3^Z7__VS_]T[_\?X3\QYNS]S^]G<2K2QC/?SJ<@I]# M^NFWX?S+3_,O\-/?)M-_#+_YGSZ._#Q/II>$_-OBUPXG7[]/AY^_S'_BE,N; MC]W\[?2?7?1&,>,(YQ")I%81:X4G3*?L>([!TOS_?_YGD:32PDJB*7-$!L.) ME5(3QWT HT(0/"X>.AJ.__'/Y8_@9_ 3LC>>+;[]US]]F<^__O///__VVV]_ M_CU,1W^>3#__S"D5/]]\^D_7'__]T>=_$XM/,^?7/Y:]_/IP@ M')#0Q2_.OW^%?_W3;'CY=00W/_LRA8Q/N+HD1:'4"5K>]K^6O_?SW4N_3F&& M2%DP^1Y_RQ5^D> 94KR0_PSBGS]/ MOOV,#_ZY"*%\L9#&0A*/7K>4RG9TWRRX"_SLP+/@DY**1,L9D9$Q8B&CXJV- ME.:LJ.4[D7W_;0^IOJ_-@VG\:3)-,$6+?^/FKG^*#2/PR M'*6;W\[3R64-7?D.L,TRFD]TNM/,O<@K,YVE%8?+*&QO]R MY:?XQ-'W,_@ZFB#/XA50JX)3H@6D?*7;)&B%0%$ ]> MNQ8<1/MPV%Z6C8#A8NK'LV$1_#6@#42M@T(14(,V+G!+/*>&)*\IB)2T2Z+. M[K#RYK4@(=N'Q$X2[1D51^/Y7 ::#0"T@[9PP3Q'1G EB?60$ MG/$I*JJDM3NA8?6-:Z% M8N"G238A/;/X/.P"&$\/_&7,( XQ 61X )Q(AIB X,L!-.2YPK >)&(M7!B6L=)/3DW 9L+ M__MQ0O$-\W"9G+BVA);9J)W'+3!C""5Q+10A<9*HB<:Q;*G2%0#SS.O7@HIM M'2HU9-L$2 Y20A7,KO_S?C@&-G L\J R)QDT,J$5@EQXA?NEP3A*:05JM\3$ MLZ]>"QRN=7#L*M.6@'&(7YY.+R:_C0%ZP0\&1^%)0!E:P3( MQ$:E"9/&!I:;:[A;+WW[8> !I.<6XMNIY57HY$1Q^_3,8W&9C$@\PV:Y+D M(O]F _%-ZJF\XE;F3"'M6_SG$JRE"E_%P,9R/8!!Q MX^)&>Y)-2<#9(-!:I4QHBL*$E*6P:B?UK[YQ/?4WG,/<280]J_]BZDO9R?GW MRS 9#0Q5$"3ZMSI:C'Y\0 E@Y$-BDM;;DHRCNZ4<'KQN/<4WG+;<7GB-+/JC MW^,7/_X,RWRK2YPGF8G3H23.1"08ZE B#=5"4!:=WO M!XWF4Y 51-L$1(['^#04Q_ ;O/5S?\W60!GT:S&0(0G=FN+J..*,U\2*X*,! M8-:["A!Y^NWK0:3Y1&0%T38!D7*,.SWT<_@\F7X?!!.,#HZCZPN<2)XB<> E M 6TRI9EQXVL<>#UXZ7IE4\WG(+<79!,X.+_TH]&;J]EP#+/90$;ND&F.CI!! M\BE@+$Q3"8V=R$Q8JOAN <43+UT/!\UG&[<79!,X.+J$Z6?<\GZ93GZ;?SF< M7'[UX^\#ZAS&/Q@7QY@2D2F[ FP,CJ,1RF.(;$2-8ZLG7[X>+II/,^XNV";P M^]<#PT-YQQW%&,3 M($#"+TL9QR3^X_P+RFUV>C4O%S=*9%V.WB15&@B&UB@8P0%#*DC$2"A'+B:: MM'I%8JL Y 4:U@-)P]G)RF)N S0HN:D?'8\3_/[O\'W@T"MBDB+,@6&8S9PB MZ#5E$FGTW')K@JKA8ZR\=CUH-)RYW%V8?9]7+4.E=\-9]*._@Y_>E)8[#R"E M9],QI:=A.J'CFQ>N!HN$L9PV!-H6)Y464:R:,28SI MC-Y21*%('8A+SI.4+4BFF!9547'OU>OAHN$49QVA]HR, ^0@+;@8^<\#+FRB M(#AAS@3<_72Y@* ,"0P,S5FJN*,K\>!UZR&@X0SF]L*KIO5_^?F1\-[C#[:\ MB7UZ\O;HY/SH+7YQ?OK^^.W!Q=';-P?O#TX.C\Y_/3JZ./\T]E=I.(>5JVGK MW=?>X.DU;G5OR\R.=[^O9N2S]U\'BS*Y H[3_&XX]N,X1",Q6=[VND6>]L&H M;$H^TZ92*V,)>AJ(P20SHRHB\%ZZ,Y7]+"P 4C]M>M])P\:*/59H\?M4!ZX8Q++?"DCDHZ)G(4-+]TUWAXS M*X3T"YU=-/LD2'811&6ES. IO%C-L0UVUB*L!2SM!(!)U]IH &+G M7R;3^05,+X_'WV V+W9[-DB>A9@,H LO*)%(- E"(2/19B:MT5:_=-*_U3[] M!!W]=,;H#D [R[H!O)Q!!(1^&,'L!.8W]0M:TIB!!9*CAF7=>^ 85\BL(V?" M28P4*@/F24+Z:9[1'6)VEW8#D#F=?\'H\[YL!M[Y9%Q.A*N23$H!B#5.$BVT M3MYRX^A+!\/;X.4Q%?VTU>@.+#O*N0&D/"1>QDQ]=)DHL(%(SBGQCE&"P:J' M0)E/JILX:A-\5#_RZ0X?VTMW>VA,YGY4!1H?IY.O,)U__SCR*(YQ*A[8U[*# MHET<))NXR3$1@')MDRM*'*C2/\(8I7-4W-.8+.&"=&QH@6 ME!NOJ@?E&U/9@LM3)V+O5D$-0+ LG_GW#S#_,DGW0X!L11#HRQ%P*:,_)PVQ M+F _3WKQV5R MT@I&LF<8!DIJB+,V$J4@&@Z6O=PU:,<@:L,=J'H93 ?PV%W,#6!E23]&?N!T M9$@KU1@H<(F17[FL&!EG,3 ='*L-CN6;^VD\UMD)PD:";"!.>C_T83A:.$KH ML"^*0+],1BCTV7)+O!6-"RX!1;ZH!MP)O4WHON-76K)H?;8F5W,"@]'?GA9I';]1?K/JZ5??_3[5QC/8" M34IC*&A"+->F MREE*SFCSH\DJ2T;%BW<(=H'9.O0U [R=,/$,U*HKJ 'P'<18VHW./OKO)3&! MC.%/IE=(QR-9#H**P6J,)Q-GI<-Y=L3%:(E@//E@!6CYTJ6FK1RN]0W AH2+)R#Q%LK:\<0*IXB7/'/M MA9&/C-MJ3>+S3^\WBU@9'Y6$V( !.IR,%V+XVW#^Y1!MZ>02IK?,W$#;>4^I M3YH$;TL?]>2*H^ (Q%*9+:Q)YJ7;]UO5_ZQ!5[^YQ(Y,3G6%- "RDEZ_/3"V M&.JB321 52ICP'!I -)ON,Y)Y](9]Z7!3=M@Z=[K^TTT=@29;<7; #*>V$<- M#=:I9(EERZ$-E@00B60I$>A4>N^[P6=2WE80 M?R^!&DVD0: YU,7_DIDNFA4DPIU-UE(O5?7:YJ2*%+!URT)5SB@9-6F&:^Y.T!54D4#H+K' MQ,"XF!QZ_\1IIC 6<'QY>,,EHZ1,?!9%185A@(QI6#MP:YY7BM6&UX^G;/ISK[E!5 M214-@.KCS7L7+"UO((7LI:0E:E \( LF$Y^T(-HPI9-6D&+MS>T),OJ^A%I' MPX\*8G<3=P.(N=<=:DE_4I9FH0U)FEN,63DG'H(CCE.5T(12%5[J@K#MGG:? MAKX/_#O!RDZ";@ H!RDM:A[\Z*,?IN/QH?\Z1!_K'EL#9O&]TGKBE<0(( C\ MBAM*HO."6\&R3+[VF=HW*.L(3)65T0"\SF#NAV-(1WXZ1I]N=A#CU>75 MR,\AO84\C,/YP$H!HLS6@!30LNHLB2_77H+Q$,&AB\=J7P#Z,57]!F\=P:NR M,AJ UST.%BF,TC1S"E]@/!M^@S)6]!+>3V;E5N5IOO"_#RCGP:146F@R9(]R ME![+@@21@7F9P*3JE\TV(['?:*\KN]:AFAI X<44_.QJ^GTAO:6Q7OH"7''# MF6:%>H^R/J>BWSKLCV.PH[ :REQ^& MX\GT9M $S.8#Z3-GIHRJS%P2F:PA(2M-(F[;@@*P)&KGEE9IZ&? =,=0V4G0 M#6Q-C\6"V^WHJC2)_EC&UZ!RYO/I,%S-2VW=Q:0<_)3BE\D(G_CYEFON.),I M"$(7M2Y!16*#E21#3LX&+HQ\:6Y0'5NT#>7]#+;>N_WJ7*D-V+P?Y8P'AGD: MRUB5Y'G"]!)FOK=/O=]!KB[6JK!K*\6HA\7BOD" M\V'THX=XG^O!5^VTN^@*;^^PT:KCDN-\Z$J6PZ+7I1*S+AJC,N-9445?] M;NQ>.HV.1I/?\-&E1\+;R568YZO1317\7:^HNZEBP!QS@NA4S+C.N)-D&@FE M1M+,@A#5NRQM1&#?1T25A.&J/YTN!)H68?9'F"Y&CPRR M$QY%A^%2Z0\C!2M?:4N*AY'0_D<#M6O_UJ.L[R.GCK'7@7J: ]URN,W!U?P+ M!F+_#6F@'8OHG1C"RD L=%LY\0HD<@,T@%4NJMI7FE^FJ.^CJ+V";"=U- JN MX]GL"CE!_S3$R#4I&4(,[3TG3I2N]SXP%:*5$FIG:Y^GIN\#J!Y M84:&@#4 MO!G*YZH6H:Y#5]U%3QQ"KK9BVL/;( M#EL::)8 )$"*N&RXPS [.:)2<"PQL"EV6."SU9[8X7'3_K"UDR):Q-2U&3;: M6R0V$R7*)393YL<(RH@7'%W&($!7[[+P#"E]GT'M&TM;** !'#UQ%KMD9V"D M"L 2)4(+*->2&+'!9)(M_L.XI<+4SLL^2TS?AU0=8ZF.$E[1(*?S"_SSP]') MQ?GIN^.3P],/1]6G.;WTBJZRKFNS52G;NJS!N87G'1:%!T59("H"!G>4&F*U M-80F)AD$JE'WE9?N,Z3L7HCX#<97<-/*PQWD'(#FQB&I9?#J\M9J9"$5/I?*U.NKL5%QW1# M9 B>6 ^<@#)!N1@%2[6/&!X1T2].=M/IX[A_!P$W@)!K:;Q#,3W5)>3V(+[T ME<3_IU+.**P#P0(& SR7GC1.HB<'I83;N"QR\+FZ [0%F?WFRJNBK&LE-8## MNW;72SM^4]5Q,$YOA]^&";V"0<(EM1"<5+B^I%*2!,4D 2^E]R9["+5MUQID M]9LNKXJSVDIH %."\49] 1J9\-OWMUO M[KL+2[29.!LHMCK]"E-?;F%?]W2\DT:,3$:*D:ES7I2!((%@8,E(HF@F P6N MH78IX+/$]+ME=>% UY%[ W;DXV0TC-^7E6!O8 QY.+]K&7J\["ZR\/]*5V61 M#"-1+\X/.2X,,()89KFEF28N3&T'>TW:^O6[*T%AU0'O0B\-X.T<%L6MOR!+ M4S\J34+3Y7 \+!*;#[_!;6M:H9/20A//9>&*QM*:K:Q-#>CD18/2JUTQMA9E M_9JR;K#6@4X:0-I;P#?'X5(WR--E*;G^[\6W XK;/ C)B1<)@XB<,W&619(< M+ACA<-NWM3?'%\CIU]/N!E.UI-\ D&[,;[GZN"B>OA'4((KD(#M*G*>*2)8C MQJ)E@2@E/,O2RUR[GNY98OIUQKL!41W)M^2FWUVB'41M=6:<$J$\FE/%#;(0 M#%'>B*"E":SZ79TGR.C7]G3JFF\IZP;@[PWV=@*:\;?RYZH9*, M0(*4#/TY2XEU "]H9*=$ZL]H&Z$6*^BUTZ\06U=/ KM??+RJFM&_LZDWB M?CB^0MZN#>]D/'L#>3*];AAQX7^'V>KU7-S*'S[EN0F12K&@34R$L=+5U%&) M3J.,A'I//2^M3:NWP]HC>_U6WW5C/=O$1A.;^C7+UZO_VKD=^!B28*,Z\'@ M>@B,6L*52>6F>N"Q]H6;>E:NLUJ^[JU<#7TT +*/TPDNC46X)*P.V4?TYXY$2#<%HZH06M7;#U@(#U@/2J*D.W%W #YNJF8>;-O;$W?C:, PX1 M@P$620REO"?D0%PPD22#?A\SVBM;VR]ZDI#UT/*JRB!V%W@#CL\J$V^'HRLT M6@/!P!A'.08)61-IN2;!2B# :0+-+!>V=C_E9TA9#SFO*DM?0^@-8.<'%:SH M^:6K6%(:YS#]-HQP5.Z!S(:X,;\?XB8)U'S9=O\6Z9L^ \>F,FE//,P(CGI4,@R\8DK8))M1L5;$AB74=? M1"N3H(FP;#E&+$IAL,(%P>T@,XD[ R[Q_AW]KJQ>E^AXV?_?1.X-[,;K-"U' MAV-8\G2Q7,&%M[#\[UVY"LB$@0W&P1J@S(])Q#LKB54FT2!-5J;VRMJ=ZF;: M9W4.SSUKN&%,?QHC6Z/2R>+7R:AY%(TMH3*6DD(25->'14"*L3Y;7O5W7 1L]EZW^L];$I M+)J87%%;"'=#8&3)\"'_S@J)D@A ?%")9)H%%RHXKFM?U>B*EYX+\?]8JV0K M@#1PB/"2&LX@COQL-LS#N(1%^L^KY7%_21\=G!X>OYM,S_T(3O.=;.ZV4PV6 M,U"9\+QH%>4\L26FXD;:%(QD6M2NW>V.FYXO'+2Y6/8,DG8.9JL+9"$*EY.R MVI6A4!DU%-']S#:1THE$E@:CF=:N0^F"CW[KFO]H*V538#01*DXD:J":.Y=],"\Y;6+/G8DN=_JZX;A7UO=#<08 M3W!ZNUZMHU)3Z0F3Y6HK#1PEJ#GA@>G(N0/G.V@0_1PYS0Q-Z/QHH99.7M%L MK/MGWN<7IX?__NOI^[='9^='?_ET?/'W3L_X7WK=/H[XUV:W_@G_"P/>J*&) MNLB(M3EB[)L-W'6UZ_Y*)8[0'7GMH$CNB@2Z\U MGG&G<)1P+U-, 64 M>MV'U+0S'E^)2P\GCRYM;P;")=NJ5]*I!CFR;AWDT@_'@ZS01S0!W<0%$U!FUB1N4$8^,),@9E.]I/WR]0*JAS M]2K'=P- KAD %1DK=<8R*=RBJ002@G(=UD,LH]I[8YR)];O2/T5)OZF@:IBI(.8&P'(0X]7EU:@DW9_+G5XSE@W+3F1) MR@0](H-A)#AN209#<\C:.U4[I[ V9:8?L_7JZ&HCK ;0,W3'0>N>4'?3='DRFT2 M5KJB9$$<6]SWI#%(F[D(M8'S$CW].D+U ZQJLF\ 1[=YBO>X7Q_CE[,!2R$* MJH"D$-"ETP'C 89K(EMG1(:L3?6I!H^I:.2Z3<6,WW8";@ BJX?1Q^/'&?4S M7 OO)M/?_#0--/@8A U$ :@RM-$C>]R5B^;<&BO*).'*^-F0Q$92@ULBXG&C MK,[4TP#Z#E='PIY>S6=S/RY5T@//)/>X,HEGR>*FC5SY$-&4@U)<6QE-]8$9 M+]'3^Q##[H#PHT&]VVIE:X1]713*X%J:SBMMA*NRNAV-]F11S#,MGP(3V@(D M0BUH@G(P)*BHB.5)!"XX2%Y_\ZQ!>>_S@_:&W1XTW0S*[[7)HS0:CB$/X9%" MH3\2=%'1904-9="(UKKZL*'-&A!VV6QG;VC;4N);(^8;3,-DQ[WWR]7E,T'. MJN1N.[J4Y5):#Y].WY:A-C??EK]_^DF_+H4]"":J% /&2[F4-2H43Y 8B"6K MJ)44PS%8/?Q;+83:([F]]^+O'+>MZKX!5W2UB_9]09Q!@LNO"[X''JA0E"G" MLL_E=E$D/CITA[+6%/<)_*=V^F5-TGKO_K\WL]N%KE['3;!U2KF%+LU(HR F ME;;)SF1T6V0BBL>D$C F3.V]?Q^5^UVV\=\;IVP:,ZH.,_%_]Z H.(LH3 M"3F="U*X36H:OW9OY[ V5U M+;5C2V^F4\_NY30._>S+0"NJ 9@E67ET4:1SN"LX381340:,_9BJW97D.5IZ M;^^_-Z!5T48[X+J[1CB[F#Q32;-(H 64Z^+:#9K\A6+/ .4Z&\[ANB7F\F+8 M&<3)Y_'B*8M5.,B90K2&$NJIQ$A2*>),&1TJ.,N&12%#[7Q3USSU/IQ@;V!O M"AT-^ (+21_/9E>0[G)[GDGN=8H&_?*H>>G= MKA)N99&3$%"D6D7#;/W;-5L0VO_HA;[A6E&1C:-U\7>GRZ3(T>\PC4/<<0:@ M);4\14(=,]<>O6) HC,@DDF@=6T7>&,B^Q_YT 1*=U=@ PA]\5B9^ZPL#>C, M<%MFZ%!-K"G]!W1FD8LD@7=P:7_'P_X_Q!E6-;7L> YZ-*[3I['2"7#VG.J@ M@80$@D@E#?$8HI(0+940J%6Q=J'3'L_Z.YTP\=H.^S=1=560[WD*Q<'YK^_> MG_[MO-O9$X_?LI>)$S]@KGX7BI*X>C>:_#:[;3C 8N#,@$<(F8@!>50D4.^( MU]Q*[R3+J78B^R5Z*DR0*,_\.)V4K%UZ\_T3.AW'X].;4=P'<3[\MFQ>>MO! M"-UD9K4DP98E#$D1&TM;.4=+ VQK070P9F)#*ALI$-T504\,GNA270TXD/>J M;<"(R#)C! .Q,H%1"0S.C"+)6_P)0!"ZYP&KG0&H:ST_7^*TB=![+7%Z,@5; M\J?C.!S!@PDM%Y--A>DXX\D)0Y14F4B=%7%EKB.WCAOOK/*L=MC*R98J#3-;& MRKC^ 4G]VMG^,;-Z>EI1@4U,5%AO"KQ&II13&!8";CC2:MQURI!"EG@P3(CL MBW"^C6@S:&SOC+;.>B_&%/].LB3E/1;<-\<%"NHJXG]&M\L")TZ7#(0 06S6 MGK#2 -IJ%(RJWV+I&6+ZK65O#G!UE-8 ^B[\^'.9_'PPFZ$T+[_ZX;1P=8@6 M^S/,!@[-L#="D"14:1/M<"U1%0B70 ,NI)1D[?SARQ3U6YG>' XKJJ\!,#X^ MJKJ5VW5]WJW0@LN<>QV(4#02B1$502="$1JISL"=4=6!N3YU_5:J-P?2CM3: M)&!1WC#\5DXW9P/@U'++/ $=:6$F$D*>M)XH:GW*P +QV2[SU M*&NMT<&>,+>SDAH%WZ_@1_,OARC\X_'L:NK'$=X/?1B.%KO%0%,C0DBY=-I& M?\,$08+2BOB<-?5).FEK=_;B'L"9 5%=?DOOMPP=UG+4;0JMAX'V-) M!P C7F=&P%.9J Q"5,_4;$!>:RT.>K&/VZJK220NFC2@Q/XVQ/6&CCBZW-,; M!K\/K!5<"YJ(")[A'I 7#DA$#($'SFUDJO;MF0U);*UKP9X064]M#:!RQ?VX M#>=N"IQN:YX&,B;/@F(DFX2,Y0BX\(0E3'.? CAJJ^_8:Q/7[SW#I26@.C M+)_A;'EJ_K0@;<@N,5QA%DPH;8@-<8$"$9;%+!B3IGH)VN94-M+D=T]EMK74 MU8!]_.B_W]Q:7[8!>7,U&XYA-KN>B5S8OVD0,F F.Y6C(UG&BW)*4&DC* M*G@#"0RM#<5-Z&NR5+<:5A[-ANI(<4UDAQYQAV)%ZS___G'DQS>%<5\7#@GZ M'-H$IX@Q#'GCIK1IEYX8;6EP7@%7M0MSUJ>NR<+;O4&RCM+:!.3!-S\=E%K@?C6:G^7G6!\DI8R$)8B+'$-++,CI% M:9*#U=E3X[*BM5%;@_!^,YW[QO+>5=V"GWJ/Z<+)2[PM5G $D8)/G%AT_LL@ MADR\42AF;W.F(7@5.[@TMA&-_69#>T1M=04V -#UQ3D SX+)3),@.$7.*"X] M46:;1<]X=)XC![U%]/T6P>T9E!TIK=U$T[OAV(_C,X*D1KOD2RV?M*6!LB0^ M)DD2?B]D&8)5O=GUYE3VZ[7N.]%42UT]VL?2A?[&^T9#?W\;N#D6>PM?)[/A M?#8(%E=2DIF@]ZU1@@P7M;<)E[+EF8DH4*@K"'QJ@L":KVLR751-XY-NQ=_. M?:W[+)6.6J7\Y#2?PW@XF;Z?C#_CFRX7#H56*"3'!$F?IJ3)A$]7(*N@C#9-W'W&2C>WTA^P-!K^6D:X:PR3N%4D*8>N M<-*1! V4,*#&ARP=3;4O=:U)6I,)FGT8N%KJ:LR^?1K/2K0.:6FH#>.^C%X1 ML0B+@D"G-SFBRJTT%IPQU;M)/$M,DTF5?5BY[572D*&[Y:8P<>,X9<504U ML'G>B\'1:%]-XQ=D:ND27/?C'23KN7%9+U**N)*R)X%:0R HC_\KRZRZ]_9# MJOJMD^W)SE524AL'PW>V^V8@SX!JPWF(FN2L':X=PXGU2A-CDP6/49"('6ZE M-V3T.QVFORUT*S6T@:5[@@Q,:^NO@3UV?6D.@E5* 4J1^7*_QVE#@G1 J+5:4P> M?/=VUM7SM)8]@[(CK35P!EO8*O^6LL=O?E16V]T$FD5][C@]_,&]3RX'@CQV M@Z];WA_]CL[)^#.?JK%7 M#OM-(G9V]MLP3%[[(AIX8;-74(;E%8NA2H=4-!*E8Q9'ARMA %G[\&4G@OO- M7K8)\8V4N./(#I3 =-X ;C-*VE*12"SGGPN6+6"D(*G(5J'WY6CM]C[=X[:S M=&BCN-U$B:W,4[KZ^G6T$*4?W8CR>)PGT\NE,F^$JB&+I%&>)D5?VJLR@L+$ M/URV,G(67*@^_60]TOK-DG:&Q"X4TT#(=C.6J0S*Q4!@X#U3D#'.#)&7V=!6 M$Z>"(#DI"%0;*E/]7E,/2.AY8$P7:GZ46M]>YDU IK1(N/"_P^R& U"<*VZ0 M?8_1H.0BEJ1L)%X:Z5R(S/,.VO"L4-'S%>B] & G3(3#H5S5]\]3K=Y MAF,TW'>V6@90.H,KGB:45(/$O3LHDEE00(5.8*O?NE^7N'[/9+JK@>Y$.0V@ M[IT?3A>374_SLEO?[;ULT,F*TJ8O8&A#9')ER))D!(+5H*P+.M6^;_C_$D7FF@ 4O>ZFB$C5Y>0V"!8)X4!3J+@@4AO%;$Z9N3#0LGC*^5JGQ\_ M04;/IGTHY_.K[]9K(?9L*CKZ?FIMPLF0+2)02"" ME6ZW@AKBJ&!$6)^2$NA,/.J6]-1=C9V(Z+FBN5.L[5=#_2-R]:!\K;XF(@3A M5(R$I5*-83DEP7LTXBJDS#./U%6_Y%N[(4UW5<][L86=Z:OB4,FJHY??')P? MGY^^^WAV='YT'!R<71W\M4XH?LK'6N.5UGUQA MQ/)63%0:JWPZ_>S'UR--#B?CV60T3,M%,4X?[_%SFJ_AZD>W,<<=9FD&K5!\ MQ;"5K(6 V>?F*@6#56UTF=' MAVC WO_]^/S\T]';@\/#TT\G%\B6(#05-UL2 #JCRO'8WZ@ID[UZ#MC4)]Y8?8Z42 R-(1M$?D]03IV0F%+31 MAC%+6>WZW!IT]WVA?K^8?5S'MF?-MVEX#P[_\NGX_+AXE-N8UP>_7L&(/D]. M)5-Y$^X<3BX#;J[7N^XBNW@O5+]+D"N134R,9.=*CP49$6$6B',A4YNM$5 [ M2;<9A;L:P"?>]I2'D1T#P2,CRD8$NI".>*LM>CK%\CUB&: M5NU5!XIJTR(=G_SUZ/QBX2P='>*'+XZ/MK%,3SZF@H7Z,7F5+-6]T=S/3)>_ MJ^?F4H%-D3C.+.(*)'$R2Z+ ,6\X*XGNZ@?JZU*W>P'![9N.Q]?O^N"G_X!Y M:4;WZ*VX=\-T[H?CBZE/MP.WGEHJ.L:OX#"&53.+M>?"= M%N^@Q2,H+[4E@J90LN*.6B>2CY> MFL4U'DF"8;C7&ZF$L,E)5MMVO4A0OP:H&BZ>+4#860EMVHT/1V^/#P_.CCX> MG%V\W<)V//S]"O;C!8*JN577,P_O!C&5:[U**,*MHD2J#V*?._G_TGKZ=D%WT>O\8OZH\VUSWOYR>OOW;\?OW!R=O3R]^/3H[/KDX M./GE^,W[HX/S\Z.M$NT_?&0%Z[ 9V94,QB^32?IM.!JA0WF,-(\_#]';7'4F M[^9H*ME]T^F'*Y!2XFW MV>/FZP6QP S)V0BCM*.VNI^R&87]&JWNL+7JR72HMS9-W)NCDZ-WQQ?G'P_^ M?H &8IOZCI4GU*CC>(FHSAP<]%$3,)%PYRN-"S5-)"A*B1*\S"'/'@/@5AV< M1P]\"JT^!^K+J*Q$RRC-,JW:2EX.XY542I8)!+6OM[U$3VN.T";Z?YQTJ23W M-JW$T<'9R?')+^OG][='9^])=/QQ=_W\*P//&0"I;D1Z35,AV+_/PM4#SE7&>3 M"+6\](.TB=BL)*%&6,NLE)+5[G[SD(*=K]Z7_H)?)B-<:+/EDT\F\R=WR02. M41"1< 8G F*7DM!:11(,I#(!11''A21,>VM8LLE M[?N8+Y!3[:;\4ZCEP>7(&25.:DFD8(X$%P2Z]%'%&*BDU7NVOT1/WR%.'4P\ M>V-^5PVT:3?>'KVYV,)@+'ZM@J5X_/I*)J+4 CR!! !G76!HZ(VU1.: 7 M3K0!QJB'D&SM5.S3E.QJ&!X^]0Z11FN'WJ\GD8,FDD=DD,M4;@$(:8/P"/E. M&6S$'%30_ZHEJ"'R-HU R18<+^O7?OET<%;NCAV='YR\/3Q=W%8X.CG=6,"-;,%#)SI3&XL/Y;8GX9%$6#N-81J ^ 3\#V7C<>2 ONC=*69)CDO# MC 9-J>2U;P5L1.#.'?/N7O;@3?CF7Z[\U(_G<+]80D5TXZ/(A(J<-7=Z]F';I.X3 M#ZF1>_D!:94,USE\+OH^@Z^3Z>)J^>TM1J )H1&4H7C)@C<1%AY5,*C&:O M6:Q]Z>LY6G;.QZP\]TD7GIF#+$\E &RJ%3X&LG<-<@J^<6 M=C6P\2@;4UD9;1J6-6_E?YR,AL7 ;G,$O>$;]M=JX&FFFFHY8)$0HZ4BF5-7 M *9(B,F2#$YK3V.(.E=>[4VT''CC9\/9:;YW<['HZOORSWN'*M(8!M*3,I&] M#&*GQ$'(Q%)ND[(Y2*B=EEZ/LC]">X!-L/?HIE=]_370 NT,OL'X"FUKG'P> M+Z[%K3*4O4L>K"/644-*.JVP9HC7@F9)([J>M:LX?DA4O^W1^L=B7:TU ,.[ M2T2KC'#'E!0H'*IE64\!5Y8K92TV.QI=XE[5#E"?):;?3FG]PZZ.EAJ VPM= M!IZVZE)3P;SB!&PIH-"<$2^S(J"S#L9Y35WM6TR;TMAOF[3^P=FI3MN,=)ZZ M]'Q1;EUN$]2\\+".[F<_1>K^;VE' 8!A-! 5-1"9*2,!DB;: J.!"6T[*,/= MURWM\_@%TM6H=.K]YH>C(O!WD^FY'\'=NXH7@0MR-%PH=:&4>WZ$H2['H FS MAJ,?$17QN#B(8SP8&J&#_/"N-/=]"-X)\AZE*' MX_>3V>QT?$_4*\QQD7DN50!1+NY)Y#(3%$HO(A]3#M$J5ANU&Q'8;_RR)XAV MI[(&\'BW_LY6F%SARP>7573H6U"*_K S!CWCD CG+F>:%36R=@GVNK3U&\[L MW5!65%0# 'QZ3=U=AM5(-M>6P&*DB+:96%$JKX3URH/P$:K?\'N1HG[#DSV! MK:)2&H#8/1X.1WXV&^9AF2Q;CJ>+I*[\Z(.?%_%]?XN1W.IR*O-JHXN$:5J& MM0$E@5%#J$X@!+7,IMIV;Q=Z^QT9N2=X[DVA;8;+MUUPMHZ15Y]0LS5/A]'P MBXU8(#J7+"""DA>H5T\Q$ A N=&@0S,0>TAWGMIT+.\1?T!?'E\.AV?E;4T M'8X_+PYR[G =E1>:!DJX8;COR?:_+W:3P),YA^*^O_>/SU:KX2M]_5?%E!I;2!*"XCD1@5$:>\*1-\ M4];>IFQKEP559J'?N+=O('>BZ 9P?A=BG4P*(WYT<%GR\+/3?'HUG\W]N#3Z M>PO3X3=D]!M\G"P;L*Y&8$QKJA*ZQTDH9%MDA=*/D2C&:;(N&R&KUX'5(;W? M2+HS7/>AV ;PO+*M5';^,A_]U!:M" 6&, M\KP,QRN%=JR,CN44_7K*7*:&9ZYJ3UW:"V/]!OK[LO$-@*+-(.M!J\"M ZVG MGE*[CV&GQX^KS5Z"$$YI<*180B(1AABV&T&,TSG&'+)2M?>VJMT,W_A1>=3Y M%R@]U!?'[+@0)G%8YM;];3C_\J ]WQ+5*]#6G 6>*-'E!KE,95!:<.CC&)" M_KR-;C4C^52[PYT)Z?MX5OUB:SWUQ-'T#M1H,-@73R M$HOOKN9%I)?ERN.R/OGH]Z\PGJUZPQ0#;^JB("AQ4PX7 G',,L)2EIG'R+6H M?0Y6D_Y^TR[[A_7>==YF!+32NGCK@.?IY]3OK;S7I(O0QC##(XD0$6<:*$'8 M 0G9J6#0HGG=60/B^F')3;[Q^[O)]-/XJQ^FPY$?7BX:4RR_2/]YM2SON$;[ MP)9D8BK7OO)RH5EBP2AB1S?G#JW9L[U\@]$Z*27+X*1$9# %CQ1]-,VS=E1X'VOW3^NJI_/= M&EE]0SDNB;A W@Y'5W-(*]NVT](Y4_Q2RV6I%6?$41F(D8H[AEZJC%VY:AN2 MVF@_Z$TP]+QAZTYI;=JTQRV9MS9BSSZJD\[179JIA[V"LV/1E2R'8QH#2*=$ MF<(6B!2!QNA <%.[]V'=_M%OA]^&"04S>PMQA)A>1;&FUHCH,_$BENO-8,O0 MAD2!?T!24[VB-]'_H^:.%47?I@$IK5:W-AGW?KE2U]<.S<(S MO3^522&!#B25B]:2&O1PE0*B;9:J#$HRU:_1=]/[]6X3+,]?+7>BEHNRN^I8 M9BR4ZT1!,$^"9BFX:/!QM3LDHSKX(%863:%O"CIXH9$#4Y8@WM._5"@JU:)M[!>?B_>Z8BPKXF9EW,SL_<2/2[KU^LWCSV<08?CMMB1N M8+B*7$<@(-!S0 N \N(+H2FNLE):5O=+MR3UC]"%<1-TOM#WI#,--W"R?08H MJZM8+N../W\<^?'![\/9()F4LL--PS)=(F"4F??"$FZSHM( <[GVLGZ2D)[W M\7U X%'#Q5WUT2*HWDXN_7 \,-I$K9@BGG&';!A%''.,4)\D#3F&2>VYX\F;UB/VIJOZ7W](8++91XJ03B?:(C=ET/O@XG204S.GT M'*;?AA$6ZP4T-91[C=%4N>QG:,*OK"/!4IZILT#7Z^^-+[AG2?"[.RORW+O[ MK4'=Y[Y41?IMH*?(YIJ#V?7*DA GCP&RHX ;<%RNJ;\VD"@*(;*W).9222V3)DYZ3CPP)? ?*1]= M)-L]Y7>/@-[1L:M"'TT%V5:Z#4#C@:DMEW*+M;VSL.^'8SC&^',V\%D"Q)!( M%KB9RN R\9D%(B 8D)F'$&JW>5V7MGXKTOL(ISK16@-H?. J'DYFBZ6Z*$D^ MOOSJA].2!SG\XJ>? 5FS3"@M&%%1,\H2Q%[5/"#R$Y@?7DV+[ >1&1"2HX57I1 K@R3.6" Y:JZ\Q[^6 MM9.=+]'3K].^%Z154T?/N8"[=H1%3) ^#,?#RZO+P\EHY/$-?G10:@%CT=_G MQZP?JBE?'G"YA>;G^V6>.M'4UEV(GY M_8]O K9,D^)SF40*J1 ;&*>N"1ML$HYQVM?<=G?^(;R^'M/7>GTO_3#IX^VY[?&X M>,=%A,M3$/1)@@Z2!,E13$E2W&]*>WZE8_8I*R9JA\_/D-)_.6-5E:^V&:L@ M_P9@=#%%OP7??)>JPACK7E7 '7>S"WSD[.F_NDYN1>!*:.])HAR(C"81#X&2 MQ)Q-5BN;J]?8Z>QH8 MEUXR1XS+%F5I<.DC$T1K;S1E$ETC6AFJ+Q+4+_;ZP\GJ*)IJ2FL @1\FT_EG MC,[>^/@/2'>;T?%L=E7:^7\ZO^/P_&NITD(:C\9(P-?I<'9[SLP3 QF030L> M2ET#D,!L(I0Y36FBRO/:^<;,&H&TSW 8&OP(QUA4FMVYP2U_7MQM#Y< MC5'Z7_UHD2VYYHY%U4%RW'G'] M]@QJ!IK=*+,!E!Y.+B]A&G_,E^-&:B2>V,@5\J5+_B-88A6WQCCFC*Q=4K$N M;?T.9FH&HYVHL@&(+LY;GV'%\)B$C8)PK] OM[@=.%QNA,9DT&D1487:IO,% M)))#@O?2,0^T[Z#N2W,P=MMI@6MVO]ZC9!H&\8A4>\3G05%"A MJ",Z,=R+DM:X%Q6[8*-.2;/D>.T[E9O2V',MYCX!] /P5M7F]FB=S/UH'VB- M\>KRJM1EI5^FD]GLTWAZ;X3Y&\B3*>YKOP^L])'E9(A;7$0KW;$<,$N0W03H M4TD;JA=TUB"\Y\K/=G'=@=[;-\W/,ET&JM\Q;4S2(%#82CJ)*YP&XDK-K"TS M86.,3%8?$EF%\)[K2E\AV+?7^^9@=TNPC^%S(>1B#W[U0RD,,"Y12@9'0!M: MRM R"=XX8JQPWB2F*>O:AC]'6[^G!"TAMXKV*AZB=EX(?>*GT\7E]+J5SH\> MVU$I\\OD[[]6.2O.C1"**,,%VK"(WBEWE$"T,=H<0F*UBRCW5ZO\8-[,ZI7! M,ND:#46Z(^<083^<_^7*E\[XQ^,RJA"?OTS3J!23H\6Q@7(83+,CC@H,>J,' MF[P$9VNW.*]'_:NI?-X$C2\.%]J?LAOP8M\.9U\G,S]"9^7JZ\T-B;C4;ZFK MU%)[B$838*:,;K"16%<:^PF+NX3F G]2NQS_99):R73M%RF/FDO74UO;*+P^ M8V'@38[H(+,R3%:BC(A561(NK;8Y!R.J'Y[^D*B>2_=K0F!]>&VAC]8 MOP& MTFE^\[WXP2>314OGR7@^'%_AC[_"=,'JS2D<2(5K-41BO 9TAY4DSH5 LM/) M6QM3J#X(:X@%P3+.,T%"*9'"*!)D MH(0Y+Q1P:XU:=:2?ZE+QU+,;XW''.?&GN?UXZ(?AI^CB9 M3)=+*V?FA,:8@5I;LBE%*M(!R:?/6#GH4O$M%*([%>-O"Z*NH9 M:T>_XW/0WC_+T$V]H_'"*W D.($&G65# BN3++R08'BPEID*J%N3G/XZ(U94 M_*1;+?0,K(?".?B 9GZV9.R:EVA+:.4RC] M]"I'!)M1V.]Q=R-1<(=*;0"RFY<5&A]EQH48(PVX)*W$)>D$H6!TQ'49K*C= MUN%U%8EVB9>=:T(W4%Z#X'RVZ(1:;:(+EBA7;NXSW(4\RYY "9VLD5J[ZM?C M:I8,=99)[!&,593UQ^KR"9D*)P4G0D99! :=!*J,U>M?,$HFP(QZHQ-"0&>00O$JUKW^L15B_ M7N@>+6A]-36%O:4 (1W,[G$#1I79GY&4 M1R#3$2)\M5%6TD,Q@^@JM^D?-% MBOIMLM +VG963,^[]'W+?5$N)#UT..X$]\O4)[B.$ =)""X$C22YA#9*N7]]M 84][;O=JZ1EW'_SOQ8DHN89OPW1U/>#S M%QB7!?1F,DZG833\O%3K[ ?2&.1 D\B1DC+Q&/D.AGCG40)>@S?&:RU6T]=/ MP;$F3?VV6=@32GM38@-[\\M] AY>/_HXF2T.WD^N2F;V--]\/T.'!))?=#GA M/! 9A4.')!FBF7:6>P6Z>D:H"N%KP=N^8GCWI^:>#?/+#-_]S6,F!;4^,5E8 M4P[%C/N0$SP1:3Q5R@CNS&JYYE-6>&L"UL*D>\68W)]Z7L^,C2\+,C^_B MO]DDW\^FU;Q_MMV[.[JD5D$0^[_)QDL;.1$1D\R6D91&$1]5(NC3Z@@N"1=7 MQ_Z^GIMLVVP==Y=1EXV&.)BLT9/R?./%C%VAVH\P&4+KVF B? MN31>* )@#9$>(]:@:";<@J; "B+PV0"#H9,%X3 MEX0EZ)F@O&BV1'!?+I?2)*O'_?\S)G[L L1:"FL >R\/CXA<:,:M)YJ+F0).I17J_TW\Z,,0UE): PA\_N#W<'GI?G(U^T'*^?88Q('E+ $0 MJN2BZR@C5G-%=)312*:98=6M93WR6YX6TGG2OR\8-+T"GFAV7CB_:UA)J0E6 M1@*XN1 9G"&>&4$2H\H&X#F(_?5(_@&QK:\.\IJX; /7+YN1'0G\/ ML]G%%S]F_ -^\LML #RJH+@GR98^/9)1$KPN+58L)+!H87SM\HJZ'+0*_ZJP MVZBRH%,,O/H5<,/UZ?3]9/RYC!),.4;'$E&Y7%[G);!PS!"F1$[0MUY*U. M+^D/S17TV> JO4=Q7MS6QY(7"6GJ<(=*[!RA2Y)(*$L6L,]$S2GI$SMRL?J M3+1JNUMQWO>!C>8-^J8.W8I0!L: B43L=E$%(:5Q'&:B/'19^XES[1Z@_8N M&6K5Y=\+6#L-!79!3CNCL.HZAZLR84%H)]%7U%SBOLN#)"&83%)VP'W6D%WU MEO-=,O1:MZ#V5E--Y+R6U;26;@8!;/;9.Q)D&8UF\2N,KS3A^*VFWE'+][MF MUB*[U5"DO951'P4[XW\E<.G^EB$&A+/EE;J_#>=?AN.[6T;+ENN5+Q:N^[JN M[A)NQ>[^KP\RP9WCBYK3C&$)Y9PXYA,1BC.+Z\!H4[M$KOOK@S>W?)]X]-F] M_,0 $A?)JDB4PL!,:JO(8O]Q)B4M<.V#6:<'RQJO>C47^C;!P^JEZIKB;N * M_POL+,RUH,P;81EA.I5YIB:0(*PA(C*>!,M>/.HSOP5Z^G=!^T?/QN)NQSM< M9>G=MY/A@T61G0K&*DJ"BH%(97WI:V&)3=I+&2RNB]K'*S^BJ5^_KF.X=:*8 M!E)D+_&S6#^@HLS T/K&A,)24A&;7;E^: 3CD4>::Y]O_(BF?FO@&P#:QHII MQ[ ]([*;I9)XF00)Z 1H)8,"5WWZZLLD]5O-OB>TU51+ MM5.Q_027?GS=LN4,%C'U?+(JA0Y"S/5?VF6@N27K^P\W$X/$F 62LE 8 E"$ M'Y<),>@X.!&D#6O--&DJW'S)TM\N/!8,3;E<;_;EKJ?UDCA@F5")[JO)3G*H M72+\$CVO)B#=!#'K;+U;*:2!^H ?^:O+\ZBDI(D^$&8Y\H3> PG,>2*,]SDS M:=/>@XE7%;_6!MM."FHTJ'ALI$KSRHP]^?BV!27[F."9/K@?5U/0#=R*A(Z^P MGECV[R/ZY#+UI5+/E:(* Y98KG!C]IDS#Y0G5CM1L3\?\>4Q-7>Z.A^./X_@ M^OOO;]&I?SQ/Z6PR&I5A==3J\Y=W MPV\+WA_.XQMHF:4*"4HKZX#1;\@DUX2:S'0:E7>ZUH= M];'RVA9*8?F:^PL8/\&\%SY:;@V)214UA$@L,$>2\4)J#<+:OO:.M1AHM4CO M%2Z4JEAY;0OE:8YIBC1+K4B"XNLJB+B'HJ40P4:6@!KJ:Y>/[4YUO\?.?Z@E ML3LJ7M$Z*+[DY&K^ \4,6)-QSY1&6+VX2]Y7^+T>!_T> ME/]1UD<':&EPK?QPYG<6@3/O4=0HVM(3+Q&72J]13F5(DDF>NVX54V5@>V?= MY5X;WJMJO(&#U1WD?R->8Z4V9=I>0$$7\6IB,QBB5:2B=$4#6KOS_.Y4OYI# MV9[RJ=LHMT$#O59B[/:Z^H JFJ2PE%A6^O%[C2%,")XH%J71PG#!:P]$WHWB M5YLFW0I?-;*@VRG[%4'[N:S6'>->^J2=#<1H&DBIOD69!UEJNV4";Z3DMUPA<4XCMF'Q7!#2)/Q66%WBH)>Y$&W+S+> M]DT5:HFK,%FI9/C6JKT=SN)H4MY_EQ2,WFLE1"!9EW:* 6.X8&TB"#$=!4VL M_K'"2_3L/!GZME_D0MP'X_1^Z,-PM%@\-\(_O1,^?N!D,IX^T,5R%D)6SH@8 M.<$EAH))&5=S&:T9@F&AW#!FJO9HR6K$]SRMMQ;>'LV5[D6Y#6SOMXR_^7[- M9DGXOYO"?UW!.'Y?S$(&PQA/G!(5V*(I3&EZY2A)"3Q+6:)L:^_L:Y#5"!+W M"YCG8%M)>RT!\BF&K@;:C0O6(*L1 M0-:"PG-0JZ271J$VNUVQUR.SA%9>:=Q&O':F'&T*XC*3)("RT09!A>YLLWZ! MKD; 5@L,:X!M)\VTA+8WWV^__'4(4R3JR_?W\ U&BS6J *+QI 2<"%7C*,7 M$R61GE*>I ]&U<[]KT=9OX=:S>VWM738$C+OK[;'_%VO:YD\:&^ Q(2^MN2E MZH-!)#D";A\B2>UK5]MO1& CEK$B0M8QCE74U1(6C\=?K^:SA<38M<$W7$EA MRPS!@/N(E)03'T&2:*R**#+N9.T6S"^0TPC.ZH/@.;CMJ)%&P<6O6)$<(D1 M?2D==Q$X 98C-RD$S:M'IT^3T@BH^@T/*FBI ;!5'68.6C'.T;^-EI:1XRA/ MQS!HIUPI;J//-M8.%VK2W[.75P-0DT:TVP"R/YU?3!?&X#LR_\OD&TS'A9L; M;Q9W 89^!8FJW W6(A'G?""XQ3@G:$@VU78!7R2H7^SUAY-)5TIK ($?)M/Y M9_\9WOCX#TAWU1?'L]D5I#??/YW?<7C^=3*>39#&HS$2\'4ZG)6];.F^B(!8 M0EXSS>6.V&)$@W&$&VIR,M$*7OMLO0[E_08VS6"Z!QAL#7ZD(TPJP1^=KKG_ MO3A:'Z[&*/VO?G0RF=_R$Q+*T[A DJ>XF).WQ H9T/DW6?J$4C6U8?TR1?UZ MM:$SR0Y#10DEOY4U+C(%BC-'14ZU M^P2L35R_)>C-0+,;93: TL/)Y25,XX_YTII;!901FTRIVU24>$TI >UY<-30 M'&N#=%W:^JT9;P:CG:BR 8C^7_;>=+VM'$D;O*+(!_OR4Y;M+,\X+8_EJIK^ MI0>KS6Z)='/)3']7/P&*U$*1TB&)PP.YIKK+::=%+GD^F/R93-]]H M=[%B)SJ=J&#HA&C.05AIP6ONP%D9.$\NX2%0W2H^0U G!.I?'H'UE-8$!FO< M.W\;J972E/4J0R@R8.!9N=+OEY"41YK9#*DU,7".9':<'T*:M[D6;#<"T(B='G2>0-66(819,[(KJI@L[X66S">2ZEN.P5<5(DP M38 2%T!0CCM,"@]1:\MITEJIVOF9.XEY_:YH)?-815MM#INZJX3^Y*884H[^ M/&)JU.YOU2S9?I[04Q1E"RVM9=I#"E2 2!2QY'6&E(B,V24M0NUKN9,49;_Y M^<9=NW%(E]]3FO\^G2Q^X$:Z#>K6547* M%%<1%*?%"S :K-A-<1ZF@ 7@^:.:\3YTAP M)J!15T@M2L=R,,8Q4%D(GUE.P=9.S'U"1&L .D;'DYH";P Q6[97>1I:[BPM MI!+4"TB:(RO2!+#42LB.ZJQRT*[ZO=@SY#1R%7;"D^X@1;2(J<+(:K,Y'B2- MI8B?90;"A008W'*0P=N D6E,LK8]>H:_!JP)!WK M[ ,S,>1LP2F&=MHTR]D+(48TR]E%72UC<4MR2 M(5;&DNY11.4# Q^3AR!SB"9JXU)O(#NR*V3_[WXG.%>K**8EK#W32XY8ZQGZ MH"!%*B+3$L^#',I$>!JCD2'WUX'T-3=\W L*!S1\W$0H^(V2"T%6!O1@94"'5C' M'3#-0F2>A6!J%SWM0]^P[^BG F1O&FL C9??48A?T_2FU+[@S9VHL4RE06[NL="LAPQ;A]QY>'"_\%A&T\DJXXUXJ%$>T$D-Z MI30XHTL'%:)=$CE$U3N&6@@=*BCY)=@<(/$&@'/?X^2S^Y&F:T,ME V*,4AN M64G-/1C* Q"J37 I2>=KAY];"6D,-(>H>&=/F4/EW0!H+GX4%7P8Q_1WBE\G MR^YWTUDI-I[_O/WU]A%82,Z#4I"BQI H4 7>> 6466'1'PS$UWY)[T;9L$T] M>C_1>E!/XZ![L#EU4E)YD7%+!@:") T6W4LP*$-ADK=&UC[QNE$VK"WK Q-[ MP.Y !34 N\^+^2UCZW9T5'*G-4:VN;QF$.:1$6M!4NLQQ. B.U?[HNPQ">T" MZ5 M;UZ''2'R!A!S[JZO']'/- DR9@.,\C)2C2?T,&.9?<:3UFC(':ON36W0 M,.P=P0DP MK=-40P$-X*AJQSAC, K)*D$2WN.&# **-.<4<2KYV&_>L/@=@+4'T. M@=A'NPT@^T-IHYYF\R]NGB[_>"9Y&PYMY[6 M[HRPG9)?:.S#7LAX4D!YM)H: -O]<;/EL+F3W"7J=YF#<.Z6KL>#YB]""A5- MB*!M3"5SF('5Z'XD1@1WR+3.M7L\'4MS)P#;UWO GU*E#4!X=PNA;!7)KHQ< MEM*5-B%%@ +WN-=2L*RUR+7OY8YK^'2"C*)38*)SCZ=]%-0 TI[4.GY.T_(O MW+=$KS0QSDF-A]YKS!_2T4G0^ -ZJJ:D!R/TC MQ6_IKCO;@U*T\N_/%S>+ZV6_K@_C4&90I;?I]I]7@@7AHM;@540WA$6';&8+ MTACM3314D-JF[T!26ZDT'0"HIU!N QA^Z"D_YG%Y,CS(J+D2(1I;+K-2\!JE M*24XG4JO2:;P2! LN=I&M#MUK=1N#8#4GE38 #C+D_=]8'C/AB=2H;@DT(3Q MH#.93B=_H>!F5QFW M R5:@:$,7=_2S=\B]<"\UX;D*+2MG6NYA8Q64MX&P-:Q2FD 5WM"]=UN8 M1;*B3EL%I4\OH&0X>,8]CI9;/W758ANR3 M\9?)]?7[R?0O-XU7@K,4/8W $[&XE7%3VQA-Z81NO*4>RM%:"E&6VC2^M%X1@ MX)A,T6J;F.BMS5TE'AJ!_>#H[- 8XV10.7BK_$C3T22B^S4];AS2HV:5QTO@ M=S<:?YS,[@V:9DYH4GIGBJ4P@@+O602C4$;>90Q3-P.W9YN&UB>QD6>F5K9% M2X#XM0Z2M2@^C,/U KW;#^-W;CHNMS;T2E$5,O$","HJ>=,8(CN'P9)WG$06 MA(CI%)TLZW,VS*'3%(C[.V]J(>I7WV<7\^]I>CZY0>:^I_'L]D%R5H@7&:BHU7J=6V]YY@=YJS[C]V-U7#W:VW0SXMI^.YF M:79%5>(Q!P>^C(X1B69PB7+@VD<9G#9$UVXATP^(:R2]I92.T 8(C M1BU_<_,4O[9XAI1!U+,R8=60G#T$HR0(3LM52PR@K,\D*2^D[JWW8B4>&LF- M:67+- &57\O=NDSS^?5MO]\K9UBDQDFPP1>5) N&Z@3<>6TX4316+XGOAY-& MTGY^Y6US(&Q^R>/FKF;O8C&_R+=/UU?(.LU2!G1%A0&G/8:ABD?EF<-_ MT=NDYWY8:B29Z1?>54<#Z9?<7KT39' D)D!EZ8 "(2ZYT,Q+A3 MS*#H_8VU_YRM7W@#[0^5(]]8WXUC[UE@=_*9Y%*(??9MFFY/W@JY7R]^NV;& MUWZ,G"+/RUEE=)EGIE1!BK$!7 P9B)74,A^C%;$OH])GGM=SM==,!VJ$I$", M+LTRT5WS7&:(EE/NF$W"]C9@Y1FZ&DE .18ESPR]J*.2!L+/QV4KRV8HR45' M K/ .>-H]0W& "@9X-2)P*V4TM=.F'Q*12,0JJ;I9ZN%]A9[<\#YY&[N.K'* M)'V*' AE*)80(X:0R^QP&97!L]SXS;3YNO"YIV58$!VKXV>( MLT]F3FQ[_.B\8$M0.52WD[X%/3AZ?K.2/,N56''E&1%&4 (FZ))>'058G0EP M@^&VM"+DN)GKL1T^75<<-KFP!_ST(NJA 80F=BM/9XMOB]D<&;'K]J8\Z!P5 M [M\1,@4W43-*$C<&DI[X[7HDLW:><%A$POJPZ<700^-'OG\CI!KD^J%5R(+ M ZKL ]P:&3R:6>"*&<9M"%1NOKUL-S[=UAOV+;X'T].#F(>&COA-L>T[XFT* M2W9P3[#UY(%(DB6VM)I"H0F)@:KQ4N'O&"4*=X0VG0ZO?18=]G6Z/HAZ$_CP M2-IA6B_"?'++UOID#BBX9!)N$$H""&\Y&%ZR#U52D3@9Z9/Y@3MPU'7)81]K M^T!1+\(>&D/R-[W#QI[]F(ZNT<:*NZ%=W#K)&4:H'/<#,1(\266.G,C>%@M, MN^2@=5]QV(?)/OSH/D3=P/W/Q\GXVWQS>%,R2L=L:#)Z>C/54?*]7%>VJLN-Q(>J$$J M4S)$?DK/T"\:M;2^$TY'JF#@(.S) M3(9ES^F@&N)8B(<(X*D!3#&I$@).=5=@J^75VH%*L=J=-*; M>-L%RSI\S"H%9XV"4@5;4DO+_0/WX$V6)+/,K-_TA/8$2R,O7:<%RR'B;18L M=Z\N/-OH'?J$R0H4%"F=:TA0(*.VUFE/%-E,\=D/+*V\:YT4+ >)MUFPW+VS M8-P@M(H1G#$"H9\<^! (&$UD%E8PK;M<([^\TM /62<%RT'B;18L]T\IEL<8 MF02I;4;7+E@P,93!:I0*&;AP[CB?I94'J]-:ED/$VRY8UH>JS.AJ9>D@1/2[ MA&8:T#8:",'E''30675Y*']YI:'?I4X+ED/$VRQ8[MY';)0,:0[(2)G1*#T% M:V(&:X.UW)NDTV9^_Y['4"-/4*<]A@X1;P,W,;LF>2*^-KK6JZ& !G!4=4:G4YIRQ5"**A$0#D5I6=(8 M 2AJB$E4NMJ5$[_^;-Z] -7G;-Y]M-L LG<,?4V!>")0DED1!X(J!Z;D["J& MIPDA@3BN*F/TEY_-NQ5^_^L8N65JHB3X&(%^:K':2>YF#VR/H7P<7[ ;#(F0M2!0.) M,HS?A=7@%(]X)#B.\1[+^$NOP'N.NE9R[ :'8C45-@'.]>7#ITD1F+M>;3)C M5(Z19_!>H+ADCL7#,1"4)5;*2/ \Z2VWX3$MK:3+# *\"NII?$[6Y\7.Y MN[Z^N!7=NKF-NQ^J6:%9RC[+U.R; A>" M>1:%M[&W/F?]C\K"2._!_,(M/9/P+WR:C*>/6A&5__U2VU]3^#X>_>\BS6Y= MZVRCU4%ZE%#$ ,U2@JXURZ \3Q1_@C_JK:-U#_PTXED>B\H71F4-!X$&#O== M%VQ>&6Y=UD!<*"V&K0"C\%A2TB1!I/>)56\5>L25^:D&5PV(E8Y7[?LHK@'\ M5;UR*\WAJ7<$'"^%FM9D,-[8DIX5K!':>_O_7[7O>]6^%Z#ZO&K?1[L-(/O6 ME;L87Q9;L#(7MXE@CDKC/ 6>+>YZDP)X*3 05%2Y:&((J7;;\EVT_$+7[7NA M8]*#JAJ W(/KW[O?_F.4IJ5'PL]EM]GECM8Q!\YX!"E*"@BZ4>"-X6!5)!E'G8 @# /AF 2G9 054G;$ MT4C%*;H#[R2P$2^U(D(Z-/&MHZZ6L/AP./DZNU('9QC7P#6W&&E2AWLX46#: M!N(PZ,R^MQ:R3\EI!&?U0; +;D=JI(G"TP?26K)S5[T=G'!27$F4P($=5OP;M1UAZX#L'!"_"JH)0&H':.2X[FE[B\B[<< MK?AP,1H=#(%03+C@.H.E 7]'J<]X^C/C-YMP'@NN7;0,&Z[V!*HOC17KW]VC^Q^)Z/OIQG=;]M(+6.4D"4OO2 27H\B8N($HAG#"D9 ]WJ!?9 MN<"P7E1E2-0390,&95,VY5&QI$F4#)TUPC.3P2$SS 0TD;2D3CA&@5(5M0^$ M1]:W(_24JF$K1DYT9AVIC ;A53HP?4W3F]7^^7TZ^6O^_0%[A+@8DBHC7'D9 M.2(BN-)=5!DBJ*,A>=UWY/<"B<-F,I\(>#75-" *9]/YU1XPC_=8^K1@HT4M;5R=7"X,EI MT-K\8EC+9<(@0;E86L4I6#:OH(YGB=$#C]UZZ'7!T)#!V1'*VE3W 9(;6.%_ MC,:CF\7-BG"JN(Q1)R"$EHK?P, I00!]>^2(9:]"IW3>%U3^:-&!E7Z(RB8U MY#>TXMW?#P@W7@:57.&WQ'.,67 6PSO.B;3:<$%\IPS/EQ3_<-%A8N=JBC]8 M?@VXJCT=F!_OLMD3X2DR])*T5!R$4K9TQ(H0*3-2YQ@SV6SWTF@6[,?&ROI: M<7&:A%(#6^N^%F,ID+4P?GY*\\W(X\HKDC)5&HRQ$L,8@VY&U YH-I9'*AQW MG;ST@ZIG7B2OD7?F)G"UL^"FKI+;K,'YX]W;#^=G7]Y]/OOR]>WA-39;/U.A MAN9E\BK5R'P8HV9+<==="8+$_Q#'!#A1=)LX R,C7]971<^XL+E^TX0-(HYN MGAZ^I[BX3A?Y,GU;MN--/R;3.>ZA#^,\F=XL]?'FY^J'MP=&X#X&&R-H7NK* M,A5X8&#,)+,3AFOG*:V=97T F<,:L./0\J3W>L]::N#D/)^,2WGL]';P^VCV M/V]^ODGC\/W&36_;0PLO6)0V@6(.+7:R!!T6KH%PKQV1GAI2.VOZ)9J&A5CO MH-A\&*RIH281M^9F=<^LE99):@,VE+8MG#@,#B.#J+U7R)"4MO9ST$LT#8NX MN@AX$5Y'J&/H]V=*[R <&TOG-['+A9Z.(8<_% M=/U*NJY.2X%)/L V< M9,^<__<1K_0<(TX64#[%-E/&P3"6"F-.X\]T%K6O&[K0-2R^3NU#5==4 ^B[ MF']/T]M[FO/%M$C]BC&B"7$6.-5H805S8&,@H%/,DAC/>:H=(3ZE8F#OO+JF M-VL6CQ-[ \ Y"[=&][/[63;6V3CBOYDNTL.[OCO6.'>X[1)P3R*(2!A8K2)$ M:9CW.AMB:A?A[$'>P$:L;ZCUI:C],6AO,3A.WTI+K:/=JT]IOJ+[[A)WN:.N MA% A*2% ERL:04(&2VB&9+*0/+@4J.S@6>WZ_K!9HKWAI9I(#S=.D[F[KGVJ M?4(G=(5NKD5F+J,L*"O3-C%T<"QF8"D%RPU5LGHOI*V$#)MQ="M-8E9[2+GD)B7KP1F",4$4I0FTC%ETF:;SY,/#SD/I M&PM'"+$: JJ^XO]^??GPZ>O9I]\_O/GX[NSR\MW7 MR]\GD_C7Z/K:K^\Z9H<_]1^^5H5\@$J,5DH:6*^&(=,'9&;\;53BIZ5C<]_4 M\+ZGH?5:,4-!:Y]+IZWBZD@#!/UCZX5A1-0N;=R+P'K)!NME;V_4$I74!1E! M.E8F)1@-UN8(',_F@ +10=2N%]Y!RK!W1OVA97="P>&::,#%ONNH_&8Q0[,_ MFZWW].V,&.U3C,I!YKDT[^(>!:1M"4"3S0DE5'WT]K,$M9(N<(3*-V%43?XM M@.F6]M7#DB?>&%WR^ EN,5%F!SB;.'B!X68*4DE=/8K>_@!P@ MY<&'$:XRNE8"&T?0+CMZTT\ M81RBJDE5N0W]")_*,(=_I^OKQRR42C'),"1T.BL0GBGN[$<7)N""A?)M?7[R?3O]PT7ADFD5 K06EJ0,14WCTL >8\%3&C MJ+I551X E0=DM!'8'*C8'3 Y5,H- >5*6IVXE!*R219$J;NRV:(YC-*)J)E/ MM/:#TGKM-B!QL!)W@&(OB1Z,A!]I.II$])*G\ZIX. O_NQ@A$6^7@Y@_+U>Y M8EY1Z6,&'TW$(S@;\"$3(#H'ECV)O'KFUG/T#'ON](6;HR7?DE4)QH62AP$\ M*H_^&E'%7Z/ A=5:EPS&4+NYS%Y6I;?4AMZLRCX2/=*JO!O'H5X!EF^EFU>/ MEPO_WRG,YY.SF_+8\G^6-/3W.K _#2=X-3A2,(.\)MBL% TQ@9*EMX$O"3>) M6%")ALS+Z$'6E^-YXM>$#RC;/!J/YNGCZ,_T9.G;P,18--]1:T#&'0CD'AR/ M%FBPZ'':F*T)O3TR=*&P#7^L/K9VOSU4UUL#9_ +/+WY^8?[[\GT_-K-5G>I MCAN+#(*7!MES*H&C$<-G;8KOD22>495AN2>)K3Q;U$?+DZ'K_:FN?63>,_?) MW:Q;[46;B79"0B!4HN]D&*"K@_ZP9,$G+X72M:=N'$#FT*7>/<)F/X@>K=MNTYMA")& Y%ECK()I:L1SQCZ!4V% M0CYU[98<.XD9]I[D5+"JJY,&P+6'.;^_SK9$4V>3 DTC\L@< RN=!,-)TDBD M5JQV<'$(G:T\&;7DRAVFQ/:!^N[O<+V(N"'O[K R$5[A/L:-J R(TH;&,85^ MB/*&\A@X39U:NM8#Z1,:FSZ**Z!F/Y@>I\(&('J_X]^_M-M%Q/,&X8,G3BGD M)]JB5RPBY! ]S\$SPVL_A'6GKHTGCU->S5355P-(?(:?)P%:<(H*3PA$+3WN M:(D!6L9?DDC143Q[\%"J#,4]R&OE.J8N0IX.-^]%76TC<:M3SJ,P5G #7!7W MV:- +>$.@J6,LB""E[6+ O8DNC-M(&7AB[BD- M4@5=#/RT4*J[)S<_TCR5;N++?([U8$SE,6SV$JQPI?^]IB@8:8'&3.MB=5-0##W<+[YRSEQ?7'44Y72D4;C5)EZ*(I M_2_Q=S98((P+0K6UDE>?[M.!KJ&?#OI"16?K=Z"*#H;=GVGJ)_T?NK]/)[/9 ME12"2Z+*B.%L03!:IL%B_,MY]$(D'77UD?(OT33T^_[@@#M -0W8N*U,/'UI MPPWD/'HCX!1?%J@Y<*6@*(GDC93,&E;[VK4;9<-&G2>#70]J:J"KY#.;Z2R$ MQUA/<*6#<$+)"$&4\6P&=Y:)WF ,Y61,6@BO:]]W[$_EL#%N"[:P MAOH:L([/<(A2O5*>1!.- )<"AS)H&PS) K()&E'$1):U4TB>IVC8YI4M &]? MM31@!;N([IFO8'IB#';]'J^AU MMD7\Y*;3Y:3'_NH=GRQQ@G+&Y]D:IO=A"$8SQL$YBN>D<@HS#>KII3>'!I)S M9-81TR"F51/"2.06++,)0Q"?P7)C@(<@G=711U>[B.^DIO49YWBG=E8S*I"^ M]_B_NUR$D%+Q;=XC=>[ZOY*;SN[DQP,C23$"6JC2 HU%\,6\>)-EMH04'^MT M04\-EEZ3<=\'O7N$32='1MO!_19!?$DE(0"A4-YSU[Q?V2"BS$%#S%,F! MB13C32Z,\%J9R$YY'=61[&;?)$\/PSVNM/K Q*O;!I_PS/[Z5[K^,_TQ&<^_ MSZX4)]$Q:4 Q7<8*" ^FE%I02[UGS%!:O5OY<10WF_/XRL!_%!)>'>Z+E+_^ M-;E2P64,=0@$'U1).L;-S6@$14(61&@;8NU&V <1VFPVYBM#^2%Z?YW@1K2F M*QV\<;KT'DZEHC(Z7]@D92,323,7,M5NKG@@J3Q?0J M).>8$Z7%-BO-NT4$HP(#EH6PU$CBW ES59^A=-BWO%\+X'MK_G7B&__NE7-4 M4.D#\,A#N2"0X$2R$).,,=!@<(SK]Y]^G=^P]? M+S^?_==9N6H.\]&?H_G/T?A-&J<\NANY?/B=^[XK5+A*/XJI2C?D=U-'[O I M:,J:! &$($Y$SHA/$3GPH).@/MI4?:#/$R*.;WRUFDCX?C+]Y_B'&\7S:S>Z M*14WJ]_$_U[,YJ7[TEW,.K^3 (E,N& H8%CJ00C!P042(&8;E'$MH>ZU2::^ @?\CL2VQ>:;1529?IJJ&<&X:A$TY2ALPXBQAF:E8] MLWL?^H8%X0EA\PQ@J^JPF9D+^\MV/0QM.2M@-BH@F%WE' P3TH+RL;1D,@$< M,0Y%H37/0CI/:[N?=2@?]EJX#62?2.^-V>1N7'^X'8>]_O&=GR]8$)P)B$9H MY%M+]/-C@N B8YPNQ_<,CO?MM ][1?R:$%]!]PU@_G+Q P.DPI:[?C A'*7P M>3K!XV3^\]S-%NYZ_O/.V?MG>=S\:SHJ1*RBWQ)NOG@"6J-<\ACSFES&&:JH M\7?> 57:*9^MPC"X\JXX'7>OS0>J@=[-SGAM0NGU;[+/Z-1-.\J%Q1@DAY R M1;EX I89"=P&;54@DL;J SQ.Q-MK<\7:VV#]P*B![76L(;J K;G^';?_T9_^:#[K>2Y! L M)$+138XB@)=!@D@DF.!0^*;VYP=^)+V2++KH M68;(&>YOERPX7A)V",]2N:!2]>$\M6A_;1'%L:BK"/N#(; _].TM],?I6ZET M&1S\=SX>GFV)BN@I=9!*.U^1(@.;.9YMU-JLN'6I^L"-2J2_-E^_(>@?"H F MD/_9_5Q.Q4&^/TYFLV6;Q/*;IQ%*$I9PKTM:<6(8H3 %CGE7IC%)JK*F/-5^ MI^U,W&MSS"NCMQ\E'HO/K[WXX"]&TEY%PK*W@"*,Z/@I"U9J BI'R?"_6A#? M^LMM;^F$;?C45758=:[U$#7[%@ ME,R) W6VM+,H9>1E[GLFC&A&N%"Z=J)L7[P,W9MNV-29'O3=9OK@N[,OGSY\ M^OWR\[LOYQ=__''QZ?(?9U_>X6\___/KV=9X+5;3ZYN9F,E[W ;QLTH^^2&5,!4BQ5U\11<-HJ,)8P1E#J3/4W MCJLCD<->(E3!S>X!7'THJH'+K[._W#1^Q;]\.PK9N"0D^AS.E=;PTB/=40?@ MSG.%] N9:Z/L$0&MS-+J1=F;C6X.EGP#L%E+)<7S,F1@/%LI";V,;[?#9M_\ MO/\[JRAMR?$]V^/X^=J-'XPZ\,%YI601GR!X_GN/,N 49,R441$E3;7]O3[X M&!;$1\!JT_8-K>,&/S(J+GUQN14&WE;"1EXN$EKJ#M>60T@;JOC\_%N3H=;MG<2$E2D M%N63+&X=%H!EK1R1)/'JI9W/4]3*@)U3.(P5==, TCZE^80C$O.2::9U$X3>41 6Z'K,9J=U!)S$W-(_IW*>+L4S_"C M[EOZM"A&]2(OI32[6,QG5,EW>( ME5&T%X'#6JL>4=:?FAJP5+A_IJM$V%M[?LO6V1R/>[^8%[O^=?+4U7C@B5SE M%+CT!!U-G7B9BD'*S;;#S>!1.I%F[WSUO)<=I S;4>B$^#E$] T@Z&P\ M'\5">NF>E,)B.IJ/TFJ*68KO4:+E,FDQ7TT?>/*D>)NGH%/25*#_JCUSZUM$ MW$4\B>BRL,+2VD.7JA#>"9WZ%:+S]&IM,_WD\NO%^?_]CXN/;]]]N7SW__SS MP]?_>COZ1_%Z/YS[M4@:@#XZJ,1M=1H#DK M Y0L.OA$,9EC,"*EZB?)(PJ.-7#+J\:+_'6:W&PQ_;F\B;Z]>90\2RZU!.T4 M Y$T6FHF"8(]2/03%675IP3O)&;@V[;#=;YI>.J(>\"#<3:=7UVBZ)=A[65( M8S<=398OQSIYRHGPD#,O4V1%!H^" LICYI)H'EBGI'=E6T!RA'P;",)NS]]M5O8^&I!)!B>0)>EIP&@@ M)W#,:,@I!!53((15OQ!ZF:QAWV_JGDM]::,!@*TN]0L/=T'$.M8[=[/OI?KL M*F&X9[G&_4)MR0I&&^V#YQ"]58X2)UGU@M4N=+7@&E<$PZ:_7%LS#:#MCI$' MS%UYR5PFG(.V48&P 4TRXPDHX8Q3'7.L_H"RC8Z!'YQ[1M/1DG\MMS@5IAYW M^&@OMS@GF6R\$=$CTR:2$,#%B)A2FI>"8@&9.^VXYU88U8OS<();'*MCB,M> M=!H]1^K+C%T,-*(WY<&/I.QJ9[B\CEN.O8J9^B7]&,Q#=_= M+'V>3KY-WB?5 M9=TD8E8A:O3*9*X-9!-*!_&RLX0/0#)+3I',N>WDP!R$F<&O=BKI]T7('"#L M 4&#I_W5&:J/GXUCT>(&3V>+^??)=#4:9G4U09.P*B _C#H+@J W9HW(8 +E MQ"ACO=@\BC<]E_U7;0TXAVAYOA]8B35%GL#5SJ7"S]+_[LH#4S^Q%_NJFD](RE$02&(DJ,2 M9=D:D8.*PEM/D<)P 3[% M!#$8GRS*C<3:P?M.8@8N&:ZAZI?A\RHR(&!5NE<0Y"!$H MQ@S*@4I6,F%+/4IM%ZD+72W<55<$PQ[/J@=II@&T+;EYPPR3Z3% MH6_2MW)YS]R:)<>"2,$(8-EY]%%B!!>B!6ZCQ+VIG5.=.AB^F%/;B9R!ZWM[ M0EY?^FBB'<(C.:VJELL,S&+?><#M0EB ;$P$X8,";\LS5DL/#9RSCUCYE[M>I#4GYY.288I[!GT'PDU2A@"7E* M)A[*5#P@ M"265HDZR^HG:A:Z!RW5/";(:FFD-;6MV5J7NA:NUUWI%%*4Q) V69HU\E08+ MR6 L[GEF3G(F?>T:RZZT#5SD>TK4U=+0P*]#&R\4LR_I^G9,PZ-.@4^;R95& M<;-;\WX5O;6$1P'4<5)R]B-8IRU8;DU(63(:-NNAMKT<52!EX#+>GO WA)Y> M,RR7!\*55UPKP3UX8Y%;HP@81A0$YH13!*.D)S-8JZ-R24DG4)K_.%#NKZ4V M?X)=(JY1C?=M'[ZOY^.YJ%ZPD"[+[# M/'.&I5PJ%KS*Y:(X@2G]';.5:'L"L2S7KJU^AIRC'Q)R3J&D;-^M\04!?SX9 MST?CQ6C\[>)'FBZU5)HV!!6,BA"X=&ALK0!?QMU10J0W1E-OJH]DZ$S=L'>^ MM?#RY&&A'^VT:7;>OGOS]6WR\P<-KPXW/\]\K((9ZDIJ)7-4EMJ"+)^UX0:] MGYBS!2$#AH/"<3!2*6H3J;#T4I^"38'2+P! MX)2G]C0-(W?]V:&GM4H5(DAQ,"&!5HZ"L"5UEI&(TBF9/--"+(G<#(41 "SBK<3R+&7%+1M*L]>V,[)<,: MF>,U_ )D#A!W Z"Y3./19/II,D^SE8V,DH;$T$9:GP0L:Q:=G\=/PN9 P4^=!TF_\W(S^BPE[Z(][;R[2)=A/D$[651[7H8 M'S#IJVUF-V7; DNA^IWTK^PA\:0D&0K M5V<_IJ-KY$FNJU:CY\DI"8:6*)#JA/;9!$A!.VD\_B1T>?SNNEY+D5(-]/0A MYJ&A(_5VGOY DKXC3VK%D](L28YA0DHNX=%>\I9BF0YNT&135:ZY-A\NMT*G MXWHM^38UH-.'F(>&#N7;;>G[Y*<+-_V);.D56UE(*71FZ!@&= Q5X. 9[@@J M50S&2I3K2X^1>RXY;#IU?0#U).RA,<1_L]OY6F^,-5.<)1,26)(CP" MXB*5YKT,;%8&<2("]]'F'+I%\!T7'#;)N(=3K ]!#XX>RK8?S6>+;XO9_ %7 M@AL=&![+5I0YP,I3##$)QV!!H1"Y9UIMOFAMAT_7%3OAQ[XB_/0BZJ$!A,?J M#JYN+R8X63&5(LO>"@5!1P?"XA%MDM:0N=3<,%OBS4[W/QT7['9]2%X/?GJ1 M]-#PD;_Q%[BB*ZZL1QR(;""+B%:5F@PN2X+\&?RFDDR$3LT .Z_8#4"OZ *Z M'UD/C2!&7[JD67T?W(>F@$F=]V&-;_:S%.R-/='1=1DJ,1!D?P%]P($?<'_LX2/)E= M27WI%L1W7*\;>E[1570?Z2]QGT6XH>D57TKU)?'@H[7BINT6#_W&1N9U[@5,*0L MC>Q9 N-% *MX-"PDJVRG>*SK@MT ](JNI'N1]-#PX3LVQ?J:5*RO24-"]"OO M@8IE=3Y!$ZMB@&2I$=EJH^QF3<[V&^F."W:#SVNZD>Y#TD/#1SX?'MWS$5W0=W8>8].710&O&0&0HI)*MPMVG9+ZNBZ8C?\O*K;Z#YDW5PIQL>[ MEE:**B^83R4]A6$<4'J=&1N !N>-C_A;5KN=_PY26LI/K%V\Q=6 MO;6OLDB1,2;** N_ZC\D,H'LC%$F,Q52[;9-NVAIJ23C0$4_"YX#I=X<>CZ, M\RM"Z;^E*)!G*1#@(/&00+DFP'BVV([CM:(I1^=JE[-VI M:ZELHP^$5=-, YB[ZR#Q9C*=3OX:C;^AI%PT)K$(E*(-%]GC64W+C5=4*M#L MJ)+5ZYB?DM%2!4<=%!TKZP;@4@J\U_U&SA?3(LDK3\L<7J'!\B*2K!'L 3T] M[9S31EK.66VX;"&C)7^H#ER.E74#<'E$NLM&^)SH#:S>F72(; ^'Q63NKJM;D4^3<5AQP45V(I1,-U$JUIS&HQ,) MARA)4$DP)Y^4"-8T)/>4M%1]4=^6'"CQBJTTJG83%7PS7 MRY,S)>URUM4[AQ_8>>>D_4GW4NS+G7?VD7)S.'EP,RYU\D:',I?=4J2>1_ F M4(AX^NK,F/2R#Z?U573>V4O'73OO["/PX5^:7LS%/QO'[F\D+"MKL_3 J!I)+Q M5EYS.&/H.>04,0KA2G$4B_GR %_E?'71]J*>E%O%B"&N)Z79/U%>,LVSUK5'SFVG9%BT#8>,274U M-0"V76_JV07B''JP>>F4<";!AH!<22FYC9(F4?OT?37YW/6>A Z3=W.P>9!9 MC)ZK-_@?C'>D!$%+>[A@.;#(> A1"\(W&QG]9^5S[Z7HKOG<^TB].?0\FS6L MM6)$'26!7P68A6)F60FA$QT 9,#E14 P=!6(I=%8- MFM4S1;^D/R?7?V(L=8XDC>9GWZ8IW89*1^6-OOC92EFD^Y'?;TYI3@FM4DDU M3PJ],16V6)6T4BU\EA8HS1Y$ M5@(#9R9 6DZ]5D)RO=EHZ>C'GUW$#._G'XF!)R] 5<3>P"GXF(7EI2!ZC(I) M-- 8.S,0R5JP*;AEPY8TK%P,] ==2[.9WZ.%DWAY;5#5U*-C)K M!<284FG.@I$M<1&<+SG;,?-,:M]#;:-C6,07#\^S9&R;@XM#SM+D8!0 M3Q$2+5-0O"/@,FXCDFUBQCCG9.T3ZM74S^REX\Z3J_<0^,!YX;ON,FZ[.#/^ M?O1G^J_DINNAN$X82T) S@@OY48$;)FG[*TS/C/%#>\R0':_55L"S:%:GIQ$ MY&V#B6YPIFSD.08"E!#<>[SL/6+PC*>$!J\B%W8SWCH 3/0 , TP1Z0?,!TC M\D;!](Y&8;2VMH\9BRQZRS0'XD0$0:T&+R-N$JMT(HGI8+O,QMIKT99>MTYP MO!TN\ &1-)O.K[ZX\;?;D@O*K$DL">#.*'0:RU334H=%DR>>D$A=IET<:OSJ M V<:_W3O2#]:<%A34S?>.ER2+:A_/5X[Q(C'I@:3C0"1D&*;N0&N8YGJ%DR6 MG9ZDN@!@2!_X"&5MJOL R0VL\#]&X]'-XF9%N'8J2TTSY&"+H3)E!I*GB'6? M7%#:$-(I)?H%E3]:=&"E'Z*R20WY#:UX]_<#PIED+E(AP6IA2MZV!\=527KD M&D4C;@>N7>/,5^[EV/EG>#F%EYT$;GY!'ZX&B9%:.3 D\H T*DT)X' M:I^,N/R/J5K>2\/=JI;W$7<3H''CV6?WL^R@=3UM4FA@96D@4@:ZP/*3EBG\SA.1XPFU2T!99#=/L$+D<)N@6H;+&\'^_R4),1D42A@1F*;CG^ M 0/UWCN*^\&$+---BLO_ZZ-_KG[@3^9 M_[R2R3A&4WFKHNCP*U$Z&Z.9I8)%F@0SL7I9WC[TM9>\4 =EO>EHX O\??AZ M4B^A@I0N.@%$Q5(X%@Q8EPRHB%ZFS$Y1TZ6!WC$TM'=Y>QS>3JJ3!FS?8^O] MQLU<NDQ<6+\;_<=%1(]*2T'#7(EE&* \4L$ MX4SP@2KDL]-CU)''[0[RV@L&^CMM:VAHX,/V\88ZG_R9QFX\7P;C$S3HH[F[ M'OV?I?KN^5L9_BL9K G18E"=::F'U![WF')@@TZ!XQ\5ZS+'_ @2AAT9TL]1 M>RJ-O$+@G87YPEU?!2%<+-.[G*"R^+(>?&E$K:(7/$G-W9-XHQ;N;BGH!#O] MZ\/N 'TTI!53>:-X&93.E]2N:W&X.=IQ&TTYTP3=#E]:=,J<%>8TBM<1_0_62**Q%/< MTNZFL!/6[.O$6D]Z:O!FY)_CL/1"YRDN ^]BO=WU'7=4$ZFMEN"E78XOL^"Y M(."MLHQG/ _-9O/)KO1#/;;\R,Y%4Q0 90TZ-83BQB*&%YJF@V" MU4G6+?MP\)X?E^%[BHOKTH5I/95WZ6$NG^LDY=%1] 22, X$,Q:<0H>2"!V# M1M:%J][#^QEZAB]".A()3]IYUQ)^ [[88P[6.29$66JTI)"I=:5380 C3009 MF.#X,YY#;9=K*R'#0J>>GG=-TCY8Z"TB9Y5P(IQ@MG02L+[TU"'(D V> L4# M.D3ML]2U'\1WD#(P>HY7\DNP.4#B#0!GPT.XZ\C,5";* )%HAH7R"HPM&:]2 MNC*?PWE1O>70-D(: \TA*MYL)'.TO!L S?N$@G?7_YCO# 2-*<1>;*A9P_HCI*!(702%^@PL;<"GG72[>KM MZ+;9]\5B/IMC\(N![MO%%'_]G*:C2;PBVMD<@P2ELBF[0Z+%Q3]&87W(4I%< MO6/_WD0V= 0>B(QM8.M-3:W@\.NCVY4KR@)C>)*C60^F6/D,+O 0:80M&%9 MDNJW $_):.@$K(BE(T1=<9I7U_O[/LR]GG[Z^>W=Y M]NGM^<6GKQ\^_?[NT_F'=Y>'WTGN]?D*5Y&'LU/I!O(^I:7,P#F?C.<(E30. MHS3;\/*TXJ>H_4P>(GQ?T^F MYXO9'".0Z6QYIZ(H]R9( 18M+0I$J])EE8,*D8OD/=.Y4[7@BW7&FRL/7?!U MO"XGU00[,"Q*^Y6+_(B']>!.*J*FT8,SI6*M5,%Y%CF$F*2/@<;0K9;T!73L M)&"X5@3':G126[P#O_K_D>(HH-36-V \FU#&3@A.RU@YB794Y #:"\'0RT]< M;)ZYVU[T'W]U.&U74M&DBKP&G5E[3_LHKFAWF=$L@@!#<\E3X$B[9P245XQ+ MHZAZ4J6W6]?KKP[7:Z(O71\DKZ%W=4D><=.?MV,FUV UP6D6#0&.D1[*@;C2 M&(NAM?,I",=\\/.5D M4DG$;($K0HHP,OC T4,VF@5*'?[KS:> ;7PU1->6YE<;P5K/ MK=4U;/S[,X5Y%5;O5?H#DM2D:+[NT6^ZP5#.@.$213V%1 M3:IM@.0/-W;?4CQ'85XN?OR83.=KEM[EG$(9%5>4ONZXE95S-!-(AM!28(N! M$G<).).J9-AK0C8K I]!S5YK#W.R] :C_N0^\$7#Q]%\]&VIEW,WN\WI8=1I M69[262K/"6B4P2N3@'#DD#(\D'VGDI<7;AB>KCQP@7S=^Z[O+^GZM\MY^C.-+\-D/O_7;_]8/F1]&(??UHWG=;(T MY@S:$HSLRNAP5Y)W#&=),"60SB[%P8>NWPJ #M7ZY,0J:" ;X(EA_GCW\ATU M89Q2/%G+T2XD%^!IX$",L"E(RXWKU(OWF >WCWNE-O776Z/>\559\ -;JONR MY(O\=3)WUY^GZ6:TN#D;Q]4MT>Q+V2V+A&PQPBDC"135I2V#M^"D]J 317Y# M-LA:!^.TQY*-O;D=J.%)_^(>&$6?%L5T7N1;!SU)O!& M@+25#Y+0;RPIQI)F%%;AR$>&06M,A@IE;#8O92:]M$9C058]H!PMT+: L?O& MX3&'GCD3?;"0E! (?>_!T.0@LNR8%5('L8^MV6_UQER>ZF#J0PF-P&S3KN[- ML]*AS$G5980#!<&6X^AX !:I$U[*;%B7-^A:] S<7^QT!V"OBFK]EOM-"9U+ MW]Q=A2:704F2-?!$4A"&4:HV4P..O0-]AIR!FX?5A5AM\;?9Q^GRW>^EL.C#I_<77_XX M^_KAXM,G-YVZ\J9]>(%4AX]6*(O:E_1*Q5"7Z5M1_I=43 UB[:Z6!<,]HT,T MH)U,I:4^ Y-3AF08]]PG257M J!=M!QK("*&8( MGM2Q.(1X7!-)2%319,9K5W?MIF;@ZMX:2-@T-Y5$/["3]/ODSS0=%[+/QO$? MR5W/OW^^=N/;-\C+A9^-(AKHV[KEJ^B-",H[")&&TAG;@S5&E9 #K:O3U(8N M[0CW67/@4MZ:P.E5W(/W@\95P^A6,>.(#*"\;AL.GU^[V6R41RF>S6ZO/.;O M_OZ1QK-TA:#P+F@)-I6"=XPA4(JX3R3W0E.BC4Y=,M\.6GS8&_;JP.I? :_% M+;H3[6R!AU5-WVC[EWMQD#HPT;>7Y#1Q.6ETQX2]^A4*=C=WU7P/CFY^?I M)"["LDAZ_31^F[1A2NC 2(!8VL*B4"@XYC3XD$5VS*NL^^MX69&11GVS??"W MNUGF4 H?.#,4P^O9Y'H4E^PN0^O;,:[$,RN3@E2Z 0HF/3AG+!"?K2)&I>PZ M13XOY(5N7[V5OIJ#06)253_-(6R5**DY8RZ;! F/4A .MZRU99J.4BXFS0D) MG6ZZ]L;8T+G'-73Z+$0.$' #MZ(7I2%WL>SK\'@]U!<-N&0^% Y*YWY"2AO( M #0[RBF7BJ3:I(+J-ZO99:)6BXNOU>C$L]X3> MI&72SG(4Y6)61AS-UA9S>7#[H%@BN"-(,95".#RXO#L05& M&?1)!\=MCM#VKS=Q+W2(JB95Y3:T*YS*B?OO='W]F 7C>;8Q.M!XYH*048+5 M.8+C>'J')(7HU%QJQ^>;>'8[4O!H%C(YXD2J<8FW;>V!'\V:<4&JZ*8-;#T4R&K#J>"LD9Z 8N7&RN%6 M6_F2I LE/.1F0INQ8$=TWNK?VW+:SU2+\TV7"?"]"*$2^CE3%U2L;Y)1JN[Z713@W7]Q'OT*V9'S<0URJF,AL.F-4"A(T>3.($ M@@K$2F-D[E1YWW[#];U4M+OA^C[R:D33RUF I9?-^A7*18(L&# D9Q#:( M! M>: A>I*I1%%T>1[>\?GA6J\>HZDM"C]&;(.WVO]].EG\V,6)TS::9 A0X='M M4F74EN0.9:31@>9.TR>IJUOK%)Y98[C.J9504$V C1B!RS)1[^QZ,DZ?41EA M.EK6DKZ=+K[=%UA<2:N8S=(!#]2#B#: \4I!#CYJ*X37NE.#_CW6'"8LZ<%< M5!?PT \K=Q.*WR^NKW\N7XK2>A0%3L2 MJ3ZW1HN#/ [U(:K)/=@Z(*==U)B/YA"?@+FJ3.;%9;-Y];@/%ED\/T_*J'Q@<*[FA M>QA/1S=N^O/\WN=.03D;%0?F+1(O@@5C.0.FA:(RDVATETY"3SX\3#>J?I1^ MG-2&5OEW-[UQX>T^BD382Q+C["CL\/TR&J M)_57D& SD>39Y<6*_""8$\YF(%ZPTB<-HVV!Y%,:$R/%H^DT0&'+IX?IW=1W MW'B8Y(:.%%9S##=\E2B8M"8GB,1[M%^1@5S"_N!U]^-=9S/"A1?>+AOH!PQTC =/'7)'H_4Y44Y][79,7>@: MMB%O.V_CO>FR 7RN9CO,WKGI.,5/:7[%9+;6.5O&*",7,7-PZ'6AF'S@Z'"3 M:&N#\0D139075-3SD[2^8X3> &H>;+YU4%YZ=*XWX(=QN%[$TK!C-DOX__&K M^_M*N9"LX@%,*/5_5! P6>#.P_#=6AZ5?W)/>BRN#B"SB>*&_I#7M^(&??O= M8')VE8U.(DH)UD@%PF:,$Y1BX*/C3 ;!D]OL]%0)5V>!%$(1:V2GW<)]F MF$_)&#@1L6_ '"OX)@S+Y\GU*/S\/KE&9:S?L-##/+]VHYL9,K4H5)7C/*;@ MA+$.,C<9XU0,5IV7:#=-"$0P@8%*]3J(CK0-[-3W[EKUH:(&/*[+=(T_^O8[ MLC1UUZ6+8[P9C4>E'UKIE;QNVDB<]U+^?^U=V7+;.A)]GW_1C/;E9:H4+[FN M2BR5K>NJ/+E $I1Y0Q$."#G6WP] [107$&RFX1J_Y-[$KH/N^FMD,W!95KRI;AOK[1>-@U((\%05=P<>@S&8_&R0O9 M[D#^T??E9&78@_L$1^/A!26$!3&U3\KJHG^J4O.N M;\3/SK!+AKUANS7I.*35'SE>:]Q6U]M.1I[RQ?6=$7!$Y1J#^\Y&X_$$(X(% MX_G#?6;;(:7RYYGTG*%T8]R:$*KN!!CX+<C(&0X();U!%WH1M-@BO=#ZN$OM@'I4CZ[)-KHBNB1B][OUD]8^ MW>[7<(-HK=Z4W/K'HO@+E132[>\MR#N-OP<1XX'8['N9_-R?H]S\6LL??Z?B MA7G'11J9S[U!ISUR^ZU!O]=K]>7GOT6(.E?L.N.QT^YU.P1Z)^@/NJ<7^1]W MJ=_62+'BRZ_C5-_QNDY_-)8S*36Q&I%NB_1/,N.)&"!A'AFX18^25SU;X=2Y:;]OWTV>^WVPY5SU73 M-E'O(K-.B.7H!_W+T06R(!,1-O[U^L3,-4"!XX MZ^1%M07+H6#8[O8F'E$G4OOJF20YG!N/W4G+&0_<=M_Q1[Y7]KY/@^;I!??' MVX"Q15'443H("?-$R&=O,)(]MS-L#:G34R^\^2UGU%;=V:$]TG>Z9)A^ Z&1 M,-Z:HQ>V'V\#!TLQL-QK_&):@AU3]]]+]O8?ZGI;^.EOPKV%NKM]>1W$;LC4 M:=USHS-?2#L=3IR";D<2KG<<0&2W4/&E-&/C:[Z,)IMZWK:R2IHX!)\Q'?F( MACGH%/![]!HHT(5T^XO\X4\0,R]14_2RXL$>HO]OMH'VP&S(%&*84S$JZ8&V0!#]_48$6]6\:OV.KUB82UNUL1 M+DHY627I-%BQH>/%5W*8+. N\-0F3ZXCK")6"PIV4%7/.R@C [DIA>+1K?[-"K4Z4!8BF4 [G M3(\ "\ILMOU?_G))IS'9V3K'QITL:_6B0E(L$.OQ13J[N\%II>IN=OQQ$BV3 M&[_B+YOC[\S)1OU;XLS1H\A3-TFJ6P9V=VK#:MZ(B:B'F+.#(7ULH4%E+ B\ MF]5KR#:4/@HY2)N]GCR\"AL]^>W@GF-O4EU6D6H+PB&Q;?IZ/$KQ$"Q?1/PX M?7AL)"S*V\,];/X'PT.;>@O"Y('&@@>NH%YB=2.AD=T&[IGQ/Q@.A10;AT#8 MR 1:#H.50_!3Z#TPRD&1^I/H%"_8$S9EXM^1Q\/-\I&Z:QZ(@,;3E:BO6R8J MSHF,ZJH546*#9#?OW)W+5 #0OXY0.&<:JHMSX;P-BGR5"5]<$T%O2<"?2+@& MD"8#$Z?ZOKI&^70@BW7>LS???XHDE*Y>HN7FEZ%O#,M$OZO-\\:&9WH MBO*Y;?:Y;59)FWL6W5,&(C0A)WREDNQI#5>Q0_Y]R=\47,;V(1;$]\09Z1T&H K4[85-4JM"$K/%N+6+T>JBZ= MADNE^:AHA<.F6I829,\'\)Z)'_3PI:901?PZ#:#5$0-\+$MI0U;X5H*RB.X] MA=@0S8%$JR5?$9=Y.A==UD6Z4=M,UN((5U2+10 M]J> A0G-,U\]I'C%UI'@FV_D=Q/:%S:&MW$.&0$Z?%H8!M+C7VL2!G[@[JQ? MD/?#->D-A$)I@WA;]9#AH,NK72$ATUA(HIW!=ZM7]1J,=,!1#Z]M8,9N9BWB MU08 !44U9NV9@4$.\0I@\0H( "9A=H[U,@P$GD>G87$N:0,6T:ZI].ER-Z.Q MG!<^T%_K@!_R"DQ2KM ,SF5E4%L&>AS:6@4T?VNJ N@<&:3ZI\!8@,J?.=D\ MQ7/*DTN_(I="%_[HX-?HUY*<^K4^!Q"T#=<**ISVR+3WV!M"[]1=JT=YKF2: M6#*^J5TZDHV()U.:;Z;I//9"]56A%*P:+\C2S2D#T.F( M@EE34LXU*W ,3U]#)_S!(32KW!KF2"U/,09 GP6R*YNEB_'CFWL5 M"R!U,T$Q1W::(A:1@3WY@=;)6*-F.EH9^TR/"DM4FG,.+E0:$Z\_&6B50PCV M*MTOL9G^YEZL3 20*@L/[WYMK;170($MXC0\'*G2#MXZ7H%,66I^F#'(F6,W M[VZXE".HAU !8-RH'5V_FKX,CFSD6%'3J[MH9W_:TK0_\-W]H;>9??S6WBNPV]Q++#IXA7R@EU> M)DWQ#K58,]\/7(E[&\'TM7)TO!1HIJ4V7]@YDU+^E;/UZUT%]E"O?$.<7POC85V2XIQG\OD M E^AJ2O6) PW.U.Q,JK=/_GHJ[ MR&4KH#5TK0;P;AH!TSJ?-NL4OEAD;DKI@H:T%+=J[MFT8%1 B@U+_""OFIT":0EDTRI/%@WH@Q!6NU1RCZ&E MATUK,"GG[2CSKBU'U7K5KDW+)!:6J;+HJQRX[ R[IK'+@V0;!JA.M1Q>2T2; M%D#T*4/_+GF!LHN$_7;W[>@=U/9S&;J6LC:MA6@3AOU9B^+H2^0+=80(K/XX M!U/K3(!-JR(EY*!7$!Q/?\&5"F1C:DEGTS)("3FVOCYP%\6!)'/!2?+R).>J M;EJ]JI!: :CY%$%!,R#O$NBZ ?!(P453%V%A>-EO+FR=%>@#W!?UDDW]YPDR M 1%OPBW3XFS-N8 ,[)V"@VFUSY*FH-"T*60[4Q6+3I=.PS CE\!?,Z5A_ZO(7]\Q;V:BM:@H<+RE?QS%]P3\87S&B^ !:M#U4;(Y03 M@SY24%9!O-QXCH1V?K[J&"[#?5LD602B]O#Z# KM(+RA*&<$(*ORL YII^T, M.FI4X[%70;W;D"QKR9.'B7;(O9I.)93@+^ M*P]:)]M^PL!7P?91>*!,F$;$.[END@US^+!"JYOWUX!#2I4"Q#N7;J)4-AM6 M"'6]WAH&(-$!"N^4N8DX:0:LD.61NFL>B(#&T^5R^D:"L/;YA@)"S9AK8#LYW WP[^+2IBQ@!V!?.QJ^U:;*#]TZA MH>;>Y>B6;!T7ZG:^TZ+)%_IF6):=]TSL3(59[]=OQ9+E_YHZ%_#7?$;?_4#] MX9"8_O=?_P-02P,$% @ +G)>65::W/CMA7]WE^!VE/'GI%D/5>VY/6,XO5.W.FL M4]N9M)\Z( &:J$F 4#)ZJ_O 4#J8=_.OMSLTD^J;C,N;0DUIQ:SDAIA+PG/S)N'DBS6OT! M[7\XH:?18)@DG9.D=W+*>L/NOSI[6(KI88VQ\XQ_W,N%;*;<[3_J=UO#06'' M,\%L.NJTVW_9\U//SQ(E+?;36!^^!C&;PJB^A[Q(6:ORT2ED6?YHFS03]W+D MC=P+PNH%L;VQ\F7^[(W36YO;SP]WKM+KG^3&XG-]].OES>-J__ M\;?+?Y+)Q9V[VVVWN[M;_9O;V-]JXU6#_)4Z>9,6N>%Q:H5LD$(+&8N"9H0_ M\KBT8LJ)2A(1-6@^">%93P6<@"9L* P<42MLG)I)#FW)26[6CNA,M:/;K ME#S8[_7'K]SVJWKI0N4%E?/_0\N/B)+DL](YZ;2;?R>)TL1AH( TQ0B7S!64 M6UY8GD=<'^QW/K3'O7;#EQ+DP.DOR8$M1+\K2?Z[-"X%Q_\3">99I=LBWU*# MM((?\SEYD&J6<7;/&R'/=,@SIK"C5*C4$$B%)$ ;*:75)8?"J-V^C",;*NZFY/2!^_@M9!K<8U &6V:^!\ >;D(L M-&H^IDDLAR8,?#=+19P24[J/Y?H9U[P2X@S(A.P57 %. MK*98QD@T7W7#RX#Y@P6^]T+@.4F$A&M=E):N;"#JF(YAO3(N))(.,160@UJ4 ME0PR$:X5OS40:J&S.:H5-PXH#D!9MD1"%03S9&N C0DGN.%FE!DF(/P*,?+; M&:]/3$U*DDS-3(T-S>^%L9IB(^IN!KVA96,EQ*969D/;=Q7E?HOCFN-5W2PBJU:)Y1']N*J)?Q:52TXP8%* *Z&)4)YD^4IHR,8()J MX0P0H9QXLI-.4FD>"I0AD,AG"7]HH("5'&94<=@,,LKL2P56!$* MSVJ]Q+>(NXD@&:SG["N3RIMB)WJ*G9T3 +Z^!"[#=Y)F!FX(7AP,Q+NS% 58C^R-=RO8 17*U0X68MTC-E;&X[YY109:)(>BG$KP.T8?/+$D '.3JD]F5XF@Z>1UX*F6Y4.PH MJ)52LRAC+LT]TCCS_.<=4G'3'*>:!YY5AY\G\QN_VD>_ ;K>MIT=_-)VUC]" M8C4R&\M\=/2PBHYE:KKXOJ*R;?0E"]4H>A.KM%D4$W\#(G.F(HYMYZVWUOI0%LY085(--*C 5=S MG]$(EG]L4T6U$?A5R*G*IMR1K*3WU=,G79$ SXM,S3E&9ZD*F4_7,(,8?Y42 MU-K1\QWO4^M[T6I"A*ASW81O,UH8/JJ_C,%114;G(R&]A_RB\;HX]PIJZH@. MA:D*I@]B&*[>3IV>MDX&/?>"RFK\9_7&U;NKEG]W=6S9YEBWV^IU/SP[W&YU MGAU[2>QPT.H/^SN)/?8J![7A&%-0^7&OMUP'_+]K=)B%+=G#1 MVM3W@I5;;$\MSA?O#C '^WVPJO_<>(&Y#3Q? 2D5N\)FQ[W$/PXBM:6O=%Q@ MU3?RW8:_(GW^_>*5[^7BE>]U:'8WW7GL"\B6"O7D)PV%,OY)^R@\9YORC1\Y M+'WKBU![N81&<'!IGU_RW*\$GOW%1/49?K]Q['\W\E]02P,$% @ +G)> M67SX(U+U!P <"8 !< !H=6TM,C R-# Y,S!X97@S,7@R+FAT;>U:;5/C M.!+^?K]"!W4L5"4AKP-)&*JR#%-'U=ZP!VSMW:G)A+@X_"#EE4KS?D;VP&73#[E'4Z7>ZS6Z_'XGV4:<5'H>B1Y'H_Z>U M@ZD0]W-,/H_I_4XBT_J$[/J#;KMQU,ORX4R*?#)H-9M_VW&BIR>12G.LIS'? M?_5JUI5Q/8:^0.6Y2@9]Z,KI+J_S6([3@7-RQRNK)H0J5GJPVW3_AG:D'O%$ MQO/!=S?V(\_75W_-/IT MPVXNV?7YF;O6:;;9Y4=V/;KZ?O3I_+I^^:\?SO_-1F:)246.9EFDH,QZS2*8<7_%-19$,2>,O^WN!93F[2,-& MC>%:+J,YRR<\W]OM'0\?==F%5:8"(1VTNP[TO[W3K3:<;C78!9OP*3%-4TDS MD$0^D89=4:9T_L!%MI]/B%5>;6GN2&//OL[(O=U.=_C,95]TE\Y4DO%T_B?T M_("IE'U4.F&M9OV?+%*:60QDT*8$HU38@G)-64Y)0'IOM_6N.>PT:ZZ4( ?Z M7Y(#&XA^6Y+\;V%L"@Y_%PGF6*7=8-]S@[3"/B9S=INJ64QB3#6?9]KGF5!8 M,56HU%#(9F5KMA M96TEQ*8R9LW:-Q7E;H/=W-N2O=WC=NMH:,HXECV!38>J;;";=<&X)A<6;+,, M8G+,2L!"$$LSL>)6+ $56#JPOX4T8:Q,@7F6)+2*?7PRK4(2N&S8/L(A"/'U M>WY^%TYX.B8V0OY=%3$D6AU>;_7VZTL$HMFF+N8EL2]3(^ MM9)V[* $1< 6HV(IW(G2%(&10G(MK0/2EQ-'=JG55!A+\2X5C*L'C@J4(1B$ MLZ2;E'& *BQB;AD,;CDCEJ4",WSA6:V7^!:0%03)8#Z)%R:55\5.\! [6R?F M&H2V3^FMD03T3:6P .%&I=QR%S< E^T4+&JX%E4$@2G) QG+?&YKQZ9E+9Y= ML%T6>DN@"0_8^93'A,6;,.#?"%-MB&*/M\YLJ!JM1SLR>\$['$AM@N\D3 +<(/?P?5( MV#-#68C=R,9P/X,1;*U085AHN]\KQ+Q!:Z),CNOV'A5TF1"*?BG ZU"]_\B4 M",!!KCZ0+@U'TTE5X'F:%@O##KQ9$VX692!?^^H]^@;H>MUVMO>E[:R[A20J9-:6^6CI814=R]2T\7U&95OK2Q:F&-=ZPCG1ML#2$37-N>VS0\E(1QE(5ATCS/BMY;9?0UVW.ZZ!W=/ MHCI#/BO(9:/GCT8;,I@+3#2T2.!' 5'V')B"J*(UJ/GR8E!;3)$@)M@3YTS) MG!M/VV^M=*"M'*%"1!KI4<-6D\MH!,O=MBFC6O/\*M.IBJ=D23;EX_+NDRY) M@)(L5G/"Z&RB?.;S>YA!C%^D!#5>[YG!NZVVU-_OW-+*EK,R=QUS*1 FZ3K ML#;FF:%!]64()LUB/A_(U"WJ)@WOJ[,/RJ:6CE$^2\@YJ/GA\AE:O]\X[G7L M8[1'FXW6%XVU&[WC+YOYE+%'O4;WJ+>5 MVD.W$;H2*,/9\;&Q[65L,IZ^W^GL5"(9%_9$,V@R'\%JB6\@6AKWN3GM[,[. M6F6;F*)U.*CLMZ<:]]#V ]CD?EW\_$9LZ92']TO[=;R56P_2_<5\>KU 7:+G M"4"^U2.;>[YM3I7>UZ3*NS\'_J^Q/,]QF/U_$OP!HK6WVT5;XC[7W@#8E! O MP/YEX8?/MBU@[GXJJSQ]BV#X_3N\;6H_!$B@3W]S8W\'?FI[3V6M1R;UU#V%Q.X0$VN,@?G_+8>T6/OF-5?OHW MO@[=FV:_ E!+ P04 " N#,R+FAT;>U8;6_;-A#^OE]Q<[ V!2Q%+W;JMP;P' ?-L,5=[*+; MIX$6J8BK1*HDE<3[]3M2LI,TS>9LV8RM#0(C,8_'N^>>>R%'F2GRHU'&"#WZ M:O2UY\&Q3*J""0.)8L0P"I7FX@+>4:;?@^D M7C?>P&RR[<9_0 M7K^;LH30M/=+V,*M*%[OT6:5LU>M@@LO8_;\02?R7W9+,[SBU&2#, B^:3G1 MHU$JA<'S%.ZO_ZS5W%=&U 7J6TIC9#'HHR[#KHU'5L3H3W-%$]K0(EZ(/Q,[+.Q*% 0/A]9YQ@5%KP91QY'\'_>M\TG? M3@4D4@B6&"X%7'&3@W%G^,ACGQ2DB2Q*(E:?H>#]"*E4CAXE:I,4F*"V?\Q9:5BQ M9.K97G@8#&/,=][6Z+?BZ)@I_C7>;@KW\/=[#IG*Q@GK@C:8MX&[JC)%22D) DW*Z<4*9NF'$WYJ%JV49B89WO= MWO O](%/##?;]LI?*XVHK(:WE8>]G768_? %+&Y:2EKE.48.*VINR\"F-"CV MH>**V;%26R3G=4NJ2TH8[Q,L10K"[CY]L8G533795)(F8&$_[B#T_:&M,X^ ML234EC0O9ZD9Q*%+EC^!U@MC?W?]>S^JT>4":W-!7!?'AFX(MWE2,W8#/>$* ML2\5TQ9E1VB2YX#;F"T9& -=(NRZ[7:E7!"1V.]1(>5.M:W:*%7E#F6)?< = MJ=8:T>_[O6YL;Q(&,\S0]<'-)<-WEXP#0^^O]7M^/WAX M.?##S=J!TUWK1P\T@O*J%;?6&QJ:#:+R&L*[%+/,N^>$+/]]>@5U&^B\'&KW M"=\1JWCL(YV2S'"QB?$6#C=114=LS$'+G%-8F_](-.IH[@B0>R!@F7ZC..9) MB8DRO<:29/@E@UG=$SZ%T=KD1F]?$+5MOE MX;Q"3?"##\><%/)6>_N<\O >"'?R\&33NK[DX1/DX8%KMD\QA^[VL6,,S?U! M*HYV(SW"_9"A?*GG)*4KA M5>+V2XF=DZXXSE9+.]DVTQAJ^E@FK93@.JL5;'M#5L!Q1D93TQ2J$K^QMC)M M'IZZ/GI/+:5VX]Q L9S8=G7OA?6F7KC(!C=;R!*+1F4>WO+0J]V#S[7-9_UX M?. >K7\'4$L! A0#% @ +G)>690VK>$$WP$ CM\A ! M ( ! &AU;2TR,#(T,#DS,"YH=&U02P$"% ,4 " N XML 82 hum-20240930_htm.xml IDEA: XBRL DOCUMENT 0000049071 2024-01-01 2024-09-30 0000049071 2024-09-30 0000049071 2023-12-31 0000049071 2024-07-01 2024-09-30 0000049071 2023-07-01 2023-09-30 0000049071 2023-01-01 2023-09-30 0000049071 us-gaap:CommonStockMember 2024-06-30 0000049071 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000049071 us-gaap:RetainedEarningsMember 2024-06-30 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000049071 us-gaap:TreasuryStockCommonMember 2024-06-30 0000049071 us-gaap:ParentMember 2024-06-30 0000049071 us-gaap:NoncontrollingInterestMember 2024-06-30 0000049071 2024-06-30 0000049071 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000049071 us-gaap:ParentMember 2024-07-01 2024-09-30 0000049071 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000049071 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0000049071 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000049071 us-gaap:CommonStockMember 2024-09-30 0000049071 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000049071 us-gaap:RetainedEarningsMember 2024-09-30 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000049071 us-gaap:TreasuryStockCommonMember 2024-09-30 0000049071 us-gaap:ParentMember 2024-09-30 0000049071 us-gaap:NoncontrollingInterestMember 2024-09-30 0000049071 us-gaap:CommonStockMember 2023-06-30 0000049071 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000049071 us-gaap:RetainedEarningsMember 2023-06-30 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000049071 us-gaap:TreasuryStockCommonMember 2023-06-30 0000049071 us-gaap:ParentMember 2023-06-30 0000049071 us-gaap:NoncontrollingInterestMember 2023-06-30 0000049071 2023-06-30 0000049071 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000049071 us-gaap:ParentMember 2023-07-01 2023-09-30 0000049071 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000049071 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000049071 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000049071 us-gaap:CommonStockMember 2023-09-30 0000049071 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000049071 us-gaap:RetainedEarningsMember 2023-09-30 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000049071 us-gaap:TreasuryStockCommonMember 2023-09-30 0000049071 us-gaap:ParentMember 2023-09-30 0000049071 us-gaap:NoncontrollingInterestMember 2023-09-30 0000049071 2023-09-30 0000049071 us-gaap:CommonStockMember 2023-12-31 0000049071 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000049071 us-gaap:RetainedEarningsMember 2023-12-31 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000049071 us-gaap:TreasuryStockCommonMember 2023-12-31 0000049071 us-gaap:ParentMember 2023-12-31 0000049071 us-gaap:NoncontrollingInterestMember 2023-12-31 0000049071 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000049071 us-gaap:ParentMember 2024-01-01 2024-09-30 0000049071 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-30 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0000049071 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0000049071 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0000049071 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000049071 us-gaap:CommonStockMember 2022-12-31 0000049071 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000049071 us-gaap:RetainedEarningsMember 2022-12-31 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000049071 us-gaap:TreasuryStockCommonMember 2022-12-31 0000049071 us-gaap:ParentMember 2022-12-31 0000049071 us-gaap:NoncontrollingInterestMember 2022-12-31 0000049071 2022-12-31 0000049071 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000049071 us-gaap:ParentMember 2023-01-01 2023-09-30 0000049071 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0000049071 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000049071 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0000049071 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0000049071 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000049071 hum:ValueCreationInitiativesMember 2024-07-01 2024-09-30 0000049071 hum:ValueCreationInitiativesMember 2024-01-01 2024-09-30 0000049071 hum:ValueCreationInitiativesMember 2023-07-01 2023-09-30 0000049071 hum:ValueCreationInitiativesMember 2023-01-01 2023-09-30 0000049071 us-gaap:ServiceMember 2024-09-30 0000049071 us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000049071 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-09-30 0000049071 us-gaap:NontaxableMunicipalNotesMember 2024-09-30 0000049071 us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:CommercialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000049071 us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hum:GentivaHospiceMember 2024-09-30 0000049071 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hum:GentivaHospiceMember 2023-12-31 0000049071 srt:StandardPoorsAAMinusRatingMember 2024-09-30 0000049071 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2024-09-30 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2024-09-30 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000049071 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NontaxableMunicipalNotesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000049071 us-gaap:InvestmentsMember hum:FairValueRiskMember us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-09-30 0000049071 us-gaap:InvestmentsMember hum:FairValueRiskMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0000049071 us-gaap:InterestRateSwapMember 2024-09-30 0000049071 hum:A5875PercentSeniorNotesDueMarch2033Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2033Member us-gaap:InterestRateSwapMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2033Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A5.950PercentSeniorNotesDueMarch2034Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2034Member us-gaap:InterestRateSwapMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2034Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A395PercentSeniorNotesDueAugust2049Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2049Member us-gaap:InterestRateSwapMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2049Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A550PercentSeniorNotesDueMarch2053Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2053Member us-gaap:InterestRateSwapMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2053Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A4.625PercentSeniorNotesDueDecember2042Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2042Member us-gaap:InterestRateSwapMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2042Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A4.95PercentSeniorNotesDueOctober2044Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2044Member us-gaap:InterestRateSwapMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2044Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 hum:A5.750PercentSeniorNotesDueApril2054Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2054Member us-gaap:InterestRateSwapMember 2024-09-30 0000049071 hum:InterestRateSwapMaturing2054Member us-gaap:InterestRateSwapMember 2023-12-31 0000049071 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000049071 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000049071 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000049071 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000049071 us-gaap:CommercialPaperMember 2024-09-30 0000049071 us-gaap:CommercialPaperMember 2023-12-31 0000049071 us-gaap:PutOptionMember 2024-09-30 0000049071 us-gaap:CallOptionMember 2024-09-30 0000049071 us-gaap:PutOptionMember 2023-12-31 0000049071 us-gaap:CallOptionMember 2023-12-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputOptionVolatilityMember 2024-09-30 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputOptionVolatilityMember 2024-09-30 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputOptionVolatilityMember 2023-12-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputOptionVolatilityMember 2023-12-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:CreditSpreadOptionMember 2024-09-30 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:CreditSpreadOptionMember 2024-09-30 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:CreditSpreadOptionMember 2023-12-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:CreditSpreadOptionMember 2023-12-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember hum:RevenueExitMultipleMember 2024-09-30 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember hum:RevenueExitMultipleMember 2024-09-30 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember hum:RevenueExitMultipleMember 2023-12-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember hum:RevenueExitMultipleMember 2023-12-31 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputDiscountRateMember 2024-09-30 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputDiscountRateMember 2024-09-30 0000049071 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputDiscountRateMember 2023-12-31 0000049071 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputDiscountRateMember 2023-12-31 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputLongTermRevenueGrowthRateMember 2024-09-30 0000049071 us-gaap:FairValueInputsLevel3Member us-gaap:OptionOnSecuritiesMember us-gaap:MeasurementInputLongTermRevenueGrowthRateMember 2023-12-31 0000049071 hum:RiskCorridorSettlementsMedicarePartDMember 2024-09-30 0000049071 hum:CmsSubsidiesOrDiscountsMember 2024-09-30 0000049071 hum:RiskCorridorSettlementsMedicarePartDMember 2023-12-31 0000049071 hum:CmsSubsidiesOrDiscountsMember 2023-12-31 0000049071 hum:InsuranceSegmentMember 2023-12-31 0000049071 hum:CenterWellSegmentMember 2023-12-31 0000049071 hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:InsuranceSegmentMember 2024-09-30 0000049071 hum:CenterWellSegmentMember 2024-09-30 0000049071 hum:CertificateOfNeedMember 2024-09-30 0000049071 hum:CertificateOfNeedMember 2023-12-31 0000049071 us-gaap:LicensingAgreementsMember 2024-09-30 0000049071 us-gaap:LicensingAgreementsMember 2023-12-31 0000049071 us-gaap:CustomerContractsMember 2024-09-30 0000049071 us-gaap:CustomerContractsMember 2023-12-31 0000049071 us-gaap:TradeNamesMember 2024-09-30 0000049071 us-gaap:TradeNamesMember 2023-12-31 0000049071 us-gaap:ContractualRightsMember 2024-09-30 0000049071 us-gaap:ContractualRightsMember 2023-12-31 0000049071 hum:NoncompetesAndOtherMember 2024-09-30 0000049071 hum:NoncompetesAndOtherMember 2023-12-31 0000049071 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0000049071 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0000049071 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000049071 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000049071 us-gaap:RestrictedStockMember 2024-07-01 2024-09-30 0000049071 us-gaap:RestrictedStockMember 2023-07-01 2023-09-30 0000049071 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0000049071 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0000049071 2024-01-01 2024-03-31 0000049071 2024-04-01 2024-06-30 0000049071 srt:ScenarioForecastMember 2024-10-01 2024-12-31 0000049071 us-gaap:SubsequentEventMember 2024-10-01 2024-10-30 0000049071 hum:A2023ShareRepurchaseAuthorizationMember 2024-02-16 0000049071 hum:A2024ShareRepurchaseAuthorizationMember 2024-02-16 0000049071 hum:A2023And2024ShareRepurchaseAuthorizationMember 2024-01-01 2024-09-30 0000049071 hum:A2023ShareRepurchaseAuthorizationMember 2023-01-01 2023-09-30 0000049071 us-gaap:SubsequentEventMember 2024-10-29 0000049071 hum:A3.85PercentSeniorNotesDueOctober2024Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A3.85PercentSeniorNotesDueOctober2024Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A450PercentSeniorNotesDueApril2025Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A450PercentSeniorNotesDueApril2025Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 us-gaap:SeniorNotesMember 2024-09-30 0000049071 us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A570PercentSeniorNotesDueMarch2026Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A570PercentSeniorNotesDueMarch2026Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A135PercentSeniorNotesDueFebruary2027Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A135PercentSeniorNotesDueFebruary2027Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A3.95PercentSeniorNotesDueMarch2027Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A3.95PercentSeniorNotesDueMarch2027Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5750PercentSeniorNotesDueMarch2028Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A5750PercentSeniorNotesDueMarch2028Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.750PercentSeniorNotesDueDecember2028Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A5.750PercentSeniorNotesDueDecember2028Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A3700PercentSeniorNotesDueMarch2029Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A3700PercentSeniorNotesDueMarch2029Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A3125PercentSeniorNotesDueAugust2029Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A3125PercentSeniorNotesDueAugust2029Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A4875PercentSeniorNotesDueApril2030Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A4875PercentSeniorNotesDueApril2030Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.375PercentSeniorNotesDueApril2031Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A5.375PercentSeniorNotesDueApril2031Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A215PercentSeniorNotesDueFebruary2032Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A215PercentSeniorNotesDueFebruary2032Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5875PercentSeniorNotesDueMarch2033Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.950PercentSeniorNotesDueMarch2034Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A8.15PercentSeniorNotesDueJune2038Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A8.15PercentSeniorNotesDueJune2038Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A4.625PercentSeniorNotesDueDecember2042Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A4.95PercentSeniorNotesDueOctober2044Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A4.80PercentSeniorNotesDueMarch2047Member us-gaap:SeniorNotesMember 2024-09-30 0000049071 hum:A4.80PercentSeniorNotesDueMarch2047Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A395PercentSeniorNotesDueAugust2049Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A550PercentSeniorNotesDueMarch2053Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.750PercentSeniorNotesDueApril2054Member us-gaap:SeniorNotesMember 2023-12-31 0000049071 hum:A5.375PercentSeniorNotesDueApril2031Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A5.750PercentSeniorNotesDueApril2054Member us-gaap:SeniorNotesMember 2024-03-31 0000049071 hum:A5.375PercentSeniorNotesDueApril2031And5.750PercentSeniorNotesDueApril2054Member us-gaap:SeniorNotesMember 2024-03-01 2024-03-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2023-06-01 2023-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2023-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2021FiveYearMember 2021-06-01 2021-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2021FiveYearMember 2021-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-05-01 2024-05-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-05-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementMay2024OneYearMember 2024-05-01 2024-05-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementMay2024OneYearMember 2024-05-31 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember 2023-06-01 2023-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023OneYearMember 2023-06-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-01-01 2024-09-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementMay2024OneYearMember 2024-01-01 2024-09-30 0000049071 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-01-01 2024-09-30 0000049071 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-01-01 2024-09-30 0000049071 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementMay2024OneYearMember 2024-01-01 2024-09-30 0000049071 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementMay2024OneYearMember 2024-01-01 2024-09-30 0000049071 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0000049071 us-gaap:LoansPayableMember 2024-09-30 0000049071 us-gaap:LetterOfCreditMember 2024-09-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementJune2023FiveYearMember 2024-09-30 0000049071 us-gaap:RevolvingCreditFacilityMember hum:RevolvingCreditAgreementMay2024OneYearMember 2024-09-30 0000049071 us-gaap:CommercialPaperMember 2024-01-01 2024-09-30 0000049071 us-gaap:FederalHomeLoanBankAdvancesMember 2024-09-30 0000049071 hum:MedicareMember 2024-01-01 2024-09-30 0000049071 hum:MedicaidMember 2024-01-01 2024-09-30 0000049071 hum:MilitaryServiceMember hum:TRICARE2017EastRegionContractMember 2024-01-01 2024-09-30 0000049071 hum:TRICARE2017EastRegionContractMember 2024-09-30 0000049071 hum:TRICARE2017EastRegionContractMember 2024-01-01 2024-09-30 0000049071 hum:TRICAREManagedCareSupportContractEffective2024Member 2022-12-31 0000049071 hum:TRICAREManagedCareSupportContractEffective2024Member 2022-12-01 2022-12-31 0000049071 hum:UnitedStatesOfAmericaExRel.StevenScottV.HumanaInc.Member 2024-08-15 2024-08-15 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:MedicareAdvantageMember us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:GroupMedicareAdvantageMember us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:MedicareMember us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:CommercialFullyInsuredMember us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:SpecialtyBenefitsMember us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:MedicareSupplementProductMember us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:StateBasedContractsAndOtherMember us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:HomeSolutionsMember us-gaap:ServiceMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:PrimaryCareMember us-gaap:ServiceMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:PharmacySolutionsMember us-gaap:ServiceMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:CommercialASOMember us-gaap:ServiceMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:MilitaryAndOtherMember us-gaap:ServiceMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:ServiceMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:ExternalRevenuesMember 2024-07-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ServiceMember 2024-07-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember 2024-07-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:IntersegmentEliminationMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:InsuranceSegmentMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CenterWellSegmentMember 2024-07-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember 2024-07-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:MedicareAdvantageMember us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:GroupMedicareAdvantageMember us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:MedicareMember us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:CommercialFullyInsuredMember us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:SpecialtyBenefitsMember us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:MedicareSupplementProductMember us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:StateBasedContractsAndOtherMember us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:HomeSolutionsMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:PrimaryCareMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:PharmacySolutionsMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:CommercialASOMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:MilitaryAndOtherMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:ServiceMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:ExternalRevenuesMember 2023-07-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ServiceMember 2023-07-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember 2023-07-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:IntersegmentEliminationMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:InsuranceSegmentMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CenterWellSegmentMember 2023-07-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember 2023-07-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:MedicareAdvantageMember us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:GroupMedicareAdvantageMember us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:MedicareMember us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:CommercialFullyInsuredMember us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:SpecialtyBenefitsMember us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:MedicareSupplementProductMember us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:StateBasedContractsAndOtherMember us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:HomeSolutionsMember us-gaap:ServiceMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:PrimaryCareMember us-gaap:ServiceMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:PharmacySolutionsMember us-gaap:ServiceMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:CommercialASOMember us-gaap:ServiceMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:MilitaryAndOtherMember us-gaap:ServiceMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:ServiceMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:ExternalRevenuesMember 2024-01-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ServiceMember 2024-01-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember 2024-01-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:IntersegmentEliminationMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:InsuranceSegmentMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CenterWellSegmentMember 2024-01-01 2024-09-30 0000049071 hum:CorporateAndEliminationsMember 2024-01-01 2024-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:MedicareAdvantageMember us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:GroupMedicareAdvantageMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:GroupMedicareAdvantageMember us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:MedicareStandAlonePrescriptionDrugPlanMember us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:MedicareMember us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialFullyInsuredMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:CommercialFullyInsuredMember us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:SpecialtyBenefitsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:SpecialtyBenefitsMember us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MedicareSupplementProductMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:MedicareSupplementProductMember us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:StateBasedContractsAndOtherMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:StateBasedContractsAndOtherMember us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:HomeSolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:HomeSolutionsMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PrimaryCareMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:PrimaryCareMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:PharmacySolutionsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:PharmacySolutionsMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CommercialASOMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:CommercialASOMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:MilitaryAndOtherMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:MilitaryAndOtherMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:ServiceMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:ExternalRevenuesMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:ExternalRevenuesMember 2023-01-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ServiceMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ServiceMember 2023-01-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember us-gaap:ProductMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember 2023-01-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:InsuranceSegmentMember 2023-01-01 2023-09-30 0000049071 us-gaap:OperatingSegmentsMember hum:CenterWellSegmentMember 2023-01-01 2023-09-30 0000049071 hum:CorporateAndEliminationsMember 2023-01-01 2023-09-30 shares iso4217:USD iso4217:USD shares pure hum:position hum:state hum:beneficiary hum:option_period hum:segment 0000049071 --12-31 2024 Q3 false 0.1667 0.1667 http://fasb.org/us-gaap/2024#HealthCareMember http://fasb.org/us-gaap/2024#HealthCareMember http://fasb.org/us-gaap/2024#HealthCareMember http://fasb.org/us-gaap/2024#HealthCareMember P1Y 10-Q true 2024-09-30 false 1-5975 HUMANA INC DE 61-0647538 500 West Main Street Louisville KY 40202 502 580-1000 Common stock, $0.16 2/3 par value HUM NYSE Yes Yes Large Accelerated Filer false false false 120411343 5116000000 4694000000 19033000000 16626000000 93000000 88000000 2144000000 2035000000 6633000000 6631000000 32926000000 29986000000 2693000000 3030000000 400000000 382000000 729000000 740000000 9590000000 9550000000 3669000000 3377000000 50007000000 47065000000 11125000000 10241000000 5915000000 6569000000 356000000 353000000 195000000 266000000 1136000000 1443000000 18727000000 18872000000 11886000000 10213000000 1770000000 1662000000 32383000000 30747000000 1 1 10000000 10000000 0 0 0 0 300000000 300000000 198718810 198690082 33000000 33000000 3471000000 3346000000 29118000000 27540000000 -653000000 -999000000 78307467 76465862 14404000000 13658000000 17565000000 16262000000 59000000 56000000 17624000000 16318000000 50007000000 47065000000 27951000000 25099000000 84354000000 76144000000 1103000000 1016000000 3265000000 2993000000 343000000 308000000 929000000 775000000 29397000000 26423000000 88548000000 79912000000 25120000000 21745000000 75283000000 65612000000 3339000000 3271000000 9529000000 9361000000 210000000 201000000 631000000 578000000 28669000000 25217000000 85443000000 75551000000 728000000 1206000000 3105000000 4361000000 169000000 114000000 496000000 347000000 92000000 6000000 -26000000 -40000000 651000000 1098000000 2583000000 3974000000 155000000 256000000 629000000 911000000 -16000000 -12000000 -57000000 -39000000 480000000 830000000 1897000000 3024000000 0 -2000000 -3000000 -6000000 480000000 832000000 1900000000 3030000000 3.99 6.74 15.76 24.37 3.98 6.71 15.72 24.26 480000000 832000000 1900000000 3030000000 619000000 -365000000 458000000 -314000000 142000000 -85000000 104000000 -73000000 477000000 -280000000 354000000 -241000000 10000000 -3000000 10000000 -56000000 2000000 0 2000000 -14000000 8000000 -3000000 8000000 -42000000 469000000 -277000000 346000000 -199000000 949000000 555000000 2246000000 2831000000 198719000 33000000 3420000000 28745000000 -1122000000 -14405000000 16671000000 57000000 16728000000 480000000 480000000 480000000 2000000 2000000 469000000 469000000 469000000 1000000 1000000 1000000 107000000 107000000 107000000 53000000 53000000 53000000 -2000000 2000000 0 198719000 33000000 3471000000 29118000000 -653000000 -14404000000 17565000000 59000000 17624000000 198690000 33000000 3313000000 27468000000 -1226000000 -12754000000 16834000000 57000000 16891000000 832000000 832000000 -2000000 830000000 -277000000 -277000000 -277000000 383000000 383000000 383000000 109000000 109000000 109000000 53000000 53000000 53000000 -3000000 3000000 0 -1000000 -1000000 -1000000 198690000 33000000 3362000000 28191000000 -1503000000 -13134000000 16949000000 55000000 17004000000 198690000 33000000 3346000000 27540000000 -999000000 -13658000000 16262000000 56000000 16318000000 1900000000 1900000000 -3000000 1897000000 6000000 6000000 346000000 346000000 346000000 774000000 774000000 774000000 322000000 322000000 322000000 153000000 153000000 153000000 29000 -28000000 28000000 0 198719000 33000000 3471000000 29118000000 -653000000 -14404000000 17565000000 59000000 17624000000 198667000 33000000 3246000000 25492000000 -1304000000 -12156000000 15311000000 59000000 15370000000 3030000000 3030000000 -6000000 3024000000 7000000 7000000 5000000 5000000 -199000000 -199000000 -199000000 1011000000 1011000000 1011000000 331000000 331000000 331000000 142000000 142000000 142000000 23000 -30000000 30000000 0 4000000 3000000 7000000 7000000 198690000 33000000 3362000000 28191000000 -1503000000 -13134000000 16949000000 55000000 17004000000 1897000000 3024000000 10000000 -49000000 -57000000 -39000000 153000000 142000000 682000000 628000000 46000000 51000000 129000000 31000000 109000000 126000000 -258000000 935000000 884000000 870000000 -498000000 39000000 -71000000 7250000000 76000000 53000000 3494000000 11115000000 37000000 223000000 421000000 721000000 6403000000 3366000000 2214000000 885000000 1758000000 815000000 -2889000000 -2610000000 638000000 -2481000000 2232000000 1215000000 48000000 1719000000 -895000000 1618000000 0 500000000 7000000 4000000 3000000 -52000000 768000000 1002000000 323000000 320000000 261000000 -135000000 -183000000 1582000000 422000000 10087000000 4694000000 5061000000 5116000000 15148000000 416000000 317000000 570000000 957000000 49000000 454000000 12000000 236000000 0 -5000000 37000000 223000000 BASIS OF PRESENTATION AND SIGNIFICANT EVENTS<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Employer Group Commercial Medical Products Business Exit</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. We anticipate the exit of this line of business to be finalized in the first half of 2025. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value Creation Initiative</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges, primarily in asset impairments, of $55 million and $151 million for the three and nine months ended September 30, 2024, respectively, and $52 million for the three and nine months ended September 30, 2023 within operating costs in the condensed consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024, accounts receivable related to services were $428 million. For the three and nine months ended September 30, 2024, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at September 30, 2024.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, services revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in a securities lending program to optimize investment income. We loan certain investment securities for short periods of time in exchange for collateral initially equal to at least 102% of the fair value of the investment securities on loan. The fair value of the loaned investment securities is monitored on a daily basis, with additional collateral obtained or refunded as the fair value of the loaned investment securities fluctuates. The collateral, which may be in the form of cash or U.S. Government securities, is deposited by the borrower with an independent lending agent. Any cash collateral, which is reinvested by the lending agent primarily in short-term, highly liquid investments, is recorded as a securities lending collateral asset within other current assets on our consolidated balance sheet at September 30, 2024. We record a corresponding liability to reflect our obligation to return the collateral within trade accounts payable and accrued expenses on our consolidated balance sheet at September 30, 2024. Collateral received in the form of securities is not recorded in our consolidated balance sheets because, absent default by the borrower, we do not have the right to sell, pledge or otherwise reinvest securities collateral. Loaned securities continue to be carried as investment securities on the consolidated balance sheet at September 30, 2024. Earnings on the invested cash collateral, net of expense, associated with the securities lending payable are recorded as investment income.</span></div> <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2023, that was filed with the Securities and Exchange Commission, or the SEC, on February 15, 2024. We refer to this Form 10-K as the “2023 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. For additional information regarding accounting policies considered in preparing our consolidated financial statements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Employer Group Commercial Medical Products Business Exit</span></div>In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. We anticipate the exit of this line of business to be finalized in the first half of 2025. 55000000 151000000 52000000 52000000 <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues include premiums and services revenue. Services revenue includes administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, services revenue includes net patient services revenue that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For additional information regarding our revenues, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. For additional information regarding disaggregation of revenue by segment and type, refer to Note 14 to the unaudited Condensed Consolidated Financial Statements included in Part I, Item 1, "Financial Statements" of this Form 10-Q.</span></div> 428000000 <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in a securities lending program to optimize investment income. We loan certain investment securities for short periods of time in exchange for collateral initially equal to at least 102% of the fair value of the investment securities on loan. The fair value of the loaned investment securities is monitored on a daily basis, with additional collateral obtained or refunded as the fair value of the loaned investment securities fluctuates. The collateral, which may be in the form of cash or U.S. Government securities, is deposited by the borrower with an independent lending agent. Any cash collateral, which is reinvested by the lending agent primarily in short-term, highly liquid investments, is recorded as a securities lending collateral asset within other current assets on our consolidated balance sheet at September 30, 2024. We record a corresponding liability to reflect our obligation to return the collateral within trade accounts payable and accrued expenses on our consolidated balance sheet at September 30, 2024. Collateral received in the form of securities is not recorded in our consolidated balance sheets because, absent default by the borrower, we do not have the right to sell, pledge or otherwise reinvest securities collateral. Loaned securities continue to be carried as investment securities on the consolidated balance sheet at September 30, 2024. Earnings on the invested cash collateral, net of expense, associated with the securities lending payable are recorded as investment income.</span></div> 1.02 RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Effective in Future Periods</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We do not believe the adoption of ASU 2023-07 will have a material impact on our consolidated financial statements or disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.</span></div> <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Effective in Future Periods</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity’s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We do not believe the adoption of ASU 2023-07 will have a material impact on our consolidated financial statements or disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09 — Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted. We are currently evaluating the impact on our income tax footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.</span></div> ACQUISITIONS<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024 and 2023, respectively, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in 2024 and 2023, respectively, have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in 2024 and 2023, were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the quarter of acquisition, were not material for disclosure purposes.</span></div> INVESTMENT SECURITIES<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities classified as current and long-term were as follows at September 30, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:45.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(998)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own certain corporate debt securities of Gentiva Hospice. The book value and fair value are $381 million and $396 million, respectively, at September 30, 2024. The book value and fair value were $379 million and $398 million, respectively, at December 31, 2023.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in a securities lending program where we loan certain investment securities for short periods of time in exchange for collateral, consisting of cash or U.S. Government securities, initially equal to at least 102% of the fair value of the investment securities on loan. Collateral with a fair value of $361 million was held at September 30, 2024. At September 30, 2024, collateral from lending our investment securities has been reinvested in short-term, highly liquid assets. In addition, we participated in non-cash securities lending with a fair value of $148 million at September 30, 2024. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at September 30, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or more</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,835 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(989)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(998)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,046 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,667 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by Standard &amp; Poor's Rating Service, or S&amp;P, at September 30, 2024. Our remaining debt securities below investment-grade were primarily rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unrealized losses from all debt securities were generated from approximately 1,300 positions out of a total of approximately 2,290 positions at September 30, 2024. All issuers of debt securities we own that were trading at an unrealized loss at September 30, 2024 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time these debt securities were purchased. At September 30, </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position for the three and nine months ended September 30, 2024 or 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detail of gains (losses) related to investment securities and included within investment income was as follows for the three and nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:62.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on investment securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recognized gains (losses) on investment securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses related to equity securities for the three and nine months ended September 30, 2024 and 2023 was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:65.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains recognized on equity securities during the period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net gains recognized on equity securities sold during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized on equity securities still held at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of debt securities available for sale at September 30, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,669 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,279 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,433 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>For additional information regarding our investment securities, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities classified as current and long-term were as follows at September 30, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:45.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(998)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 3203000000 13000000 33000000 3183000000 4501000000 33000000 351000000 4183000000 602000000 0 18000000 584000000 555000000 1000000 54000000 502000000 1292000000 2000000 78000000 1216000000 1533000000 11000000 20000000 1524000000 8593000000 92000000 444000000 8241000000 20279000000 152000000 998000000 19433000000 2717000000 1000000 51000000 2667000000 3946000000 1000000 425000000 3522000000 879000000 1000000 22000000 858000000 465000000 1000000 66000000 400000000 1471000000 0 126000000 1345000000 1813000000 2000000 44000000 1771000000 7011000000 28000000 594000000 6445000000 18302000000 34000000 1328000000 17008000000 381000000 396000000 379000000 398000000 1.02 361000000 148000000 <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized losses and fair values aggregated by investment category and length of time of individual debt securities that have been in a continuous unrealized loss position for which no allowances for credit loss has been recorded were as follows at September 30, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or more</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,835 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(989)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(998)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,046 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,667 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 551000000 2000000 518000000 31000000 1069000000 33000000 330000000 2000000 2378000000 349000000 2708000000 351000000 77000000 0 417000000 18000000 494000000 18000000 57000000 2000000 361000000 52000000 418000000 54000000 26000000 1000000 1124000000 77000000 1150000000 78000000 218000000 1000000 571000000 19000000 789000000 20000000 290000000 1000000 4466000000 443000000 4756000000 444000000 1549000000 9000000 9835000000 989000000 11384000000 998000000 1899000000 12000000 431000000 39000000 2330000000 51000000 958000000 12000000 2269000000 413000000 3227000000 425000000 160000000 1000000 523000000 21000000 683000000 22000000 0 0 373000000 66000000 373000000 66000000 18000000 0 1303000000 126000000 1321000000 126000000 120000000 1000000 1364000000 43000000 1484000000 44000000 466000000 2000000 4783000000 592000000 5249000000 594000000 3621000000 28000000 11046000000 1300000000 14667000000 1328000000 0.97 0.01 1300 2290 <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detail of gains (losses) related to investment securities and included within investment income was as follows for the three and nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:62.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on investment securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recognized gains (losses) on investment securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 14000000 0 16000000 15000000 4000000 4000000 6000000 65000000 0 0 0 1000000 0 0 0 0 10000000 -4000000 10000000 -49000000 <div style="margin-bottom:9pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses related to equity securities for the three and nine months ended September 30, 2024 and 2023 was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:65.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains recognized on equity securities during the period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net gains recognized on equity securities sold during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized on equity securities still held at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 0 0 1000000 0 0 0 0 0 0 0 1000000 <div style="margin-bottom:9pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of debt securities available for sale at September 30, 2024, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,669 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,584 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,279 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,433 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1082000000 1079000000 5669000000 5584000000 4407000000 4261000000 1240000000 1084000000 7881000000 7425000000 20279000000 19433000000 FAIR VALUE<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our fair value measurements at September 30, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:49.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,433 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending invested collateral</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,735 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,302 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:58.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 assets had a fair value of $291 million, or 1.2% of total invested assets, and $218 million, or 1.0% or total invested assets, at September 30, 2024 and December 31, 2023, respectively. During the nine months ended </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.946%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Private Placements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains or losses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Swaps</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on Secured Overnight Financing Rate (SOFR), to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our condensed consolidated balance sheets at fair value as of the reporting date. Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative, aggregate adjustment to the carrying value of the senior notes was approximately $117 million at September 30, 2024. The swap asset, included within other long-term assets on our condensed consolidated balance sheet was approximately $117 million at September 30, 2024. The swap asset, included within other long-term assets on our condensed consolidated balance sheets, was approximately $68 million at December 31, 2023. We include the gain or loss on the swap agreements in interest expense on our condensed consolidated income statement, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the three and nine months ended September 30, 2024 and 2023. The following table summarizes the notional amounts at September 30, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:59.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.625% due December 1, 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 4.950% due October 1, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000 million, 5.750% due April 15, 2054</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt is recorded at carrying value in our condensed consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $13.0 billion at September 30, 2024 and $10.8 billion at December 31, 2023. The fair value of our senior notes debt was $12.9 billion at September 30, 2024 and $10.6 billion at December 31, 2023. The fair value of our senior notes debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates fair value for our commercial paper borrowings. We had no outstanding commercial paper borrowings at September 30, 2024. The commercial paper borrowings were $0.9 billion at December 31, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Put and Call Options Measured at Fair Value</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The put and call options fair values associated with our Primary Care Organization strategic partnership with Welsh, Carson, Anderson &amp; Stowe, or WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $742 million and $24 million, respectively, at September 30, 2024. The put and call options fair values, derived from the Monte Carlo simulation, were $595 million and $18 million, respectively, at December 31, 2023. The put liability and call asset are included within other long-term liabilities and other long-term assets, respectively, within our condensed consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.</span></div><div style="margin-bottom:9pt;text-align:right;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:59.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5% - 18.3%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1% - 17.8%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit spread</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8% - 1.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% - 1.1%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue exit multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average cost of capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 14.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 12.5%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term growth rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets and Liabilities Measured at Fair Value</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances. As disclosed in Note 3, we acquired various health and wellness related businesses during 2024 and 2023. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs. The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based primarily on the income approach. The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, revenue growth rates, the amount and timing </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of future cash flows, discount rates, contributory asset charges and future tax rates, among others. The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the assets and liabilities acquired during 2024 and 2023, there were no other material assets or liabilities measured at fair value on a recurring or nonrecurring basis during 2024 and 2023. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our fair value measurements, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our fair value measurements at September 30, 2024 and December 31, 2023, respectively, for financial assets measured at fair value on a recurring basis:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:49.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,433 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending invested collateral</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,735 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,302 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government<br/>    corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:58.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 4941000000 4941000000 0 0 3183000000 0 3183000000 0 4183000000 0 4183000000 0 584000000 0 584000000 0 502000000 0 500000000 2000000 1216000000 0 1216000000 0 1524000000 0 1479000000 45000000 8241000000 0 7997000000 244000000 19433000000 0 19142000000 291000000 361000000 361000000 0 0 24735000000 5302000000 19142000000 291000000 4582000000 4582000000 0 0 2667000000 0 2667000000 0 3522000000 0 3522000000 0 858000000 0 858000000 0 400000000 0 396000000 4000000 1345000000 0 1345000000 0 1771000000 0 1733000000 38000000 6445000000 0 6269000000 176000000 17008000000 0 16790000000 218000000 291000000 0.012 218000000 0.010 During the nine months ended <div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024 and 2023, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:    </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.946%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Private Placements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains or losses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 218000000 101000000 0 0 6000000 -1000000 72000000 13000000 0 4000000 0 0 5000000 0 0 4000000 291000000 105000000 117000000 117000000 68000000 The following table summarizes the notional amounts at September 30, 2024 and December 31, 2023, respectively, for our senior notes under the swap agreements:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:59.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.625% due December 1, 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 4.950% due October 1, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000 million, 5.750% due April 15, 2054</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 750000000 0.05875 650000000 650000000 850000000 0.05950 800000000 400000000 500000000 0.03950 450000000 450000000 750000000 0.05500 700000000 300000000 400000000 0.04625 400000000 0 750000000 0.04950 400000000 0 1000000000 0.05750 400000000 0 13000000000.0 10800000000 12900000000 10600000000 0 900000000 742000000 24000000 595000000 18000000 The table below presents the assumptions used for each reporting period.<div style="margin-bottom:9pt;text-align:right;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:59.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5% - 18.3%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1% - 17.8%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit spread</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8% - 1.4%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% - 1.1%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue exit multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average cost of capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 14.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 12.5%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term growth rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.165 0.183 0.161 0.178 0.008 0.014 0.009 0.011 1.5 2.5 1.5 2.5 0.110 0.140 0.110 0.125 0.030 0.030 MEDICARE PART D<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with the Centers for Medicare and Medicaid Services, or CMS. The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at September 30, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:41.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.570%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,594)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,825)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net long-term asset (liability)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The accompanying condensed consolidated balance sheets include the following amounts associated with Medicare Part D at September 30, 2024 and December 31, 2023. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.<div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:41.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.570%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,594)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,825)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net long-term asset (liability)</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net asset (liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 107000000 846000000 224000000 514000000 114000000 1594000000 232000000 1825000000 -7000000 -748000000 -8000000 -1311000000 298000000 0 17000000 0 62000000 0 77000000 0 236000000 0 -60000000 0 229000000 -748000000 -68000000 -1311000000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for our reportable segments for the nine months ended September 30, 2024 were as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:55.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,590 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2024 and December 31, 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/<br/>    relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and <br/>    technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetes and <br/>    other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible <br/>    assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For the three months ended September 30, 2024 and 2023, amortization expense for other intangible assets was approximately $15 million and $17 million, respectively. For the nine months ended September 30, 2024 and 2023, amortization expense for other intangible assets was approximately $46 million and $51 million, respectively. The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at September 30, 2024:</span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:88.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our goodwill and intangible assets, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> <div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for our reportable segments for the nine months ended September 30, 2024 were as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:55.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,590 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2663000000 6887000000 9550000000 0 40000000 40000000 2663000000 6927000000 9590000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2024 and December 31, 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/<br/>    relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and <br/>    technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetes and <br/>    other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible <br/>    assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at September 30, 2024 and December 31, 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/<br/>    relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and <br/>    technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetes and <br/>    other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible <br/>    assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1092000000 1092000000 1092000000 1092000000 288000000 288000000 288000000 288000000 P9Y4M24D 956000000 749000000 207000000 956000000 718000000 238000000 P6Y8M12D 139000000 116000000 23000000 139000000 109000000 30000000 P11Y10M24D 67000000 63000000 4000000 67000000 62000000 5000000 P8Y4M24D 85000000 49000000 36000000 84000000 44000000 40000000 P9Y2M12D 2627000000 977000000 1650000000 2626000000 933000000 1693000000 15000000 17000000 46000000 51000000 The following table presents our estimate of amortization expense remaining for 2024 and each of the next five succeeding years at September 30, 2024:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:88.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 15000000 58000000 43000000 33000000 29000000 27000000 BENEFITS PAYABLE<div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,612 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,742)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,125 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,196 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At September 30, 2024, benefits payable included IBNR of approximately $7.2 billion, primarily associated with claims incurred in 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts incurred related to prior periods vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development). </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> <div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,612 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,742)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,125 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,196 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10241000000 9264000000 0 62000000 75976000000 66370000000 -693000000 -758000000 75283000000 65612000000 65282000000 56700000000 9117000000 8042000000 74399000000 64742000000 11125000000 10196000000 7200000000 EARNINGS PER COMMON SHARE COMPUTATION<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:53.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions, except per common share results; number of shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available for common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average outstanding shares of common stock <br/>    used to compute basic earnings per common share</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,405 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,426 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,609 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,335 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted earnings per common share</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,764 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,983 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,899 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,885 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.74 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.76 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.37 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.72 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.26 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of antidilutive stock options and restricted stock <br/>    excluded from computation</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>For additional information regarding earnings per common share, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detail supporting the computation of basic and diluted earnings per common share was as follows for the three and nine months ended September 30, 2024 and 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:53.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions, except per common share results; number of shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available for common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average outstanding shares of common stock <br/>    used to compute basic earnings per common share</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,405 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,426 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,609 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,335 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted earnings per common share</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,764 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,983 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,899 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,885 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.74 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.76 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.37 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.72 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.26 </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of antidilutive stock options and restricted stock <br/>    excluded from computation</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 480000000 832000000 1900000000 3030000000 120405000 123426000 120609000 124335000 3000 26000 4000 31000 356000 531000 286000 519000 120764000 123983000 120899000 124885000 3.99 6.74 15.76 24.37 3.98 6.71 15.72 24.26 361000 137000 759000 251000 STOCKHOLDERS’ EQUITY<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/29/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/26/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/29/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/26/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/28/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/26/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/25/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Board declared a cash dividend of $0.885 per share payable on January 31, 2025 to stockholders of record as of the close of business on December 31, 2024.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Declaration and payment of future quarterly dividends are at the discretion of our Board and may be adjusted as business needs or market conditions change.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Board of Directors may authorize the purchase of our common stock shares. Under the share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions, including pursuant to accelerated share repurchase agreements with investment banks, subject to certain regulatory restrictions on volume, pricing, and timing.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824 million remained unused) with a new share repurchase authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. During the nine months ended September 30, 2024, we repurchased 1.9 million shares in open market transactions for $750 million at an average price of $384.65 under the February 2023 and 2024 share repurchase authorizations. During the nine months ended September 30, 2023, we repurchased 2.0 million shares in open market transactions for $980 million at an average price of $478.20 under the February 2023 share repurchase authorization.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our remaining repurchase authorization was $2.93 billion as of October 29, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with employee stock plans, we acquired 0.05 million common shares for $18 million and 0.06 million common shares for $31 million during the nine months ended September 30, 2024 and 2023, respectively.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of dividend payments, excluding dividend equivalent rights for unvested stock awards, during 2024 under our Board approved quarterly cash dividend policy:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/29/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/26/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/29/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/26/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/28/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/26/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/25/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8850 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.8850 108000000 0.8850 107000000 0.8850 107000000 0.8850 107000000 0.885 824000000 3000000000 1900000 750000000 384.65 2000000 980000000 478.20 2930000000 50000.00 18000000 60000.00 31000000 INCOME TAXES<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The effective income tax rate was 24.4% and 24.9% for the three and nine months ended September 30, 2024, respectively, and 23.5% and 23.1% for the three and nine months ended September 30, 2023, respectively. The year-over-year increase in the effective income tax rate is primarily due to a change in the mix of current year earnings between our Insurance segment and our CenterWell health services segment, as our CenterWell health services segment is subject to a higher effective tax rate than our Insurance segment. In addition, the prior year income tax rate was favorably impacted by the recognition of a non-taxable gain.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information regarding income taxes, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K.</span></div> 0.244 0.249 0.235 0.231 DEBT<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at September 30, 2024 and December 31, 2023:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:60.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.850% due October 1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 4.500% due April 1, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 4.500% due April 1, 2025</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.700% due March 13, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 1.350% due February 3, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.950% due March 15, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due March 1, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due December 1, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 3.700% due March 23, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.125% due August 15, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 4.875% due April 1, 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,250 million, 5.375% due April 15, 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 2.150% due February 3, 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$250 million, 8.150% due June 15, 2038</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.625% due December 1, 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 4.950% due October 1, 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.800% due March 15, 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000 million, 5.750% due April 15, 2054</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In March 2024, we issued $1.3 billion of 5.375% unsecured senior notes due April 15, 2031 and $1.0 billion of 5.750% unsecured senior notes due April 15, 2054. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $2.2 billion. We used the net proceeds for general corporate purposes, which include the repayment of existing indebtedness, including borrowings under our commercial paper program.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on some of our senior notes payable from fixed rates to variable rates, based on Secured Overnight Financing Rate (SOFR), to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities, as further described in Note 5. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value caused by an increase or decrease in interest rates. The cumulative, aggregate decrease to the carrying value of the senior notes was approximately $117 million at September 30, 2024.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our Senior Notes, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Agreements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into an amended and restated 5-year, $2.5 billion unsecured revolving credit agreement (replacing the 5-year, $2.5 billion unsecured revolving credit agreement entered in June 2021). In May 2024, we entered into an amendment to increase commitments $0.142 billion resulting in a $2.642 billion borrowing capacity. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, we entered into a 364-day $2.1 billion unsecured revolving credit agreement (replacing the 364-day $1.5 billion unsecured revolving credit agreement entered in June 2023, which expired in accordance with its terms). </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SOFR spread, currently 114.0 basis points under the 5-year revolving credit agreement and 116.0 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 11.0 basis points, under the 5-year revolving credit agreement and 9.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 42.3% as measured in accordance with the revolving credit agreements as of September 30, 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At September 30, 2024, we had no borrowings and approximately $18 million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of September 30, 2024, we had $2.624 billion of remaining borrowing capacity under the 5-year revolving credit agreement and $2.1 billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750 million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information regarding our Revolving Credit Agreements, refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the nine </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">months ended September 30, 2024 was $2.7 billion, with no outstanding amount at September 30, 2024 compared to $0.9 billion outstanding at December 31, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information regarding our Commercial Paper refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Short-term Borrowings</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. </span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At September 30, 2024 we had no outstanding short-term FHLB borrowings.</span></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of debt outstanding, net of unamortized debt issuance costs, was as follows at September 30, 2024 and December 31, 2023:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:60.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.850% due October 1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 4.500% due April 1, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 4.500% due April 1, 2025</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.700% due March 13, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 1.350% due February 3, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.950% due March 15, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due March 1, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due December 1, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 3.700% due March 23, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.125% due August 15, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 4.875% due April 1, 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,250 million, 5.375% due April 15, 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 2.150% due February 3, 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$250 million, 8.150% due June 15, 2038</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.625% due December 1, 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 4.950% due October 1, 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.800% due March 15, 2047</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000 million, 5.750% due April 15, 2054</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,886 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 871000000 600000000 0.03850 559000000 572000000 600000000 0.04500 577000000 0 1136000000 572000000 1136000000 1443000000 600000000 0.04500 0 598000000 500000000 0.05700 499000000 498000000 750000000 0.01350 689000000 688000000 600000000 0.03950 537000000 537000000 500000000 0.05750 489000000 495000000 500000000 0.05750 495000000 495000000 750000000 0.03700 585000000 590000000 500000000 0.03125 433000000 433000000 500000000 0.04875 496000000 496000000 1250000000 0.05375 1239000000 0 750000000 0.02150 744000000 743000000 750000000 0.05875 762000000 750000000 850000000 0.05950 853000000 840000000 250000000 0.08150 260000000 261000000 400000000 0.04625 390000000 396000000 750000000 0.04950 738000000 740000000 400000000 0.04800 396000000 396000000 500000000 0.03950 534000000 529000000 750000000 0.05500 745000000 728000000 1000000000 0.05750 1002000000 0 11886000000 10213000000 11886000000 10213000000 1300000000 0.05375 1000000000 0.05750 2200000000 117000000 P5Y 2500000000 P5Y 2500000000 142000000 2642000000 P364D 2100000000 P364D 1500000000 0.01140 P5Y 0.01160 P364D 0.00920 0.01300 P5Y 0.00940 0.01350 P364D 0.00110 P5Y 0.00090 P364D 0.00080 0.00200 P5Y 0.00060 0.00150 P364D 0.60 0.423 0 18000000 2624000000 P5Y 2100000000 P364D 750000000 2700000000 0 900000000 0 COMMITMENTS, GUARANTEES AND CONTINGENCIES<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Contracts</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare products, which accounted for approximately 85% of our total premiums and services revenue for the nine months ended September 30, 2024, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997, or BBA, and the Benefits Improvement and Protection Act of 2000, or BIPA, generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service, or FFS, program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies’ risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted premium amount for the year under audit. In doing so, CMS recognized “that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).” To correct for this difference, CMS stated that it would apply a “Fee-for-Service Adjuster (FFS Adjuster)” as “an offset to the preliminary recovery amount.” This adjuster would </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be “calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.” CMS stated that this methodology would apply to audits beginning with PY 2011. Humana relied on CMS’s 2012 guidance in submitting MA bids to CMS. Humana also launched a “Self-Audits” program in 2013 that applied CMS’s 2012 RADV audit methodology and included an estimated FFS Adjuster. Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster. CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011. On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule). The Final RADV Rule confirmed CMS’s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS’s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed. However, CMS’s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology. CMS instead stated its general plan to rely on “any statistically valid method . . . that is determined to be well-suited to a particular audit.”</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana’s actuarially certified bids through PY 2023 preserved Humana’s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years. The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members. It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state-based Medicaid business, which accounted for approximately 8% of our total premiums and services revenue for the nine months ended September 30, 2024 primarily consisted of serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At September 30, 2024, our Military services business, which accounted for approximately 1% of our total premiums and services revenue for the nine months ended September 30, 2024, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the U.S. Department of Defense, or DoD, and is currently scheduled to expire on December 31, 2024, unless further extended. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD.The T-5 East Region contract comprises 24 states, and Washington D.C., and covers approximately 4.6 million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is <span style="-sec-ix-hidden:f-1206">one</span> transition year followed by eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings and Certain Regulatory Matters</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States of America ex rel. Steven Scott v. Humana Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in United States District Court, Western District of Kentucky, Louisville division. The complaint alleged certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action sought damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening. During 2023, we accrued certain anticipated expenses in connection with this matter. On August 15, 2024, Humana settled the claims in this suit, and paid the United States $90 million.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will prevail in the lawsuit. See “Government Contracts” in this footnote to the unaudited Consolidated Financial Statements of this Form 10-Q for additional information regarding this matter.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2024, a putative stockholder class action was filed against Humana Inc. and certain of our current and former executive officers under the federal securities laws in the United States District Court for the District of Delaware. The case, now captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Humana Stockholders Litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, alleges that between July 2022 and January 2024, Humana made false or misleading statements in its periodic SEC filings and statements to the financial markets about our financial performance and the medical costs in our Medicare Advantage business. In July 2024 and October 2024, parallel stockholder derivative action captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Silva v. Broussard and Spikes v. Broussard, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">respectively, were filed in the United States District Court for the Western District of Kentucky alleging that the same claimed acts and omissions underlying the federal securities law case also constitute a breach of fiduciary duty by certain of our current and former directors and executive officers. We will vigorously defend against the allegations in all cases.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2024, Humana Inc., along with co-plaintiff Americans for Beneficiary Choice, filed suit against the United States Department of Health and Human Services, Centers for Medicare and Medicaid Services, Xavier Becerra in his official capacity as Secretary, and Chiquita Brooks-LaSure, in her official capacity as Administrator, in the United States District Court, Northern District of Texas, Fort Worth Division, seeking a determination that they violated the Administrative Procedure Act in administering the Medicare Advantage and Part D Star Ratings program. We seek to set aside and vacate Humana’s 2025 Star Ratings and remand the matter to CMS for recalculation and to declare that CMS’s policy refusing to disclose all relevant data and information is arbitrary, capricious, and unlawful. There is no assurance that we will prevail in the lawsuit. For additional information on this matter, refer to Part II, Item 1A, "Risk Factors" of this Form 10-Q.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Lawsuits and Regulatory Matters</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider and vendor contracting and oversight, risk adjustment, competitive practices, commission payments, marketing payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, personal injury nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.</span></div> 0.85 0.08 0.01 32 6000000 24 4600000 8 P9Y 90000000 SEGMENT INFORMATION<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our Military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CenterWell segment includes our pharmacy, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail- order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our CenterWell intersegment revenues include revenues earned by certain owned providers derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $5.6 billion and $5.7 billion for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, these amounts were $14.1 billion and $14.7 billion respectively. In </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $32 million and $35 million for the three months ended September 30, 2024 and 2023, respectively, and $96 million and $102 million for the nine months ended September 30, 2024 and 2023, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2023 Form 10-K. Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our segment results were as follows for the three and nine months ended September 30, 2024 and 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:52.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30, 2024</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,177 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,165)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,014)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,096 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,659 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,086)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,669 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30, 2023</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,825 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,825 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,976 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,789 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,260 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,832)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,217 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:52.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.837%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30, 2024</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,069 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,619 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,256 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,594 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,806 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,852)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net losses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:54.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External Revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,874 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,137 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,432 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,695 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,072)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,912 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,974 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,941 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 5600000000 5700000000 14100000000 14700000000 32000000 35000000 96000000 102000000 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our segment results were as follows for the three and nine months ended September 30, 2024 and 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:52.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30, 2024</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,490 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,177 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,701 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,165)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,014)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,096 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,659 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,086)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,669 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30, 2023</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,825 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,825 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,748)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,976 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,789 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,260 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,832)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,217 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:52.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.837%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30, 2024</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,069 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,619 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,256 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,594 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,806 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,852)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net losses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:54.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External Revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,874 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,137 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,848 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,432 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,695 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,072)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,912 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,974 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,941 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21856000000 0 21856000000 1913000000 0 1913000000 721000000 0 721000000 24490000000 0 24490000000 85000000 0 85000000 238000000 0 238000000 217000000 0 217000000 2921000000 0 2921000000 27951000000 0 27951000000 0 326000000 326000000 0 319000000 319000000 0 232000000 232000000 12000000 0 12000000 214000000 0 214000000 226000000 877000000 1103000000 28177000000 877000000 29054000000 1000000 1463000000 -1464000000 0 2701000000 -2701000000 1000000 4164000000 -4165000000 192000000 0 151000000 343000000 28370000000 5041000000 -4014000000 29397000000 25319000000 0 -199000000 25120000000 2595000000 4602000000 -3858000000 3339000000 182000000 57000000 -29000000 210000000 28096000000 4659000000 -4086000000 28669000000 274000000 382000000 72000000 728000000 0 2000000 167000000 169000000 0 0 92000000 92000000 274000000 380000000 -3000000 651000000 -1000000 -15000000 0 -16000000 273000000 365000000 -3000000 635000000 0 0 0 0 273000000 365000000 -3000000 635000000 19637000000 0 19637000000 1695000000 0 1695000000 493000000 0 493000000 21825000000 0 21825000000 842000000 0 842000000 252000000 0 252000000 185000000 0 185000000 1995000000 0 1995000000 25099000000 0 25099000000 0 342000000 342000000 0 214000000 214000000 0 203000000 203000000 55000000 0 55000000 202000000 0 202000000 257000000 759000000 1016000000 25356000000 759000000 26115000000 1000000 1307000000 -1308000000 0 2594000000 -2594000000 1000000 3901000000 -3902000000 154000000 0 154000000 308000000 25511000000 4660000000 -3748000000 26423000000 21976000000 0 -231000000 21745000000 2634000000 4207000000 -3570000000 3271000000 179000000 53000000 -31000000 201000000 24789000000 4260000000 -3832000000 25217000000 722000000 400000000 84000000 1206000000 0 1000000 113000000 114000000 0 0 6000000 6000000 722000000 399000000 -23000000 1098000000 0 -12000000 0 -12000000 722000000 387000000 -23000000 1086000000 -3000000 1000000 0 -2000000 725000000 386000000 -23000000 1088000000 66519000000 0 66519000000 5840000000 0 5840000000 2409000000 0 2409000000 74768000000 0 74768000000 493000000 0 493000000 717000000 0 717000000 620000000 0 620000000 7756000000 0 7756000000 84354000000 0 84354000000 0 996000000 996000000 0 882000000 882000000 0 672000000 672000000 44000000 0 44000000 671000000 0 671000000 715000000 2550000000 3265000000 85069000000 2550000000 87619000000 3000000 4293000000 -4296000000 0 7963000000 -7963000000 3000000 12256000000 -12259000000 522000000 0 407000000 929000000 85594000000 14806000000 -11852000000 88548000000 75752000000 0 -469000000 75283000000 7354000000 13638000000 -11463000000 9529000000 553000000 166000000 -88000000 631000000 83659000000 13804000000 -12020000000 85443000000 1935000000 1002000000 168000000 3105000000 0 4000000 492000000 496000000 0 0 -26000000 -26000000 1935000000 998000000 -350000000 2583000000 -2000000 -55000000 0 -57000000 1933000000 943000000 -350000000 2526000000 -3000000 0 0 -3000000 1936000000 943000000 -350000000 2529000000 59195000000 0 59195000000 5192000000 0 5192000000 1677000000 0 1677000000 66064000000 0 66064000000 2810000000 0 2810000000 758000000 0 758000000 546000000 0 546000000 5966000000 0 5966000000 76144000000 0 76144000000 0 997000000 997000000 0 605000000 605000000 0 661000000 661000000 190000000 0 190000000 540000000 0 540000000 730000000 2263000000 2993000000 76874000000 2263000000 79137000000 30000000 3584000000 -3614000000 0 7848000000 -7848000000 30000000 11432000000 -11462000000 385000000 0 390000000 775000000 77289000000 13695000000 -11072000000 79912000000 66096000000 0 -484000000 65612000000 7597000000 12526000000 -10762000000 9361000000 516000000 152000000 -90000000 578000000 74209000000 12678000000 -11336000000 75551000000 3080000000 1017000000 264000000 4361000000 0 2000000 345000000 347000000 0 0 -40000000 -40000000 3080000000 1015000000 -121000000 3974000000 -2000000 -37000000 0 -39000000 3078000000 978000000 -121000000 3935000000 -7000000 1000000 0 -6000000 3085000000 977000000 -121000000 3941000000 false false false false